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Scope, aim and outline of this thesis 
This thesis describes the study of markers of nutrition and intestinal motility in 
mental disorders with a focus on schizophrenia and autism, and the development, 
evaluation and application of a biomarker discovery method for urine. The aim of 
the thesis is to investigate the role of long-chain polyunsaturated fatty acids 
(LCPUFA), B-vitamins and platelet (PLT) serotonin (5-HT) in schizophrenia and 
autism. The thesis proposes also that biomarker research in psychiatric disease is of 
great relevance and describes a biomarker discovery method in urine using a non-
hypothesis driven ‘-omics’-like approach. The thesis ends by summarizing its 
contents and putting biomarker research in psychiatric disease and its implications 
in a broader perspective. 
 
In the Introduction the complex etiology and potential role of non-hypothesis 
driven biomarker research in psychiatric disease is reviewed, with an accent on 
schizophrenia and autism. The enormous economic and psychosocial global burden 
of mental disorders is described as well as their epidemiology, clinical presentation 
and classification/diagnosis. Hypothesized etiological factors are discussed to create 
a framework in which biomarkers and the research thereof can be positioned. 
Furthermore, advances in the field of biomarker research in psychiatry are 
discussed in the context of epigenetics, proteomics and metabolomics. 
  The first part (Part I) of this thesis describes a study of LCPUFA and B-
vitamins in schizophrenia, of PLT 5-HT and intestinal permeability in autism, and 
of the value of PLT 5-HT as marker of intestinal motility in newborns. The 
chapters, in which these studies are described, are preceded by a review (Chapter 
1), which gives an overview of the role of LCPUFA and folate in the etiology and 
severity of psychiatric diseases such as depression, bipolar disorders, schizophrenia 
and autism. Pregnancy complications and folate-substrated carbon-1 metabolism 
are considered and their possible epigenetic effect on the etiology of mental 
disorders is described. Other nutritional factors, such as LCPUFA, that are 
important for brain development, physico-chemical properties of membranes, 
signal transduction and DNA-transcription, and that have been used in 
supplementation trials, are suggested to be important factors in the origin and 
severity of schizophrenia. In Chapter 2 we describe the results from a study 
concerning the essential fatty acid (EFA) and functional B-vitamin status in patients 
with schizophrenia. Aberrant EFA-status and increased homocysteine (Hcy; a 
marker of functional B-vitamin deficiency), have been reported before in subgroups 
of patients with schizophrenia. We describe the characteristics of large subgroups 
with marginal to severe deficiencies of LCPUFA and B-vitamins, notably folate and  
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vitamin B12. Deficiencies proved easily correctable in the most severely deficient 
patients upon supplementation with ω3 fatty acids and B-vitamins. Chapter 3 
attempts to integrate and link previously reported findings of increased intestinal 
permeability and increased PLT 5-HT levels in subgroups of children with 
pervasive developmental disorders (PDD). Platelet 5-HT and intestinal permeability 
were assessed in children with PDD in Curaçao. Differential urinary excretion of 
inert sugars after ingestion of a sugar solut i o n  w a s  us e d  as  mar ke r  o f i n t e s t i n al 
permeability. In Chapter 4 we examined the potential of PLT 5-HT as marker of 
intestinal motility. For this we studied whole blood and PLT 5-HT in mothers 
(normal motility) and their newborns (developing intestinal motility) at birth. The 
course of PLT 5-HT in relation to changes in feeding mode (i.e. parenteral/enteral) 
was investigated in a small group of preterm born infants to see whether PLT 5-HT 
was responsive to changes in intestinal motility. Chapters 2, 3 and 4 describe 
hypothesis-driven research in mental disorders. However, the advance of 
knowledge about mental disorders is slow a n d  i t  i s  l i k e l y  t o  b e n e f i t  f r o m  
complementation by information that is generated through non-hypothesis driven 
research with state-of-the art techniques that profile proteins (i.e. proteomics) and 
metabolites (i.e. metabolomics). These ‘-omics’ techniques are likely to deliver a 
multitude of candidate diagnostic and prognostic markers as well as therapeutic 
targets, compared to hypothesis driven research. 
 Part  II is thus devoted to the development, evaluation and application of such 
a non-hypothesis driven method. In Chapter 5 we describe the comparative 
analysis of low molecular weight urinary components using LC-MS and subsequent 
multivariate statistical analysis of the processed LC-MS data. This chapter deals 
with the development, evaluation and preliminary application of the method to 
proteinuria in humans. The potential and pitfalls of the method are contemplated 
upon. Chapter 6 describes an advanced proof-of-principle of the method through 
the comparison of urinary profiles from pregnant and non-pregnant females using 
the improved methodology described in Chapter 5. The methodology is 
significantly optimized with respect to data processing and multivariate statistical 
analysis. More focus is put on the selection of discriminatory peaks.  
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Abstract 
Amongst complex diseases, psychiatric disorders are probably the least understood. 
Unfortunately, at the same time they contribute enormously to psychological, social 
and economic suffering on a global and individual level. Especially in third-world 
countries an affected relative is really detrimental for a household. It is remarkable 
that despite the wide availability of psychiatric services and psychiatrists in 
Western countries, under-diagnosis and under-treatment are still common. This 
may be related to currently available diagnostic and treatment modalities that are 
far from perfect. A largely unknown disease etiology and a diagnostic system that is 
based on the observation of symptom clusters can be held, at least partially, 
responsible for this situation. In view of the large number of epidemiological 
studies, studies of animal models for anxiety, depression and addiction and 
extensive research into mental disorders, one might expect otherwise. Today most 
new medication for psychiatric disorders is still being discovered by serendipity in 
spite of our growing knowledge of molecular and cellular processes involved in 
neural signaling and neuronal development. In most cases there is no effective 
medication without harmful side-effects that can cure neurodevelopmental and 
mental disorders. 
  Research has, however, enriched our knowledge with the identification of 
psychosocial and cultural risk factors and early-life events that increase the risk of 
developing a mental disorder. Genetic analysis has yielded some candidate genes 
that, depending on the disorder in question, have a rather small to negligible 
contribution to the overall risk. Notwithstanding all these efforts no single gene has 
thus far been identified that can explain the complex etiology of a mental disorder 
except for Rett’s syndrome. Altered expression of genes caused by epigenetic 
deregulation rather than mutations of the DNA sequence may be more relevant for 
the development of mental disorders. Upcoming unbiased, non-hypothesis driven 
approaches based on genomics, transcriptomics, proteomics and metabolomics 
technologies hold promise to increase our comprehension of mental disorders 
through the (expression-) profiling of hundreds to thousands of genes, gene-
transcripts (mRNA), proteins and metabolites, respectively. For the interpretation 
of the results, powerful bioinformatics approaches are crucial. Integration of these  
‘-omics’ results in comprehensive functional correlation networks offer the 
possibility to study psychiatric diseases in a systems biology approach. By doing so 
it is expected that new prognostic, diagnostic and therapeutic biological markers or 
panels of markers will be discovered, because ‘childhood-diseases’ that have 
impaired biomarker research in cancer seem to have been dealt with. 
  New markers or marker panels should have superior sensitivity and specificity 
and should preferably relate in a causative manner to the organ, tissue, cell or                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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molecular pathway that is involved in the pathophysiology of the given disease. 
This may also simplify the present picture of mental disorders that is defined by 
phenomenological observations into biochemically related classes. In the end it may 
even be possible to make mental disorders run a less severe course, to prevent or 
delay the onset, to decrease the impact of environmental risk-factors, to identify 
highly-susceptible individuals, and to prevent or even cure mental disorders in 
generations to come. GENERAL INTRODUCTION 
- 18 - 
1. Introduction 
The world health organization (WHO) reported in 2001 that 450 million (10%) of 
all people suffer from mental or neurological disorders or from psychosocial 
problems such as those related to alcohol and drug abuse [1]. One in 4 people will 
be affected by a neuropsychiatric disorder at some stage of their life [1]. Men and 
women are equally affected with some exceptions, such as a higher prevalence of 
alcohol and substance abuse disorders in men and of unipolar depressive disorder in 
women [1]. Other examples of neuropsychiatric disorders include bipolar affective 
disorder (BD), schizophrenia, epilepsy, Alzheimer’s and other dementias, post 
traumatic stress disorder (PTSD), obsessive and compulsive disorder, panic disorder, 
and primary insomnia. All of these involve cognitive, emotional, behavioral and 
interpersonal impairments. It is alarming that the largest portion of individuals 
with neuropsychiatric disorders remains untreated [2]. Next to the enormous 
suffering of families with affected relatives there is the associated economic burden 
of mental disorders caused by health care and social service needs, lost employment 
and reduced productivity (e.g. mental health problems account for 35–45% of 
absenteeism from work [3]), impact on families and caregivers, levels of crime and 
public safety, and the negative effect of premature mortality. 
  The high life-time prevalence puts also a significant burden on primary care, 
because 24% of all patients attend these facilities because of a mental disorder [4]. 
Mental disorders thus contribute largely to the global burden of disease and health 
care costs. Importantly, projections based on figures of the 1990 WHO Global 
Burden of Disease Study in 1997 by Murray and Lopez [5] note that there will be a 
40% increase (from 10.5 to 14.7%) of disability-adjusted life years (DALY; see 
‘glossary’ at the end of the ‘References’ section) caused by neuropsychiatric 
disorders from 1990 to 2020. An update of these projections, based on figures of the 
WHO from 2002, even shows unipolar depressive disorders will be ranked as the 
second leading cause (5.7%) of DALYs in 2030 [6]. 
  In regions with high-income countries such as Europe, neuropsychiatric 
disorders account for over 40% of chronic diseases and these disorders are the 
greatest cause of years lived with disability (YLD). With 19.5% of DALYs, they 
come in second after cardiovascular disease [3]. In westernized countries unipolar 
depressive disorder will become the leading cause of illness, while in low-income 
countries it will rank third [6] on the list of DALY causatives. 
  Few reports are available regarding the economic impact of mental disorders in 
developing countries. However, reports from industrialized countries show, for 
example, that in the U.S.A. 7% of total health care expenditures are spent on 
mental illness and that the total cost of mental disorders is about 2% (38.4 billion €)                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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o f  t h e  U . S .  g r o s s  d o m e s t i c  p r o d u c t  [ 7 ] .  E u r o p e ’ s  m e n t a l  h e a l t h  c a r e  b u d g e t s  
constitute on average 5.8% of total health expenditure with a wide variation 
between countries (0.1% to 12%) [3]. The cost of mental disorders constitutes a 
significant proportion of the overall economy and the negative economic 
consequences of mental illness greatly exceed the cost of treatment. It is thus 
important to prevent and treat mental illness for these two reasons. 
  One of the ten recommendations in the world health report of 2001 by the 
WHO is to support research into biological and psychosocial aspects of mental 
health in order to increase the understanding of mental disorders and to develop 
more effective interventions [1]. The European Union adds to this that 
interventions should also be evaluated for their cost–effectiveness [3]. A recent 
cost-effectiveness study [8] shows that current treatments, such as first-generation 
antipsychotic, antidepressant and antianxiolytic drugs combined with psychosocial 
treatment, are very cost-effective and steps should be undertaken to increase 
treatment coverage and adherence. However, even if unlimited funding was 
available and all individuals affected by a psychiatric disease were treated 
optimally, about 60% of the burden would remain unavertable [9]. The burden of 
mental illness is especially heavy in developing countries in which poverty, 
HIV/AIDS, violence, prejudice etc. use up most of the resources. Treating mental 
illness is often seen as a luxury in these countries [10]. These problems need to be 
addressed before findings of more applied and fundamental research can be 
implemented. 
  Although research focusing at biological aspects of mental health may not find 
its way into pharmacological interventions directly, it will probably contribute to 
the understanding of the cause, course and outcome of disease. The use of 
biomarkers, i.e. molecules that indicate a physiological alteration due to 
development of disease for preventive, diagnostic, prognostic and therapeutic 
purposes, is relatively new, but this field of research has gained much interest in the 
past decades. This article aims to review the role and potential of biomarkers and 
biomarker research in psychiatric diseases, with the emphasis on schizophrenia and 
pervasive developmental disorders (PDD; see ‘glossary’) /autism spectrum disorder 
(ASD; see ‘glossary’). The latter two terms will be interchangeably used throughout 
this review. Although this review will cover many topics regarding the 
epidemiology and etiology of mental disorders, it will not be exhaustive in this 
respect. Many comprehensive and recommendable reviews regarding specific topics 
discussed in this review have been published and the authors will refer the reader 
to these reviews for more detailed overviews where appropriate. GENERAL INTRODUCTION 
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2.  Epidemiology and economic costs 
A more scientific view on the causes and symptoms of psychiatric diseases was 
adapted after superstition, e.g. demonic possession and witchcraft, had been 
abandoned. The puritan clergyman Cotton Mather (1663-1728) was one of the first 
to advance physical explanations for mental illnesses in Renaissance Europe [11], 
while the Arab physician Rhazes already described definitions, symptoms, and 
treatments for mental illness in the 10th century [12]. Acceptance that mental 
illness is caused by an unlucky combination of genetic background and 
environmental factors made room for epidemiological studies that identified 
gradients across time and/or space. From these studies underlying risk factors were 
identified. MEDLINE has cited studies on the epidemiology of depression, bipolar 
disorder, schizophrenia and developmental disorders since the 1970s. 
  Proper estimation of incidence and prevalence rates, and detection of trends, 
have in the past been hampered by different ascertainment strategies across 
epidemiological studies. With the global implementation and acceptance of 
classification systems for mental disorders (i.e. Text-Revision of the 4th (IV) edition 
of the Diagnostic and Statistical Manual of Mental Disorders (DSM-IV-TR) of the 
American Psychiatric Association [13], and the 10th revision of the International 
Statistical Classification of Diseases and Related Health Problems (ICD-10) of the 
WHO [14]) more reliable numbers on prevalence and incidence have become 
available. The bias of an underestimation of the prevalence of psychiatric diseases in 
the developing world may nevertheless be present, because many epidemiological 
studies reported in languages other than English, have not been accounted for in 
systematic reviews in the past. Up to a decade ago, it was, for example, believed that 
schizophrenia was randomly distributed across different cultures and regions. 
However, recent epidemiological data show otherwise [15]. 
  The many evolution-based theories that are founded on the dogmatic belief 
that the incidence of schizophrenia is invariant across time and place, are currently 
being challenged. Systematic reviews on incidence and prevalence estimates of 
schizophrenia show a median (10-90th percentile) incidence of 15.2 (7.7-43.0) per 
100,000 persons [16], and a median (10-90th percentile) lifetime prevalence of 4.0 
‰ (1.6-12.1) [17]. It seems that about 7-8 individuals per 1,000 will develop 
schizophrenia during their lifetime, which is referred to as the lifetime morbid risk 
(LMR; see ‘glossary’). In addition, the incidence estimates showed that males have a 
1.4-times higher risk to develop schizophrenia than females and that migrants have 
a 4.6-times higher risk than native-born individuals. Living in an urban area also 
increases the risk of developing schizophrenia compared to living in mixed 
urban/rural sites [16]. Remarkably, there were no differences in prevalence 
estimates for different gender and urbanicity status [17]. The investigators observed                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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a 1.8-times higher prevalence in migrants compared to native-born individuals [17]. 
Developing nations had a lower prevalence of schizophrenia than developed 
nations, but this finding should be interpreted with caution, because a country’s 
status of development was only based on a single crude economic variable (per 
capita gross national product). More research into factors that differentially 
influence the course of illness in men and women around the world, especially 
from poorer countries, is therefore warranted [17]. Risk factors associated with the 
incidence of schizophrenia were not fully congruent with those for prevalence. 
More importantly, these results call for the unraveling of factors that cause a 
differential course of schizophrenia between risk groups. For example, the fact that 
high latitude is associated with a higher prevalence of schizophrenia [18] is 
intriguing. 
  The economic burden of schizophrenia in Europe [19] and in the U.S. [20] 
(direct medical, non-medical and indirect costs) associated with psychotic disorders 
are respectively estimated to 35 billion € and 32.5 billion $ per year, which is 
primarily due to the early onset in adulthood and the fact that 2/3 of affected 
individuals have persistent and/or fluctuating symptoms despite optimal treatment 
[13]. The cost per capita spent on care for patients with schizophrenia are estimated 
at 1.1 million $ in the U.S. and 2.3 million $ in Canada [21]. Cost-effectiveness 
studies are necessary to maintain mental health care accessible for large groups of 
patients. 
  Despite its lower prevalence compared to psychotic disorders, pervasive 
developmental disorders (PDD or ASD) are also characterized by a significant 
burden of disease and economic cost, because of their early onset, lost productivity 
and required adult care. PDDs have a prevalence rate of about 60 persons per 
10,000 [22] and the prevalence of autistic disorder and Asperger’s disorder are 
estimated at about 13/10,000 and 3/10,000 [22], respectively. Childhood 
disintegrative disorder (CDD) is rarer with a prevalence of about 0.2/10,000 [22]. 
Rett’s disorder seems to have a genetic origin, i.e. mutations of the methyl-CpG-
binding protein 2 (MECP2) gene cause the majority of the cases of Rett syndrome 
(80% of affected females [23]) via an influence on chromatin remodeling [24]. A 
more recent systematic review of PDD prevalence studies showed slightly lower 
prevalence estimates of 7.1/10,000 for autism and 20/10,000 for ASD [25]. The 60% 
of variation in prevalence estimates between studies was attributed to changing 
diagnostic criteria, age of the sample, urban or rural location of sampling and 
retrospective or prospective case-assessment [25]. The Center for Disease Control in 
the U.S. [26] found that 5.2-7.6 of 1,000 children aged 8 years have ASD. This CDC 
study group also noted a trend for non-Hispanic white children to have slightly 
higher prevalence estimates than non-Hispanic black children. It is unclear why GENERAL INTRODUCTION 
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prevalence estimates varied by race/ethnicity. Overall, their data also corroborate 
the notion that more males than females are affected (male-female ratio: 3.4-4.2 / 1) 
[26]. Interestingly, females (58%) were more prone to be cognitively impaired than 
males (42%) [26]. There is an apparent increase in incidence of PDD [26;27], but it 
is disputed whether this trend can be accounted for by other than methodological 
factors and increased awareness [22;27]. However, environmental risk factors 
cannot be ruled out. It is important for decision makers in health care to 
acknowledge this increasing trend. The CDC urges policy makers to improve early 
identification of ASD. In the future results from developmental epidemiology can 
contribute to the understanding of psychopathology as well as to the identification 
of environmental risk factors. Research into gene-environment correlations and 
interactions give hope that we can reduce the burden of child and adolescent 
mental illness by devising preventive and therapeutic measures [28]. 
  Up-to-date information about prevalence rates is important because the 
societal economic costs, including education and treatments for children with ASD, 
amount to approximately 35 billion $ per year [29]. Total expenditures per 10 000 
covered lives associated with ASD increased 142.1% over a 5-year period [30], 
because of a 20% increase in average health care expenditures from 2000 to 2004 
and rising prevalence rates. Ironically, ASD creates a smaller burden on health 
insurances than other childhood disorders such as mental retardation, because of 
the relatively lower prevalence. 
  The lifetime per capita incremental societal cost of autism is $3.2 million [31]. 
Earlier identification and more proactive treatment will increase the burden of 
autism on the health care system, so efforts should be made to ensure that access to 
care for this vulnerable population is not compromised. Overall the utilization and 
cost of health care are significantly higher for children with PDD compared with 
children without PDD, underscoring the need to find more appropriate treatment 
options including biomedical approaches that target the core PDD symptoms [32]. 
Biomarker research into the causes, traits and treatment options of children with 
PDD should be stimulated by governmental institutions at least for matters of cost-
effectiveness. 
3.  Diagnosis and classification 
The statement that “current (diagnostic) criteria reflect perceived similarity of 
symptoms and prognoses, which is potentially influenced not only by actual 
etiological similarity, but also by the cultural and inherent person-perception biases 
of those perceiving the sufferer, and the categorization demands of legal, medical 
and research systems” [33] is both frustrating as well as liberating, because it might 
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certain psychiatric diagnosis. It also stresses the need for other than categorical 
ways to characterize the different symptom dimensions of mental disorder, e.g. by 
endophenotypes [34]. Endophenotypes (see ‘glossary’) may provide an alternative 
approach to observation-based classification systems of heterogeneous disorders. An 
example of an endophenotype is the inability of schizophrenia patients and their 
unaffected family members to avoid looking at a visual cue that they have been told 
to ignore (antisaccade eye movement task). By definition only, endophenotypes 
differ from biological markers by the fact that the latter lack a (known) genetic 
basis. However, the question is to what extent and for what means the difference 
between endophenotypes and biological markers should be upheld. 
3.1. Schizophrenia 
Schizophrenia [35] is a disabling mental disorder that is caused by disruptions in 
thought processes. It is characterized by psychosis, apathy, social withdrawal, and 
cognitive impairment [13]. The positive symptoms of schizophrenia, including false 
beliefs (delusions) and perceptual experiences not shared by others (hallucinations), 
and bizarre behavior, are most prominent during a psychotic episode, whereas its 
negative symptoms, including blunted affect, apathy (loss of interest and 
motivation), anhedonia (inability to experience pleasure from normal activities) and 
alogia (diminished speech content), are more persistent [36]. These negative 
symptoms and deficits in cognition, including problems in attention and 
concentration, psychomotor speed, learning and memory, and executive functions 
are strongly associated with impaired psychosocial functioning [37;38], which is 
present in the prodromal phase of a psychosis [39]. The result is that most patients 
with schizophrenia have impaired functioning at work or school, in parenting, 
personal care, independent living, interpersonal relationships and leisure time even 
before their first psychotic episode [39]. Definitive diagnosis is usually assigned 
during hospital admission for a psychosis and a follow-up of at least 6 months is 
generally required [13]. 
  Assignment of schizophrenia is done using either the DSM-IV-TR [13] or ICD-
10 [14] criteria. These classification systems objectively define symptoms and 
characteristic impairments of schizophrenia in a similar way and the reliability of 
diagnosis between the two systems is high [40], even though a narrower definition 
of the disorder is used in the DSM-IV-TR. Temporal diagnostic consistency seems 
moderate (70%) with the highest variability immediately after onset of the disorder 
in outpatient and emergency settings [41]. However, this is far better than for most 
mental disorders, e.g. the temporal consistency of specific personality disorder is 
estimated at only 30% [41]. There is growing support for the view that these 
disorders should not be seen as discrete ‘disease entities’ but rather as dimensions of GENERAL INTRODUCTION 
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continuous variations [42]. While the onset of schizophrenia occurs in the 2nd or 3rd 
decade of life, subtle abnormalities of cognition, social interaction, motor function 
and physical morphology are frequently observed in individuals who later develop 
schizophrenia [43], which is suggestive of a developmental vulnerability. The 
question arises whether there is a gold standard for the assignment of a mental 
disorder and so whether current treatment recommendations and interventions are 
always appropriate. The holy grail of biological psychiatry, a lab test for mental 
disorders [44], remains difficult to attain, because it relies on widely used 
classification systems of which the short-term consistency seems poor to at most 
moderate [41]. Multidisciplinary biomarker research may hold the promise of 
improving classification and follow-up of therapeutic efficacy. 
3.2. Autism 
Autism and the other PDDs were first described in 1943 by Kanner [45]. Since 
then, its criteria and ways of assignment have changed considerably. The term ASD 
is often used to refer to autistic disorder, PDD-NOS and Asperger’s disorder, while 
the term PDD additionally comprises Rett’s disorder and CDD [13]. Pervasive 
developmental disorders are characterized by severe and pervasive qualitative 
impairment in several areas of development: reciprocal social interaction skills, 
communication skills, or the presence of a restricted, stereotyped, repetitive 
repertoire of behavior, interests and activities [13;14]. Children with PDD also 
suffer frequently from mental retardation (30-70%), seizures (25%), hyperactivity 
and other behavioral problems [46]. 
  A failure to develop joint attention, including a child’s ability to share 
interests, pleasurable experiences or requests by using gestures or verbal 
communication in combination with eye contact, is one of the earliest indicators of 
autism [47]. Impairments are usually evident from about 18 months of age [48]. 
Early identification of children with PDD is important because early intervention is 
more effective in children with autism than in children with other developmental 
disabilities [49] and it helps minimizing the impact on the family. Having a PDD 
leads to major difficulties in daily living, school and work performance and most 
families are confronted with extraordinary demands on their time, energy and 
financial resources. 
  In addition to general medical evaluation, children are evaluated for the 
presence/absence of a PDD (categorical diagnosis), different dimensions of PDD 
(e.g. intellectual functioning, language, behavior) and the individual’s most 
disruptive symptoms, which then become the focus of treatment [46]. Assignment 
of diagnosis usually involves a 2-level approach, with additional, more specific 
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Information from parents, teachers and pediatric clinicians working in primary care 
settings about the developmental profile in conjunction with standardized 
instruments is used to assign the clinical diagnosis, since DSM-IV TR criteria, 
which are considered the gold standard for ASD diagnosis, leave too much latitude 
for clinical judgment [48]. Autism-specific diagnostic tools are the Autism 
Diagnostic Interview (ADI-R, [50]) and the Autism Diagnostic Observation 
Schedule (ADOS, [51]). The ADI-R is a standardized investigator-based semi-
structured interview that is applicable from about 18 months into adulthood. It 
aims to provide data on the behavior of a child or young adult to differentiate 
between autism and other developmental disorders [50]. It is, however, not suitable 
for children with a mental age below 2 years [52]. The ADOS is a semi-structured 
observational instrument based on DSM-IV criteria, which is used to differentiate 
between autism, PDD-NOS and other developmental disorders by assessment of 
social interaction, communication, play and imaginative use of materials [51]. The 
ADOS is highly sensitive in classifying children with ASD in their 2nd and 3rd year 
of life but its specificity is poor [52]. Revision of ADOS algorithms is ongoing to 
improve the diagnostic validity [53]. 
  Biomarkers such as proteins, metabolites and cells of the immune system are 
being tested for their potential in early diagnosis of PDD. However, definitions of 
PDD and the ways of assigning them have changed throughout time making any 
correlation with biochemical markers difficult. Because PDD represents a spectrum 
of disorders with impairments in different areas that range from very mild sub 
clinical to severe clinical forms, it is inherent to PDD that their presence or absence 
in an individual can never be confirmed with 100% certainty. The question 
whether a diagnostic biomarker for PDD is feasible should not deal with the 
question whether symptom-based diagnosis is better than biomarker based 
diagnosis (i.e. is the biomarker the consequence of an established diagnostic 
system?), but merely with the fact whether a biomarker can identify those at risk of 
developing an impairment, which may be a part of a disorder named ‘PDD’, and 
whether these individuals are responsive to available interventions. 
4.  Etiology of schizophrenia and autism 
The etiology of many psychiatric disorders is unknown. To determine which 
biomarkers (for prevention, diagnosis and treatment) are necessary, it is first 
important to consider what is known about the etiology. For example, current 
biomarker research will be less fruitful in establishing the biological causes of 
increased risk of schizophrenia in migrants, because the causes are likely to be very 
heterogeneous. Biomarker research should rather aim to identify and characterize 
groups or individuals with (epi-) genomes, transcriptomes, proteomes or GENERAL INTRODUCTION 
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metabolomes that confer susceptibility to develop a mental disorder or that are 
responsive to available therapies. Integration of evolutionary medicine (see 
‘glossary’), epidemiology and life sciences is necessary to identify those individuals 
carrying susceptible ‘-omes’. For this we believe it is better to describe mental 
disorders as arbitrarily defined sets of symptoms that may have a hierarchical or 
dimensional (e.g. dimensions of positive, negative or general symptoms of 
schizophrenia) structure rather than as discrete categories [54]. We suggest that an 
extended model of Mills and Petronis [55] (Figure 1) best represents the 
components of modern complex disease and mental disorders, in particular. 
 
Figure 1. Model of disease/phenotype. 
Adapted from [55]. Biomarker research and systems 
biology focus at molecular changes that determine the 
phenotype in response to the interplay of 
environmental factors, DNA polymorphisms and 
epigenetic factors. The etiology of disease, including 
that of mental disorders, can be found either in our 
hardware, i.e. DNA and highly heritable epigenetic 
imprints, or our software, i.e. the interplay between 
‘-omes’ and environmental and epigenetic factors, or 
both. 
 
 
 
 
 
 
 
 
 
 
 
 
 
This section focuses on environmental risk factors, genetic susceptibility genes and 
epigenetic regulation in mental disorders to find the many, presumably 
overlapping, causes of mental disorders. Table 1 shows a summary of the different 
risk factors putatively involved in the etiology of schizophrenia, and Table 2 
summarizes the risk factors implicated in the etiology of PDD. 
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Table 1. Risk factors for schizophrenia. 
 
Psychological, Social and Cultural factors  References 
  Migration: migrants vs. native born (RR 2.9), 1st generation migrants (RR 2.7), 
2nd generation (RR 4.5), dark-skinned migrants (RR 4.8) 
[17;57] 
  Urbanicity: urban birth and urban childhood  [16;64] 
  Socioeconomic stress: socioeconomic deprivation at birth, social defeat, 
discrimination, acculturative stress 
[35;64;74] 
  Childhood trauma: stressful events alter HPA axis and CRF system  [69;71] 
Early life events   
  Advanced paternal age: >35 years  [79] 
  Prenatal and perinatal risk factors (RR ±2.0): fetal growth retardation, fetal 
perinatal hypoxia, perinatal infections, perinatal stress, Rhesus incompatibility, 
and pre-pregnancy high and late-pregnancy low maternal BMI 
[90;93;97;98] 
  Season of birth  [84;85] 
  Folate deficiency: periconception folate status, high 3rd trimester maternal 
homocysteine (Hcy) levels 
[63;101;102] 
 Vitamin  D  deficiency  [61;62] 
Genetics (RR 1.5-2.0)   
  NRG1, DTNBP1, DAOA (G72), Tbx1, COMT, PRODH2, NPAS3, GRK4, DISC1,   [142-144] 
Epigenetics   
 RELN,  GAD67, MB-COMT  [153;155] 
 
4.1.  Psychological, Social and Cultural Risk Factors 
4.1.1. Schizophrenia 
Several factors such as migration, urbanicity and environmental stress have been 
associated with increased risk for schizophrenia [35] and other mental disorders. 
These risk factors seem to be strongly intertwined, because the many suggested 
causatives show considerable overlap and mutual modes of action. Unification of 
risk factors for different mental disorders may prove valuable in establishing 
common causes of closely-related mental disorders. 
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Table 2. Risk factors for pervasive developmental disorders. 
 
Psychological, Social and Cultural factors  References 
  Migration: being born to mothers born outside Europe (adj. RR 1.4)  [76] 
  Urbanicity: high degree of urbanization of birthplace (adj. RR >1.6)  [76] 
Early life events   
  Advanced paternal and maternal age  [77] 
  Prenatal and perinatal complications (RR 1.5-2.5): low birth weight, short 
duration of gestation, obstetric complications associated with intrapartum 
hypoxia, Rhesus incompatibility 
[77;94] 
  Prenatal and perinatal exposure to toxic substances: environmental pollutants, 
alcohol, tobacco, substances of abuse, medication 
[125;126;128] 
Genetics   
  TSC1, TSC2, NF1, MECP2, SHANK3, SLC6A4, NBEA, PRKCB-I and -II, EN2, 
MET, de novo CNV 
[146-149; 
167;168] 
Epigenetics   
  BDNF, DLX5, UBE3A, GABR, RELN, FMR1  [146;152;153] 
 
Migration does not seem to be generally associated with an increased risk for mood 
disorders [56] but this is not the case for schizophrenia. There is an increased risk of 
schizophrenia in migrants, notably 2nd generation (relative risk; RR 4.5) and dark-
skinned migrants (RR 4.8), which is attributed to psychosocial factors including 
discrimination, social defeat and acculturative stress (i.e. stress caused by the 
psychological and social counter-part of cultural diffusion and admixture) as well as 
to biological factors such as folate and vitamin D deficiency [57]. The idea that 
experiences of psychosocial adversity by, possibly also genetically susceptible, 
individuals belonging to an ethnic minority increase their risk of developing 
schizophrenia fits findings of increased risk in white migrants [58] and non-black 
minority groups [59]. Furthermore, the high prevalence of PTSD (10%), major 
depression (5%) and general anxiety (4%) in refugees [60] emphasize the role of 
psychosocial and cultural factors. However, the vitamin D hypothesis of 
schizophrenia [61] is also attractive, because it explains many epidemiological issues 
of schizophrenia [62], for example, why 1st generation dark-skinned migrants and 
their offspring (2nd generation) are at increased risk. Next to vitamin D, qualitative 
and quantitative changes in the diet of carbon-1 (C1) substrates (e.g. folic acid) in 
combination with polymorphisms in genes related to C1-metabolism (e.g. the 
methylene tetrahydrofolate reductase (MTHFR) gene) are suspect of aberrant 
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susceptibility for mental disorders [63]. Overall, one can conclude that although 
factors of psychosocial and cultural nature are important in the etiology of mental 
disorders, it seems that these risk factors are less easy targets for intervention and 
prevention than factors of dietary nature. E.g. nutritional fortification is more easily 
instituted than accomplishing a change in behavior in those that discriminate. 
  Urban birth or urban childhood compared to rural locations is suggested to be 
associated with an increased risk for schizophrenia. It explains around 30% of all 
schizophrenia incidence, thus being a major environmental risk factor [64]. 
Exposures to infectious agents, low prenatal vitamin D and folate levels [62], toxins 
associated with pollution and stress (social isolation) have been mentioned, 
although the real underlying cause remains to be elucidated [65]. Cognitive social 
capital, aspects of the degree of mutual trust, bonding and safety in neighborhoods 
are suggested to be important during the rearing of children and each of them 
modulates the risk of schizophrenia [64]. Selective migration to urban areas of 
individuals with proneness to schizophrenia has been explained by various factors 
related to poverty, the availability of services and easier access to cheap 
accommodation [17]. Remarkably, urbanicity as risk factor seems specific for the 
psychotic symptoms of schizophrenia and bipolar disorder, because affective illness 
of bipolar disorder was not shown to be associated with urbanicity [66;67]. While 
Williams et al. [25] found an increased prevalence rate of PDD in urban areas 
compared to rural/mixed areas; they attributed this finding to different diagnostic 
practices between locations. In addition, major depression was more prevalent in 
urban than rural areas if controlled for confounding factors like age, immigration 
status, race, working status and marital status [68]. Taken together, urbanicity is 
associated with an increased risk for at least some mental disorders. The 
biochemical background against which urbanicity acts in conjunction with other 
genetic and environmental risk factors will be difficult to draw. 
  Traumatic events, independent of migration and urbanicity, have been 
implicated in the etiology of schizophrenia by some [69], but not by others [70]. 
The relation between childhood trauma and depression, anxiety and panic 
disorders, PTSD, drug abuse and suicide attempts is much less debated [71]. A 
neurobiological explanation is sought in persistent, long-term effects of stressful 
events during a critical period of development on respectively the activity and 
sensitivity of the corticotropin-releasing factor (CRF) system as well as the 
hypothalamic-pituitary-adrenal (HPA) axis [71]. These systems are important in the 
mediation of mood and anxiety symptoms. For example, the CRF system shows 
increased activity in patients with depressive symptoms [72], while depressed 
abused children compared to controls or to depressed non-abused children showed 
increased corticotropin (ACTH) excretion post CRF administration [73]. Altogether, GENERAL INTRODUCTION 
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childhood trauma may be one of the many environmental factors lowering the 
threshold to develop a mental disorder in those individuals that are (epi-) 
genetically more susceptible. 
4.1.2.  Pervasive Developmental Disorders 
Risk factors of psychosocial and cultural nature for PDD are less easily identified, 
because the etiological role of these factors may prove less distinct. Kanner 
emphasized in 1943 the unusually high educational background and professional 
achievements of parents [45] of children with autism but the association between 
autism and socioeconomic class could not be confirmed [22]. In contrast to PDD, 
socioeconomic deprivation at birth at the level of the individual and community is 
associated with increased risk of schizophrenia [74] and another recent study 
implied that socioeconomic status partially explains the observed higher risk of 
schizophrenia in African Americans compared to white Americans [75]. A recent 
study in Denmark [76], investigating familial risk factors for autism, identified 
having an affected sibling (adjusted RR 22.3), maternal history of psychiatric 
disorder (adj. RR 2.0), a high degree of urbanization of birthplace (adj. RR > 1.6) 
and being born to mothers born outside Europe (adj. RR 1.4). The latter factor, i.e. 
maternal migration, is explained by missed immunizations in the new country of 
residence and/or selective migration of people with a genetic vulnerability to 
autism [77]. We believe that similar factors underlying the association between 
migration and urbanicity and schizophrenia, also apply to PDD, because the 
etiology of several psychiatric disorders might not be so different. 
 
Summarizing, the available literature supports an important role of psychosocial 
and cultural risk factors in the development of mental disorders. It seems that many 
of the psychosocial and/or environmental factors, such as urban location, can be 
termed “mental stress factors”, which challenge the human brain/organism more 
than it was meant to deal with. Susceptible individuals probably are unable to cope, 
or cope differently, with this stress and are experienced by others as ‘crazy’. 
Obviously, identification of key risk factors is important, because it allows us to 
develop selective or universal preventive measures and targeted interventions. 
However, the complexity and interaction of the underlying causes may thwart a 
clear definition of these targets. 
4.2. Early-life  events 
There is reasonable evidence to believe that the origin of many disorders, including 
that of mental disorders, can be found in utero. In analogy to the Barker hypothesis 
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cardiovascular disease in later life, perinatal factors disrupting brain development in 
utero may confer increased vulnerability to develop a mental disorder. Suboptimal 
neurodevelopment may only be partially reparable during post-natal life. In this 
section we will discuss several early-life events that may be deleterious for 
cognitive and mental functioning in later life. 
  Advanced parental age has been implicated in many mental disorders. In 
autism, advanced paternal and maternal age, were consistently shown to be 
associated with an increased risk of having a child with ASD [77] and similar results 
were obtained from a meta-analysis of the effects of paternal age for schizophrenia 
risk [79]. At the time of conception, the fertilized egg has undergone a maximum of 
23 replications, whereas for sperm cells this number varies non-linearly with age 
from 35 to 840 at the age of 15 and 50 years, respectively [80], with each replication 
carrying a chance of mutation in the germ-line. Interestingly, paternal and also 
maternal age independently have an effect on offspring IQ-scores, with increasing 
maternal age affecting fetal neurodevelopment through age-related alterations in 
the in-utero environment [81]. Paternal de novo mutations and/or altered genetic 
imprinting [82] and maternal nucleotide repeat instability [83] have been proposed 
as mechanisms. 
  The season of birth effect on mental disorders has been most consistently 
shown for schizophrenia [84;85]. Winter/early spring birth in the Northern 
hemisphere and births 3-4 months after rain season in northern Brazil [86] are 
associated with an increased risk of schizophrenia. However, winter/spring births 
are also associated with superior outcomes with respect to physical and cognitive 
development in the general population, suggesting an impact of season of birth on 
developmental trajectories [87]. Remarkably, the season of birth effect was not 
observed in neurodevelopmental disorders such as ASD, hyperkinetic disorder, 
Tourette syndrome and obsessive-compulsive disorder (OCD), although in this 
study such an effect could not be ruled out [88]. Significant seasonal effects on 
dietary intake of micro- and macronutrients, including fat, carbohydrate, vitamin C 
and D, and B-vitamins during pregnancy has been proposed as explanation for the 
season of birth effect on cardiovascular diseases and mental disorders [89]. In 
addition, McGrath et al. [87] suggested differential exposure to the complex of 
interacting downstream consequences of biometeorological variables (temperature, 
rainfall, UV-radiation etc.), including those that have an impact on health status, 
energy expenditure, disease exposure, vitamin D status etc. at critical periods of 
development  in utero, to be responsible for the counterintuitive result of the 
association of winter/spring births with both better physical and cognitive 
outcomes in the general population and with an increased risk for schizophrenia. GENERAL INTRODUCTION 
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  Prenatal and perinatal complications are frequently associated with increased 
risk for mental disorders, including autism (RR 1.5-2.5) [77], schizophrenia (RR 
±2.0) [90] and eating disorders [91]. For bipolar disorder, however, no robust 
evidence for such an association is present [92]. Low birth weight (LBW), short 
duration of gestation and obstetric complications associated with intrapartum 
hypoxia were most consistently found to increase the risk of autism [77]. Fetal 
growth retardation, fetal perinatal hypoxia and other prenatal risk factors such as 
infections, medication, stress, nutritional deficiency and Rhesus incompatibility, 
were found to increase the risk of schizophrenia [93], while growth restriction and 
newborn hypoxia were found to be risk factors for autism [77]. Smoking, the use of 
contraceptives at time of conception and Rhesus incompatibility during pregnancy 
were also found to be associated with an increased risk for autism [94]. There seems 
to be a consistent association with adverse events during pregnancy, at delivery and 
during the neonatal phase with the development of at least some mental disorders 
in early or later life. Perhaps these adverse events are early expressions of the 
presence of a risk factor, like a susceptible (epi-)genotype that predisposes to the 
development of obstetrical complications in the mother and mental disorders in the 
offspring. 
  Likely, low weight at birth (LBW) (<2500 g) and fetal growth restriction can 
be considered to be indicators of a heterogeneous set of adverse intrauterine effects. 
However, both LBW as well as fetal growth restriction are associated with preterm 
birth. Black race, maternal thinness (BMI<20), a history of a prior preterm birth, a 
short cervical length and a positive test result for cervical or vaginal fluid fetal 
fibronectin were identified as strong predictors of preterm birth in the U.S. [95]. 
Also, intrauterine bacterial infections are thought to be responsible for 85% of 
spontaneous preterm births [96], especially malaria and HIV in the developing 
countries. Interestingly, high maternal BMI seems to protect against two risk 
factors for growth restriction which are maternal smoking, and maternal stress, but 
interventions directed at increasing birth weight seemed only effective in thin 
women [96]. Nevertheless, both late-pregnancy low [97] and pre-pregnancy high 
maternal BMI [98] have been linked to increased risk for schizophrenia in the 
offspring. Low maternal BMI may mediate its effects by similar mechanisms that 
are implicated in a two-fold higher risk of having offspring with schizophrenia in 
women that experience starvation during early pregnancy [99;100]. Low 
periconception folate status [101] and, conceivably associated, high 3rd trimester 
maternal homocysteine (Hcy) levels [102] have been implicated as key nutritional 
mediators of the adverse effects of famine during early pregnancy. The many 
possible effects of folate and homocysteine on schizophrenia are discussed in detail 
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subtle damage to placental vasculature thus compromising oxygen delivery to the 
fetus [102]. It is likely that besides many factors that adversely affect the fetus’ 
growth, psychosocial factors are important for risk-increasing obstetric events 
themselves. The quest for a single risk factor that accounts for the effects of LBW 
and growth restriction on the development of mental disorders should thus be 
discouraged. 
  Prolonged or acute oxygen deprivation to the fetus may be a major risk factor 
for neuropsychological and neuropsychiatric disturbances. Cerebral hypoxia-
ischemia harms fetal brain development considerably, but timing and severity 
determine the outcome in terms of the severity of the damage and the regions of 
the brain affected [103].  Energy depletion and subsequent generation of reactive-
oxygen species are primarily responsible for hypoxia-associated neuronal cell death 
[103]. The origins of fetal hypoxia are heterogeneous and may include, in addition 
to overt fetal distress, maternal hypertension (e.g. caused by pre-eclampsia), 
gestational diabetes mellitus (DM), hemolytic diseases (e.g. Rhesus incompatibility), 
cord encircling of the neck and prolonged labor [77;104]. The suggestion that 
genetic vulnerability for schizophrenia [105], autism and other mental disorders 
increases obstetric sub optimality, is intriguing and warrants further research 
[77;106]. This relation between genotype and obstetrics would mean that obstetric 
events are early indicators of susceptibility genes present in individuals at risk of 
developing a mental disorder. 
  Several reports have suggested that prenatal exposure to bacterial and viral 
infections contributes to the etiology of schizophrenia (reviewed in [107]), autism 
[108;109] and mental retardation [110]. Prenatal infections with polio, rubella, 
influenza and toxoplasmosis have been associated with schizophrenia. In contrast to 
the 5-10% increase in risk of schizophrenia through second trimester exposure to 
the poliovirus [111], prenatal exposure to rubella, a well-known central nervous 
system teratogen, is associated with a 10-20 fold increase in risk of schizophrenia 
[112] and with an increased risk of autism [108]. First trimester exposure to 
influenza confers a 7-fold risk, while early to mid gestation exposure was associated 
with a 3-fold risk of developing schizophrenia [113]. A 2.5-fold increase of risk for 
schizophrenia was noted to be associated with elevated maternal IgG antibodies 
against Toxoplasma gondii, a ubiquitous intracellular parasite [114]. Interestingly, a 
recent report by Cetinkaya et al. [115] found that two third of patients with 
schizophrenia had elevated serum levels of anti Toxoplasma gondii antibodies 
compared to 20-25% of depressed patients and controls. Second trimester increases 
of maternal cytokine levels, including interleukin 8 (IL-8), are also significantly 
associated with pregnancies giving rise to schizophrenia cases [116]. It is important 
to note that the results from studies of prenatal infection and schizophrenia might GENERAL INTRODUCTION 
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have public health implications, because there are many possible preventive 
strategies for bacterial and viral infections. 
  For autism, exposure of the fetus to the cytomegalovirus (CMV) in the 3rd 
trimester has been implicated in the etiology of some children with autistic-like 
behavior [109]. Other congenital infections have been implicated in autism, but 
evidence is less convincing for measles, mumps, varicella and intrauterine human 
parvovirus [117]. Congenital rubella [118] and herpes simplex [119] seem more 
consistently associated with autism, mental retardation and behavioral pathology. 
Prenatal infection with CMV [110] or Toxoplasma gondii [120] is also suggested to 
increase the risk of mental retardation. Altogether, prenatal bacterial or viral 
infections seem to disrupt normal neurodevelopment with neuropsychiatric 
consequences in later life, suggesting that the downstream consequence (e.g. 
cytokine release) of the inflammatory process rather than the inflammatory agent 
itself (e.g. lipopolysaccharides [121]) is responsible for abnormal 
neurodevelopment. 
  A possible explanation for the mechanism by which maternal infection affects 
embryogenesis is through hypoxia, hyperthermia, malnutrition, and the effect of 
elevated levels of circulating cytokines on gene expression in the brain. Fatemi et 
al. [122] showed altered regulation of a subset of genes in brains of mouse offspring 
exposed to prenatal infection. This potentially leads to permanent changes in brain 
structure and function. Cytokines, probably of maternal, placental and fetal origin, 
might suppress expression of genes resulting in subsequent reduced protein 
availability [123]. Reelin [124], for example, is an important glycoprotein involved 
in guidance of neuronal and glial cells during embryogenesis, and reduced 
expression of the reelin-gene through mutation or promoter hypermethylation has 
been shown to result in cognitive deficits that are similar to those that are often 
observed in autism and schizophrenia. It is hypothesized that disrupted 
neurodevelopment, rather than neurodegeneration, is associated with prenatal 
infection and central to the etiopathogenesis and disease process of schizophrenia 
and autism [125-127]. 
  Environmental exposure to toxic substances in fetal life such as alcohol, 
substances of abuse, heavy-metals (lead, methylmercury, arsenic), dry-cleaning 
agents (tetrachloroethylene), toluene, PCBs, certain classes of medication, and 
many other industrial chemicals are implicated in the etiology of, mainly, 
neurodevelopmental disorders [128]. Exposure of the embryo to ethanol is 
associated with increased risk of the Fetal Alcohol Syndrome (FAS) and its less 
severe variants known as Fetal Alcohol Effects (FAE). Although congenital 
anomalies that are usually observed in children with FAS are often not seen in 
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common factor. Therefore, the complex cognitive, behavioral, and physical 
symptomatology in children with FAS [129] may frequently be misdiagnosed as 
PDD, for psychological and political reasons that will not be discussed in this 
review. Prenatal cocaine exposure (PCE) has, however, not been linked with 
congenital anomalies or medical complications, but it has been found to be an 
independent risk factor for behavioral problems at school age [130]. Remarkable, 
this study [130] showed that the combined effects of prenatal and postnatal 
exposure to tobacco and alcohol on childhood behavior were found to be greater 
than that of PCE. Use of thalidomide, misoprostol and valproic acid during the 1st 
trimester, notably during the first 8 weeks of embryogenesis, is associated with 
autism [126;131], while the use of analgesics during the 2nd trimester [132] and of 
diuretics for treatment of maternal hypertension in the 3rd trimester [133] are 
thought to play a role in the etiology schizophrenia. The neurodevelopmental and 
neurotoxic effects of some industrial chemicals are diverse and a universal mode of 
action will be hard to find. Disturbance of thyroid function and subsequent harm to 
the embryo and fetus has been proposed [134]. The different effects, ranging from 
minor anomalies to malformations, resulting from short-term (1-3 weeks) exposure 
to the aforementioned exogenous substances during the first trimester, suggest that 
each of these agents strikes during a critical phase (“vulnerability window”) during 
the embryogenic period, with physical and neuropsychiatric consequences at birth 
and thereafter. Unfortunately, such insults are often permanent, because there is 
little potential for later repair. It is imaginable that presence of a susceptible 
genotype, i.e. a maternal and/or fetal genotype less able to detoxify, can moderate 
the effects of environmental toxicity. Studies (in animals) into the teratogenic 
effects of toxic agents may thus benefit from complementary biomarker-related 
research. 
  Other life events that are implicated in the etiology of mental disorders are 
brain trauma and substance abuse. For autism, e.g., a case-series study of patients 
with PDD in Tanzania with severe malaria and subsequent recovery during the first 
years of life showed an immediate onset of autistic-like behavior in some patients, 
which had entirely normal development before their malaria-infection [135]. 
Tourette syndrome and tics have also been associated with insults to the basal 
ganglia, such as head trauma, encephalitis and other causes [136]. While substance 
abuse, e.g. amphetamine (dopamine D2-receptor), ketamine (N-methyl-D-aspartic 
acid [NMDA] receptor), phencyclidine (PCP), LSD, heroin, cocaine, can merge into 
psychosis-like symptoms, the diagnosis of schizophrenia is generally not established 
in this group of patients. However, substance abusers tend to be overrepresented 
among patients with mental disorders, advancing a common vulnerability [137]. GENERAL INTRODUCTION 
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It is also rewarding to investigate potential links between somatic diseases and 
psychiatric symptoms to obtain better insight into cause-symptom relations. For 
example, adults with celiac disease have a high prevalence of depressive symptoms 
[138]. It seems that these patients are at increased risk for non-affective psychosis 
[139] and are more likely to have ADHD-like symptomatology [140]. Primary 
hyperparathyroidism (PHPT), characterized by thirst, fractures, osteoporosis, 
urolithiasis, is also associated with psychosomatic symptoms that are usually 
encountered in obsessive-compulsive disorders, depression, anxiety, and paranoia 
[141]. The occurrence of psychiatric symptoms in somatic disease, and parallels 
between mental disorders and somatic disorders, may provide new insights into 
disease-mechanisms and yield valuable ideas regarding new therapies. 
  In summary, early life events ranging from those that affect the quality of 
germ-line cells to those that disrupt neurological and cognitive function later in 
life, and all adverse events in between, have been implicated in the etiology of 
mental disorders. On one hand this large number of identified risk factors 
emphasizes the speed of science, but the fact that only few risk factors have been 
linked to a proven mechanism shows that there is still a large gap in our knowledge 
on the other hand. Integrative approaches, studies using extensively-characterized 
population cohorts, longitudinally acquired bio-repositories and life-long follow-
up, performed on different continents are only one part of the answer. 
Intervention/prevention-based medicine might be the other part. Of course, this 
research can be supported and complemented by biomarker research, elucidating 
disease-mechanisms, prognostic and diagnostic phenomena and supporting tailored 
interventions. 
4.3.  Genetics and epigenetics of mental disorders 
There has been a great focus on the genetic and, recently, epigenetic basis of mental 
disorders. Evidence for a genetic contribution in the etiology of schizophrenia [142-
144], bipolar disorder and major depression [143;145], and autism [146-149] has 
been comprehensively reviewed. The concept of a strongly genetic contribution in 
the etiology of mental disorders is fuelled by a body of studies in twins and affected 
families. A major problem with genetic research is the assumption that mental 
disorders have a predominantly genetic basis, which underestimates the 
contribution of environmental factors. The assumption appears incorrect because of 
large effect-sizes of some environmental factors, e.g. 10-20 fold higher risk of 
schizophrenia associated with prenatal rubella exposure. In addition, the value of 
conclusions from twin-studies is questioned because these studies of MZ or DZ twin 
reared-together or reared-apart, may not measure anything more than 
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twins increasingly differ in their epigenotype, resulting in different phenotypes and 
different susceptibility for diseases like mental disorders [151]. The role of 
epigenetic mechanisms in psychiatric disorders is also increasingly recognized 
[146;152-155]. 
 
To understand the mechanisms by which predisposing genes interact with the 
environment to result in the precipitation of a mental disorder, we will review 
literature regarding the role of genetics and epigenetics in the etiology of mental 
disorders. This section, however, will not exhaustively discuss all chromosomes, 
loci, alleles, and genes etc. that have ever been implied in schizophrenia, bipolar 
disorder, major depression and autism. Instead, some current achievements and 
failures as well as difficulties and new approaches in genetic analysis of psychiatric 
disorders will be reviewed. In addition, their value in diagnostics and treatment 
will be discussed. 
4.3.1.  Genetics of mental disorders 
It seems a paradox that susceptibility alleles that confer an increased risk for 
developing a mental disorder are still among us, notably when mental disorders are 
considered as common, harmful and heritable. Some believe this to be the result of 
a polygenic mutation-selection balance [156], i.e. that our complex genotype, which 
is required for our underlying human behavioral phenotype is inevitably prone to 
suffer to some extent from mutations. This idea is supported by the notion that 
mental disorders do not inherit by Mendel’s law. The majority of the scientific 
community is in favor of a multi-loci (polygenic) mode of inheritance of mental 
disorders. Other explanations for the presence of susceptibility genes throughout 
the millions of years of evolution are based on ancestral neutrality (mismatch 
between ancestral and current environments) and on balance-selection (adaptive 
benefits). The different models are commented by Keller and Miller [156], and it 
might be important to view the genetic etiology of schizophrenia and autism and 
other mental disorders against this background. 
  Two approaches are being adopted in the search for mental disorder genes: 
linkage studies and association studies. Linkage studies aim to select candidate gene 
loci by genome-wide or local gene mapping in families and by defining the 
tendency for alleles closely spaced on the same chromosome and coinciding with 
the phenotype of interest to be transmitted from one generation to another as an 
intact unit through meiosis. The next step is generally to examine candidate genes 
by means of association studies. Most molecular genetic studies on mental disorders 
follow the common disease common variant (CDCV) model, which implies the 
study of relatively common polymorphism that confer susceptibility to common GENERAL INTRODUCTION 
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diseases like heart disease. However, by doing so rare causative variants may be 
overlooked. 
  Unfortunately, unclear diagnostic boundaries, multiloci-type inheritance, 
epistasis (gene-gene interactions), clinical and etiologic heterogeneity and 
confounding gene-environment and environment-gene interactions have impeded 
linkage and association studies considerably leading to many inconclusive and non-
replicable findings [142]. More stringent criteria for publication of results from 
association studies are under way [157] to avoid future statements like “to date, no 
causative gene or genetic risk factor has been identified for bipolar disorder or 
depression” [145] and “no gene has been proven to not be an autism disease gene” 
[158]. 
 
While the genetic causes of mental disorders have not been uncovered yet, parallels 
should also be sought in the ways the etiology and pathogenesis of 
neurodegenerative disorders, such as Alzheimer’s disease, Parkinson’s disease and 
Huntington’s disease are investigated. It is important (i) to understand rare familial 
variants, (ii) to identify (interacting) causative genes to define pathogenic pathways 
and therapeutic targets, (iii) to investigate commonalities among different disorders, 
(iv) to identify mutations that increase the risk of developing a disease but that 
themselves are not causally related, and (v) to consider the neurotoxicity of RNAs 
and proteins (e.g. in Huntington’s disease [159]) deriving from genetic changes such 
as point or frameshift mutations or deletions [144]. For schizophrenia, which is 
increasingly viewed as a subtle disorder of neurodevelopment, clues to the etiology 
and pathogenesis may be provided by severe disorders of cortical development like 
lissencephalies [144]. For example, an established cause of lissencephaly is mutation 
of the RELN-gene, which codes for reelin. Reelin has a key role in cortical neuronal 
migration [124] and reduced expression of RELN in post-mortem brains of 
individuals with schizophrenia and bipolar disorder has been reported [160]. 
Moreover, neuropathological investigations of schizophrenia point more to a 
neurodevelopmental abnormality than a neurodegenerative disease [161]. Most 
genes that have been implicated in mental disorders have a key role in 
neurodevelopment and/or neurotransmission. 
4.3.1.1.  Genetics of schizophrenia [142-144] 
The 10-times higher LMR in relatives of patients with schizophrenia [162], the 
higher concordance rates in monozygotic (MZ, ~50%) than dizygotic (DZ, ~17%) 
twins [163] have led to an estimate of the heritability of tendency to develop 
schizophrenia of about 80%. Gene-environment interactions certainly contribute to 
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mediated but not determined [142]. Interestingly, the relative risks for 
schizophrenia at the loci identified so far are rather low (range 1.5-2.0) indicating 
modest effect sizes [144]. 
  Regions 1q, 5q, 6p, 6q, 8p, 10p, 13q, 15q and 22q have been confirmed in more 
than one linkage study, and association replication has been observed for 
neuregulin 1 (NRG1) and dystrobrevin binding protein I (dysbindin; DTNBP1). 
Other genes that have, though not consistently, been associated with schizophrenia 
are D-amino acid oxidase [DAO] activator (DAOA; formerly called G72) and genes 
located on chromosome 22, catechol-O-methyl transferase (COMT) and proline 
dehydrogenase 2 (PRODH2). 
  Neuregulin 1 was identified by fine mapping of chromosome 8p and is believed 
to code for multiple protein products that are implicated in neuronal differentiation 
and migration as well as in expression and activation of neurotransmitter receptors 
like the NMDA-receptor. Polymorphisms leading to alternative splice variants of 
NRG1 may lead to proteins with enhanced or reduced function. Dysbindin was 
shown to be associated with schizophrenia through chromosome 6p linkage [142]. 
Its pre- and postsynaptic presence, its suggested role in glutaminergic 
neurotransmission, and its reduced expression at both RNA and protein levels in 
certain brain regions of schizophrenia patients have fostered the search for 
dysbindin polymorphisms. Dysbindin seems to interact with serine-threonine 
kinase 1 (AKT1), a protein that is involved in growth-factor induced neuronal 
survival. The AKT1 gene has recently been shown to be associated with 
schizophrenia [164]. D-amino acid oxidase is activated by DAOA which oxidizes D-
serine, a coagonist at the “glycine site” of the NMDA receptor. The potential 
therapeutic efficacy of D-serine and reports of reduced blood and cerebrospinal 
fluid (CSF) D-serine levels in individuals with schizophrenia warrant further 
investigation of the DAOA-system. Most replication studies have confirmed a role 
of DAOA in schizophrenia. 
  Twenty to 30% of patients with the chromosomal microdeletion syndrome 
(velo-cardio-facial syndrome; a deletion in chromosome 22q11 that encompasses 
appr. 27 genes) have schizophrenia or another major psychiatric disorder with 
psychosis-like symptoms. Among the deleted genes is T-box 1 (Tbx1; transcription 
factor involved in regulation of otocyst development), which is expressed in the 
microvasculature of the brain. The COMT gene is also coded on chromosome 22q11 
and has received more attention, because the enzyme participates in the clearance 
of catecholamines, including dopamine, from the synapses. Replacement of 
methionine by valine at codon 108 (soluble form; S-COMT) or codon 158 
(membrane-bound form; MB-COMT) has been suggested to decrease COMT-
activity, thus resulting in prolonged elevated levels of dopamine in critical central GENERAL INTRODUCTION 
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synaptic clefts. However, reduced COMT-activity appears to be more strongly 
associated with cognitive function than with schizophrenia. Altered PRODH2 
activity influencing the availability of glutamate, has also been linked to deletions 
in the 22q11 chromosome region. The only two reports considering chromosomal 
translocations in individuals with schizophrenia deal with neuronal PAS domain 
protein 3 (NPAS3) and G-protein receptor kinase 4 (GRK4), which code for a 
transcriptional regulatory factor and glutamate kainate receptor, respectively. 
  DISC1 (disrupted in schizophrenia 1), is emerging as the best supported 
candidate gene for schizophrenia. It has been identified via a balanced (1:11) 
chromosomal translocation, segregating with schizophrenia, bipolar disorder and 
other mental illnesses. Affected individuals have either schizophrenia or an 
affective disorder. Also, endophenotypical reduced P300 amplitude and latency 
linked to schizophrenia, was associated with translocation in both unaffected as 
well as affected carriers. On a structural/functional level, DISC1 haplotypes are 
associated with alterations in hippocampal function, fMRI signals, working memory 
and cognition. Although it is presently unclear whether haploinsufficiency or 
dominant-negative interactions mediate DISC1 loss-of-function, elucidation of 
normal DISC1 function is critical for understanding DISC1-related diseases. DISC1 
is distributed throughout neurons, nuclei, mitochondria and neurites and its 
function is linked to neural development via neuronal migration, neurite outgrowth 
and neuronal maturation, and to neural functioning via modulation of cytoskeleton 
function, synaptic transmission and plasticity. DISC1 protein interacts with many 
other proteins to form complexes that are vital for proper neurodevelopment and 
neural functioning. 
  The interactivity of DISC1 is suggestive of the idea that multiple subtle 
dysfunctional genes and/or gene-products can lead to endophenotypes associated 
with several mental disorders such as schizophrenia, bipolar disorder and 
depression. Also, the interactivity-requirement supports the notion that the 
functionality of a protein complex can be adversely affected if a single protein 
constituent is reduced in quality or quantity. For example, DISC1 interacts with 
phosphodiesterase 4B to regulate neuronal c A M P  c e l l  s i g n a l i n g .  T h u s ,  i f  s u c h  a  
protein-complex is involved in critical processes of brain development, brain 
functioning and behavior, it can have differential down-stream consequences. 
Other processes, of which the functionality is subject to genetic variation, may 
increase or repair the damage, thus adding to the importance of epistasis in mental 
disorders. Taken together, genes associated with schizophrenia probably have 
different etiologic and pathogenic effects, each affecting particular neurobiological 
processes to different extents, in turn causing specific phenotypes.                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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4.3.1.2.  Genetics of bipolar disorder and unipolar depression [143;145] 
Familial aggregation is higher for bipolar disorder than for unipolar depression as 
shown by higher rates of sibling recurrence risk (5-10% vs. 2.5-3.5%) and MZ-twin 
concordance (45-70% vs. 40-50%). The heritability estimate for bipolar disorder 
(80-90%) is higher than for unipolar depression (33-42%), supporting a stronger 
environmental contribution in unipolar depression [143]. The genetic contribution 
to the etiology of bipolar disorder resembles that of schizophrenia, suggesting a 
common genetic background. Results from family and twin linkage studies show 
convergent or overlapping clinical features and susceptibility genes (DAOA, DISC1, 
NRG1 and COMT) for schizophrenia, schizoaffective disorder and bipolar disorder 
[165]. 
  Linkage studies in bipolar disorder resulted in suspected loci at 2p, 4p, 4q, 6q, 
8q, 9p, 10q, 12q, 11p, 13q, 14q, 16p, 16q, 18q, 21q, 22q and Xq [145]. Unfortunately, 
results from these linkage studies and subsequent association studies of specific gene 
loci have not provided unambiguously identified susceptibility genes for bipolar 
disorder or depression. Functional genetic studies in bipolar disorder have focused 
on neurotransmission cascades that are also implicated in schizophrenia: the 
monoamine pathway (dopamine, serotonin [5-HT] and noradrenaline), intracellular 
signaling systems, the GABA (γ-aminobutyric acid)ergic system, proto-cadherin 
and genes encoding for other targets of mood-stabilizers such as lithium. Although 
effect-sizes were modest (RR < 2), functional polymorphisms for monoamine-
oxidase-A (MAO-A), COMT and the 5-HT transporter (5-HTT) genes have been 
implicated. However, these positive results still await replication in independent 
samples of sufficient size. 
  For DAOA (13q34), which is also implicated in schizophrenia, no 
pathologically relevant variant has been identified despite independent 
confirmation of its variation influencing susceptibility to bipolar disorder. In view 
of these findings the DAO containing region 12q23, which is implicated in both 
bipolar disorder as well as unipolar disorder, warrants more thorough study. 
Another interesting candidate gene is brain-derived neutrophic factor (BDNF). 
BDNF (putatively located on 11p13), a neurotrophin, has a role in promoting and 
modifying growth, development and survival of neuronal populations and, in the 
mature nervous system, it is involved in activity-dependent neuronal plasticity. The 
common functional Val66Met polymorphism of BDNF is thought to be associated 
with susceptibility to a specific aspect of the clinical bipolar phenotype, rather than 
influencing susceptibility to bipolar disorder as a whole. G-protein receptor kinase 
3 (GRK3) and XBP1 (encodes a transcription factor that regulates MHC class II 
genes) (both 22q) have also been associated with bipolar disorder through GENERAL INTRODUCTION 
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circumstantial evidence coming from a rodent model of mania and an effect of the 
functional polymorphism on mood stabilizer action, respectively. Many other genes 
have been implicated in bipolar disorder and of these, association of DAOA is most 
robust [145]. Some studies have increased the meaningfulness of the association by 
being able to relate gene polymorphisms to persecutory delusion or psychosis, but 
these findings could not be replicated. 
  Compared to bipolar disorder, unipolar depression is more heterogeneous and 
there is evidence for a large environmental component in its etiology. Large sample 
sizes and correction for confounding environmental factors are thus required. It is 
not surprising that few consistent positive findings of genetic studies concerning 
depression have been published. The 12q22-23 region is the only region that has 
been linked to unipolar depression, and also to anxiety traits. Gender-specificity in 
linkage signals has been observed, but awaits replication. Functional 
polymorphisms of 5-HTT, tryptophan hydroxylase 2 (TPH2) and BDNF have often 
been studied in combination with environmental factors to explain the onset of 
depression. Most interesting is the interaction between polymorph 5-HTT and 
occurrence of life events in early childhood. A rare loss-of-function mutation in 
TPH2, a brain-specific enzyme involved in 5-HT synthesis, was found in 
approximately 10% of patients with major depression, but this finding was not 
replicated in four subsequent studies. Despite initial positive findings, many 
subsequent studies have not been able to associate 5-HTT, BDNF and COMT with 
depression, possibly due to poor study design or false-positive initial findings. 
  More robust strategies identifying genetic risk factors or causative genes for 
mood disorders are required. In addition, researchers may consider experimenting 
with psychiatric nosologies other than DSM-IV and ICD-10, because the Kraepelin 
dichotomy that distinguishes schizophrenia and bipolar affective disorder as distinct 
entities with separate underlying disease processes and treatments seems outdated 
[165]. Further, the idea of convergent or overlapping susceptibility genes leading to 
a spectrum of disorders ranging from bipolar disorder to schizophrenia supports the 
view of Keller and Miller of a polygenetic mutation-selection model for mental 
disorders [156]. 
4.3.1.3.  Genetics of pervasive developmental disorders [146-149] 
Concordance of the narrow phenotype of ASD in monozygotic twins is 82-92%, 
while this is only 1-10% for dizygotic twins. Sibling recurrence risk is estimated at 
2-3% and heritability is estimated to be >90%. Social and non-social autistic traits 
seem highly, but independently, genetically determined in ASD. Sub-threshold 
autistic traits are also more frequently present in siblings and parents of individuals 
with ASD. Together, these findings have incited researchers to believe that autism                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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is one of the most genetically determined neuropsychiatric disorders. However, the 
finding of concordance rates below 100% points to a weak but definitely significant 
influence of environmental factors on the ASD phenotype and the value of results 
coming from twin-studies should be reconsidered [150]. Gene-environment 
interactions, the high degree of genetic heterogeneity, the polygenic or oligenic 
mode of inheritance, and significant epistasis have complicated the search for 
autism-genes significantly. 
  Cytogenetic, linkage, candidate gene association, and recently also de novo 
copy number variation (CNV) studies are used to identify ASD susceptibility genes. 
The former kind has yielded valuable information through the study of ‘syndromic’ 
autism. About 10-15% of autism is syndromic, which means that the autism is 
secondary to a genetic disorder such as the chromosomal rearrangement syndromes 
Angelman and Prader-Willi (PWS), fragile X syndrome, tuberous sclerosis and 
neurofibromatosis, or the result of exposure to teratogenic agents. For the majority 
of autism cases (85-90%) the genetic origin is unknown. However, the cases in 
which autism is syndromic are especially relevant with regard to prevention of ASD 
by genetic counseling. Moreover, the syndromic cases present an opportunity for 
pinpointing the underlying genetic abnormalities and for investigating parallels 
with non-syndromic cases. 
  The rate of cytogenetic abnormalities in autistic disorder is estimated to be 3-
5%. Duplication or inversion of the chromosomal 15q11-13 region, e.g., has a 
p r e v a l e n c e  r a t e  o f  a b o u t  1 %  i n  A S D  a n d  t h i s  r e g i o n  i s  a l s o  r e l a t e d  t o  o t h e r  
developmental and behavioral syndromes. Deletions of the maternal or paternal 
chromosome 15q11-13 region are associated with the Angelman syndrome and 
PWS, respectively. Several genetic mechanisms have been implicated in Angelman, 
such as interstitial deletion of a maternal chromosome (70-75%), mutation of the 
ubiquitin-protein ligase E3A (UBE3A) gene or mutation in the imprinting center 
(20%), abnormal methylation (3-5%), and paternal uniparental disomy (UPD) in 
combination with the lack of a maternal copy (2-3%). Angelman syndrome has 
many characteristics in common with ASD, including moderate to severe mental 
retardation, absence of language development and motor stereotypies. For PWS 
similar mechanisms have been proposed such as interstitial deletion of the maternal 
chromosome (70-80%), maternal UPD in combination with the lack of a paternal 
copy (20-30%), and mutation in the imprinting center (1-2%). PWS subjects with 
UPD tend to have autistic-like impairment in social interaction. 
  The other syndromic cases are associated with single-gene mutations of the 
following genes: fragile-X mental retardation 1 (FMR1), tuberous sclerosis 1 (TSC1), 
tuberous sclerosis 2 (TSC2), neurofibromatosis 1 (NF1) and MECP2. More rare but 
treatable syndromes associated with ASD are phenylketonuria (PKU) and the GENERAL INTRODUCTION 
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Smith-Lemli-Opitz syndrome. PKU as a cause of ASD has become rare in countries 
with an established neonatal screening program. Individuals with the Smith-Lemli-
Opitz syndrome, which is associated with increased serum 7-dehydrocholesterol 
and syndactyly (webbing of fingers or toes) of toes 2 and 3, can be treated with a 
high-cholesterol diet. The X-linked genes MECP2 and FMR1 are involved in autism 
secondary to the Rett and the fragile X syndrome, respectively. MECP2 is a 
methylated-DNA binding protein that regulates gene expression through chromatin 
remodeling. MECP2-activity is thought to be important for synapse maintenance 
and remodeling because of the regressive nature of Rett. FMR1-gene silencing by 
promoter hypermethylation and subsequent reduced translation of FMR protein, 
which is involved in mRNA transport, results in fragile X syndrome (2-5% of 
individuals with ASD), a common cause of mild to moderate mental retardation in 
boys. The FMR protein function is modulated by GTPase activity which is crucial 
for control of cytoskeletal dynamics. Next to GTPase activating proteins, guanosine 
exchange factors are involved in ASD and mental retardation. 
  Mutations in tumor-suppressor genes (TSC1 and TSC2) related to tuberous 
sclerosis may be responsible for the localization of tubers to the temporal cortex 
generally observed in ASD. Tuberous sclerosis is an autosomal-dominant 
neurocutaneous disorder, which is 100-times more prevalent in ASD. 
Neurofibromatosis type 1 is a disease in which the growth properties of neural-crest 
derived cells are affected. It is caused by mutation in NF1 (encodes neurofibromin 
which is a tumor suppressor protein) and is associated with features such as toe 
syndactyly, cutaneous malformations and mental retardation. Despite fine-mapping 
of the X-chromosome, which is driven by the marked sex-difference in ASD, most 
linkage study outcomes are negative. However, linkage studies have shown 7q, 16p 
a n d  1 7 q  t o  b e  l i n k e d  t o  A S D  i n  m a l e  o n l y  p a i r s .  S t u d i e s  o n  m a t e r n a l l y  a n d  
paternally imprinted loci are, to date, inconclusive. 
  Unfortunately, chromosomal abnormality studies have not led to the 
identification of a common autism risk allele yet. Combining results from studies to 
rare non-syndromic chromosomal abnormalities in families of ASD subjects with 
those from candidate genes that reside in suspected chromosomal regions, have 
indicated a role for UBE3A and GABA-A receptor (GABR) β3, both mapped to 
15q11-13, and the neuroligin (NLGN) gene family. The five NLGN-genes are X-
linked and encode cell adhesion molecules localized at glutaminergic synapses or 
GABAergic synapses. They are thought to play a crucial role in synapse formation 
and their association with scaffolding proteins seemingly regulates the glutamate-
GABA balance, possibly explaining the high prevalence of epilepsy in ASD. The 
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value and investigations of phenomena of phenotypic overlap is of fundamental 
importance. 
  At the synapse, appropriate connectivity between cytoskeleton and membrane 
proteins is mediated by scaffolding proteins, such as encoded by the SH3 and 
multiple ankyrin repeat domains (SHANK3) gene, which are crucial for dendritic 
morphology. SHANK3 is also a binding partner for neuroligins, which is suggestive 
for a role of SHANK3 in the NLGN-pathway of autism. This pathway connects 
actin cytoskeleton to the postsynaptic scaffold at glutaminergic synapses. Variants 
of genes encoding neurotransmitter receptors and transporters might also confer 
susceptibility to or modulate ASD-associated behavior. 
  The most studied gene is the SLC6A4-gene, which encodes 5-HTT. However, 
SLC6A4 gene variants seem to have small effects on blood 5-HT levels in ASD. 
Functional polymorphism of 5-HTT have also been implicated in stereotyped 
behavior. The second most genotyped neurotransmission-genes are those of the 
GABA-receptor cluster. Significant epistasis of GABR α4 – GABR β1 has been 
reported. This is especially interesting, because of the involvement of the GABA-
ergic systems in seizures in ASD. Glutaminergic receptor genes are also likely to be 
relevant in ASD pathogenesis, because their products are, next to neurotransmission 
processes, also involved in synapse maintenance and plasticity, and they play a 
pivotal role as neurohypophyseal hormone receptors in animal models of social 
interaction. 
  Second-messenger proteins such as neurobeachin (NBEA), an anchoring 
protein able to recruit protein kinase A, and protein kinase C β (PRKCB) I and II, 
are implicated in the differentiation of antigen-presenting dendritic cells whose 
dysfunction could contribute to altered immune responsiveness in ASD. These 
proteins are also involved in Ca2+ signaling, and perturbation of their synthesis 
could translate into altered synaptogenesis. Remarkably, while there is no putative 
genetic explanation, reduced programmed cell death leading to increased cell 
numbers and maintenance of misplaced cells are described consistently in 
neuropathological studies of ASD. 
  Secreted molecules, such as the reelin-protein (RELN), have a pivotal role in 
neuronal migration and prenatal development of neural connections. This has been 
confirmed in reeler-mice, which lack reelin and display cytoarchitectonic 
alterations in numerous brain regions. Post-mortem brain analysis of autistic 
individuals shows impaired reelin signaling and reduced blood reelin levels have 
been found in individuals with autism and first-degree relatives. RELN-variants 
that cause decreased reelin expression are suggested to confer vulnerability to ASD. 
However, the genetic heterogeneity and reported inconsistencies suggest 
interpretation of RELN-variants within a framework of a region-specific gene-GENERAL INTRODUCTION 
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environment interaction model. For example, a gene-environment interaction is 
thought to occur between RELN-variants and exposure to organophosphates. The 
latter inhibit RELN-associated proteolytic activity on matrix proteins, which is 
essential for neuronal migration. This assumption is further strengthened by the 
finding that variants in the paraoxonase (PON) gene, which encodes the 
organophosphate deactivating enzyme paraoxonase, are linked with RELN-variants 
in ASD. The laminin β1 (LAMB1)-gene, encoding the β1-chain of laminin, is 
another interesting candidate. Laminin is an important glycoprotein promoting 
neuronal migration and neurite outgrowth in the developing nervous system. A 
knock-out mouse model of the engrailed 2 (EN2) gene (7q) lacking the EN2 
homeobox transcription factor resulted in a hypoplastic cerebellum and decrease in 
the number of Purkinje cells. Neuropathology reminiscent to that of the EN2 
knock-out mouse was observed in post-mortem brain studies of individuals with 
ASD. Moreover, reduced expression of EN2-gene products has been associated with 
PDD. Reduced expression of the MET gene has recently been implicated in autism 
[166]. MET receptor tyrosine kinase mediated signaling is involved in neocortical 
and cerebellar growth and maturation, immune function, and gastrointestinal 
repair, possibly explaining some of the comorbidity observed in ASD. 
  It can be concluded that individual genes have been implicated by means of 
their positional (through association or linkage) and/or functional (through their 
involvement in neurodevelopment and/or neurotransmission) properties. Findings 
of reduced programmed cell death and/or increased cell proliferation, altered cell 
migration with disrupted cortical and subcortical cytoarchitectonics, abnormal cell 
differentiation with reduced neuronal size, and altered synaptogenesis have been 
proposed to explain the unbalanced local versus long-distance and inhibitory versus 
excitatory connectivity possibly underlying altered social information processing in 
autism. The presented evidence implicates three pathways in ASD pathogenesis: (i) 
cell migration, (ii) glutamate-GABA equilibrium, (iii) synapse formation and 
maintenance, as well as dendritic morphology [146]. Genes that are implicated in 
these pathways encode proteins that can be divided according to their involvement 
in (i) chromatin remodeling (e.g. MECP2) and regulation of transcription (e.g. 
FMR1), (ii) actin cytoskeleton dynamics (e.g. TSC1, TSC2 and NF1), (iii) synaptic 
scaffolding (e.g. SHANK3), (iv) neurotransmission (e.g. SLC6A4), (v) second-
messenger systems (e.g. NBEA), (vi) apoptosis, (vii) cell adhesion (NLGN), and (viii) 
paracrine cell-cell communication (e.g. RELN). 
 
Recently, through the development of high-resolution genome analysis techniques 
to identify de novo genomic deletions and duplications of tens to thousands of 
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underlying genetic causes of autism has been raised to 10-20% [167;168] and this 
number may even grow to 30-40%. De novo CNV encompasses at least 12% of the 
human genome and hundreds of genes [169]. Copy number variation can result in 
the loss of copy, gain of copy and disruption of a dosage-sensitive gene all with 
effects at the protein level [170]. Copy number variation might contribute to the 
interindividual genetic variability even more than single-nucleotide polymorphism 
(SNP). The existence of a higher rate of CNV and also de novo CNV in ASD 
compared to controls suggests that genetic causes of autism have high heritability 
but mutations are not inherited, which is explained by the de novo aspect of CNV 
[171]. This new understanding explains a part of the puzzling data from twin 
studies in autism. 
  The potential existence of less penetrant CNV that has smaller effects but also 
c o n t r i b u t e  t o  a u t i s m  i s  i n t e r e s t i n g .  C o py number variation does not seem to 
increase with age in contrast to point mutations associated with increased paternal 
age. Beaudet [171] proposes a mixed epigenetic and genetic de novo and inherited 
model for autism (Figure 2), in which individual patients have a genetic (mutation) 
or epigenetic (epimutation) cause of autism and these components could be 
inherited in some cases and could be acquired de novo in others [172]. 
 
 
 
Figure 2. 
From [171]. The causes of autism according to genetic contribution and sex. 
Male
Female
Male
Female
 GENERAL INTRODUCTION 
- 48 - 
In summary, results from (epi-)genetic and neuropathological studies in ASD and 
related behavioral and developmental disorders provide a putative role for genes 
involved in brain development and all aspects of neurotransmission that are 
determinants of behavior. These genes should be prioritized for future genetic 
research. Nevertheless, the impact of the environment should not be neglected as 
well as the modest effect sizes of individual genes and poor consistency of most 
implicated genes. Future studies should conform to guidelines for genetic analysis 
of complex disease [157]. 
4.3.1.4.  Outlook and discussion 
Additional research strategies for the identification of mental disorder susceptibility 
genes have been proposed: (i) use of mouse-models for study of gene-environment 
interactions, (ii) the study of genetics in a pedigree of a mental disorder 
accompanied by a specific somatic syndrome, (iii) study of mitochondrial DNA in 
cases where mental disorders are more frequently observed in maternal relatives of 
children with mitochondrial diseases or metabolic diseases compared with their 
paternal relatives, (iv) use of microarrays to study the expression of a large set of 
genes hypothesized or known to be involved in neurodevelopment, neuroplasticity, 
neurotransmission, and remodeling or migration of neurons. It is probably also 
beneficial to focus on single large families to avoid genetic heterogeneity, to take 
into account geographic origin, or to genotype isolated populations. Another 
important question is whether to use tissue, e.g. of the brain or other neuronal 
tissue, or lymphocytes for genetic analysis. The latter is thought to be less 
representative for gene expression in the brain [145]. However, genotype 
characteristics are inevitably related to psychiatric phenotypes classified by the 
DMS-IV and ICD10 criteria, spurring the subject of psychiatric nosology. 
Phenotype definition is generally difficult in mental disorders, because no sensitive 
and specific tests are available to distinguish different disease entities. 
  Another interesting notion is the significant publication bias, which has made 
the genetic research community to call for a platform for negative results. 
Interestingly, among the 166 putative associations with bipolar disorder studied at 
least three times, only six associations were replicated in more than 75% of the 
studies, which can be explained by small sample-size, population stratification, 
phenotype definition, genetic heterogeneity, low relative risk, multiple testing, 
genotyping error, selection bias especially for the control group, and many other 
factors [173]. Publication bias has likely compromised genetic meta-analyses and 
published positive findings may prove to be oversimplifications after more detailed 
analysis. For example, re-analysis of a polymorphic region of the 5-HTT-allele 
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alleles. This finding is important, because different alleles have functional 
differences. Guidelines are in preparation to prevent the aforementioned problems 
and to increase the validity of future reported results. 
  Evenly important, the unequivocal identification of susceptibility genes caused 
by the advancement in genotyping raise ethical and psychological concerns 
regarding the availability of information and services for those under consideration 
for genetic testing. Age at testing, consent procedures, and post-testing implications 
for the individual require careful consideration of researchers and policy-makers. 
However, identification of causative genes provides an opportunity for genetic 
counseling, and via increased insight in disease mechanisms it may result in the 
development of effective therapies. For example, careful genetic assessment of 
children with ASD can be used to determine whether the autism is of syndromic or 
idiopathic nature. This will help to inform parents with regard to the recurrence 
risk (e.g. 2-8% for idiopathic autism) of the disorder and it will help them with the 
psychological coping with the impact of the disorder. 
  If future research discover genes and their specific pathogenic mutations that 
can be unambiguously linked to certain mental disorders or associated traits, the 
feasibility of the following increases: (i) rational drug design, (ii) characterization of 
genotype-phenotype relations, (iii) identification of environmental risk factors 
interacting with specific genes, (iv) realistic research into prevention focusing at 
identifying high-risk individuals [142], and (v) improved psychiatric nosology. It is 
important that future studies on the ‘genes of mental disorder’ account for 
epigenetic regulation of gene expression via interaction with the environment, 
because gene-mutations alone are not expected to explain the origin of the majority 
of mental disorders. 
4.3.2. Epigenetics 
Some evidence for the involvement of epigenetics in several mental disorders has 
already been presented in the previous section: altered epigenetic control of COMT, 
RELN, and glutamate decarboxylase (GAD67) in schizophrenia and bipolar disorder, 
mutations in MECP2 and UBE3A in autism, and of the glucocorticoid receptor (GR) 
in anxiety and depression [174]. Interaction of our genome with the environment 
may be mediated through epigenetic modifications of our genotype. The 
epigenetically modified genome is referred to as the epigenome. Epigenetics refers 
to heritable, but reversible regulation of various genomic functions, mediated 
principally through changes in DNA methylation and chromatin structure [175] 
and non-coding RNA (ncRNA) [176]. The extent and consistency with which 
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meiosis and from cell to cell during mitosis (for cell differentiation) are, however, 
still subject of debate. 
  A key issue of epigenetic modifications is their lasting effect on gene 
expression by either up- or down-regulation of gene expression. While the DNA 
sequence of an organism defines the primary structure of the proteins, epigenetic 
mechanisms control the quantity, location and timing of gene expression [55]. 
Epigenetic processes are thus essential for normal cellular development and 
differentiation, and are thought to be mitotically stable. Parent-of-origin specific 
effects, also referred to as genomic imprinting, are presumed to be under epigenetic 
control. Genomic imprinting is the differential expression of genetic material at 
either a chromosome or allelic level depending on whether the genetic material has 
been transmitted from the paternal or maternal side [55]. Two metastable 
epigenetic processes are transgenerational inheritance of phenotype (meiosis) and 
the interaction of the genome with the environment (fine tuning of phenotype). 
  Epigenetic control is exerted through cytosine methylation at CpG 
dinucleotides, the post-translational modification of histones by means of 
acetylation or methylation, ubiquitylation or small ubiquitin related modifier 
proteins-ylation (SUMOylation), phoshorylation and ADP-ribosylation, and 
transcriptional silencing and alterations of DNA-methylation by ncRNA [153]. CpG 
methylation occurs through DNA methyltransferase catalyzed transfer of a methyl-
group (CH3 or C1 group) from S-adenosyl methionine (SAM) to cytosine residues. 
Histones may also be de-methylated or methylated by enzymes that abstract (e.g. 
demethylases) or transfer (e.g. methyltransferases) a methyl group. Other 
chromatin remodeling systems that have been implicated in epigenetic changes are 
nucleosome sliding (mediated by ATP-dependent chromatin remodeling proteins) 
and histone substitution (exchange of histones from nucleosome with external 
histones) [153]. 
  Typically many genes show an inverse correlation between the degree of 
methylation and the level of expression [177]. Methylated CpG sites (2-5% of all 
DNA bases) are overrepresented in CpG islands of the promoter regulatory region 
of many genes. Methylation disrupts binding of transcription factors and attracts 
methyl-binding proteins that are associated with gene silencing and chromatin 
compaction. The X-linked gene encoding MECP2, e.g., is mutated in Rett’s 
syndrome resulting in decreased MECP2 activity. Decreased MECP2 activity leads 
to transcriptional de-repression of specific promoters thereby decreasing the 
expression of genes encoding proteins which are crucial for brain development and 
plasticity [146]. There is a clear interaction between CpG methylation and histone 
modification. For example, methylated CpG islands normally recruit active MECP2, 
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histone deacetylase (HDAC) complexes. HDAC deacetylates histones thereby 
changing the chromatin structure from an activated, open state, which allows gene 
transcription (euchromatin), to an inactivated, condensed state, which does not 
allow gene transcription (heterochromatin). However, permissive and repressed 
intermediate chromatin states have also been suggested [153]. Chromatin 
remodeling has a high temporal and spatial resolution with regard to modulating 
gene expression by permitting or inhibiting access of the transcriptional machinery 
to specific promoter regions [153]. The diversity of histone modifications and their 
different spatial effects on chromatin structure enables the definition of a specific 
epigenetic state of gene activation or silencing also referred to as the “histone code 
hypothesis” [178]. 
  Many researcher have adopted an epigenetic perspective in mental disorder 
research for the fact that it might explain a number of the observed phenomena 
[55;153]: (i) discordance of MZ twins, (ii) contribution of the environment, (iii) 
high heritability but slow progress in identifying risk genes, (iv) gene-environment 
interactions, (v) frequently observed unequal sex-ratios, (vi) parent-of-origin 
effects, (vii) gradual onset, chronic and remitting course over a lifetime, and (viii) 
necessity for chronic administration of psychiatric medication to mediate effects. 
Improved insight into these phenomena through the study of epigenetic processes 
will contribute to the development of new diagnostic methods and treatments. 
  Another important aspect of epigenetic traits is their potential heritability. It is 
not completely clear how epigenetic traits are transferred during gametogenesis and 
meiosis, or how they are maintained during mitosis. The answer to this question 
seems to be nuanced. In somatic cells the epigenetic profile is transferred from 
maternal to daughter chromatids during mitosis [55]. However, there seems to be 
considerable infidelity in the maintenance of methylation patterns in mammalian 
cells and de novo methylation events are fairly common during mitosis [179]. 
Especially unmethylated regions outside the promoter regions are unreliably 
inherited [180]. Metastability of the epigenetic profile during mitosis may have 
profound effects. Generally it is also assumed that epigenetic profiles are reset and 
erased during gametogenesis and early embryogenesis, but evidence is mounting 
that for at least some genes epigenetic marks (epi-alleles) are transmitted during 
meiosis and thus transmitted from generation to generation [181]. In addition, 
histone modifications, e.g. methylation, are potentially inherited through ‘template 
reading’ and ‘writing’ mechanisms or indirectly as a result of gene transcription. 
The coupling of DNA methylation replication and subsequent gene-silencing to 
modifications of newly-synthesized histones is of special interest and requires 
further investigation [182]. Taken together, the finding of only partial erasure of GENERAL INTRODUCTION 
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epigenetic marks during gametogenesis has significant implications for heritability 
and inheritance research in mental disorders. 
  Because most neurons do not divide in the adult brain, chromatin 
modifications and DNA methylation are sustained within individual cells and affect 
activity, survival, and morphology of neurons and ultimately integrated regulation 
of complex behavior [153]. It is therefore that most epigenetic modifications 
associated with neurobiological adaptations are long-lasting. In the section dealing 
with genetics of schizophrenia, bipolar disorder, depression and PDD some 
epigenetic ‘mutations’ have already been linked to the increased risk or occurrence 
of traits/symptoms associated with these mental disorders. The following sections 
briefly discuss in more detail the possible role of epigenetics in the etiology and 
severity of these disorders. 
4.3.2.1.  Epigenetics of schizophrenia and bipolar disorder 
The most widely studied epigenetic alteration in schizophrenia concerns that of 
genes aberrantly expressed in GABAergic neurons (e.g. RELN-promotor region 
methylation [183]), causing dysfunction of GABA-mediated neuronal circuitry. 
Recent studies conducted in post-mortem brains of patients with schizophrenia and 
bipolar disorder found increased expression of DNA-methyltransferase 1 (DNMT1), 
and reduced expression of RELN and GAD67 in GABAergic neurons in several brain 
regions of patients with schizophrenia [184;185] but not in patients with bipolar 
disorder [185] compared to non-psychiatric controls. Another study found 2-3 fold 
increased levels of SAM, the universal methyl-donor, in brains of patients with 
schizophrenia and bipolar disorder compared to patients with unipolar disorder and 
controls [186]. The increase in SAM levels in these patients was associated with 
DNMT1 overexpression in prefrontal cortex GABAeric neurons [186], which is 
suggestive for SAM-substrated and DNMT1-mediated RELN- and GAD67-promotor 
hypermethylation and consecutive by reduced gene expression. S-
adenosylmethionine is intimately linked to nutrition through C1-metabolism [63]. 
  Another candidate gene for epigenetic alteration is COMT. Recently, a 2-fold 
lower rate of promoter region methylation of the gene encoding for MB-COMT 
was found to be a major risk factor for schizophrenia and bipolar disorder [187]. 
The authors also found a corresponding increase in MB-COMT transcripts, an 
inverse relation with dopamine receptor D1 (DRD1) and a tendency for the Val 
allele polymorphism to be associated with hypomethylation. This could cause 
degradation of dopamine at increased rates through overexpression of MB-COMT 
and hyperactivity of the COMT-allele together with secondary downregulation of 
DRD1 expression. The latter is suggested to reduce RELN-gene expression through 
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of the RELN-promoter region [187]. Treatment of patients with schizophrenia and 
bipolar disorder with epigenetic drugs such as inhibitors of methylating enzymes 
(e.g. DNMT1) might reverse promoter hypermethylation of suppressed genes. 
Noteworthy is the finding of DNMT1-inhibition by doxorubicin and subsequent 
reactivation of the human RELN and GAD67 genes in neuronal cell culture, genes 
that are down-regulated due to modifications in the epigenome [188]. Interestingly, 
the concentration of doxorubicin used for DNMT1-inhibition did not induce 
significant cell death, while it resulted in robust induction of RELN and GAD67 
mRNA [188]. However, the cell, gene and promoter specificity and selectivity 
should be extensively investigated in vitro and in animal models before these 
potentially toxic compounds are tested in human subjects. 
4.3.2.2.  Epigenetics of depression 
The persistence of depression is thought to be mediated by slow but stable 
adaptations, including those of epigenetic nature [153]. It is interesting that one of 
the proven therapies of depression, i.e. chronic electroconvulsive seizures (ECS) 
upregulates BDNF expression through changes in chromatin remodeling, which 
were distinct from changes in chromatin after acute ECS. BDNF upregulation 
mediates antidepressant activity in animal models [153]. The notion that altered 
epigenetic regulation is involved in depression is supported by the fact that chronic 
social defeat stress in an animal model of depression downregulates expression of 
BDNF splice variants, which is reversed upon chronic administration of imipramine 
[189]. The possibility to use specific HDAC, HMT and histone demethylase (HDM) 
inhibitors to treat depression is raised by some [153]. 
  Interestingly, in rats, offspring of mothers with high licking, grooming and 
arched-back nursing (LG-ABN), display increased expression of glucocorticoid 
receptor mRNA and protein, and decreased GR promoter methylation compared to 
pups of mothers with low LG-ABN (reviewed in [190]). The difference in promoter 
methylation emerged in the first week of life, persisted into adulthood but could 
surprisingly be reversed by cross-fostering. Furthermore, pups with high LG-ABN 
mothers have increased expression of nerve growth factor inducible factor A 
(NGFI-A), which binds the GR promoter regions and enhances its transcription 
[191]. The third argument in favor of a role for epigenetic contribution to the 
etiology of depression comes from proband sex effects. 
  Skewed X-chromosome inactivation is an epigenetic process which might 
explain the excess rate of unipolar depression in women and the female MZ twin 
discordance [192]. It is generally assumed that in women X inactivation is stochastic 
for each cell lineage and that this is maintained throughout subsequent cell 
divisions. However, in 5-20% of women without X-linked disorders, there is GENERAL INTRODUCTION 
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constitutional skewing of X-inactivation [193]. Moreover, it seems that as many as 
15% of genes are expressed from both X-chromosomes [194]. These genes are 
obvious candidates for explaining sexual dimorphism in disease prevalence in 
women [55]. Another explanation for sex effects of depression might be mediated 
by hormone-specific modification of certain genes. A fourth argument is a parent-
of-origin effect, i.e. disease susceptibility is mediated by parental factors in a sex-
specific manner, e.g. preferential maternal transmission of a GluR7 gene risk allele 
to patients with recurrent depression has been reported [195]. Genomic imprinting 
seems to be the underlying mechanism. Last, the interaction between the genotype 
and epigenotype may be commonplace, and it may better predict the risk of 
developing mental disorders such as depression. For example, the T-allele of the 
C677T polymorphism in the MTHFR gene is implicated in depression [196] and the 
Val allele of COMT has been associated with promoter hypomethylation [187]. 
These results suggest it is better to perform comprehensive analyses of both the 
genotype and epigenotype to evaluate whether some epigenetic changes may be 
associated with specific polymorphisms. Especially for complex diseases with a large 
environmental component it is unacceptable to study the contribution of genes 
without the study of DNA methylation and histone modification. 
4.3.2.3.  Epigenetics of autism 
The causative role of epigenetic mechanisms in autistic-like behavior is best 
exemplified in fragile-X syndrome in which CGG repeat expansion in the FMR1 
gene renders it susceptible for epigenetic silencing and subsequent reduced FMR1 
expression, and in Rett’s disorder heterozygous females in which the gene encoding 
a key-modulator in epigenetic control (MECP2) is mutated [152]. MECP2 brings 
about silencing by binding to methylated promoters and recruiting co-repressors 
and histone-deacetylases. This alteration of gene-expression by decreased MECP2 
activity leads to altered levels of products of the following genes: BDNF ↑, distal-
less homeobox 5 transcription factor (DLX5) ↑, UBE3A ↓ and GABR β3 ↓ (reviewed 
in [146]). Expression of the RELN-gene is modulated by promoter methylation 
[124]. In addition to altered epigenetic control of single-gene expression, parent-of-
origin effects and genomic imprinting have been implicated in PDD [197]. 
Especially in Angelman syndrome and PWS the effect of genomic imprinting is 
clear (see ‘genetics’ sections). The aforementioned gene products are implicated in 
brain development and plasticity. Next to other chromosomal regions subject to 
imprinting, imprinting errors of 7q and 15q have been associated with Angelman 
syndrome, PWS and Turner syndrome (X monosomy) [146;152]. The gender bias in 
autism may also have epigenetic roots, because it is maintained after exclusion of 
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which genes involved in neurodevelopment and neural signaling interact with 
genes encoding for products having endocrine functions has been suggested, but 
could not be confirmed. One suggestion is that maternally derived X-linked loci are 
silenced and thus not expressed in males, rendering them more vulnerable to 
impairments in social and communication skills [198]. 
 
Taken together, epigenetic mechanisms definitely play an important role in the 
etiology of mental disorders and it is thus of the utmost importance to take these 
effects into account when performing analyses directed at the ‘genetic’ origin of 
such disorders. With this in mind the function of ligands for transcription factors, 
e.g. certain long-chain polyunsaturated fatty acids (LCPUFA), and methyl-donors, 
e.g. folate, requires closer examination because these compounds explain many risk-
factors, and gene-environment and environment-gene interactions that are 
associated with the development of schizophrenia and autism [63]. Furthermore, it 
is important to recognize the very exciting possibility that we inherit next to the 
DNA of our ancestors also their lifestyle. It is most likely that the purported genetic 
and epigenetic changes are observed as differential expression of proteins and 
metabolites in tissues and bodyfluids. Profiling of protein expression and metabolite 
abundance could shed more light on the consequences of these changes. 
5.  Biomarkers for mental disorders 
In the previous paragraphs we have dealt with the socioeconomic burden, 
epidemiology, diagnosis, classification and the etiology of mental disorders. With 
regard to the vast amount of research that has been performed to mental disorders 
it is fair to question what knowledge is still needed with regard to prevention 
(ranging from pre-pregnancy measures to risk-factor reduction in adolescence), 
diagnosis (psychiatric nosology based on definitive objective and preferably 
quantifiable measures with a link to etiology) and treatment (effective treatment 
adapted to an individual’s geno- and phenotype) as well as outcome monitoring 
(remission and relapse estimation) of mental disorders. The review of literature 
describing hypothesis-driven research may seem somewhat disappointing with 
respect to findings of generally applicable biomarkers for these purposes. For 
example, still no diagnostic blood test is available for any mental disorder and 
treatment outcome monitoring is usually done by assessing a patient’s behavior and 
socioeconomic functioning. Genomic, transcriptomic, proteomic and metabolomic 
approaches using an in-depth qualitative and quantitative assessment by expression 
profiling of the respective ‘-omes’ in health, the target disease and closely related 
diseases, may generate biomarkers that comply with criteria for diagnostic or 
therapeutic markers. GENERAL INTRODUCTION 
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A consensus definition of a biomarker, shorthand for biological marker, is “a 
characteristic that is objectively measured and evaluated as an indicator of normal 
biological processes, pathogenic processes, or pharmacologic responses to a 
therapeutic intervention” [199]. Another definition of a biomarker is “a measurable 
indicator of a specific biological state, particularly one relevant to the risk of 
contraction, the presence or stage of disease” [200]. Nowadays, the term ‘biomarker’ 
is often used to refer to a molecular biomarker but physical traits or physiological 
metrics (e.g. results from molecular imaging) should be considered [200]. 
  Biomarkers can be used for the diagnosis, staging, screening and prediction of a 
disease and for monitoring the effectiveness of and patient compliance with a 
treatment [201;202]. With respect to mental disorders, there is a great need for 
biomarkers that enable the development of objective, differential diagnostic 
systems that enable treatment monitoring. The identification of distinct 
phenotypical subtypes through the use of biomarkers may complement and even 
replace current diagnostic criteria. The combined use of biomarkers and 
endophenytopes for early recognition [203] and classification may be another 
promising approach. Moreover, the identification of biomarkers and other 
endophenotypes would likely facilitate the setting up of effective programs for 
prevention and early detection of mental disorders leading to better treatment 
outcome and a less severe course of the disorder. 
  Biomarker research into the causes, traits, states and treatment options of 
patients with mental disorders should be stimulated by governmental institutions 
for matters of cost-effectiveness. In addition, the psychiatric community is likely to 
benefit from an objective measure for the classification and treatment of patients 
with mental disorders. To achieve this, a multidisciplinary approach and multilevel 
analysis of the results is essential. Unfortunately, using hypothesis-driven research 
no single biomarker or panel of biomarkers has been discovered that fulfils the 
criteria for a diagnostic or surrogate-end-point marker. Other approaches 
complementing hypothesis-driven research are therefore being pursued integrating 
results from genomic, transcriptomic, proteomic and metabolomic studies. 
5.1. Diagnostic  biomarkers for mental disorders 
A diagnostic biomarker test for a mental disorder preferably should fulfill the 
following eight criteria [204]: (i) detect a fundamental feature of disease with high 
sensitivity and specificity, (ii) be validated in confirmed post-mortem cases, (iii) be 
standardized with proper bioinformatics and proper statistics, (iv) be specific for the 
disease compared with related disorders, (v) be reliable in many testing 
environments/labs, (vi) be preferably non-invasive, (vii) be simple to perform, and 
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because a longer duration of untreated psychosis after the first manifestation is 
associated with a deteriorating prognosis. Early intervention, already in the 
prodromal phase, in these patients reduces the period of untreated psychosis and 
sometimes it even prevents or delays the onset of psychosis in high-risk individuals 
[205]. In addition, early intervention improves social and functional outcomes and 
is cheaper than standard care models that start treatment once a psychosis is 
manifest [205]. Early intervention in children with autism is likewise associated 
with a better prognosis [49]. The current diagnostic systems, i.e. DSM-IV and ICD-
10, are neutral with respect to theories of etiology. These systems therefore only 
provide limited insight into which therapy, either pharmacological or psychosocial, 
is most effective. 
  Unfortunately, a number of factors hampers biomarker discovery in mental 
disorders: the absence of an objective biological ‘gold standard’, frequently 
prevalent psychiatric comorbidity, heterogeneity and equifinality (same 
symptomatic or syndromatic clinical diagnostic entity represents different initial 
conditions that lead to the same clinical endpoint), quantitative traits or 
intermediate phenotypes and a presumed polygenic/multifactorial etiology [206]. It 
is also virtually impossible to study the primary affected organ in humans, except 
for special cases, where cerebrospinal fluid may be taken. Novel approaches of 
molecular imaging may also allow a more detailed study of brain disorders in 
humans. A generally applicable biochemical diagnostic marker should, however, be 
preferably detectable and quantifiable in either peripheral cells, tissues, or body 
fluids that are easily accessible to be routinely examined in patients. Another major 
problem is to determine the proper cut-off level of a biological marker or a marker 
panel: where does normal interindividual variability end and where does pathology 
start [207]? 
  Functional tests, e.g. the dexamethasone suppression test (measures the 
cortisol- response of the adrenal glands to ACTH) that is used to study the HPA-
axis, have also been proposed as useful tools in the diagnosis of mood disorders. 
Despite the poor sensitivity and specificity of the dexamethasone suppression test 
for patients with depression in general [206], it is a quite well-established predictor 
of risk of suicide in depressed patients, along with serum cholesterol [208]. If future 
research uncovers other pathophysiological mechanisms or affected systems that 
are specific to certain mental disorders, functional tests may be devised that address 
hypo- or hyperactivity of these systems. Functional testing may provide an 
alternative path that also provides valuable information with respect to the proper 
diagnosis and to the most effective treatment. 
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5.2.  Biomarkers for treatment monitoring of mental disorders 
Biomarkers for monitoring treatment and outcome for mental disorders are less 
easily qualified than those for somatic disorder like diabetes. In the (bio)-
pharmaceutical industry biomarkers are qualified according to whether they are 
“fit-for-purpose” [209]. Exploratory biomarkers are used as research and 
development tools accompanied by some preliminary clinical evidence. Their main 
purpose is to support the generation of new hypotheses (e.g. gene expression 
profiling). Valid exploratory biomarkers have demonstrated, but not yet 
reproducibly, adequate preclinical sensitivity and specificity and are linked to 
clinical outcome. These biomarker candidates can assist in clinical decision-making 
(e.g. adiponectin). Fully validated biomarkers have reproducibly proven their 
adequacy in terms of sensitivity, specificity and their link to clinical outcomes in 
multiple prospective clinical studies in human. These biomarkers are also used for 
dose finding in clinical trials and secondary/tertiary claims (e.g. fasting plasma 
glucose). If a biomarker can function as a substitute for a clinical endpoint it is 
designated as a surrogate end point. These biomarkers can be used for registration 
purposes of new pharmaceuticals (e.g. hemoglobin A1c). However, few biomarkers 
make it from the exploratory phase to the final status of surrogate end point. 
  A biomarker that may serve as a surrogate end point is most interesting in 
psychiatry, since clinical endpoints of mental disorders are diverse and not well-
defined. The most important indicators of recovery from a mental disorder are: 
having paid work fit to the patient’s educational background, having normal 
interpersonal relationships and being devoid of any symptoms that impair daily 
living. Of course, it will be very hard to link these complex psycho-socioeconomic 
outcomes to any biochemical marker. It thus seems more feasible at present to use 
biomarkers for the identification of novel pharmaceutical targets and compounds 
that share the same mechanism of action. Biomarkers may also be valuable tools to 
validate animal models for mental disorders and to translate preclinical results into 
the clinic. The study of efficacy and toxicity of new drugs in animal models with 
predictive power for human clinical trials is another field of application [204]. 
5.3. Biomarker  discovery 
5.3.1.  Tissue banks and sample collections 
Hypothesis-driven biomarker research in mental disorders focuses at those tissues, 
organs, cells and pathways which are implicated in the etiology and severity of the 
disease, because of their obvious relation with symptoms. Though this approach has 
yielded reasonably effective treatments for some mental disorders, it may overlook 
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peripheral cells are easier to obtain than post-mortem brain tissue and a spatial 
constraint might thus be that the investigation of peripheral tissue or cells (e.g. 
leukocytes) may not fully resemble molecular and cellular processes in the brain, 
although this is disputed by some [210]. Analysis of fluid more proximate to the 
affected organ than blood or urine, such as CSF, is preferable but also more difficult 
to obtain without a clear medical indication. With respect to the temporal 
constraint, one may have to conclude that earlier and current research has exposed 
only those abnormalities secondary to the primary causative process. The presumed 
neurodevelopmental origin of many mental disorders suggests that biomarker 
studies should start before clear symptoms of the disease are visible. Disease entities 
with similar symptomatology but different underlying causes can probably not be 
differentiated by the study of secondary processes. All together, it may be that the 
search for true diagnostic markers that can differentiate between psychiatric 
disorders with different etiologies was unsuccessful because we were just too late 
and studying the wrong thing. 
  To circumvent these problems large-scale biobanking projects have been set up 
that coordinate the collection of whole-blood, serum, plasma, erythrocytes, 
leukocytes (for DNA) and other biofluids (e.g. urine, CSF) and/or post-mortem 
brain tissue from affected individuals and controls. For proper biobanking, it is also 
necessary to collect samples from affected and unaffected relatives. Especially a 
collection of biofluids and pregnancy tissues from the mother before and during 
pregnancy of the affected individual is important to define vulnerability windows 
of intrauterine neurodevelopment and their association with psychiatric disorders 
in later life. For the father pre-pregnancy DNA might be considered important 
because of changes in epigenetic markers over time and imprinting effects. 
  Several post-mortem brain collections (http://www.intbbn.org/) are available 
for studies of schizophrenia, bipolar disorder and depression: the Stanley 
Foundation brain collection [211], the Oxford brain bank [212], the Harvard brain 
collection [213], the BrainNet Europe Consortium [214] and others. The tissue in 
these banks is generally accompanied by the necessary information. Generally, 
brain tissue is dissected into several brain regions that are sliced and stored as 
freezing coupes. These brain slices give an opportunity to study different affected 
regions resulting in increased homogeneity of the sample. Collaboration between 
tissue banks and standardized collection of tissues as well as extensive 
accompanying information is the key to successful exploitation of these banks, 
because only then will sample size be sufficient to control confounding factors and 
to draw firm conclusions. For autism research, the Brain and Tissue Bank of the 
University of Maryland is probably the best established collection [215]. Several 
other initiatives, notably in the USA, have led to the collaboration of different brain GENERAL INTRODUCTION 
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tissue banks to increase the number of samples for the study of (neuro-) 
developmental disorders. This is necessary because of the low prevalence and 
decreased likelihood of early death in children with PDD. 
  Several population cohorts such as the Northern Finland 1966 Birth Cohort 
Study, the Danish population-based cohort studies, and the NIMH (National 
Institute of Mental Health) epidemiological catchment area studies [216] have 
increased the understanding of mental disorders significantly. Prospective 
collection of blood specimen, DNA together with epidemiological information of 
both affected individuals, their (un)affected relatives and controls is to this moment 
less common practice. If biobanking is to be implemented in these cohort studies, 
standardization of sample collection, sample storage and sample management is of 
utmost importance. An example of DNA-biobanking in PDD is the International 
Molecular Genetics Study of Autism Consortium (IMGSAC) initiative from 1994. 
IMGSAC has provided many researchers with genetic material and clear diagnostic 
and anthropometric information of a sufficient number of patients to test their 
hypotheses. These and other large-scale initiatives provide the international 
research community with a wealth of high-quality samples and information. New 
diagnostic and therapeutic biomarkers for mental disorders are likely to come from 
the analysis of these tissue banks (e.g. the human proteome organization (HUPO) 
brain proteome project (BPP; http://www.hbpp.org/)) using non-hypothesis driven 
techniques. These techniques assess in a qualitative, semi-quantitative and/or 
quantitative fashion DNA (genomics), RNA (transcriptomics), proteins (proteomics) 
and metabolites (metabolomics). The complementary and integrated analysis of 
these ‘-omics’ data allows evaluation of complete systems using a systems biology 
approach [217]. 
5.3.2.  Multi-analyte analysis by ‘-omics’ technologies in biomarker 
research 
As mentioned before, many ‘-omics’ techniques use multi-analyte profiling and 
subsequent analysis of data using bioinformatics to extract useful information from 
the large amount of data that are generated by these techniques. Generally this 
causes the problem that datasets contain a low numbers of samples (10’s-100’s) and 
a large numbers of variables (1000’s-10000’s). This is also referred to as the high-
dimensionality small-sample-size (HDSS) problem [218]. The analysis of  properly 
collected and well-characterized samples by sophisticated low-throughput ‘-omics’ 
techniques and subsequent data analysis by appropriate bioinformatics approaches 
that control or correct for the HDSS problem, enables the extraction of valuable 
information from which a diagnostic or therapeutic biomarker (or set of 
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diagnostics coming from these ‘-omics’ techniques has been disappointing until 
now. 
  While large investments are being made in this area, the rate of introduction 
in the clinic of new protein biomarkers is falling, at least for cancer diagnostics 
[219]. The regulatory part of this problem is tackled by the creation of a consortium 
consisting of regulatory institutions (e.g. food and drug administration; FDA) and 
(bio)-pharmaceutical industries. This consortium focuses at the evaluation of cost-
effectiveness and the qualification of biomarkers for regulatory decision-making 
[220]. In addition, researchers have begun to propose coherent and comprehensive 
processes (pipelines) for biomarker development consisting of: discovery, 
qualification, verification, research assay optimization, clinical validation and 
commercialization [200] in accordance to guidelines defining the minimal 
information about experiments for genomics and transcriptomics (MIAME), 
proteomics (MIAPE) and metabolomics (MIAMET). These pipelines are designed to 
provide some directions in facing the challenges associated with biomarker 
discovery. For proteins in blood, these challenges are related to the complexity and 
dynamic range of proteins in biofluids, the low relative abundance of many disease-
specific biomarkers and the extent of variation between individuals and within a 
given disease [200]. 
  Genomic and transcriptomic methods profile genes or gene-expression using 
microarrays of PCR-amplified material. However, gene expression data do not 
consistently correlate with protein expression and cannot identify post-
transcriptional (e.g. alternative splicing) or post-translational modifications, which 
are major modulators of protein function, and presumably pathogenesis [217]. 
Proteomics and metabolomics may better reflect the dynamics of states and traits of 
patients. For proteome and metabolome profiling highly selective, sensitive and in 
certain cases also specific assays are required and these assays are usually preceded 
by extensive pre- and/or sub-fractionation methods (restricted-access 
chromatography, affinity-chromatography, depletion of high-abundant proteins 
etc.). Compared to the enormous number of articles about cancer proteomics, the 
input of proteomics and metabolomics in psychiatry research is scarce [204]. Some 
proteomic and metabolomic approaches have been applied to schizophrenia 
(proteomics reviewed in [204], [221-227]; metabolomics: [222;228]), bipolar 
disorder [proteomics [221;229]], depression [proteomics [221;223;230]; 
metabolomics [231]] and autism [proteomics [232;233]], or related animal models 
[all proteomics: schizophrenia [234;235]; depression [236;237]; anxiety [238]]. 
However, most of these studies have only shown changes in high abundant markers 
that are less likely to be related to the primary disease process. As a consequence GENERAL INTRODUCTION 
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these studies have made limited contributions to the understanding of these 
disorders. 
  Routinely applied proteomics techniques are two-dimensional gel 
electrophoresis for protein analysis (2-DE) or liquid chromatography hyphenated 
with mass spectrometry (LC-MS). These techniques and their application in 
proteomics have been extensively reviewed [239-241]. In this review no further 
attempts will be made to review these techniques with respect to their advantages 
and drawbacks for biomarker discovery. We will merely describe the workflow 
(Figure 3) and challenges that proteomics faces in finding biomarkers for mental 
disorders as well as the findings of proteomic and metabolomic studies in this area. 
 
 
Figure 3. Process flow for the development of novel protein biomarker candidates 
From [200]. ‘Numbers of analytes’ refers to the number of proteins expected to be evaluated as candidate 
biomarkers in each phase of development. ‘Numbers of samples’ refers to the sample requirements for each 
phase. LC-MS/MS, liquid chromatography tandem mass spectrometry; SID, stable isotope dilution; MRM, 
multiple reaction monitoring. 
 
5.3.3.  Biomarker discovery pipeline in mental disorders and challenges 
Biomarker discovery starts with the proper selection of patients and controls. 
Including large groups of patients having different but related mental disorders 
(symptom domains) according to the DSM-IV or ICD-10 criteria and a control 
group seems the best approach to find a diagnostic marker or marker panel. 
However, for the analysis of data an unbiased/unsupervised approach should be 
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used, since DSM-IV and ICD-10 classifications are not based on etiology. 
Furthermore, proper matching for age, gender, medication, duration of illness, 
lifestyle and other factors is of imminent importance to reduce the effect of 
confounding factors. For ‘-omics’ studies of animal models for psychiatric disorders 
similar considerations are valid. 
  The next step in biomarker discovery is the selection of relevant samples, 
which can be biofluids such as blood or its derivatives (serum, plasma or specific 
cells), urine, CSF, or tissues (e.g. specific areas of post-mortem brains). Biofluids and 
their protein constituents are generally used in diagnostics and are thus a logical 
starting point for biomarker discovery, because of their comprehensiveness and 
accessibility [200]. Unfortunately, blood contains tens of thousands of proteins, 
which span ten to eleven orders of magnitude in concentration [200]. Disease-
specific markers coming from the brain are likely to be highly diluted in blood and 
even more diluted in urine, which makes their discovery challenging. Higher 
concentrations of these markers are more likely to be found proximally to the 
affected brain in the CSF. A disadvantage of CSF is that it is not readily available, 
because it can only be acquired by an invasive lumbar puncture in limited volume 
(mL-scale). Analysis of post-mortem brain tissue is interesting, because it provides 
direct access to the affected organ, thereby increasing the chance of finding 
abnormalities that relate directly to the symptomatology. However, post-mortem 
brain analysis often means analyzing samples of convenience with little control 
over matching and confounding factors. In addition, brain abnormalities in later life 
might not be reflective of early processes that are responsible for the onset of, for 
example, depression or psychosis. Independent of the nature of the sample, samples 
should be collected in a standardized fashion and should be accompanied by the 
relevant information in a way that global exchange of material is possible. 
  Sample pre-treatment and analysis is the next step in the workflow. Often, 
sample pretreatment is crucial to reach into the lower concentration range of 
proteins and metabolites. For this, immunodepletion to remove high abundant 
proteins and affinity-chromatography to enrich proteins with specific post-
translational modifications (e.g. glycosylated proteins) or a given functionality are 
frequently exploited [242]. Another interesting approach is the use of the blood 
peptidome, which accumulates on high-abundant circulating blood proteins like 
albumin, thereby serving as concentrators of potential disease-specific peptide 
markers [243]. 
  Sample analysis is done using relatively low-throughput techniques, because 
extensive prefractionation must be generally performed. Consequently, one sample 
results in multiple fractions that need to be analyzed, for example, by LC-MS [242]. 
This improves sensitivity when hyphenated with hybrid mass spectrometers GENERAL INTRODUCTION 
- 64 - 
exhibiting high mass resolution and mass accuracy, (e.g. linear ion trap/Fourier 
transform ion cyclotron resonance (LTQ/FT) or LTQ/Orbitrap mass spectrometers 
[200]). However, such an approach results in many tens of hours analysis time per 
sample [218]. Each sample may generate data files on the order of hundreds to 
thousands of Mbytes. There is thus an increasing need for data storage, processing 
and analysis capacity that should be managed by skilled bioinformaticians with an 
understanding of analytical chemistry. 
  Analysis of high-dimensional data from relatively few samples requires 
extensive knowledge about multivariate statistics and methods to reduce data 
complexity (binning/meshing), to extract relevant information (noise-
reduction/peak-detection [244]) and to render LC-MS data comparable 
(normalization [245] and alignment of data in m/z and/or time domains [246]). Data 
processing methods that reduce data complexity by removing redundancy caused 
by isotopes and charge-states in the raw data have to be integrated in the data-
processing workflows [247]. After data processing a matrix is constructed that 
contains values (intensity/area/volume) of individual peaks (for example, 
characterized by retention time and mass-to-charge ratio) from different samples 
(organized in columns). This matrix is subjected to unsupervised or supervised 
multivariate statistical analysis and visualization [218]. 
  Depending on the goal of the study, multivariate analysis is performed in an 
unsupervised or supervised manner. In the search for a diagnostic biomarker or 
biomarker panel that differentiates between bipolar disorder and schizophrenia it is 
advisable not to use supervised classifying algorithms, because an intermediate 
phenotype might exist that affects sample classification and that would go 
undetected by using a supervised classification algorithm. In those cases it is better 
to use unsupervised principal component analysis (PCA) for class discovery, which 
in this example might result in the discovery of three classes (e.g. bipolar disorder, 
intermediate phenotype and schizophrenia) instead of the expected two. On the 
other hand unsupervised PCA reduces the chance of finding significant differences 
between classes, which makes it a risky strategy and at the end of the line it may 
prove an unviable option. The separation of groups of samples can be visualized by 
the projection of individual samples in a 2D- or 3D-plot consisting of principal 
components (PC) 1, PC 2 and PC 3. In contrast to diagnostic biomarkers that 
differentiate between psychiatric disorders, treatment biomarkers and biomarkers 
distinguishing between controls and affected individuals are more likely to be 
discovered through the use of supervised classification algorithms. Supervised 
classification pinpoints to those compounds that best discriminate a group of 
individuals or individuals before and after treatment. Next to the multivariate 
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of groups of individuals is probably even more sensitive in finding biomarkers, 
because intra-individual noise is better estimated and corrected for. 
  The output of the multivariate analysis consists of a number of peaks 
representing one or more parent compounds. To decide which of the 
discriminatory peaks should be further studied (for example, after identification by 
LC-MS/MS), visual inspection, univariate statistical analysis and confirmation in an 
independent dataset should be performed. Confirmation of the discriminatory 
properties of identified compounds can be accomplished through spiking 
experiments or through dedicated analysis schemes (e.g. immunoassays; selective 
LC-MS/MS approaches). 
  The last step in the biomarker discovery workflow is the interpretation of the 
role of the discovered biomarker(s) in disease etiology and its validation in larger 
groups of patients in comparison with controls. Systems biology may be helpful in 
relating a given biomarker to disease etiology [217] as may be the study of the 
literature. Qualification, verification and validation according to FDA-guidelines 
and the Clinical Laboratory Improvement Amendments law of 1988 guidelines of 
the biomarker in larger groups should be performed with high-throughput assays 
such as stable-isotope dilution (SID) multiple-reaction-monitoring (MRM) LC-
MS/MS on a triple quadrupole mass spectrometer or with sensitive 
immunotechniques such as radioimmunoassays (RIA) or enzyme-linked 
immunosorbent assays (ELISA) [200]. For clinical validation is important to 
consider the consequences of the chosen (multivariate) cut-off(s). At least 
sensitivity, specificity and preferably also the negative and positive predictive value 
should be assessed and compared with other existing assays through receiver 
operating characteristics curves (ROC). If the marker holds with respect to clinical 
and analytical validation, it can be implemented in routine care. 
5.3.4.  Results from proteomic and metabolomic studies in mental 
disorders 
Compared to cancer research, few studies report the use of ‘-omics’ technologies in 
psychiatry research. In this section we focus on studies that used general 
proteomics techniques such as 2-DE, LC-MS and MS for the simultaneous analysis 
of proteins in brain tissue, CSF, plasma and serum as well as on some metabolomics 
studies that have used special analytical platforms usually GC-FID of derivatizated 
analytes or 1H-NMR for profiling of glucose, fatty acid and oxidative 
phosphorylation pathways etc. 
  Advances of proteomics technologies in schizophrenia research have recently 
been reviewed [204]. Using 2-DE of the hippocampal proteome of seven patients 
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found. Among these were the diazepam binding inhibitor (DBI) and manganese 
superoxide dismutase (MnSOD) (both decreased), and the overexpressed collapsing 
response protein 2 (CRMP-2) and t-complex protein 1 (TCP-1) [248]. The first two 
proteins are involved in the regulation of GABA-ergic activity and in antioxidant 
activity, respectively [204]. TCP-1 aides in protein folding and arrangement. 
CRMP-2 is involved in axon formation. An alteration in turnover of the 
cytoskeleton through differential post-translational oxidation/nitration was 
suggested to be ongoing in the brains of patients with schizophrenia [248]. 
  Another study of 89 frontal cortices obtained post-mortem from individuals 
with schizophrenia (n=24), bipolar disorder (n=23), major psychiatric disorder 
(n=19) and non-psychiatric controls (n=23) used 2-DE and MS sequencing of 
proteins [221]. Eight differentially expressed proteins were found: glial fibrillary 
acidic protein and dihydropyriminidase-related protein 2 were decreased in 
psychiatric patients, while ubiquinone cytochrome c reductase core protein 1 was 
only decreased in depression. The authors concluded that because some alterations 
in proteins were found in patients with different psychiatric diagnoses they may 
represent features that are common to the different diseases such as non-specific 
markers of inflammation or a common second messenger pathway [221]. 
  Analysis by LC-MS of trypsin-digested serum proteins from 69 children with 
autism and 35 typically developing children showed only few differentially 
expressed peptides that barely reached statistical significance [233]. These peptides 
could be related to relatively high-abundant proteins such as apo-B100, 
complement factor H related protein, complement C1q and fibronectin 1, which do 
not seem to be very specific for autism and may reflect alterations in lipid 
metabolism and/or the immune system. 2-DE post-mortem brain tissue analysis of 
individuals with autism revealed a more acidic (polar) form of glyoxoalase I (Glo1) 
after identification of differentially expressed protein by LC-MS/MS [232]. This 
more acidic from of Glo1 was traced to a SNP in the Glo1 gene. The gene-product 
of Glo1 gene was found to have decreased enzyme activity and was later termed as 
predisposing factor in the etiology of autism [232]. 
  Analysis of CSF from ten patients with schizophrenia and ten controls using 2-
DE and MS protein sequencing showed downregulation of apolipoprotein A-IV 
(apo-AIV) in schizophrenia [249]. Decreased expression of apo-AIV was suggested 
to lead to reduced satiety signaling thereby increasing the risk of weight gain and 
insulin-resistance in patients using atypical antipsychotics [204]. MS sequencing of 
a differentially expressed protein in 2-DE analysis of plasma from treatment-
resistant patients with schizophrenia and chlorpromazine-treated rats showed a 
decrease of plasma apo-AI in patients with schizophrenia and an increase in 
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with the pathology of schizophrenia and an association of increased apo-AI with 
the therapeutic action of chlorpromazine [227]. The 2-DE analysis of CSF from 
patients with major depression that aimed at finding differences in the CSF-
proteome between suicide attempters and non-attempters is another example of 
how proteomics can be applied to a clinical question [230]. 
  Another frequently used proteomic technique is surface-enhanced laser 
desorption/ionization (SELDI) time-of-flight (TOF) MS. This technique was applied 
for the analysis of post-mortem dorsolateral prefrontal cortex from 34 individuals 
with schizophrenia and 35 controls [250]. Using a combination of 10 peaks the 
authors were able to diagnose schizophrenia patients with a sensitivity and 
specificity of around 70% after cross-validation. However, none of the peaks was 
identified, diagnostic performance was poor and confounding by medication was 
not controlled for, raising questions about the applicability and usefulness of this 
SELDI method and study design. SELDI-TOF analysis of CSF from patients with 
drug-naïve first-onset schizophrenia, depression, OCD and Alzheimer was more 
successful with a sensitivity of 88% and a specificity of 95% of the discriminatory 
proteins in an independent test-set [223]. Up-regulation of a VGF-derived peptide 
and down-regulation of transthyretin, which was co-regulated with a peptide 
c l u s t e r ,  w e r e  f o u n d  t o  b e  d i s c r i m i n a t o r y  i n  t h i s  s t u d y  [ 2 2 3 ] .  A l t h o u g h  C S F  i s  
generally not collected for the diagnosis of schizophrenia, a CSF-based diagnostic 
assay seems feasible, and it is of interest to see whether such an assay can also be 
used for treatment monitoring. Recently, SELDI-TOF MS protein profiling of 
dorsolateral prefrontal cortex tissue of patients with schizophrenia and bipolar 
disorder in comparison with controls revealed different groups of proteins involved 
in cell metabolism, signaling cascades, regulation of gene transcription, protein and 
RNA chaperoning, and other aspects of cellular homeostasis that could differentiate 
between the diagnostic clusters or between psychiatric patients and controls by 
their up- or downregulation [229]. Protein identification was done using matrix-
assisted laser desorption-ionization TOF post-source decay MS [229]. Integrated 
transcriptomic, proteomic and metabolomic analyses of post-mortem prefrontal 
cortex from 10 patients with schizophrenia and ten matched controls suggested 
altered mitochondrial energy metabolism and oxidative stress in schizophrenia (in 
9/10 patients) [222]. These findings were suggestive for low-grade hypoxia and 
energy depletion in the prefrontal cortex caused by reduced cerebral blood flow 
[222]. This study is a fine example of how systems biology can improve the 
understanding of disease mechanisms and at the same time provides new directions 
for research. 
  To improve insight into disease mechanisms and metabolic side-effects of three 
atypical antipsychotics, a metabolomics platform capable of quantifying 300 lipids GENERAL INTRODUCTION 
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was used to analyze plasma of patients with schizophrenia before and after 
treatment [228]. Olanzapine and risperidone seemed to affect a broader range of 
lipid classes than aripiprazole and the former two caused increases of 
triacylglycerols and decreases of free fatty acid levels in contrast to aripiprazole, 
which may be related to metabolic side-effects. Interestingly, 
phosphatidylethanolamine (PE) levels increased after treatment for all drugs, 
suggesting PE-levels to be associated with therapeutic benefit. Moreover, 
metabolome profiling may be a promising tool for the identification of therapeutic 
response markers and non-responders (i.e. pharmacometabolomics), and to assess 
metabolic side-effects [228]. A metabolomics approach has also been adopted to 
advance knowledge about late-life depression [231]. Using GC-MS, plasma from 
depressed, remitted and never-depressed adults was studied. Remitted patients 
resembled never-depressed adults with respect to their metabolome, and depressed 
patients had altered levels of several fatty acids, glycerol and GABA, suggesting 
altered lipid and neurotransmitter metabolism. 
  The application of proteomics and metabolomics in animal models of mental 
disorders has been diverse: (i) validation of animal models by studying the 
underlying pathology (e.g. mechanism by which methamphetamines bring about 
behavioral sensitization [226]); (ii) investigation of changes caused by the NMDA-
receptor antagonist MK-801 (compound with psychotomimetic effects) in the 
thalamus [235] and cortex [234]; (iii) discovery of anxiety-related proteins in mouse 
brains [238]; (iv) observation that enduring high levels of circulating cortisol lead to 
altered cellular morphology and cell death pathways [237]; (v) for monitoring of 
the effects of medication. The effects of chlorpromazine [225;227] and clozapine 
[225] treatment on the plasma proteome in rats were studied and a study to the 
effects of monoamine reuptake inhibitors such as fluoxetine and venlafaxine 
showed changes within the hippocampal formation, beyond 5-
HT/norepinephrenine neurotransmission, which may reflect long-term functional 
adaptations that are required for antidepressant activity [236]. 
5.4.  Outlook and discussion 
‘-Omics’ technologies provide a new opportunity to study complex diseases such as 
mental disorders through an integrated approach based on systems biology. These 
techniques may extend our view beyond present hypotheses. Non-hypothesis 
driven research is especially needed to solve those clinical questions where 
hypothesis-driven research has failed up to now. Although biomarkers for 
diagnostic and treatment purposes should preferably have an etiology-supported 
basis, their discovery might be through the use of techniques without any 
etiological assumption on forehand, at least theoretically. The needs of the                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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psychiatric community in biomarkers that aid in providing directions to the most 
(cost-) effective treatment with the least side-effects drive this research. A 
treatment biomarker may even turn out to be responsive to psychosocial therapy. 
In the end it may be possible to predict the onset of a disorder, to relate alterations 
in a causative manner to symptoms, and to define markers for recovery, remission 
and therapeutic response. Of course, all this is not possible without an extensive 
network that supports biomarker discovery, validation and implementation. 
Especially in mental disorders of low prevalence, international collaboration is 
required. The mental disorder biomarker discovery network has to extend from 
policy-makers that enable the collection of human material in large population 
cohorts and that provide financial support to researchers, to the end-users that 
benefit from the outcomes (i.e. the affected individual and his/her family). 
Technological advances in the field of genomics, transcriptomics, proteomics and 
metabolomics have been significant and it seems that there are mainly logistic and 
financial limitations to exploit these techniques in psychiatry research in a manner 
that is presently done in cancer. Results from cancer research are promising, but a 
marker discovered by ‘-omics’ approaches has yet to conquer a place in the 
diagnostic arsenal of a clinical chemistry laboratory. 
6. Conclusion 
Mental disorders cause enormous psychosocial and socioeconomic suffering to 
those that are affected and to those living close by (e.g. relatives, friends and 
neighbors). Future projections about the incidence and prevalence of mental 
disorders are pessimistic with e.g. predicted increases in unipolar depression. A 
major problem of most mental disorders is their chronic nature, resulting in 
impairment of normal living (e.g. in work, relations, family-life etc.) after onset 
until death. The chronic nature of mental disorders is probably the most important 
contributor to the large burden-of-disease. For some disorders such as 
schizophrenia, abnormal behavior may already be present before the disorder is 
recognized and treated. For autism, children are impaired already from the early 
start of their life. Significant underdiagnosis and undertreatment in psychiatry is a 
fact of live, especially in third-world countries. This is mainly due to unequal 
distribution of psychiatric resources such as medication and the number of 
psychiatrists per capita. We still lack objective and quantifiable diagnostic 
measures, such as biological markers. Even in western countries available treatment 
modalities, either pharmacological or psychosocial, are far from being effective and 
most patients have residual symptoms for the rest of their lives or experience 
relapse. More insight into the causative mechanisms and risk factors may enable us 
to increase the efficacy and reduce the toxicity (e.g. metabolic side effects of GENERAL INTRODUCTION 
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antipsychotics) of existing drugs, or to generate novel pharmacological targets. It is 
important to account for early-life events and environmental factors as wells as for 
genetic and epigenetic influences equally when investigating mental disorders. 
Especially adverse early-life events seem to do considerable harm, thereby 
significantly increasing the risk of developing a psychiatric disorder. Defining risk 
factors at different stages of life, ranging from optimal guidance of pregnancies to 
the prevention of depression in the elderly, through epidemiological research seems 
fruitful. If it is possible to link these risk factors in a mechanistic way to pathology, 
we may be able to intervene on a population level or set-up screening programs 
that track-down high-risk individuals. One possible way by which we can relate 
risk-factors to mechanistic pathways that cause disease is through the use of well-
established ‘-omics’ technologies (genomics, transcriptomics, proteomics and 
metabolomics). These unbiased (non-hypothesis driven) profiling techniques 
promise to extend our knowledge through systems biology-based mental disorder 
research. However, reflection upon the results of proteomics studies in cancer show 
that the field of biomarker discovery and validation is still in its infancy with regard 
to the number of biomarkers that have reached the clinic. It seems that, 
metaphorically speaking, the ripe fruits of knowledge and biomarkers have yet to 
be harvested from the tree of ‘-omics’ technologies, and these fruits need to be 
undone of bugs and leaves before they can be eaten. Nevertheless, it is expected 
that if we combine the results from ‘classic’ hypothesis-driven experiments with 
those from unbiased non-hypothesis driven profiling techniques, it will be possible 
to improve the prospects of people suffering from these devastating disorders.                                                                                                                                                        BIOMARKERS IN PSYCHIATRY 
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Glossary (see also ‘List of abbreviations’) 
 
abbreviation   explanation 
ASD autism  spectrum 
disorders 
see 'PDD' 
DALY disability-adjusted 
life year 
a time-based measure that combines, in a single indicator, 
years of life lost from premature death and years of life lived 
with a disability 
LMR lifetime  morbid  risk  theoretical  prevalence at any point in life for anyone, 
regardless of time of assessment 
NPV negative  predictive 
value 
proportion of patients with negative test results who are 
correctly diagnosed 
PDD pervasive 
developmental 
disorders 
umbrella-term encompassing autistic disorder, Asperger's 
disorder, Rett's syndrome, childhood disintegrative disorder 
and PDD-not otherwise specified 
PPV positive  predictive 
value 
proportion of patients with positive test results who are 
correctly diagnosed 
  endophenotype  heritable, measurable traits or facets in between genotype 
and phenotype reflecting neurobiological features underlying 
a readily apparent disease 
 evolutionary 
medicine 
study of present medical conditions in the context of possible 
discrepancies between current human environments and 
behaviors and past conditions under which we evolved 
  sensitivity  true positive rate: proportion of true positives of all positive 
(e.g. diseased) cases in the population/sample 
  specificity  true negative rate: proportion of true negatives of all negative 
(e.g. healthy) cases in the population/sample  
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Abstract 
Schizophrenia, autism and depression do not inherit by Mendel’s law and the 
search for a genetic basis seems unsuccessful. Schizophrenia and autism relate to 
low birth weight and pregnancy complications, which predispose to developmental 
adaptations by ‘programming’. Epigenetics might constitute the basis of 
programming and depends on folate status and one-carbon metabolism in general. 
Early folate status of patients with schizophrenia might be compromised as 
suggested by i) coinciding incidences of schizophrenia and neural tube defects 
(NTDs) in the Dutch hunger winter, ii) coinciding seasonal fluctuations in birth of 
patients with schizophrenia and NTDs, and higher schizophrenia incidence in iii) 
immigrants and iv) methylene tetrahydrofolate reductase 677C→T homozygotes. 
Recent studies in schizophrenia and autism point at epigenetic silencing of critical 
genes or chromosomal loci. The long chain polyunsaturated fatty acids (LCPUFA) 
arachidonic (AA, from meat) and docosahexaenoic (fish) acids are components of 
brain phospholipids, and modulators of signal transduction and gene expression. 
Patients with schizophrenia and possibly autism, exhibit abnormal phospholipid 
metabolism that might cause local AA depletion and impaired eicosanoid-mediated 
signal transduction. National fish intakes relate inversely with major and 
postpartum depressions. Five out of 6 randomized controlled trials with 
eicosapentaenoic acid (fish) have shown positive effects in schizophrenia and 4/6 
were favorable in depression and bipolar disorders. We conclude that folate and 
LCPUFA might be important in both the etiology and severity of at least some 
psychiatric diseases.       FOLATE AND LCPUFA IN PSYCHIATRIC DISEASE 
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1. Introduction 
The stable cross-cultural and cross-racial incidence of schizophrenia, initially 
noticed by the WHO in 1970, suggests that schizophrenia susceptibility genes have 
been with us since the origin of homo sapiens, some 160,000 years ago. This, 
together with the lower fecundity of, notably male, schizophrenics raises the 
question why the disease has survived natural selection [1;2]. Family studies of 
schizophrenics indicate that schizophrenia is rarely the only psychiatric illness, but 
that there is a continuum of disorders that is likely to derive from the combination 
of a small number of susceptibility genes, with intermediate outcomes such as 
‘schizotypy’, depression, bipolar disorders, sociopathy and learning disabilities 
(including dyslexia). These genes might have been conserved during evolution 
because they actually code for exceptional creativity and intelligence. There is a 
long list of famous musicians, writers, philosophers, scientists and inventors with 
schizophrenic or schizotypal characteristics [2]. Our rapidly changing lifestyle, 
beginning with the agricultural revolution (commencing some 10,000 years ago), 
and its acceleration since the industrial revolution (beginning some 200 years ago) 
might have turned this ‘advantageous genotype’ into a disadvantage. The WHO 
predicts psychiatric disease, notably depression, to be ranking in the top of chronic 
diseases in Western countries in the near future. The present consensus is that the 
prevalence of autism exhibits an increase that is unlikely to be explained by 
changes in diagnostic criteria or improvements in case ascertainment. It is e.g. 
estimated that the prevalence in the USA has shown a >10-fold increase in the past 
decades, with <3 cases per 10,000 children in the 1970s to >30 per 10,000 in the 
1990s [3]. 
The rapidly increasing incidence, and perhaps severity, of some psychiatric 
diseases suggests that, analogous to other typically Western diseases such as 
coronary artery disease, diabetes mellitus type 2 and some cancers (e.g. prostate, 
breast, colon, lung), we are dealing with a conflict between our contemporary 
lifestyle and our slowly adapting genome. We review the currently available data in 
support of the hypothesis that (early) environmental factors, notably those of 
nutritional nature, play an important role in the etiology and severity of at least 
some psychiatric diseases. Emphasis is laid on the role of folate and long chain 
polyunsaturated fatty acids (LCPUFA) in the etiologies of schizophrenia and autism, 
and the role of dietary folate and LCPUFA in the severity of schizophrenia and 
depression.  CHAPTER 1 
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2.  Influence of genetics, birth weight and pregnancy 
complications 
Psychiatric diseases, such as schizophrenia (1% of population) and autism (0.1% of 
children), are among the ‘complex’ diseases that by definition do not inherit by 
Mendel’s law. They are generally considered to derive from a combination of 
heritable and environmental factors. Currently, autism holds a respectable list of 
over 89 candidate genes, provoking the comment that ‘as of this date, no gene has 
been proven to not be an autism disease gene’ [4]. Also the list of schizophrenia 
candidate genes is on steady growth, while genes alone cannot explain the 2.7 times 
higher schizophrenia relative risk of first generation migrants and the 4.5 times 
higher relative risk of second generation migrants, which notably affect subjects 
migrating from the developing to developed countries [5]. 
  The higher concordance of monozygotic twins for schizophrenia (about 50%; 
[6]) and notably autism (60-90%; [7]), as compared with dizygotic twins 
(schizophrenia: 17%; autism: 0-10%), seem to argue in favor of the importance of 
genetic factors. Twin studies in support of a genetic background have, however, 
been seriously criticized because of methodological problems and questionable 
assumptions [8]. Taking chorionicity into account, it was found that simple 
monozygotic concordance rates may overestimate schizophrenia heritability, with 
low birth weight and notably ‘programming’ probably being of more importance 
[9;10]. 
  Birth weight has only a small genetic component and reflects mainly the 
quality of the intrauterine environment [11]. Small and disproportionate babies 
derive from a dysbalance between fetal nutrient demand and maternoplacental 
nutrient supply in early and late gestation, respectively, causing what is named the 
‘thrifty phenotype’ [12]. The underlying process of ‘programming’ stems from a 
stimulus or an insult at a sensitive or critical period of development with long-term 
consequences. ‘Programming’ is a well-known phenomenon in biology. The 
underlying mechanism contributes to ‘developmental plasticity’ [13]. Its occurrence 
is not limited to an adverse environment in intrauterine life that stems from under 
or malnutrition, but it may also be triggered by infection, season of birth and 
smoking, or adverse environmental conditions in early infancy. By down-
regulation of growth and the induction of other developmental adaptations it is 
now presumed to affect many tissues, organs and systems, including the central 
nervous system. Such adaptations may be beneficial for short-term survival but are 
in the long-term, notably when stimulated by unfavorable postnatal lifestyle, 
implicated in a number of chronic non communicable diseases at adult age, 
including schizophrenia [12;14]. A recent study showed that at adolescent age, very 
low birth weight babies are at risk of developing psychiatric symptoms and reduced       FOLATE AND LCPUFA IN PSYCHIATRIC DISEASE 
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social and academic skills, while term small for gestational age babies have higher 
risk of emotional, behavioral and attention deficit symptoms [15]. A study of 
perinatal risk factors for autism among cases, unaffected siblings and controls in W-
Australia concluded that we might be dealing with genetic factors that predispose 
to obstetric complications and that these factors may precipitate to autism by 
exposure to certain environmental stimuli [16]. Similar perinatal risk factors, 
including low birth weight, but also parental psychiatric history, were reported in 
another recent autism case-control study [17]. A meta-analysis of prospective 
population-based studies revealed that schizophrenia is associated with 
complications of pregnancy as well [18]. 
  Taken together, the available data suggest that birth weight, pregnancy 
complications and parental psychiatric history might be important to the 
development of at least some psychiatric diseases. The plausibility of causality 
would, however, benefit greatly from the identification of the offending 
environmental factors and the elucidation of the underlying pathophysiological 
mechanism(s). Recent developments have shed more light into these issues. 
3.  Nutritional factors in the etiology and severity of 
psychiatric disease 
Indications in favor of nutritional factors in prenatal life as causative factors in 
psychiatric disease derive from the two times higher incidence of schizophrenia in 
the Dutch offspring cohort that was conceived in the last month of the 1944-1945 
Dutch hunger-winter [19]. The schizophrenia incidence in this cohort coincided 
with a 2.5 times higher incidence of neural tube defects (NTDs), which suggests 
involvement of low folate status. The about two times higher schizophrenia relative 
risk associated with maternal undernutrition was recently confirmed in a study of 
the massive 1959-1961 famine in China [20]. Folate involvement is further 
strengthened by the demonstration of coinciding seasonal fluctuations in birth 
incidence of patients with NTDs and schizophrenia, with both disorders exhibiting 
highest conception rates in May-June [21]. A third indication of folate involvement 
may come from the study of immigrant populations. Immigrants are less likely to 
use folic acid supplements preconceptionally and in the first trimester [22-25], and 
they also have higher NTD rates [23]. Both of these seem to relate to the alarmingly 
higher incidence of schizophrenia in the second-generation offspring (5). A recent 
meta-study of 2,265 schizophrenia cases and 2,721 controls revealed that the 
homozygous methylene tetrahydrofolate reductase (MTHFR) 677C→T variant is 
characterized by a 1.36 (1.07-1.72) higher odds ratio for schizophrenia, as compared 
with the CC wildtype [26]. MTHFR TT homozygotes are in need of higher folate 
status for similar MTHFR functioning compared with CT and CC counterparts, CHAPTER 1 
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because of the thermolability and reduced activity of the MTHFR 677C→T enzyme 
[27]. Finally, Moretti et al. [28] reported on a 6-years-old girl with cerebral folate 
deficiency, developmental delay, psychomotor regression, seizures, mental 
retardation and autistic features, who after one year of folinic acid supplementation 
responded favorably with regard to neurological development to exhibit 'classic' 
autistic features. Other indications in favor of nutritional imperfections in 
pregnancy and early postnatal nutritional status derive from the association 
between short birth intervals and schizophrenia in the offspring [29], and the 
association of schizophrenia with the total number of siblings per household during 
childhood [30]. Patients with schizophrenia living in ‘developing countries’ have 
consistently been found to have a differential advantage in course and outcome of 
the disease, which is probably on account of environmental factors and notably diet 
[31]. Schizophrenia runs a more severe course in countries with a relatively high 
saturated fat intake and low unsaturated fat intake [2;32]. Many studies of patients 
with schizophrenia have shown low circulating folate and mildly increased 
homocysteine [33-36] and, occasionally strongly, impaired LCPUFA status, 
including  ω3LCPUFA status [37;38]. Serum folate concentrations in patients with 
schizophrenia correlate inversely with the severity of negative symptoms [34], 
while a randomized controlled trial with methylfolate in patients with major 
depression or schizophrenia improved both clinical and social recovery [39]. The 
picture emerges that low folate status, or possibly abnormal one-carbon metabolism 
in general, and low polyunsaturated fatty acid status might be among the offending 
factors that are involved in both the etiology and the severity of at least some 
psychiatric diseases.  
4.  Folate, one-carbon metabolism and epigenetics 
‘Epigenetics’ refers to modifications in gene expression that do not entail a change 
of DNA sequence. The discipline studies heritable, but potentially reversible, 
c h a n g e s  i n  g e n e  e x p r e s s i o n  b y  D N A  m e thylation and alterations of chromatin 
structure [40-44]. DNA methylation makes use of S-adenosylmethionine (SAM) as a 
substrate. SAM is the methyldonor of over 80 methylation reactions known to date, 
and many micronutrients, including those in the folate cycle, are indirectly 
involved in its synthesis from the essential amino acid methionine (Figure).       FOLATE AND LCPUFA IN PSYCHIATRIC DISEASE 
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SAM-substrated DNA methylation by DNA methyltransferases is predominantly 
directed at CpG dinucleotides, in which the cytosine is converted to 5-
methylcytosine. These CpGs tend to occur in ‘islands’ that are abundant in 
promoter regions of genes that are regulated in their expression by methylation. 
Epigenetic modification of chromatin structure occurs by SAM-substrated 
methylation of histones and also by their acetylation, phosphorylation and 
ubiquitylation. Different phenotypic characteristics of somatic cells within a single 
organism provide a lively example of the biological importance of the resulting 
'epigenotype' of which much is based on gene-silencing by DNA methylation, or, 
alternatively, on gene-activation through methylation of suppressor genes. Most 
somatic cells are in this manner ‘locked’ into specific patterns of gene expression, 
which provides the basis of cell differentiation, and thereby the typical 
characteristics of e.g. a hepatocyte or neuron. Analogous to the memory contained 
within a liver cell that it is to remain a liver cell, even after mitosis, it has been 
suggested that synaptic input or other environmental stimuli lead to epigenetic 
changes that are at the basis of synaptic plasticity and thereby the formation of 
long-term memory and adjustment of neural functioning [45]. 
  It has for long been believed that epigenetic modifications that are acquired 
during the life of an animal are erased during gametogenesis (i.e. meiosis) to restore 
the totipotency of the fertilized egg, and that these modifications can therefore not 
be transmitted to the next generation. This proved however incorrect for at least 
some mammalian alleles (so called metastable epialleles), and it is now clear that 
through this mechanism phenotype can be inherited by events that are mostly 
considered stochastic in nature. Transgenerational inheritance of the epigenetic 
state conserved in meiosis is distinct from parental imprinting and from epigenetic 
maintenance during mitosis. Following erasure of epigenetic marks during meiosis, 
parental imprinting entails epigenetic silencing of an allele according to the sex of 
the animal. It causes ‘parent-of-origin specific effects’ that derive from monoallelic 
expression in somatic cells of the offspring and in which the epigenetically 
inactivated gene may derive either from the mother or father. Mitotic epigenetic 
maintenance on the other hand refers to the propagation of the epigenetic state 
during cell division. The fidelity of DNA methylation maintenance in dividing 
cultured mammalian cells amounts to 97-99.9% per mitosis, whereas the de novo 
methylation amounts to 3-5% per mitosis [43]. The changes in the epigenome 
following mitosis, driven by (e.g. hormone initiated) developmental programs of 
cell and tissue differentiation, aging, microenvironment but also stochastic events, 
may induce further variation in the ultimate phenotypic characteristics. It has e.g. 
recently been established that with advancing age monozygous twins may exhibit 
deviant gene activities that trace down to epigenotypic differences [46]. Phenotypic CHAPTER 1 
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Figure. One-carbon metabolism and its immediately surrounding metabolic pathways. 
Indicated are the folate cycle (top, left), the methionine-homocysteine cycle (top, middle), the 
transsulphuration pathway and its connection with cystathionine/glutathione synthesis (middle, and middle-
bottom), the betaine-homocysteine regeneration pathway (top right) and the choline-betaine connection with 
phospholipid synthesis and phospholipid interconversion (top right, and top middle to bottom). One-carbon 
metabolism might play an important role in epigenetics, which refers to modification of gene expression that 
do not entail a change of DNA base sequence. Epigenetics studies heritable, but potentially reversible, changes 
in gene expression by DNA methylation and/or alteration of chromatin structure. DNA methylation occurs by 
SAM-substrated methylation of cytosine bases in notably CpG sequences and is catalyzed by DNA 
methyltransferases. Dysbalances in one-carbon metabolism may cause altered states of DNA methylation and 
thereby phenotypic changes that in early life are connected with developmental plasticity, and that at later 
life are associated with complex diseases, including cardiovascular disease, some cancers and psychiatric 
disease. 
 
•  10f-THF, 10-formyltetrahydrofolate;  
•  5,10-CH_THF, 5,10-methenyltetrahydrofolate; 
•  5,10-CH2-THF, 5,10-methylenetetrahydrofolate;  
•  5mTHF, 5-methyltetrahydrofolate;  
•  AICAR, aminoamidazolecarboxamide ribotide. 
•  AICART, aminoimidazolecarboxamide ribotide 
transformylase;  
•  B2, vitamin B2 (flavin adenine dinucleotide)  
•  B12, vitamin B12 (methylcobalamin), 1+ and 2+ refer to 
oxidation state of cobalt atom;  
•  B6, vitamin B6;  
•  BHMT, betaine homocysteine methyltransferase;  
•  CBS, cystathionine β-synthase;   
•  CDP, cytidine diphosphate;  
•  Chol ox, choline oxidase;  
•  CK, choline kinase;  
•  CPT, CDP-choline:1,2-diacylglycerol 
cholinephosphotransferase;  
•  CT, CTP-phosphocholine cytidylyltransferase; 
•  Cys, cysteine;  
•  Cys-Gly, cysteinylglycine;  
•  decSAM, decarboxylated S-adenosyl methionine;  
•  DHF, dihydrofolate;  
•  DHFR, dihydrofolate reductase; 
•  DMGlycine, dimethylglycine;  
•  dTMP, thymidine monophosphate;  
•  dUMP, 2'deoxyuridine monophosphate;  
•  FAD(H2), oxidized (reduced) flavin adenine 
dinucleotide (vitamin B2);  
•  Fin and Fout, the rates at which 5mTHF enters and 
leaves the cell, respectively;  
•  FTD, 10-formyltetrahydrofolate dehydrogenase; 
•  FTS, 10-formyltetrahydrofolate synthase;  
•  GAR, glycinamide ribotide;  
•  Glu, glutamine;  
•  Glu-Cys, glutamylcysteine;  
•  Gly; glycine;  
•  GSH, reduced glutathione (Glu-Cys-Gly);  
•  GSSG, oxidized glutathione;  
•  MAT, methionineadenosyltransferase;  
•  MTR, methionine synthase;  
•  MTCH, 5,10-methylenetetrahydrofolate 
cyclohydrolase; 
•  MTD, 5,10-methylenetetrahydrofolate 
dehydrogenase; 
•  MTF, methyltransferases (including DNA 
methyltransferases);  
•  MTHFR, 5,10-methylenetetrahydrofolate 
reductase;  
•  MTRR, methionine synthase reductase;  
•  NADP(H), oxidized (reduced) nicotinamide 
adenine dinucleotide phosphate;  
•  NE, nonenzymatic interconversion of THF 
and 5,10-CH2-THF;  
•  PC, phosphatidylcholine;  
•  PE, phosphatidylethanolamine;  
•  PEMT, phosphatidylethanolamine N-
methyltransferase;  
•  PGA, pteroyl-L-glutamic acid (folic acid);  
•  PGT, phosphoribosyl 
glycinamidetransformylase;  
•  PS, phosphatidylserine;  
•  PSD, phosphatidylserine decarboxylase;  
•  PSS1 and 2, phosphatidylserine synthase;  
•  ROOH, peroxide;  
•  SAH, S-adenosylhomocysteine;  
•  SAHH, S-adenosylhomocysteine hydrolase 
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  adjustment by epigenetic modification, together with long-term adjustment of 
DNA base-sequence by mutation and short-term adjustment by interaction with 
the environment through transcription factors, are at the center of our ability to 
adapt to the ‘conditions of existence’, which on its turn constitutes the major 
driving force of evolution. Any change of environment (e.g. current lifestyle) 
beyond the flexibility of base-sequence, epigenetics or physiological interaction 
with nuclear transcription factors, puts us at risk of disease development.  
  Epigenetic deregulated (otherwise perfectly normal) genes, or combinations of 
these with disease susceptibility genes, are more likely to be at the basis of complex 
diseases than gene mutations or polymorphisms per se. Epigenetic deregulation may 
notably account for the incomplete penetrance, such as encountered in autism and 
schizophrenia. Parent-of-origin specific gene regulation by imprinting, and triggers 
like gender (i.e. hormones) and endocrine rearrangements during life, may 
unfavorably affect epigenetic status and thereby explain [40;44] the relation of 
complex diseases with low birth weight and obstetric complications (autism and 
schizophrenia), gender inequality (male/female=4 in autism), as well as the late 
onset, the peak periods of onset during life and the fluctuating course of psychosis 
in schizophrenia [43]. Parent-of-origin imprinting and hormones are well known 
factors to affect epigenetic status but also nutrition proved intimately involved in 
epigenetic status and its heritability. The latter was elegantly demonstrated by 
Waterland and Jirtle [47;48], who studied the influence of 'methylation diets' on 
phenotype. They supplemented female mice with extra folic acid, vitamin B12, 
choline and betaine (see Figure) from 2 weeks prior to conception until weaning to 
show augmented methylation of a retroviral element within the so called ‘agouti-
gene’, which is a gene that determines the color of their coat. The intervention 
(partially) silenced the agouti-gene by methylation and thereby caused the coat 
color of the offspring to shift permanently from yellow into the brownish (pseudo-
agouti) phenotype, while there was also evidence of transgenerational transmission. 
Another study emphasized the importance of homocysteine and S-
adenosylhomocysteine (SAH). These are products of SAM methylation (Figure) and 
SAH is a potent inhibitor of methyltransferases. In this study Friso et al. [49;50] 
showed that genomic DNA methylation correlates directly with folate status and 
inversely with levels of plasma homocysteine. The study group was a mixed 
population of patients with and without coronary artery disease, and, consistent 
with MTHFR activity, the encountered association of global DNA methylation with 
folate tracked down to lower DNA methylation in MTHFR 677C→T homozygotes 
with low folate status [49]. Their results suggest that interaction between 
nutritional status and genetic polymorphism has the potential to modulate gene 
expression through DNA methylation [49;50]. A study of Ingrosso et al. [51] with       FOLATE AND LCPUFA IN PSYCHIATRIC DISEASE 
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hyperhomocysteinemic patients on hemodialysis revealed global and locus-specific 
DNA hypomethylation, which was probably mediated by the associated increase of 
the methyltransferase inhibitor SAH. Importantly, subsequent folic acid 
supplementation augmented both global and locus-specific DNA-methylation, as 
derived from the switch from abnormal biallelic expression to normal monoallelic 
expression for a number of genes with known sensitivity to methylation. The study 
showed that folate status affects the expression of sex-linked and imprinted genes, 
which are both characterized by the expression of specific alleles, and that these 
effects are not limited to early life. A recent study of Lillycrop et al. [52] showed 
that dietary protein-restriction of pregnant rats, a well known model that reduces 
fetal growth, causes lower methylation status and activation of the genes for the 
glucocorticoid receptor and peroxisome proliferator activated receptor-alpha 
(PPAR-α) in the livers of their offspring. These receptors are important in 
embryogenesis, and in postnatal blood pressure and metabolic control, and are 
among the many candidates to be involved in fetal programming. The observed 
changes proved persistent up to at least 6 days after weaning and could be 
prevented by fortification of the protein-restricted diet with folic acid. The study 
showed that methylation of specific genes in specific tissues, as induced by an 
unbalanced diet, might be at the basis of phenotypic changes in early development 
[52]. Other causes may be reduced uterine blood flow, maternal postnatal behavior 
and social interaction [53]. The altered epigenotype might persist throughout the 
lifespan, passed on to the next generation and one-carbon metabolism might be 
central from a mechanistic perspective. 
  There is as yet no solid evidence of epigenetic factors in schizophrenia. The 
disease has, however, been linked to prenatal deficiencies of folate (see above), 
vitamin B6 and vitamin B12 [29], which are micronutrients that are either directly or 
indirectly involved in one-carbon metabolism and thereby in gene expression and 
repression through methylation (Figure). Petronis et al. [54] conducted a pilot study 
on the epigenetic status of the 5'-regulatory region of the dopamine D2 receptor 
gene (DRD2). DRD2 has been listed as a candidate gene for schizophrenia 
susceptibility and DRD2 antagonism is common to all antipsychotics. They studied 
two pairs of monozygous twins, one concordant and one discordant for 
schizophrenia. It appeared that the affecte d  t w i n  f r o m  t h e  p a i r  d i s c o r d a n t  f o r  
schizophrenia was epigenetically 'closer' to the affected concordant twins than to 
his unaffected monozygous co-twin, suggesting that schizophrenic patients have 
similar epigenetic status of DRD2. Schizophrenia symptomatology is already for 
some time known to become exacerbated by high doses of methionine (Figure) [55]. 
Mice receiving prolonged treatment with methionine exhibit behavior patterns that 
mimic specific phenotypic aspects of schizophrenia and this coincides with CHAPTER 1 
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augmented brain contents of SAM, hypermethylation of the reelin promoter and 
downregulated expression of both reelin and glutamic acid decarboxylase (GAD67). 
Both reelin and GAD67 carry CpG islands in their promoter regions, and the degree 
of reelin methylation in this region correlates inversely with reelin expression 
[56;57]. The reelin protein is necessary for neuronal migration, axonal branching, 
synaptogenesis and cell signaling, while GAD67 is one of the two isoenzymes that 
synthesize the neurotransmitter gamma-aminobutyric acid. Several studies have 
shown reduced reelin mRNA and protein levels in postmortem brains of patients 
with schizophrenia, and also in patients with bipolar disorders [58]. Recent studies 
of postmortem brains of schizophrenic patients and controls revealed reelin gene 
promoter hypermethylation and downregulation of reelin and GAD67 expression, 
suggesting an epigenetic basis for their hypoactivity in schizophrenia [58-60]. Also 
postmortem brains of autistic patients contain low levels of the reelin mRNA and 
protein, which together with some other anomalies suggest impairment of the 
reelin signaling pathway in autism as well [61]. Iwamoto et al. [62] reported a 
tendency towards a highly methylated state of the CpG island of the SOX-10 gene 
i n  t h e  b r a i n s  o f  p a t i e n t s  w i t h  s c h i zophrenia. The SOX-10 gene codes for an 
oligodendrocyte-specific transcription factor and it was found that the percentage 
methylated allele correlated inversely with relative SOX-10 expression. Catechol-
O-methyltransferase (COMT) is a strong candidate in the etiology of schizophrenia. 
Methylation of the promoter of soluble COMT in the brain of patients with 
schizophrenia was ruled out as a common cause, but one patient with extreme 
negative symptoms showed the unique feature of full methylation of the 23rd 
cytosine [63]. James et al. [64] reported on 20 children with autism and 33 controls 
in which they studied the plasma concentrations of several metabolites in the 
methionine transmethylation and transsulfuration pathways (Figure). In autism 
they found higher SAH, adenosine and oxidized glutathione (GSSG) in conjunction 
with lower methionine, SAM, SAM/SAH ratio, homocysteine, cystathionine, 
cysteine, total glutathione and total glutathione/GSSG ratio. This profile is 
consistent with lower methylation capacity (i.e. lower SAM/SAH ratio) and 
increased oxidative stress (relatively increased GSSG) and proved correctable by 
supplementation with folinic acid, betaine and methylcobalamin. A recent study by 
Lamb et al. [65] identified two discrete loci underlying linkage of autism to 
chromosome 7 with possible parent-of-origin specific effects and a role of (an) 
imprinted gene(s). The involvement of epigenetic  rather than genetic  variation 
might explain the lack of causative base-sequence variants so far identified in 
candidate genes in these regions. It may be concluded that the number of studies on 
the epigenetic basis of psychiatric disease and the number of investigated patients is 
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what is presently considered to be single disease entity and given a possible multi-
hit etiology that starts in the maternal uterus, or perhaps even prior to conception 
up to oogenesis in the grandmaternal womb. 
5.  Long chain polyunsaturated fatty acids and brain 
development 
Low status of long chain polyunsaturated fatty acid (LCPUFA; ≥20 carbon atoms 
and  ≥3 methylene-interrupted cis-double bonds) may play a role as one of the 
offending factors in both the etiology of psychiatric disease and its severity. 
LCPUFA are either of the ω6 or ω3 series. Qualitatively and quantitatively 
important LCPUFA are arachidonic acid (AA, an ω6LCPUFA notably from meat), 
eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) (both ω3LCPUFA 
from fish) [66;67]. They derive from the parent essential fatty acids (EFA) linoleic 
and alpha-linolenic acids and some of the C20 members (i.e. AA, EPA and dihomo-
gamma-linolenic acid) are precursors to eicosanoids (prostaglandins, thromboxanes, 
leukotrienes). LCPUFA are building blocks of membrane phospholipids of all cells, 
in which they contribute to the physical properties of the membrane and to 
(synaptic) signal transduction. EFA make up 20% of brain dry weight, including 
about 6% for AA and 8% for DHA. DHA and AA are determinants of membrane 
fluidity, which is important for the efficacy of neurotransmitter-receptor 
interaction and transporters. AA is of special importance as a second messenger in 
signal transduction [68]. DHA is the major structural lipid of the retinal 
photoreceptor outer segment membrane, where its fluidity is essential to 
accommodate the extremely rapid conformational changes of rhodopsine [68]. Both 
AA and DHA are important to maintain a healthy endothelium of our 
cardiovascular system [69;70], of which the brain is obviously dependent for 
adequate nourishment. LCPUFA synthesis from the parent precursors may be 
subject to ‘programming’ that affects the vascular endothelium. A high saturated fat 
diet given to pregnant rats caused reduced AA and DHA and increased linoleic and 
alpha-linolenic acids in the aorta of their offspring, suggesting poor conversion of 
precursor EFA to LCPUFA. These abnormalities coincided with vascular 
dysfunction and persisted to adulthood [71]. 
  LCPUFA are not only important membrane structural elements, but, together 
with their eicosanoid products, they are also firmly implicated in gene expression. 
For example, dietary LCPUFA are ligands to peroxisome proliferator activated 
receptors (PPARs) and suppress the expression of sterol regulatory element binding 
proteins (SREBPs). These are nuclear transcription factors that can be considered as 
main switches in the coordinated expression and repression of a variety of (key) 
enzymes in intermediary metabolism, thermoregulation, energy partitioning, CHAPTER 1 
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growth and differentiation, and inflammatory responses [72-75]. ‘Nutrigenomics’ 
studies in rats revealed that ω3LCPUFA (i.e. notably EPA and DHA) modulate the 
expression and repression in brain of a sizeable number of genes that are involved 
in structure, energy metabolism, neurotransmission, signal transduction and 
regulation [76;77]. Dietary LCPUFA also influence neurotransmitter physiology. 
Experiments with rats showed that fish oil supplementation influences several 
neurochemical and behavioral features of monoaminergic function, causing a 40% 
higher dopamine content in the frontal cortex, a reduction of monoamineoxidase-B 
activity, greater binding to DRD2 and 25% lower ambulatory activity as compared 
to controls [78]. 
  LCPUFA-rich fresh- and salt-water shoreline-based diets are likely to have 
been at the basis of our larger and more sophisticated brains compared with other 
primates. A constant dietary LCPUFA supply and notably that of DHA might 
therefore be important [79-87]. DHA might at least be conditionally essential, since 
we have limited ability for its synthesis from the parent essential fatty acid alpha-
linolenic acid [88-91]. Higher dietary DHA intake may on its turn require higher 
AA intake to prevent competition between ω3LCPUFA and ω6LCPUFA, while 
alpha-linolenic acid has an independent role as a precursor to cholesterol synthesis 
in brain [92]. This lays emphasis on a dietary ω3/ω6 balance [66;67;93;94]; a balance 
that since the industrial revolution has increasingly become violated in favor of 
higher intake of ω6 fatty acids (notably linoleic acid), decreasing intake of ω3 fatty 
acids and increasing intake of saturated and trans fatty acids [94]. Deficiency of ω3 
fatty acids in primates is, amongst other conditions, associated with psychiatric 
pathology [95], and with reduced learning, abnormal electroretinograms and visual 
impairment in humans [96]. AA and DHA status in preterm babies is related to 
birth weight, head circumference and length at birth [97-100], and both AA and 
DHA may be protective against the central nervous, visual and auditory damage 
that is typical for (very) premature babies [101]. Various studies have shown 
suboptimal neurodevelopment of both preterm and term babies receiving infant 
formulas without LCPUFA, although many of these effects might be transient [102-
108]. It is clear that LCPUFA have important functions in brain and that notably 
the low ω3LCPUFA status of the contemporary Western diet might put us at risk of 
suboptimal brain development and functioning. 
6. Schizophrenia-phospholipid hypothesis 
There are (anecdotic) reports that i) feverish illness in schizophrenics ameliorates 
their psychiatric symptoms, ii) schizophrenics rarely suffer from rheumatoid 
arthritis (suggesting a generalized reduced inflammatory response), iii) 
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induced) cutaneous flush that follows nicotinic acid ingestion or topical application, 
and iv) schizophrenia in developing countries with higher LCPUFA intakes runs a 
less severe course [2;31;32;109]. Horrobin [2] linked these observations to develop 
the so called ‘phospholipid hypothesis’ that states that schizophrenia is a systemic 
disease with a central theme of impaired AA release and consequently insufficient 
production of its eicosanoid metabolites to support adequate signal transduction 
[110]. In other words, we are possibly dealing with a genetically determined 
generalized ‘abnormality’ of phospholipid metabolism that might be sensitive to 
prevention or correction by nutritional factors. These nutritional factors are likely 
to be LCPUFA, of which the intake has been subject to tremendous decline since 
the industrial revolution. Lower contemporary intake in Western countries is e.g. 
suggested by the relatively high AA and DHA status of Tanzanian women who 
consume an AA and DHA-rich, fresh water fish-based, diet that (in this respect) is 
likely to be close to our ancient diet [111]. It is possible that the genetic make-up of 
patients with schizophrenia would in the past not have precipitated to disease and 
that the LCPUFA-rich diet of our ancestors enabled them to take full evolutionary 
advantage of the associated intelligence and creativity [2]. 
  Consistent with the increased LCPUFA losses postulated by the phospholipid 
hypothesis, both patients with schizophrenia [32;112] and autism [113] have 
increased activity of phospholipase A2, which releases AA from membrane 
phospholipids (a process vital to brain cell signaling), while their LCPUFA in 
erythrocytes appear more sensitive to oxidative stress in vitro [113;114]. Brain 
magnetic resonance spectroscopy studies in schizophrenics showed signs of 
increased phospholipid turnover, electroretinograms of patients with schizophrenia 
are abnormal (suggesting low retinal DHA content), and incorporation of AA into 
phospholipids seems to occur with difficulty [2]. Taken together, these data suggest 
local AA depletion and insufficient synthesis of AA-derived eicosanoids, which 
becomes e.g. noticeable by amelioration of psychiatric symptoms by fever-
associated eicosanoid release, pain resistance by eicosanoid-shortage at basal 
conditions, and poor ability to exhibit an eicosanoid-induced flush upon nicotinic 
acid treatment. Das [115] hypothesized that perinatal supplementation of LCPUFA, 
especially EPA and DHA, may prevent schizophrenia in the adult. He considers 
schizophrenia to be a low-grade systemic inflammatory disease with origins in the 
perinatal period, probably triggered by maternal infection in a genetically 
susceptible individual that leads to excess production of pro-inflammatory 
cytokines both in the mother and fetus. The infection compromises LCPUFA status 
with devastating neurodevelopmental effects that should theoretically be favorably 
responsive to augmented LCPUFA status. 
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7. Fish  oil,  schizophrenia and depression 
Low intake of the fish oil fatty acids EPA and DHA is implicated in the high 
incidence of depression in Western countries. The incidence of depression has 
increased markedly in recent decades [116] and there is a strong inverse correlation 
between national dietary fish intakes and rates of major and postpartum depressions 
[117;118]. Depressive symptoms are more likely to be encountered in infrequent 
fish consumers and EPA and DHA status is low in depressive patients. There are 
also close relationships between fish consumption and the incidence of 
cardiovascular disease and depression, which fuelled the suggestion that depression 
should be included into the cluster of diseases that are associated with the 
metabolic syndrome [32]. Data from the UK show that the peak age of 
schizophrenia onset (i.e. 19-24 years) coincides with the highest intake of burgers 
(i.e. saturated fat) and full-sugar carbonated drinks and the lowest intake of oily fish 
[119]. A meta-analysis of dietary patterns in various countries linked the intake of 
refined sugar and dairy products to a worse 2-year outcome of schizophrenia, while 
a high national prevalence of depression became predicted from low intake of fish 
and seafood [120]. These data demonstrate that there are basically no differences 
between dietary risk factors for poor mental health, cardiovascular disease and 
some cancers. Five out of 6 double-blind placebo-controlled trials with add-on ω3 
fatty acid (notably EPA) supplementation in schizophrenia have so far produced 
positive results, whereas 4/6 of such trials produced positive effects in depression 
and bipolar disorders [32;37;121]. In other words, LCPUFA are likely to be involved 
in the etiology of at least some psychiatric diseases, but also in their presentation in 
terms of severity at later age. 
8. Conclusions 
Current research on the etiology of psychiatric disease seems to fall short of the 
input of nutrition and may be somewhat overdosed with genetics and the 
traditional search for abnormal neurotransmitter metabolism per se. Folate, other 
one-carbon metabolite micronutrients, and dietary LCPUFA might play important 
roles in the etiology of at least some psychiatric diseases in their capacity as 
modulators of gene expression through epigenetic mechanisms (folate), and as brain 
structural components, precursors of signal-transducing eicosanoids and ligands to 
nuclear transcription factors (LCPUFA). Low status of micronutrients involved in 
one-carbon metabolism and low LCPUFA status are also likely to be factors in 
psychiatric disease severity.       FOLATE AND LCPUFA IN PSYCHIATRIC DISEASE 
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Abstract 
We assessed essential fatty acid (EFA) and B-vitamin status, together with their 
determinants, in 61 patients with schizophrenia and established whether those with 
poor status responded biochemically to the appropriate dietary supplements. As a 
group, the patients had high erythrocyte saturated fatty acids (FA), 
monounsaturated FA and low polyunsaturated FA of the ω3 and ω6 series. Patients 
reporting not to take vitamin supplements had low vitamin B12 and high 
homocysteine. Homocysteine variance proved best explained by folate in both the 
total group and male patients, and by vitamins B12 and B6 in females. Alcohol 
consumption and duration of illness are risk factors for low polyunsaturated FA 
status (<P2.5 of reference range), while male gender and absence of fish 
consumption predict hyperhomocysteinemia (>P97.5 of reference range). Two 
patients exhibited biochemical EFA deficiency and 7 showed biochemical signs of 
ω3/docosahexaenoic acid (DHA) marginality. Four patients exhibited moderate 
hyperhomocysteinemia with plasma values ranging from 57.5-74.8 μmol/L. None of 
the 5 patients with either moderate hyperhomocysteinemia, biochemical EFA 
deficiency, or both, was predicted by their clinicians to have a poor diet. That diet 
was nevertheless at the basis of these abnormalities became confirmed after 
supplementing 4 of them with B-vitamins and with soybean and fish oils. We 
conclude that a subgroup of patients with schizophrenia has biochemical EFA 
deficiency,  ω3/DHA marginality, moderate hyperhomocysteinemia, or 
combinations. Correction seems indicated in view of the possible relation of poor 
EFA and B-vitamin status with their psychiatric symptoms, but notably to reduce 
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1. Introduction 
Patients with schizophrenia have frequently been shown to have a low status of 
essential fatty acids (EFA) of both the ω3 and ω6 series. Low erythrocyte (RBC) 
c o n t e n t s  o f  l i n o l e i c  a c i d  ( L A ;  1 8 : 2ω6) and the long chain polyunsaturated fatty 
acids (LCP) arachidonic acid (AA; 20:4ω6) and docosahexaenoic acid (DHA; 
22:6ω3) are the most consistent findings [1]. Some results of former studies may 
have been confounded by LCP losses in the pre-analytical phase, which might be 
due to the higher sensitivity of the LCP in the RBC of patients with schizophrenia 
to oxidative stress in vitro [2]. Other possible causes for low LCP status in 
schizophrenia might relate to a reduced rate of LCP incorporation into 
phospholipids and increased phospholipase-catalyzed loss (the so called ‘membrane 
phospholipid hypothesis’ [3]), the interaction with gender and smoking, or low 
dietary intake [4;5]. Low dietary intake of LCP [6] and low RBC LCP status [7;8], 
notably AA and DHA, are associated with an increase of psychiatric symptoms that 
may be at the basis of the well known cross-cultural differences in schizophrenia 
severity [9;10]. A meta-analysis of 2003 concluded that the use of ω3LCP in 
schizophrenia is still experimental and that the outcome of large, well designed, 
studies has to be awaited [11]. At present six out of 7 trials with (add-on) 
eicosapentaenoic acid (EPA; 20:5ω3) supplements yielded positive results on 
psychiatric end points [4;12;13]. 
  Patients with schizophrenia also have low functional B-vitamin status which 
becomes noticeable from above-normal level s  o f  p l a s m a  h o m o c y s t e i n e  [ 1 4 - 1 8 ] .  
Increased homocysteine levels in schizophrenic patients have, however, not 
consistently been found [19-21]. Homocysteine is a cytotoxic amino acid that is 
likely to be involved in both neurodegenerative disorders, like Alzheimer’s disease 
[22], and psychiatric disorders, including schizophrenia [23]. The major 
determinants of increased plasma homocysteine in the general population are low 
serum folate, vitamin B12 and betaine [24-26], which share functions in one-carbon 
metabolism [27]. Folate status in schizophrenic patients correlates inversely with 
negative symptoms [19] and in one study supplementation with methylfolate was 
found to enhance social and clinical recovery [28]. 
  Life expectancy of patients with schizophrenia is 20% shorter compared with 
the general population. The excess mortality is for 60% attributable to physical 
illness (circulatory, respiratory, digestive and genitourinary disease) with the 
remainder on account of suicide (28%) and accidents (12%) [29]. Some newer 
atypical antipsychotic drugs may have side effects such as weight gain, elevation of 
serum triglycerides and increased risk of diabetes mellitus type 2. All of these 
constitute risk of cardiovascular disease in a population segment with little exercise, CHAPTER 2 
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poor diet, almost universal smoking, and unhealthy lifestyle in general [13;29]. In 
other words, patients with psychiatric diseases, especially patients with 
schizophrenia, may benefit from good nutrition, and not merely with the aim of 
ameliorating psychiatric end points. Also mild hyperhomocysteinemia [30;31] and 
low  ω3LCP status [32-34] are risk factors for cardiovascular disease events and 
death. No matter the origin and whether these are features of all patients, both mild 
hyperhomocysteinemia and low ω3LCP status are correctable by supplementation 
of folic acid (or a folic acid, vitamin B12 and vitamin B6 combination) and fish oil, 
which calls for patient-individual dietary counseling and dietary supportive care, if 
necessary. 
  Using a cross-sectional study design we determined the frequency of low EFA 
and B-vitamin status in a representative group of patients with a schizophrenia 
spectrum disorder. We were also interested to see whether low status of EFA and 
B-vitamin in patients is predictable by their physicians. Finally, we examined 
whether those with low statuses improved biochemically after short term 
supplementation of soybean and fish oils and B-vitamins, including folic acid. 
2.  Patients and Methods  
2.1.  Patients, samples and analyses 
One hundred patients, classified as having schizophrenia according to the DSM-IV 
TR [35], were randomly selected from the files of the department of Psychiatry of 
the University Medical Center of Groningen in The Netherlands. The selected 
patients were asked to participate through invitation by mail, telephone or during 
therapeutic sessions with two of us (HK, RB). There were no other inclusion or 
exclusion criteria. Sixty-one (61%) patients agreed to participate. The study was 
performed in the summer of 2003. The protocol was in agreement with local ethical 
standards and the Helsinki declaration of 1964, as revised in 2002. 
  The participants were physically examined and their anthropometrical data 
were recorded. Information regarding smoking, alcohol consumption, drug abuse, 
use of nutritional supplements and fish consumption was obtained with the aid of 
an assisted questionnaire. Ages at onset of the illness, comorbidity and 
contemporary medication were taken from the hospital records. Non-fasting blood 
samples were obtained by venepuncture between 10.00 and 16.00 h for analyses in 
whole blood, serum, EDTA-plasma and isolated RBC. We analyzed routine clinical 
chemical and hematological indices in serum and EDTA-blood by standard clinical 
chemical methods. Serum folate and vitamin B12 (cyanocobalamin) were analyzed 
with a fluoroimmunoassay (Autodelfia, Wallac Oy, Germany), plasma 
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Illinois, USA), whole blood vitamin B6 (pyridoxine) by HPLC [36] and the RBC 
fatty acid composition (expressed in mol%) by capillary gas chromatography [37]. 
Addition of the RBC to the antioxidant-fortified transmethylation mixture, 
following the immediate isolation of RBC by washing, ensured the stability of 
unsaturated fatty acids in the preanalytical phase [37]. The typical day-to-day 
coefficients of variation range from 1.1-17.6%, dependent on the abundance of the 
analyte expressed in mol% [38]. 
2.2. Supplementation  of  patients with poor B-vitamin and EFA 
status 
Patients with isolated biochemical EFA deficiency were supplemented with a 
combination of soybean and fish oils and those with isolated moderate 
hyperhomocysteinemia were supplemented with B vitamins. For those with 
combined biochemical EFA deficiency and moderate hyperhomocysteinemia we 
chose to supplement first with EFA and second with B vitamins. No supplements 
were to be taken during the day prior to sampling. The patients were asked to 
continue supplementation beyond the twelfth week until they had their blood 
samples taken. 
  Patients with biochemical EFA deficiency (i.e. RBC 20:3ω9>0.46 mol% [38]) 
were supplemented for 12 weeks with purified fish oil capsules (Triomar; Pronova 
Biocare, Norway) corresponding with daily dosages of 310 mg EPA and 200 mg 
DHA. In this period they also received 15 mL soybean oil per day (generic brand 
from local grocer; Albert Heijn, The Netherlands) corresponding with daily dosages 
of 1 g ALA and 7 g LA. Soybean oil was added to the hot meal. Folic acid (800 μg) 
was added to this regimen from weeks 4 to 6 and the B-vitamin combination (800 
μg folic acid, 8 mg vitamin B6, 4 μg vitamin B12) was provided from weeks 6 to 12. 
Generic brand folic acid and B-vitamin supplements were purchased from a local 
drugstore (Etos, The Netherlands). Blood samples for analyses were taken at 0, 4, 6 
and 12 weeks. 
  Patients with moderate hyperhomocysteinemia (i.e. homocysteine levels 
ranging from 31-100 μmol/L [31;39]) were selected for supplementation with 800 
μg folic acid per day during 2 weeks. They were subsequently supplemented for 10 
weeks with an additional B-vitamin preparation, which resulted in a total daily 
intake of 800 μg folic acid, 8 mg vitamin B6 and 4 μg vitamin B12. From 4 to 12 
weeks the patients also received the same daily dosages of fish and soybean oils (310 
mg EPA, 200 mg DHA and 15 mL soybean oil). Blood samples for the analyses of B-
vitamin status parameters and RBC fatty acids were taken at 0, 2, 4 and 12 weeks. CHAPTER 2 
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2.3.  Data evaluation and statistics 
Patient characteristics (i.e. BMI, smoking and use of alcohol) were compared with 
age and sex matched data of the Dutch general population, as derived from the 2003 
Dutch National Food Consumption Survey [40]. Subgroups were defined according 
t o  m e d i c a t i o n  t y p e  i . e .  c l o z a p i n e ,  s i ngle atypical antipsychotic, multiple 
antipsychotics and classical antipsychotics. Antipsychotic medication dose was 
expressed as defined daily dose [41] and chlorpromazine (CPZ) equivalents [42]. 
Fish fat intake was expressed as ‘Q’, which equals the product of the number of days 
of fish consumption per week and a measure for the average fatness of the fish 
consumed. The average fatness ranged from lean (0.5-5% fat/g flesh) to oily (>5% 
fat/g flesh), giving rise to a measure of fatness ranging from 1 to 4. Using this index 
of fish fat intake (Q), the recommended intake of at least two servings of medium-
oily fish per week [43] would translate into a Q of 4. 
  Clinical chemical data were evaluated with the use of reference values as 
applied in our laboratory. For RBC fatty acids we used reference values (i.e. 2.5 and 
97.5 percentiles of healthy omnivorous controls) as previously reported [38]. These 
cut-off values are independent from the age of 0.2 years and apply for both sexes. 
RBC 20:3ω9 above 0.46 mol% was defined as biochemical EFA deficiency; an RBC 
22:5ω6/AA ratio above 0.068 mol/mol was considered to reflect isolated ω3-
deficiency; an RBC 22:5ω6/DHA ratio above 0.22 mol/mol but equal or below 0.48 
mol/mol was defined as ω3/DHA marginality; and an RBC 22:5ω6/DHA ratio above 
0.48 mol/mol was indicative for ω3/DHA deficiency [38]. For homocysteine we 
employed the 14.6 μmol/L upper limit of the reference range (i.e. P97.5) as derived 
from our previous study of healthy controls [44]. In addition we used a cut-off 
value (P97.5) of 9.3 μmol/L, as derived from data of apparently healthy subjects 
following supplementation with folic acid and the vitamins B12 and B6 (‘vitamin-
optimized cut-off value’; [44]). These cut-off values apply for both sexes, but may 
provide a somewhat conservative estimate for premenopausal female patients. 
Numbers of patients with scores below and above the local reference values were 
calculated and expressed as percentages of the total. Stratification for age was 
employed to investigate the age-dependent increase of homocysteine in young male 
patients [14;15]. 
  Statistical analyses were performed with the Statistical Product and Service 
Solutions package version 11.5 (SPSS Inc., Chicago). Differences in characteristics 
between patients and the Dutch general population were tested by Chi-square tests. 
Differences between patient and control data were tested at p<0.05 using either the 
Students' t or Mann-Whitney U tests, dependent on the normality of the 
distributions. P-values were corrected for relevant confounders (i.e. age and 
gender) using ANOVA or logistic regression, if applicable. Comparison of multiple                                                                                            B-VITAMIN AND LCPUFA DEFICIENCIES IN SCHIZOPHRENIA 
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subgroups (e.g. based on medication or DSM-IV TR classification) was performed 
with ANOVA (parametric) after Bonferroni correction or with the Kruskall-Wallis 
(non-parametric) tests. Bivariate correlations were examined by calculating either 
the Pearson (linear) or Spearman (non-linear) coefficients. Outcomes were 
considered significant at p<0.05. RBC fatty acids were examined for correlation 
with B-vitamin status parameters to explore general patterns in nutrition. 
Predictors of low PUFA (<P2.5 of reference range) and increased homocysteine 
(>P97.5 of the reference range) in the whole group were examined by multinominal 
logistic regression in which we tested a selected number of indices that in bivariate 
comparisons proved most significantly related to PUFA and homocysteine, 
respectively. Multivariate linear regression was used to explain variance in RBC 
20:3ω9 and plasma homocysteine. For this we tested the parameters that exhibited 
the most significant bivariate correlations. 
3. Results 
3.1. Patients 
Table 1 depicts the patient characteristics. The percentages female and male 
patients with overweight (BMI>25 kg/m2) were similar to the age- and gender-
matched data of the Dutch general adult population. The percentage obesity 
(BMI>30 kg/m2) was higher in female patients (30 vs. 11%; p<0.001), but not in 
male patients. The percentages smoking (55 vs. 30.8%; p<0.001), and heavy smoking 
(31 vs. 8.0%; p<0.01) were higher, which was notably on account of heavy smoking 
in female patients (39 vs. 8%; p<0.0001). The percentage patients consuming 
alcohol was lower (65 vs. 81.7%; p<0.005), although the percentage male patients 
reporting heavy drinking almost reached significance (27 vs. 17.0%; p= 0.053). The 
percentage patients reaching the recommended fish intake (Q≥4) was 21%, while 
10% reported not to consume fish at all. Smoking, alcohol and fish consumption did 
not differ significantly between sexes. The patients reporting intake of vitamins 
and/or fish oil supplements had better B-vitamin and LCPω3 status, respectively 
(data not shown). Patients reporting gastrointestinal disturbances (24%) did not 
differ in their characteristics, RBC fatty acid composition and B-vitamin status 
parameters, compared with those not having such complaints (not shown). CHAPTER 2 
- 108 - 
Table 1. Patient characteristics. 
 
 
 
Gender (M | F)  37 | 24     
Age (years)  31.5 (9.2)     
BMI (kg/m2) a  25.5 (4.1)     
BMI (<18.5 | 18.5-25 | 25-30 | >30)  a  0 | 26 | 18 | 8     
Hospitalized | Community dwelling  14 | 47     
Age at onset of illness (years) b  23 (16-45)     
Duration of illness (years) b  5 (1-20)     
Diagnosis according to DSM-IV      
 295.3: paranoid type  21/61 (34%)     
 295.4: schizophreniform disorder  9/61 (15%)     
 298.9: psychotic disorder NOS  8/61 (13%)     
 295.9: undifferentiated type  7/61 (12%)     
 other  16/61 (26%)     
Medication    Dose (mg/day)  Defined Daily Dose c 
 olanzapine (N05AH03)  19/61 (31%)  11.8 (5-20)  1.18 (0.5-2) 
 risperidon (N05AX08)  19/61 (31%)  3.0 (1-8)  0.6 (0.2-1.6) 
 clozapine (N05AH02)  9/61 (15%)  363 (200-500)  1.21 (0.67-1.67) 
 other  17/61 (28%)     
 no medication  2/61 (3%)     
Average dose    280.5 (78.3)d  0.94 (0.26) 
  Yes (fraction; %)  Median (range)   
Diabetes Mellitus e  1/53 (2%)      
Smoking f  30/56 (55%)       
Cigarettes/day   20  (1-40)     
 heavy smoking g 17/56  (30%)       
 cigarettes/day in heavy smokers    20 (20-45)     
Recent use of cannabis b  12/55 (22%)       
Alcohol f  36/56 (64%)       
 units/day h   0.7  (0.1-23)     
 heavy drinking i 10/56  (18%)       
 units/day in heavy drinking    3.9 (3-23)     
GI disturbances j  14/58 (24%)                                                                                                  B-VITAMIN AND LCPUFA DEFICIENCIES IN SCHIZOPHRENIA 
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Table 1. Patient characteristics (continued). 
 
 
Data are for 61 patients unless otherwise indicated. Data represent numbers, fractions (%), means (SD), or 
medians (range). a n=52, BMI of the patient with diabetes mellitus was 22.3 kg/m2; b n=55; c defined daily dose 
calculated with [41]; d chlorpromazine equivalents calculated with [41;42]; e n=53; f n=56; g ≥20 cigarettes per 
day; h 1 unit equals 20 mL of pure ethanol; i ≥3 alcohol units per day; j n=58; k Q is an index for fish fat intake, 
that equals the product of the number of days of fish consumption per week and an arbitrary measure for the 
average fatness of the fish consumed; l vitamins n=4, fish-oil supplements n=2. 
 
3.2.  Erythrocyte fatty acids 
Table 2 shows the RBC fatty acid composition of patients and controls together 
with the percentage patients with values below and above the respective reference 
values. Between (sub)groups comparisons were done with patients reporting no 
intake of fish-oil supplements. Type or doses of antipsychotic medication were not 
significantly related to the RBC fatty acid composition. Most remarkable was the 
higher RBC saturated fatty acids (SAFA) content of the patients (p<0.001), with 19 
(31%) patients exhibiting levels above the P97.5. Higher SAFA was notably 
attributable to higher 16:0 (p<0.001) and 12 (20%) patients had levels above P97.5. 
The percentage monounsaturated fatty acids (MUFA) (p<0.001), notably 18:1ω9 
(p<0.001), was also higher, with 15 (25%) and 33 (54%) patients having contents 
above the P97.5, respectively. Higher RBC SAFA and MUFA coincided with lower 
polyunsaturated fatty acids (PUFA) (p<0.001), with 25 (41%) patients having 
contents below the P2.5. The lower PUFA status was attributable to different 
combinations of lower status of ω3 (p<0.001; 13% below P2.5), ω6 (p<0.001; 13% 
below P2.5), alpha-linolenic acid (ALA; 18:3ω3) (p<0.001; 36% below P2.5), DHA 
(p<0.001; 13% below P2.5), AA (p<0.05; 11% below P2.5) and 22:4ω6 (p<0.001; 
11% below P2.5). Biochemical EFA deficiency (i.e. RBC 20:3ω9>0.46 mol%) was 
found in one male and one female patient, both 53 years of age of which one 
reported to not eat fish at all, whereas no such data were available from the other. 
Isolated biochemical ω3-deficiency, as indicated by increased RBC 22:5ω6/AA 
ratio, was not observed in our study group.  
  Yes (fraction; %)  Median (range)     
Fish intake j  52/58 (90%)       
 Q k   1  (0.04-21)     
 Q≥4 of those eating fish  11/52 (21%)       
 Q of those with Q≥4   8  (4-21)     
Use of supplements e  5/53 (9%) l      CHAPTER 2 
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Biochemical ω3/DHA marginality, as derived from a 22:5ω6/DHA ratio >0.22 but 
≤0.48 mol/mol, was observed in 9 (15%) patients, including the 2 with biochemical 
EFA. We did not observe biochemical ω3/DHA deficiency. Of the remaining 7 with 
biochemical ω3/DHA marginality 4 reported not to eat fish and no such data were 
available for one. 
 
 
Table 2. Erythrocyte fatty acid composition of patients with schizophrenia. 
 
(right page) 
 
Data are for 61 patients unless otherwise indicated. Data are presented in mol%. Reference values represent 
medians (P2.5-P97.5) for controls (n=69). Data for patients represent medians (range). The reference values 
(i.e. 2.5 and 97.5 percentiles) of the controls were used as cut-off values to evaluate individual patients. The 
outcomes are expressed as the number (%) of patients with RBC fatty acid content either below the P2.5 
(n<P2.5) or above the P97.5 (n>P97.5). P<0.05 was considered significant for between group analyses. 
Biochemical essential fatty acid deficiency was defined as an RBC 20:3ω9 above 0.46 mol%. Biochemical 
isolated ω3 deficiency was defined as an RBC 22:5ω6/AA above 0.068 mol/mol. Omega-3/DHA marginality 
was defined as an RBC 22:5ω6/DHA above 0.22 mol/mol but equal or below 0.48 mol/mol, while ω3/DHA 
deficiency was indicated by an RBC 22:5ω6/DHA above 0.48 mol/mol [38]. ALA, alpha-linolenic (18:3ω3); 
EPA, eicosapentaenoic acid (20:5ω3); DHA, docosahexaenoic acid (22:6ω3); LCP, long chain polyunsaturated 
fatty acid; LA, linoleic acid (18:2ω6); AA, arachidonic acid (20:4ω6); SAFA, saturated fatty acid; MUFA, 
monounsaturated fatty acid; PUFA, polyunsaturated fatty acid. a Significance (p) for all patients (n=61) vs. 
controls;  b Significance (p) for patients reporting no intake of fish-oil supplements (n=59) vs. controls; c 
Patient (n=1) reporting intake of fish-oil supplements is included; d Patients (n=2) reporting intake of fish-oil 
supplements are included.                                                                                            B-VITAMIN AND LCPUFA DEFICIENCIES IN SCHIZOPHRENIA 
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  Reference values    Patients    Patients    Patients vs. controls 
  median  (P2.5 - P97.5)    median  (range)    n <P2.5  n>P97.5    pa  pb 
14:0  0.43  (0.30 - 0.54)    0.46  (0.26 - 0.76)    2 (3)  11 (18)    0.103  0.146 
16:0  23.77  (22.50 - 25.30)    24.35  (22.91 - 26.83)    0 (0)  12 (20)c   <0.001  <0.001 
18:0  16.41  (15.18 - 17.78)    16.8  (14.53 - 19.41)    1 (2)  5 (8)c   0.001  <0.001 
20:0  0.44  (0.36 - 0.53)    0.42  (0.31 - 0.67)    8 (13)  1 (2)    0.419  0.394 
22:0  1.85  (1.50 - 2.17)    1.69  (1.32 - 2.15)    4 (7)c  0 (0)    <0.001  <0.001 
24:0  4.62  (3.88 - 5.19)    4.44  (3.52 - 5.27)    4 (7)  1 (2)    0.129  0.169 
26:0  0.23  (0.17 - 0.30)    0.23  (0.16 - 0.33)    3 (5)  2 (3)c   0.342  0.436 
ALA  0.18  (0.13 - 0.28)    0.14  (0.08 - 0.34)    22 (36)  1 (2)    <0.001  <0.001 
EPA  0.44  (0.23 - 0.93)    0.5  (0.16 - 1.98)    2 (3)  2 (3)d   0.223  0.501 
22:5ω3  1.85  (1.40 - 2.46)    1.87  (1.24 - 2.63)    2 (3)  3 (5)d   0.878  0.587 
DHA  3.75  (2.29 - 5.45)    3.13  (1.34 - 5.91)    8 (13)  1 (2)c   <0.001  <0.001 
LCPω3  6.17  (4.39 - 8.28)    5.45  (3.35 - 10.36)    7 (11)  2 (3)d   <0.05  <0.005 
ω3  6.38  (4.59 - 8.44)    5.69  (3.44 - 10.53)    8 (13)  2 (3)d   <0.05  <0.005 
LA  10.28  (8.26 - 13.03)    9.79  (8.17 - 12.70)    1 (2)  0 (0)    0.051  0.074 
20:2ω6  0.26  (0.18 - 0.42)    0.23  (0.15 - 0.41)    4 (7)  0 (0)    <0.005  <0.05 
20:3ω6  1.57  (1.23 - 2.14)    1.78  (1.10 - 3.05)    4 (7)  12 (20)    <0.05  <0.05 
AA  13.87  (12.15 - 15.91)    13.42  (9.96 - 16.34)    7 (11)c  1 (2)    <0.05  <0.01 
22:4ω6  2.77  (1.99 - 3.53)    2.49  (1.46 - 3.28)    7 (11)c  0 (0)    <0.001  <0.001 
22:5ω6  0.50  (0.35 - 0.70)    0.47  (0.29 - 0.76)    8 (13)d  2 (3)    <0.05  0.097 
LCPω6  18.73  (16.42 - 21.42)    18.72  (13.79 - 20.29)    5 (8)c  0 (0)    0.057  0.136 
ω6  29.31  (26.48 - 31.87)    28.62  (23.51 - 31.42)    8 (13)d  0 (0)    <0.001  <0.005 
18:1ω7  1.76  (1.36 - 2.23)    1.27  (0.93 - 2.65)    42 (69)c  1 (2)    <0.001  <0.001 
ω7  1.84  (1.40 - 2.31)    1.27  (0.93 - 2.65)    42 (69)c  1 (2)    <0.001  <0.001 
18:1ω9  10.76  (9.16 - 11.48)    11.61  (9.63 -13.50)    0 (0)  33 (54)c   <0.001  <0.001 
20:1ω9  0.22  (0.14 - 0.31)    0.22  (0.13 - 0.30)    2 (3)  0 (0)    0.451  0.489 
20:3ω9  0.25  (0.13 - 0.42)    0.17  (0.09 - 0.67)    13 (21)  2 (3)    <0.001  <0.001 
24:1ω9  3.37  (2.65 - 4.29)    3.75  (2.47 - 4.71)    1 (2)  5 (8)    <0.001  <0.001 
ω9  14.48  (13.05 - 15.93)    15.78  (13.72 - 18.52)    0 (0)  27 (44)c   <0.001  <0.001 
SAFA  47.76  (46.68 - 48.88)    48.57  (46.49 - 53.82)    1 (2)  19 (31)c   <0.001  <0.001 
MUFA  16.1  (14.44 - 17.54)    16.89  (14.90 - 19.50)    0 (0)  15 (25)c   <0.001  <0.001 
PUFA  36.13  (34.39 - 37.72)    34.46  (28.62 - 37.24)    25 (41)c  0 (0)    <0.001  <0.001 
LCPω3+LCPω6  25.19  (23.16 - 27.57)    24.18  (19.57 - 26.86)    12 (20)  0 (0)    <0.001  <0.001 
LCPω3/LCPω6  0.32  (0.22 - 0.48)    0.29  (0.18 - 0.75)    4 (7)  3 (5)d   0.325  0.062 
PUFA/SAFA  0.76  (0.72 - 0.80)    0.71  (0.53 - 0.80)    36 (60)d  0 (0)    <0.001  <0.001 
ω3+ω6  35.79  (33.83 - 37.74)    34.31  (27.94 - 37.11)    23 (38)  0 (0)    <0.001  <0.001 
ω3/ω6  0.21  (0.15 - 0.31)    0.20  (0.11 - 0.45)    6 (10)  2 (3)d   0.399  0.096 
20:3ω9/20:4ω6  0.02  (0.01 - 0.03)    0.01  (0.01 - 0.06)    11 (18)  3 (5)    0.001  <0.005 
22:6ω3/22:5ω3  2.14  (1.14 - 2.97)    1.71  (0.77 - 3.64)    7 (11)  1 (2)    <0.005  <0.005 
22:5ω6/20:4ω6  0.04  (0.02 - 0.05)    0.03  (0.02 - 0.06)    0 (0)  1 (2)    0.154  0.201 
20:5ω3/22:6ω3  0.12  (0.06 - 0.20)    0.16  (0.07 - 0.33)    0 (0)  18 (30)d   <0.001  <0.001 
22:5ω6/22:6ω3  0.13  (0.07 - 0.22)    0.16  (0.05 - 0.33)    3 (5)c  9 (15)    0.465  0.194 
18:2ω6/18:3ω3  56.01  (36.03 - 82.31)    72.72  (28.48 - 142.78)    1 (2)  17 (28)    <0.001  <0.001 CHAPTER 2 
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BMI correlated positively with RBC 20:0 and 20:3ω6 (p<0.05 for both). Duration of 
illness correlated negatively with LA (p<0.005; r= -0.438). Smokers had lower RBC 
14:0 (p<0.05) and higher 24:1ω9 (p<0.01). Female smokers had lower 24:0 and 26:0 
(p<0.05 for both) levels than male smokers. Alcohol users had higher 16:0, 20:0, ω9 
(notably 18:1ω9), compared with non-alcohol users, whereas their 26:0, PUFA 
(notably  ω3+ω6) and LCPω3+ω6 were lower (p<0.05 for all). The number of 
alcohol units consumed per day did not correlate with any fatty acid except for 
22:5ω3 (p=0.05, r=0.331). Patients reaching the recommended fish-intake (i.e. Q≥4; 
11/52) had higher SAFA (notably 16:0), ω3, LCPω3 (notably EPA) and lower ω6, 
LCPω6 (notably AA and 22:4ω6) and PUFA/SAFA compared with patients who did 
not reach the recommended fish intake (p<0.05 for all). The index for fish-fat 
intake (Q) correlated (p<0.005 for all) with the ω3/ω6 ratio (r=0.397), 
LCPω3/LCPω6 ratio (r=0.441), EPA (r=0.528) and LCPω6 (r= -0.414). 
  In a logistic regression model (p<0.05) RBC PUFA below the P2.5 of the 
reference range proved best predicted in the total group by alcohol consumption 
(Wald χ2 = 5.495, p<0.05; odds ratio = 5.609, 95% CI 1.327 – 23.712) and duration of 
illness (Wald χ2 = 4.246, p<0.05; odds ratio = 0.822, 95% CI 0.683 – 0.988), when 
tested for alcohol consumption, duration of illness, age and gender. Linear 
regression showed the variance in RBC 20:3ω9 to be explained for 52% by ALA (β= 
-0.298, p<0.005), LA (β= -0.505, p<0.001) and DHA (β= -0.369, p<0.001) in the total 
group, when we tested for ALA, LA, 22:5ω6, DHA and SAFA. In females 51% of 
the variance in RBC 20:3ω9 could be explained by LA (β= -0.727, p<0.001), when 
testing for LA and ALA. In males LA (β= -0.569, p<0.001) and DHA (β= -0.643, 
p<0.001) explained 49% in RBC 20:3ω9 of the variance, when we tested for ALA, 
LA and DHA. 
3.3.  B-vitamins and homocysteine 
Table 3 shows the B-vitamin status parameters of the patients, together with the 
percentage patients exhibiting values below and above the respective reference 
ranges. Between (sub)group comparisons were done with all patients and with the 
subgroup reporting no intake of vitamin supplements. B-vitamin status parameters 
were not related to BMI, DSM-IV classification, medication type and dose, and 
alcohol consumption. In our data set levels of homocysteine did not differ among 
the various age groups of male patients. 
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Table 3. B-vitamin status parameters of patients with schizophrenia. 
 
  Reference Patients  Patients  Patients vs. Controls 
  values Median (range) N<P2.5  n>P97.5 P  a  P b 
Folate (nmol/L)  4.0 - 30.0  9  (3.4 - 38)  2 (3)  2 (3) c  0.121 0.079 
Vitamin B6 (nmol/L)  35 - 136  68  (26 - 382)  3 (5)  6 (10) c  0.587 0.317 
Vitamin B12 (pmol/L)  170 - 700  211  (77 - 944)  17 (28)  1 (2)  <0.05  <0.001 
Homocysteine (μmol/l) 4.7-14.6 d  11.6  (5.9 - 74.8) 0 (0)  17 (28)  <0.001  <0.001 
 9.3  e     13  (21)  f  48 (79)     
 
Data are for 61 patients. B-vitamin status parameters were measured in serum (folate, vitamin B12), plasma 
(homocysteine) and whole blood (vitamin B6). Data represent medians (range). The numbers (%) of patients 
with levels either below (n<P2.5) or above (n>P97.5) the reference ranges were assessed. Abnormal 
homocysteine was also assessed with the use of cut-off values at 9.3 and 14.6 μmol/L, which represent the 
P97.5 of B-vitamin optimized healthy adults and the P97.5 of these adults before B-vitamin optimization [44], 
respectively. Raw data for between-group comparisons derived from [44]. P<0.05 was considered significant 
for between group analyses. a Significance (p) for all patients (n=61) vs. controls (n=101); b Significance (p) for 
patients (n=57) vs. controls (n=79) reporting no intake of vitamin supplements; c Patients (n=2) reporting 
vitamin intake are included; d P97.5 derived from raw data [44] were used to evaluate individual patients; e 
Vitamin-optimized reference value [44]; f Patients (n=4) reporting intake of vitamins are included. 
 
 
Most remarkable were the lower levels of vitamin B12 (p<0.001; 28% below P2.5) 
and the higher levels of homocysteine (p<0.001). Twenty-eight percent of patients, 
versus 2% of controls (p<0.001), had homocysteine levels above the P97.5 of the 
reference range; while 79% had values above the ‘vitamin-optimized cut-off value’. 
A higher percentage of patients than controls had vitamin B12 levels below local 
reference values (28 vs. 3% below 170 pmol/L, p<0.001). Four patients, all males, 
aged 26-53 years, exhibited moderate hyperhomocysteinemia (range 57.5-74.8 
μmol/L). None of these reported the intake of supplements. Vitamin B6 levels were 
lower (p<0.05) in smoking than in non-smoking patients. Schizophrenic female 
smokers had lower homocysteine (p<0.005) than male smokers. Fish fat intake (Q) 
correlated positively with levels of folate (p<0.01, r=0.371) and vitamin B12 
(p<0.001, r=0.548). 
  In a logistic regression model (p<0.05) a homocysteine above 14.6 μmol/L 
proved best predicted by male gender (Wald χ2 = 4.774, p= 0.029; odds ratio = 7.693, 
95% CI 1.234 – 47.965) and absence of fish consumption (Wald χ2 = 4.224, p= 0.039; 
odds ratio = 0.1, 95% CI 0.011 – 0.894), when tested for gender, age, absence of fish 
consumption and smoking. The variance in plasma homocysteine could be 
explained for 47% by folate (β= -0.611, p<0.001) and ALA (β= -0.317, p<0.005) in 
the total group, when we tested for folate, vitamin B12, vitamin B6, fish fat intake, 
ALA and EPA. In females 45% of the homocysteine variance could be explained by CHAPTER 2 
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vitamin B6 (β= -0.508, p<0.01) and vitamin B12 (β= -0.348, p<0.05), when we tested 
for folate, vitamin B12 and vitamin B6. In males the homocysteine variance could be 
explained for 48% by folate (β= -0.701, p<0.001), testing for folate, vitamin B12 and 
vitamin B6. 
3.4. Dietary  supplementation 
None of the 5 patients with either biochemical EFA deficiency, moderate 
hyperhomocysteinemia or both was expected by their treating physicians to have 
poor diets. Four of them were available for supplementation with B-vitamins, and 
soybean and fish oils. The Figure shows the courses of their homocysteine and RBC 
20:3ω9 during supplementation. The supplementation schemes were different for 
the 3 patients with hyperhomocysteinemia-only and the one with combined 
hyperhomocysteinemia and biochemical EFA deficiency. One of the 3 patients with 
hyperhomocysteinemia-only showed an immediate homocysteine decrease upon 
administration of the initial daily dosage of 800 μg folic acid, while the remaining 2 
showed decreases upon the addition of other B-vitamins, including 8 mg vitamin B6 
and 4 μg vitamin B12. The final homocysteine levels of these 2 patients were below 
14.6 μmol/L (P97.5) and only one had a level below the more appropriate vitamin-
optimized cut-off value of 9.3 μmol/L. The patient who did not reach a 
homocysteine below 14.6 μmol/L admitted to his clinician to be incompliant with 
respect to the intake of the B-vitamin supplement. His relatively low RBC folate 
level, as compared with the two others (data not shown) also suggested poor 
compliance, since RBC folate is a parameter of the folate status of the preceding 
weeks. The patient with combined hyperhomocysteinemia and biochemical EFA 
deficiency showed an initial increase of plasma homocysteine, which was probably 
due to our request to discontinue the reported infrequent intake of a multivitamin 
supplement. Addition of folic acid and other B-vitamins reduced homocysteine to a 
final level below 14.6 μmol/L but above 9.3 μmol/L. 
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Figure.  Courses of plasma homocysteine (A) and erythrocyte 20:3ω9 content (B) for 4 
patients with schizophrenia during B-vitamin, soybean oil and fish oil 
supplementation. 
Selection of the 4 patients for supplementation was based on either moderate hyperhomocysteinemia (i.e. 31-
100  μmol/L) or biochemical signs of essential fatty acid deficiency (erythrocyte 20:3ω9>0.46 mol%). 
Supplementation schemes (bottom) were different for the 3 patients with moderate hyperhomocysteinemia 
(•), and the one with combined hyperhomocysteinemia and essential fatty acid deficiency (U). Daily 
supplements were: Folic acid (800 μg folic acid), B-vitamins (8 mg vitamin B6, 4 μg vitamin B12 and other B-
vitamins), Fish oil (310 mg eicosapentaenoic acid (EPA; 20:5ω3) and 200 mg docosahexaenoic acid (DHA; 
22:6ω3), and Soybean oil (15 mL soybean oil). The patient who exhibited an initial homocysteine decrease 
and a subsequent increase admitted to be incompliant with respect to B-vitamin intake. 
 
 
Supplementation of the patient with combined hyperhomocysteinemia and 
biochemical EFA deficiency with soybean and fish oils rapidly reduced RBC 20:3ω9 CHAPTER 2 
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to levels within the reference range. Also the 3 patients with 
hyperhomocysteinemia-only exhibited decreases of RBC 20:3ω9, although their 
changes occurred largely within the reference range. All patients seemed compliant 
with regard to the intake of the soybean oil and fish oil supplements, since all of 
them exhibited clear increases in their RBC LA, EPA and DHA (not shown). 
4. Discussion 
We assessed the frequency of low B-vitamin and EFA status, its determinants and 
its predictors in a group of patients with schizophrenia. Furthermore we were 
interested to see whether those with poor status responded biochemically to the 
appropriate dietary supplements. 
  Most remarkably we found that, as a group, the patients had high RBC SAFA 
and MUFA and low PUFA, both from the ω3 and ω6 series. Lower PUFA status 
seems in contrast to a recent study of Strassnig et al. [45] who reported increased 
fat, SAFA and PUFA intakes in schizophrenia. Their results were, however, not 
accompanied by laboratory data showing the actual PUFA status of their patients. 
RBC PUFA below the P2.5 of the reference range proved best predicted by alcohol 
consumption and duration of illness. Not unexpectedly, the index of biochemical 
EFA deficiency (i.e. RBC 20:3ω9) proved best explained by low RBC ALA, LA and 
DHA. Two patients exhibited biochemical EFA deficiency and 7 showed 
biochemical signs of ω3/DHA marginality only. Of these nine, at least 5 (i.e. ≥56%) 
reported not to eat fish at all as compared to 2% in the rest of the study population. 
The employed index for fish fat intake proved reliable, since there was also a 
positive relation between the calculated intake of fish oil fats and ω3LCP status. 
DSM-IV classification, duration of illness, gastrointestinal disturbances, BMI, 
smoking, alcohol drinking and medication were not related to the indices of EFA 
(20:3ω9) or B-vitamin (homocysteine) deficiencies. 
  With respect to B-vitamin status we found low vitamin B12 levels (28%) and 
high homocysteine (28%) in the group of patients not reporting to take vitamin 
supplements, and lower vitamin B6 in smoking compared with non-smoking 
patients. A homocysteine above 14.6 μmol/L proved best predicted by male gender. 
Homocysteine variance proved best explained by folate and ALA in the total group. 
The percentage homocysteine variance explained by folate and vitamin B12 in our 
patient group was higher than corresponding data from a recent study in Israel [46]. 
The influence of ALA was unexpected, but in a subsequent analysis both folate and 
vitamin B12 proved positively related with our index of fish oil intake, suggesting 
that we were dealing with poor dietary habits in general and not e.g. diminished 
intake of certain food products. Four patients exhibited moderate 
hyperhomocysteinemia with plasma values ranging from 57.5-74.8 μmol/L. These                                                                                            B-VITAMIN AND LCPUFA DEFICIENCIES IN SCHIZOPHRENIA 
- 117 - 
are exceptionally high values that in our experience are only rarely found in 
routine patient care. One of these patients also had biochemical EFA deficiency, 
which adds to the contention that some patients are subject to poor dietary habits 
in general. EFA deficiency [47] and hyperhomocysteinemia with homocysteine 
levels in Israeli schizophrenic patients up to 80 μmol/L have recently been reported 
[46]. It should be noted that our study was the first to show a low EFA status as 
derived from increased 20:3ω9. This fatty acid, also named Mead acid, is a 
functional parameter of the EFA status [38], and is rarely found to be increased in 
adults with undisturbed fat absorption consuming typically Western diets. 
  Importantly, none of the 5 patients with biochemical EFA deficiency, 
moderately increased homocysteine, or both, was suspected to have a poor diet, 
when we informed their clinicians of these outcomes. That diet is nevertheless at 
the basis of their abnormal indices of EFA and B-vitamin status became confirmed 
by the supplementation study that we performed in 4 of them. This study showed 
these indices to be easily correctable by supplemental B-vitamins, and soybean and 
fish oils, with folic acid probably being the most important determinant of 
hyperhomocysteinemia. However, 3 of the 4 patients did not reach the 9.3 μmol/L 
upper limit of the plasma homocysteine concentration, that we achieved by 
supplementation of healthy adults with a combination of folic acid, vitamin B12 and 
vitamin B6 [38]. Prolonged supplementation or addition of betaine to the 
supplement might be of aid to reach this treatment goal, but compliance seems to 
be a more realistic subject of concern. 
  We conclude that, as a group, patients with schizophrenia have high RBC 
SAFA and MUFA, low PUFA and increased homocysteine. A subgroup of patients 
with schizophrenia has  biochemical EFA deficiency, ω3/DHA marginality, 
moderate hyperhomocysteinemia, or combinations. This subgroup is not readily 
identified by their clinicians, while these conditions proved easily correctable by 
supplementation. Correction may be indicated in view of the possible relationship 
of poor EFA and B-vitamin status with their psychiatric symptoms, but also in view 
of the reduction of their high risk of cardiovascular disease. There is compelling, 
though not definite, evidence that reduction of homocysteine by B-vitamin 
supplementation (notably folic acid) and augmentation of ALA and ω3LCP status 
(by supplementation of soybean and fish oils) decreases risk of cardiovascular 
disease. Our study does not allow definite conclusions regarding risk factors for low 
PUFA and increased homocysteine that would allow their easy identification in 
clinical practice. Alcohol consumption and duration of illness seem to be risk 
factors for low PUFA status (i.e. <P2.5 of reference range), while male gender and 
absence of fish consumption seem to predict hyperhomocysteinemia (>P97.5). 
These factors and their predictive values should be investigated in larger studies. To CHAPTER 2 
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this end possible options for the identification of patients with poor diets are 
monitoring of dietary practices, or the more reliable, but also more costly, 
laboratory screening. Another possibility is supplementation of all patients without 
any monitoring or testing. The costs of either of these approaches and the 
anticipated compliance of intervention must be weighed against the potential 
clinical benefits with regard to the amelioration of psychiatric symptoms and the 
reduction of cardiovascular risk. 
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Abstract 
This study investigated the relationship between platelet (PLT) serotonin (5-HT) 
and intestinal permeability in children with pervasive developmental disorders 
(PDD). Differential sugar absorption and PLT 5-HT were determined in 23 children 
with PDD. PLT 5-HT (2.0-7.1 nmol/109 PLT) was elevated in 4/23 patients. None 
exhibited elevated intestinal permeability (lactulose/mannitol ratio: 0.008-0.035 
mol/mol). PLT 5-HT did not correlate with intestinal permeability or GI tract 
complaints. PLT 5-HT correlated with 24 h urinary 5-hydroxyindoleacetic acid (5-
HIAA; p=0.034). Also urinary 5-HIAA and urinary 5-HT were interrelated 
(p=0.005). A link between hyperserotonemia and increased intestinal permeability 
remained unsupported. Increased PLT 5-HT in PDD is likely to derive from 
increased PLT exposure to 5-HT. Longitudinal studies, showing the (in)consistency 
of abnormal intestinal permeability and PLT 5-HT, may resolve present 
discrepancies in the literature.                                                                                          INTESTINAL PERMEABILITY AND PLATELET 5-HT IN AUTISM 
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1. Introduction 
Autism has been linked to gastrointestinal (GI) disturbances [1]. It is, however, 
questionable whether GI anomalies in children with autism are specific [2]. An 
increase of chronic diarrhea, constipation, abdominal bloating and food 
regurgitation has been found in some studies, but could not be confirmed in more 
recent studies (reviewed in [2]). Increased GI permeability, as established through 
the differential sugar absorption test (SAT), was demonstrated in 9/21 (43%) [3] and 
19/26 (76%) [4] of patients diagnosed with autism. The SAT measures the integrity 
of the intestine by the ingestion of two indigestible saccharides that after GI uptake 
become fully excreted in urine. One of these (usually lactulose) passes the intestinal 
wall through paracellular transport (‘leakage’), while the other (usually mannitol) 
passes by paracellular and transcellular transport. The urinary lactulose/mannitol 
ratio is used as a measure of intestinal integrity and permeability [5]. In addition, a 
recent study found a high prevalence of congenital GI anomalies (adjusted odds 
ratio 5.1, 95% confidence interval 1.8-14.1), notably pyloric stenosis, in autism, 
which may be linked to the high rate of GI dysfunction reported by their parents 
[6]. 
  The implication of the GI tract in autistic pathophysiology warrants more 
detailed investigation of the gut-brain axis [2]. Especially the role of serotonin (5-
hydroxytryptamine; 5-HT), as a messenger within this axis [7], deserves attention. 
Many different aspects of the 5-HT system in autism have already been studied [8-
11]. A recent report [11] on platelet (PLT) 5-HT in PDD showed PLT 
hyperserotonemia in approximately 36% of patients with autism and in 58% of 
patients with PDD not otherwise specified (NOS). Using mixture-modeling analysis 
Mulder et al. [11] derived an empirical cut-off value that enabled dichotomization 
of patients with PDD into normo- and hyperserotonemic. Extensive behavioral 
assessments did, however, not show significant correlates with PLT 5-HT or 
hyperserotonemic status. 
  A common (developmental) factor, causing both an autistic brain and 
deregulated 5-HT release from the GI tract, years after birth, may be involved in 
the etiology of PDD [10]. The primary site of the hyperserotonemia in autism is 
likely to be located in the GI tract. Serotonin is a biogenic amine that derives from 
the essential amino acid tryptophan (Tryp) by hydroxylation and subsequent 
decarboxylation. The GI tract contains about 80% of bodily 5-HT, which is 
unevenly distributed among the enterochromaffin cells (90-95%) and neurons (5-
10%) [12]. The main functions of 5-HT are in smooth muscle contraction, blood 
pressure regulation, and peripheral and central neurotransmission. Serotonin 
localized in the basolateral stores of enterochromaffin tissue is released upon CHAPTER 3 
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neuronal, chemical or mechanical stimulation. Several 5-HT receptors control GI 
motility, sensation and secretion [7]. Following its release, 5-HT is removed from 
the interstitial space by 5-HT selective reuptake transporters [7]. However, part of 
the 5-HT enters the portal blood and systemic circulation where it is either rapidly 
taken up and accumulated by PLT, or metabolized by the liver, lung and kidneys 
into its major metabolite 5-hydroxyindoleacetic acid (5-HIAA) [12]. Platelets store 
and transport the majority (99%) of circulating 5-HT [13]. 
  Elevated PLT 5-HT levels observed in subgroups of patients with PDD, may be 
related to increased GI motility. This notion is supported by higher PLT 5-HT in 
patients with diarrhea predominant irritable bowel syndrome (d-IBS), as compared 
with healthy controls [12], although this was not consistently found [14]. Patients 
with d-IBS have augmented GI motility, which is likely to cause increased exposure 
of their circulating PLT to 5-HT [7;12;14]. Increased PLT 5-HT is also observed in 
patients with carcinoid tumors [15]. Carcinoid tumors derive from 
enterochromaffin cells and are characterized by high 5-HT production with 
diarrhea as a frequent symptom [16]. Consequently, measurement of PLT 5-HT is 
used as a sensitive marker for the early diagnosis and the subsequent follow-up of 
patients with carcinoid tumors [15]. 
  The aim of the present study was to investigate whether the subgroup of 
children with PDD having increased PLT 5-HT levels, is the same as the one 
exhibiting increased intestinal permeability as established by a SAT. 
2. Methods 
2.1. Patients 
Parents of patients with PDD (n=31) according to the DSM-IV TR [17] were asked 
for the participation of their affected children via the local patient society and 
pediatricians. Oral and written informed consent were obtained. Information 
regarding comorbidity, medication, nutritional supplements and the prevalence of 
GI related complaints was obtained from medical records and with the aid of 
assisted questionnaires. The study was performed in Curaçao (The Netherlands 
Antilles) in the summer of 2004. All collected urine and blood samples were 
transported in dry ice to the Netherlands for further analyses in the University 
Medical Center Groningen (UMCG). The study was approved by the Medical 
Ethical Committee of the St. Elisabeth Hospital in Curaçao. 
2.2.  Sugar Absorption Test 
The SAT was performed according to van Elburg et al. [5]. Shortly, the patients 
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overnight fast. All urine voidings during the following 5 h were collected and 
pooled. Urinary sugars were analyzed by gas chromatography as previously 
described [18]. A urinary lactulose/mannitol (L/M) ratio above 0.090 was 
considered to be indicative for abnormal GI integrity/increased intestinal 
permeability [5]. 
2.3. Serotonin  Assays 
For estimation of 5-HT turnover and exposure of PLT to 5-HT, we examined 24 h 
urinary excretion of 5-HIAA and total 5-HT [15]. For this, parents were asked to 
abstain their child completely from 5-HT containing foods (e.g. banana, pineapple, 
kiwi, walnuts) during collection and during the preceding 12 h. The volumes of the 
urine samples were measured before storing at -20°C. Urinary 5-HIAA and total 5-
HT concentrations were determined as previously reported [15]. Urinary 5-HIAA 
values were evaluated with the use of age-dependent reference values [19]. 
  Non-fasting venous blood (for serum antibodies) and EDTA-anticoagulated 
blood (all other assays) were collected from children with PDD. EDTA-
anticoagulated blood was placed on melting ice. Hematological indices were 
measured immediately after sampling. Within one hour after collection a 1:1 
mixture of K2EDTA and Na2S2O5 was added to PLT-rich plasma (PRP) to prevent 
oxidation of indoles. Plasma and serum were stored at -80°C. Simultaneous analysis 
of indoles [Tryp, 5-hydroxytryptophan (5-HTP), 5-HT and 5-HIAA] in PRP was 
performed as previously described [15]. PLT 5-HT data were compared with both a 
local cut-off value of 5.4 nmol/109 PLT [20] and an empiric cut-off value of 4.55 
nmol/109 PLT [11]. The local cut-off value represents the 97.5th percentile of a 
reference group of healthy adults that is employed in our laboratory for the 
diagnosis of carcinoid tumors. The empirical cut-off value represents the bottom of 
the valley of the PLT 5-HT bimodal distribution, as exhibited by patients with 
PDD. This value allows optimal classification into those who are normoserotonemic 
and hyperserotonemic. Platelet-rich-plasma Tryp data were evaluated with the use 
of age-dependent reference values [19]. 
2.4. Exclusion  of  Celiac  Disease 
Serum IgA anti-endomysium titers and HLA genotype were assessed to rule-out 
celiac disease, which is an established cause of increased GI permeability [21]. 
2.5. Statistics 
All data were analyzed using the Statistical Product and Service Solutions package, 
version 11.5 (SPSS Inc. Chicago). Data were tested for normality using the Shapiro-
Wilk W test. Group comparisons (normo- and hyperserotonemic) were performed CHAPTER 3 
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with the Mann-Whitney U test (non-parametric). Spearman (non-parametric) tests 
were used to evaluate correlations at α=0.05, minimizing type-II errors. 
3. Results 
3.1. Patients 
We enrolled the first 24 (77%) of the 31 patients with PDD whose parents agreed to 
participate. Patient characteristics are reported in Table 1. The parents reported 
13/23 (57%) of their affected children to have one or more GI symptoms. 
 
Table 1.  Characteristics of patients with pervasive developmental disorders in 
Curaçao tested for platelet serotonin and intestinal permeability. 
 
Parameter   
Gender (male/female)  18 (75%) / 6 (25%)
Age (years)  9.9 (±3.9) 
DSM-IV TR diagnoses   
- 299.00 (autistic disorder)  8 (33%) 
- 299.80 (PDD-NOS)  16 (67%) 
Ethnicity  
- Caucasian  8 (33%) 
- African-American  13 (54%) 
- other  3 (13%) 
Comorbiditya  
- epilepsy  5 (22%) 
- allergy  2 (9%) 
- asthma  1 (4%) 
- intestinal yeast infection  1 (4%) 
Medication for comorbidity  9 (38%) 
Nutritional supplements (vitamins/ω3-oils) 9 (38%) / 2 (4%) 
Diet (gluten and casein free) a  2 (9%) 
Physical complaints related to GI tract a 13  (57%) 
- nausea  0 (0%) 
- vomiting  1 (4%) 
- diarrhea  4 (17%) 
- constipation  4 (17%) 
- bloating and gaseousness  8 (35%) 
 
Data represent number (percentage) or mean (±SD) for 24 patients, unless otherwise specified. a n=23. PDD-
NOS; pervasive developmental disorder – not otherwise specified. 
 
Because of cleanliness problems, no urine samples were obtained from one patient, 
while from another we only received urine for SAT. Blood sampling from yet 
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from 23/24 patients, 24 h urine from 22/24 patients and blood samples from 23/24 
patients.  Table 2 shows the indices related to 5-HT turnover and intestinal 
permeability of these patients. 
 
Table 2.  Indices of serotonin (5-HT) turnover and intestinal permeability in 
patients with pervasive developmental disorders in Curaçao. 
 
Parameter    Reference values    < RV  ≥ RV 
PLT 5-HT (nmol/109 PLT) a  3.4 (2.0-7.1) 
<4.55 b 
<5.4 c 
  
6 (26%) 
4 (17%) 
Tryp (μmol/L) a  50.0 (±10.9) 
2-18y: 0-79 d 
 
2y: 35-73 d 
6y: 37-76 d 
16y: 54-93 d 
 
 
 
 
0 (0%) 
 
 
3 (13%) 
0 (0%) 
 
 
0 (0%) 
5-HIAA (μmol/24h) e  8.4 (3.9-36.4) 
3-8y: 2.1-29.3 d 
9-12y: 5.2-32.9 d 
13-17: 4.7-34.0 d 
>18y: 5.2-36.6 d 
 
  
1 (5%) 
 
1 (5%) 
5-HT (nmol/24h) e  305 (±92)        
lactulose (mmol/5h) f  0.024 (±0.11)        
mannitol (mmol/5h) f  1.32 (±0.59)        
L/M ratio (mol/mol) f  0.019 (±0.007) <0.090  g    23 (100%)  0 (0%) 
 
Data represent number (percentage), median (range) or mean (±SD). a platelet-rich plasma, n=23; b empiric 
cut-off derived from Mulder et al. [11]; c upper reference value derived from apparently healthy adults [20]; d 
from reference [19]; e 24 h urine, n=22; f 5 h urine from sugar absorption test, n=23; g from reference [5]. RV; 
reference value; PLT, platelet; Tryp, tryptophan; 5-HIAA, 5-hydroxyindoleacetic acid; L/M, 
lactulose/mannitol. 
 
3.2.  Sugar Absorption Test 
Intestinal permeability, reflected by the L/M ratio [median (range) 0.017 mol/mol 
(0.008-0.035)], indicated that none of the patients had increased intestinal 
permeability (i.e. L/M ratio ≥0.090). 
3.3. Serotonin  Assays 
PLT 5-HT [median (range): 3.4 (2.0-7.1) nmol/109 PLT] was elevated in 4 (range: 
5.7-7.1 nmol/109 PLT) and 6 [range 4.6-7.1 nmol/109 PLT] patients if compared to 
the local cut-off value ([20]; <5.4 nmol/109 PLT) or the empirical cut-off value ([11]; 
<4.55 nmol/109 PLT), respectively. The sole patient exhibiting detectable levels of 
plasma 5-HIAA (26.0 μmol/L), also exhibited increased PLT 5-HT (6.4 nmol/109 CHAPTER 3 
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PLT). However, this patient did not exhibit increased urinary total 5-HT or 5-HIAA 
excretions. Urinary excretion of 5-HIAA was within normal range. 
3.4. Exclusion  of  Celiac  Disease 
None of the patients were positive for serum IgA anti endomysium and 8/23 (35%) 
patients had a genotype positive for either HLA-DQ2 (n=5) or HLA-DQ8 (n=3). 
Based on the results of serology, none of the patients seemed to have celiac disease, 
although we did not perform further tests to exclude this. 
3.5. Statistics 
There was no correlation between PLT 5-HT and L/M ratio (p= 0.663; r = -0.098). 
Patients exhibiting GI tract complaints did not have higher PLT 5-HT, higher L/M 
ratios, or higher 5-HIAA and total 5-HT 24 h urinary excretions (p>0.4). Platelet 5-
HT correlated with 24 h urinary 5-HIAA excretion (p= 0.034; r= 0.465). Also the 24 
h excretion rates of 5-HIAA and total 5-HT showed a positive correlation (p= 0.005; 
r= 0.580). 
4. Discussion 
In this study of children with PDD we did not observe a relation between PLT 5-
HT and intestinal permeability, as derived from the urinary L/M ratio. The number 
of children with PDD exhibiting increased PLT 5-HT was lower compared with 
reports of others. For instance, the recent study of Mulder et al. [11] showed 23/81 
(28%) of Dutch children with PDD to exhibit increased PLT 5-HT, using the same 
analytical method and a cut-off value of 5.4 nmol/109 PLT. Also our data on 
intestinal permeability contrast with previous reports [3;4] showing that 43-76% of 
children with autism have increased intestinal permeability, as established by a 
SAT. A weakness of the current study is its small size and the lack of a local age- 
and gender matched control group. We have, on the other hand, no indications for 
deviant reference values for PLT 5-HT or L/M ratios in Curaçao, as compared with 
The Netherlands. Age and gender do not appear to affect PLT 5-HT [11], but it 
must be noted that PLT 5-HT reaches highest levels during childhood and gradually 
decreases during adulthood [22]. Dependent on the cut-off values employed, we 
nevertheless found 4 and 6 patients with increased PLT 5-HT. Neither of these 
patients had abnormal intestinal permeability or L/M ratios residing in the upper 
range of normality. However, the positive correlation between PLT 5-HT levels and 
24 h urine 5-HIAA, and also the relation between urinary 5-HIAA and urinary 5-
HT, suggest that, also in PDD, exposure of PLT to 5-HT determines PLT 5-HT and 
its consistently found increase in a subgroup. It is possible that increased PLT 5-HT                                                                                          INTESTINAL PERMEABILITY AND PLATELET 5-HT IN AUTISM 
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and GI permeability are not consistent features of children with PDD in time. Long 
term, e.g. monthly, monitoring of a well defined patient and control group may 
shed more light on this potential source of variance as a cause of the conflicting 
results found by several investigators. Differences in the activity of the 5-HT 
transporter based on genetic polymorphisms are unlikely, since these seem to have 
minor effects, if any, on PLT 5-HT levels [23]. 
  In conclusion, the finding of a subgroup of children with PDD exhibiting 
hyperserotonemia was replicated. None of the children exhibited increased 
intestinal permeability, while PLT 5-HT was unrelated to both intestinal 
permeability and GI symptoms. Additional studies are needed to elucidate the 
etiology of increased PLT 5-HT in PDD and to establish its relation with intestinal 
pathology, if any. 
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Abstract 
Background and Aims:  The usefulness of platelet serotonin (PLT 5-HT) as a marker 
of gastrointestinal motility is as yet unclear. We determined whether PLT 5-HT is 
lower at a condition of relative gut motor activity quiescence (i.e. in newborns at 
birth) compared with a condition of normal gut motor activity (i.e. in their mothers 
at birth), and whether in newborns institution and discontinuation of enteral 
feeding coincide with increases and decreases of PLT 5-HT, respectively. Design 
and Measures: PLT 5-HT was determined in 17 mothers and their 18 healthy full 
term newborns. Longitudinal PLT 5-HT data and data of feeding modes were 
available for 5 preterm born infants. Results: Newborns exhibited about 2 times 
lower PLT 5-HT compared with their mothers (medians: 1.5 and 2.9 nmol/109 PLT, 
respectively). Newborn PLT 5-HT related positively with maternal PLT 5-HT and 
newborn mean PLT volume, and negatively with newborn whole blood 
tryptophan. In the longitudinally investigated preterm born infants we observed 7 
increases and 1 decrease of PLT 5-HT during institution of enteral feeding (in 5 
infants), and 2 decreases and 1 increase of PLT 5-HT during parenteral feeding (in 3 
infants). Conclusion: Lower PLT 5-HT at birth and its change in response to enteral 
feeding in newborns suggest gut motor activity to be a determinant of PLT 5-HT in 
early postnatal life.                                                                                                                 PLATELET 5-HT AS MARKER OF GUT MOTILITY? 
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1. Introduction 
Serotonin (5-hydroxytryptamine; 5-HT) is a biogenic amine that derives from the 
essential amino acid tryptophan (Tryp) by hydroxylation and subsequent 
decarboxylation. About 80% of the bodily 5-HT is localized in the 
enterochromaffin cells (90-95%) and neurons (5-10%) [1;2] of the gastrointestinal 
(GI) tract. Serotonin localized in the basolateral stores of enterochromaffin tissue is 
released upon neuronal, chemical or mechanical stimulation. Several 5-HT 
receptors control GI motility, sensation and secretion [1;2]. Following its release 5-
HT is removed from the interstitial space by 5-HT selective reuptake transporters 
[3;4]. Part of the 5-HT also enters the portal blood and systemic circulation where it 
is either rapidly taken up and accumulated by platelets (PLT), or metabolized by 
the liver, lung and kidneys into its major metabolite 5-hydroxyindoleacetic acid (5-
HIAA) [2;5;6]. Platelets store and transport the majority (99%) of circulating 5-HT 
[7]. 
  Gastrointestinal motor activity might be reflected by PLT 5-HT. Although not 
consistently found [8], patients with diarrhea predominant irritable bowel 
syndrome (d-IBS) have higher PLT 5-HT as compared with healthy controls [2]. 
The augmented GI motility in these patients with d-IBS is likely to cause increased 
exposure of their circulating PLT to 5-HT [2]. Increased PLT 5-HT is also observed 
in patients with carcinoid tumors [9]. Carcinoid tumors derive from 
enterochromaffin cells and diarrhea is a frequent symptom [10]. Notably those 
carcinoid tumors originating from the midgut are characterized by high 5-HT 
production and measurement of PLT 5-HT is used as a sensitive marker for the 
early diagnosis and the subsequent follow-up of patients with carcinoid tumors [9]. 
Finally, 36-58% of patients with autism have been reported to exhibit increased 
PLT 5-HT [11]. Patients with autism have a higher prevalence of GI disturbances, 
but this observation is controversial [12]. A recent study shows a 5.1 times higher 
odds of congenital anomalies of the GI tract in children with autism [13]. 
  T h e  u s e f u l n e s s  o f  P L T  5 - H T  a s  a  m a r k e r  o f  G I  m o t i l i t y  i s  a s  y e t  u n c l e a r :  
increased GI motility may cause increased PLT 5-HT, while decreased motility may 
relate to low PLT 5-HT. The fetus exhibits little GI motor activity prior to 30 weeks 
of gestation, but this increases steadily thereafter [14]. After 32 weeks of gestation 
nonmigrating motor activity patterns lengthen and decrease in occurrence, and 
migrating motor complexes begin to appear [15]. The use of gut motor patterns to 
assess gut maturity has thus been suggested [14]. There is substantial evidence that 
intestinal motor activity in newborns becomes stimulated by enteral nutrition [16]. 
Better maturation of motor function [17] and increased intestinal trophic responses 
[18] are observed in enterally fed preterm animals, as compared with parenteral CHAPTER 4 
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feeding. Consequently, the rapid doubling of PLT 5-HT levels after birth to near-
adult levels during the first postnatal days [19] is likely to be caused by enteral 
feeding instituted maturation of gut motor activity. The aim of the present study 
was to contribute to the development of PLT 5-HT as a marker of GI motility by 
investigating whether PLT 5-HT is lower at an established physiological condition 
of relative gut motor quiescence (i.e. immediately after birth) and whether it 
subsequently changes as a function of feeding mode (i.e. enteral or parenteral). 
Therefore we compared PLT 5-HT of newborns with that of their mothers and 
monitored the course of PLT 5-HT in a small number of newborns that we were 
able to study during switches from enteral to parenteral feeding and vice versa. 
2. Materials  and  Methods 
2.1.  Patients and Samples 
For the comparison of PLT 5-HT from newborns and their mothers, venous blood 
samples of 17 mothers were collected together with venous umbilical cord blood 
samples of their 18 newborns (i.e. 16 singletons and 1 twin). Both samples were 
taken at delivery. Pregnant women were eligible to participate if they gave 
informed consent, had uncomplicated pregnancies, had uncomplicated deliveries at 
term, and if they did not the following: substances of abuse other than alcohol and 
tobacco, psychotropic medication and drugs affecting PLT 5-HT levels (e.g. 
selective 5-HT reuptake inhibitors). The participants were recruited from 28 
consecutive expecting mothers visiting the Department of Obstetrics and 
Gynecology. Only newborns that were appropriate or large for gestational age 
according to Kloosterman [20] were included in the final evaluation. 
  For the longitudinal study of neonatal PLT 5-HT we collected venous blood of 
20 consecutive preterm born infants (16 singletons and 2 twins) who were admitted 
to the neonatal intensive care unit (NICU). Additional blood samples (0.5 mL) were 
collected only when during their stay hematological indices were ordered by the 
pediatrician. Data on the course of pregnancy and delivery, anthropometrics, 
medication and diet, GI function (e.g. vomiting, diarrhea, bowel movements etc.) 
were gathered from the patient records. Only neonates of whom longitudinal 
samples and clinical data were available were included in the final evaluation. In all 
cases, enteral feeding consisted of (fortified) breast milk or Similac Special Care 
(Ross Products Division, Abbott Laboratories, Columbus, OH, USA), whereas 
parenteral feeding consisted of a 5-10% dextrose solution with amino acids 
(Vaminolact®); Pharmacia-Upjohn, Sweden), electrolytes, vitamins and trace 
elements prepared by the hospital pharmacy, and separately Intralipid 20% solution 
(Kabi-Vitrum, Sweden).                                                                                                                 PLATELET 5-HT AS MARKER OF GUT MOTILITY? 
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  The studies were conducted at the Department of Obstetrics and Gynecology 
and the Department of Pediatrics of the St. Elisabeth Hospital in Curaçao 
(Netherlands Antilles). Informed consent was obtained from the mothers or both 
parents. The study protocols were in accordance with local ethical standards and 
the Helsinki declaration of 1964, as revised in 2004. 
2.2. Analyses 
Blood samples were collected in K2-EDTA, immediately stored in melting ice and 
divided into two portions. One portion was used for the assay of hematological 
indices. The second was used for HPLC profiling of indoles in whole blood. A 
mixture of K2EDTA and Na2S2O5 (1:1) to a final concentration of about 10 g/L was 
added to prevent oxidation. Samples were subsequently stored at -80 ºC until 
transportation on dry ice to the University Medical Center in Groningen (The 
Netherlands). Tryp, 5-hydroxytryptophan (5-HTP) and 5-HT were measured with a 
single HPLC-fluorometric profiling method, using a previously published method 
[21]. PLT 5-HT was calculated by dividing the whole blood 5-HT concentration by 
the PLT count. The outcome was expressed in nmol/109 PLT. 
2.3.  Data evaluation and statistics 
All data were analyzed using the Statistical Product and Service Solutions package, 
version 11.5 (SPSS Inc. Chicago). Data for newborns and their mothers were tested 
for normality using the Shapiro-Wilk W test. Non-Gaussian distributed indices 
were transformed by elog transformation. Differences between indices of newborns 
and their mothers were assessed with the paired Student’s t-test with Bonferroni 
correction, at α=0.0036. Relations between indices of newborns and their mothers 
were evaluated with Pearson or Spearman correlation, following correction for 
multiple correlations at α=0.0036. Indices exhibiting correlations with newborn 
PLT 5-HT or whole blood 5-HT at α=0.05 were further investigated by backward 
linear regression analysis for their ability to explain the observed variance. The 
final model was obtained after exclusion of insignificant indices. 
  A change of PLT 5-HT was considered significant if it exceeded the reference 
change value (RCV) at a 95% confidence level [22]. The employed RCV was 
derived from the median intra-individual biological variation as established from 
PLT 5-HT data of 18 apparently healthy adults [12 males, 6 females; median (range) 
age 35.0 (20.8-56.6) years], who were monitored during five consecutive days 
(unpublished observations). Their median intra-individual coefficients of variation 
(CVi) for PLT 5-HT and whole blood 5-HT amounted to 7.3 and 7.4%, respectively. 
These figures, together with a 5-HT inter-assay variation (CVa) of ≤2.8% [21], 
resulted in RCV for PLT 5-HT and whole blood 5-HT of 21.6 and 21.9%, CHAPTER 4 
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respectively. Changes of newborn PLT 5-HT exceeding the RCV were related to 
changes in feeding mode as occurring within the corresponding time intervals. 
3. Results 
3.1.  Newborn and maternal indices and their interrelations 
Table 1 shows for both newborns and their mothers some anthropometric data, 
together with hematological indices, whole blood concentrations of Tryp, 5-HTP 
and 5-HT, and PLT 5-HT. 
 
Table 1.  Platelet indices, and indoles in whole blood and platelets of newborns and 
their mothers at delivery 
 
 Newborns  Mothers  P-value 
Anthropometrics      
Gender (Male / Female) 9 / 9a 17   
Age  38.9 (37.3-41.9) weeksb 33.1  (18.3-39.0)  years  
Weight (kg)  3.430 (2.680-4.410)  84.0 (64.0-122.0)c  
AGA / LGA  16 / 2     
      
Platelet indices      
PLT (*109/L)  278 (±70)  243 (±54)  0.018d 
MPV (fL)  8.0 (6.6-11.6)  9.2 (7.2-13.6)  0.532d 
      
Indole concentrations      
Tryp (μmol/L)e  43.1 (±8.1)  21.7 (±4.0)  < 0.001 
5-HTP (nmol/L)e 206  (17-301)f 17  (17-246)g 0.023h 
5-HT (nmol/L)e  388 (240-712)  618 (420-1856)  < 0.001d 
5-HT (nmol/109 PLT)  1.5 (0.8-3.2)  2.9 (1.9-6.4)  < 0.001d 
 
Data are medians (range) or means (±SD). P<0.0036 was considered significant. a Two girls were twins. AGA, 
appropriate for gestational age [20]; LGA, large for gestational age [20]; PLT, platelets; MPV, mean platelet 
volume; Tryp, tryptophan; 5-HTP, 5-hydroxy tryptophan; 5-HT, 5-hydroxytryptamine; M/F male/female. b 
gestational age at birth; c n = 16; d Student’s t-test performed on elog transformed data; e concentration in 
whole blood; f 5-HTP was below the 17 nmol/L [21] detection limit in 13 mothers; g 5-HTP was below the 17 
nmol/L [21] detection limit in 8 newborns; h Wilcoxon Signed-Rank test. 
 
In all samples 5-HIAA was below the detection limit of 61 nmol/L [21]. Compared 
with their mothers, newborns had significantly (p<0.0036) higher whole blood 
Tryp, but lower PLT 5-HT and whole blood 5-HT. The following correlations 
(Pearson coefficient; p-value) between the corresponding indices of newborns and 
their mothers were found to be significant (p<0.0036): RBC (r=0.757; p<0.001), Ht 
(r=0.726; p=0.001) and whole blood 5-HT (r=0.743; p<0.001).                                                                                                                 PLATELET 5-HT AS MARKER OF GUT MOTILITY? 
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 The  elog PLT 5-HT of the newborns was found to be related to: newborn PLT 
(r= -0.567; p=0.014), newborn elog MPV (r=0.476; p=0.046), newborn whole blood 
5-HT (r=0.686; p=0.002), newborn Tryp (r= -0.479; p=0.044) and maternal elog PLT 
5-HT (r=0.549; p=0.018). Newborn whole blood 5-HT correlated with: newborn 
elog PLT 5-HT (r=0.686; p=0.002), maternal elog whole blood 5-HT (r=0.743; 
p<0.001) and maternal elog PLT 5-HT (r=0.741; p<0.001). The elog PLT 5-HT of the 
mothers was found to be related to: newborn birth weight (-0.520; p=0.027), 
newborn whole blood 5-HT (0.741; p<0.001), newborn elog PLT 5-HT (0.549; 
p=0.018), and maternal elog whole blood 5-HT (0.794; p<0.001). The elog whole 
blood 5-HT of the mothers correlated with: newborn whole blood 5-HT (0.743; 
p<0.001), maternal PLT (0.590; p=0.010) and maternal elog PLT 5-HT (0.794; 
p<0.001). 
  Linear regression models for PLT 5-HT and whole blood 5-HT of both 
newborns and their mothers were constructed by backward stepwise linear 
regression analysis. Indices that were dependent to either whole blood 5-HT (i.e. 
PLT 5-HT and PLT) or PLT 5-HT (i.e. whole blood 5-HT and PLT) were excluded. 
Gestational age (GA) and birth weight were included as additional variables. 
Newborn  elog PLT 5-HT proved best explained (adjusted R2=0.799) by (beta, p-
value) newborn Tryp (r= -2.010; p=0.002), maternal elog PLT 5-HT (r=1.035; 
p=0.016) and newborn elog MPV (r= 1.750; p=0.018), when testing for newborn GA, 
newborn birth weight, newborn elog MPV, newborn whole blood Tryp and 
maternal elog PLT 5-HT. Maternal elog PLT 5-HT proved best explained (adjusted 
R2=0.668) by a constant [1.497 (std. error 0.452; p=0.005)] and newborn whole 
blood 5-HT (0.671; p<0.001) and newborn birth weight (-0.404; p=0.012) as indices, 
when testing for newborn GA, newborn birth weight, newborn whole blood 5-HT 
and newborn elog PLT 5-HT. 
3.2.  Relation between newborn PLT 5-HT and feeding mode 
Of 20 included neonates, longitudinal PLT 5-HT and feeding data were available for 
only 5, since the majority of uncomplicated patients were most swiftly discharged 
from the NICU. Table 2 shows the characteristics of the examined patients at the 
time of admission. All were preterm. One (no 3) was small for gestational age 
([20;23]; birth weight <10th percentile for GA) and all had a low birth weight 
(<2.500 kg). 
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Table 2.  Characteristics of the 5 longitudinally studied preterm neonates at the time of 
admission. 
 
no  gender  birth weight GA  corrected GA*
  (M/F) (g)  (weeks+days) (weeks) 
01 F  1740  32+5  33 
02 M  1620  32+6  35 
03 F  1560  36+5  37 
04 M  1720  30+6  33 
05 M  1780  30+6  30 
 
M/F, male/female; GA, gestational age.* Corrected GA is based on the Farr-Mitchell score which uses external 
characteristics at birth to estimate GA [23]. 
 
In this group (Figure) we observed 7 increases and 1 decrease of PLT 5-HT 
following institution of enteral feeding (i.e. in nos 1-5), and 2 decreases and 1 
increase following institution of parenteral feeding, i.e. discontinuation of enteral 
feeding (respectively in nos 1, 4 and 5). 
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Figure.  Courses of platelet 5-HT content in time in response to changes in feeding 
mode in 5 preterm born newborns. 
For patient characteristics see Table 2. PLT 5-HT is expressed in nmol/109 PLT. Feeding mode in indicated 
periods is shown by filled lines (parenteral), dashed lines (enteral) and dotted lines (enteral plus parenteral). 
All indicated changes in PLT 5-HT exceeded the reference change value (i.e. 21.6%), which implies that they 
reflect significance at the p<0.05 level. The changes of PLT 5-HT were in line with an increase upon enteral 
or enteral + parenteral feeding, and a decrease upon parenteral feeding (i.e. discontinuation of enteral 
feeding), except for 2 observations in patient no 5 (indicated by *).                                                                                                                 PLATELET 5-HT AS MARKER OF GUT MOTILITY? 
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The 2 observations that were inconsistent with our hypothesis occurred in a single 
patient (no 5), while in another (no 4) initial institution of enteral feeding and 
subsequent switches to parenteral and enteral feeding correlated perfectly with the 
expected course of PLT 5-HT. The courses of whole blood 5-HT in relation to 
changes in feeding mode (not shown) were similar to those of PLT 5-HT, but 
showed an even more pronounced pattern consistent with our hypothesis. 
4. Discussion 
We were interested to see whether PLT 5-HT is lower at the physiological 
condition of relative gut motor quiescence (i.e. newborns) and whether changes in 
feeding mode of newborns coincide with changes of PLT 5-HT. For this we 
compared PLT 5-HT of healthy term newborns (n=18) with that of their mothers 
(n=17) and linked early postnatal switches from enteral to parenteral feeding and 
vice versa to changes of PLT 5-HT in 5 preterm born infants. The most important 
observations were: newborns have about two times lower PLT 5-HT compared with 
their mothers, postnatal increases of PLT 5-HT coincide with the institution of 
enteral feeding, and postnatal decreases of PLT 5-HT coincide with the 
discontinuation of enteral feeding. The most important determinants of newborn 
PLT 5-HT seem to be newborn whole blood Tryp (suggesting a newborn PLT 5-HT 
depressing effect), newborn MPV and maternal PLT 5-HT (suggesting a newborn 
PLT 5-HT augmenting effect). A weakness of the present study is the inevitably low 
number of longitudinally investigated newborns, the inability to correlate PLT 5HT 
with a direct measure of GI motility and the use of RCV derived from apparently 
healthy adults. 
  We have no explanation for the inverse relation between newborn PLT 5-HT 
and newborn whole blood Tryp. In contrast to newborns, maternal whole blood 
Tryp proved not to be an important determinant of maternal PLT 5-HT. Maternal 
plasma Tryp decreases during pregnancy [24], while higher Tryp in umbilical 
venous plasma [25],compared with the mothers have previously been noted. The 
relation between newborn PLT 5-HT and newborn MPV seems conceivable, since 
large PLT may obviously harbor higher 5-HT contents at similar intracellular 5-HT 
concentrations, perhaps because of higher numbers of membrane-bound 5-HT 
transporters and intracellular 5-HT containing dense granules. Also remarkable 
were detectable levels of whole blood 5-HTP in 4/17 mothers and 11/18 newborns. 
This intermediate product in 5-HT synthesis is generally not detected in the blood 
of healthy adults by HPLC or in patients with carcinoid tumors [21], which adds to 
the notion of altered regulation of 5-HT synthesis in the fetus and/or the pregnant 
mother. 5-HTP has been detected before in pregnant women and their newborns 
[26] and several functions of 5-HTP in pregnancy have been suggested. CHAPTER 4 
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  The about two times lower newborn PLT 5-HT than their mothers and the 
relation between newborn and maternal PLT 5-HT have been noted before [19;27-
29]. Lower newborn PLT 5-HT has been ascribed to higher prenatal 5-HT catabolic 
activity, such as possibly originating from placental 5-HT degradation [27;29]. This 
option seems however less plausible, since 5-HT uptake by newborn PLT is 
considered to be fully functional [19], while at least some patients in the present 
study indicate that PLT 5-HT may remain below the maternal reference range up to 
at least 27 days postpartum (Figure). Differences between the intensities of 
newborn and adult GI motility seem more probable. The relation between newborn 
and maternal PLT 5-HT remains puzzling. Some have suggested heritability of PLT 
5-HT as a cause [19]. Other possibilities are mutual influence of GI motility while 
any transplacental transport of 5-HT remains implausible because of the highly 
efficient mono- and diamine placental barrier [26;30]. 
  PLT 5-HT half life amounts to 4.2 days and thereby equals approximately PLT 
half life, at least in adults [21]. This implies that each of the employed blood 
sampling intervals in our postnatal PLT 5-HT monitoring protocol (Figure) are well 
above the PLT 5-HT half life. The protocol therefore not only allowed detection of 
increases of PLT 5-HT deriving from increasing 5-HT exposure, but also detection 
of losses of PLT 5-HT content due to diminishing exposure of newly secreted PLT 
to 5-HT. Given the present time intervals we found that postnatal increases and 
decreases of PLT 5-HT were related to institution and discontinuation of enteral 
feeding, respectively, although the number of investigated neonates and 
observations was limited. Replication of our findings in larger groups is necessary, 
and preferably this study should be embedded in another longitudinal study in 
which blood is collected from healthy newborns. Our data nevertheless suggest that 
the mature postnatal PLT 5-HT content will at least partially become established by 
neurotransmission processes involved in GI motility. One of the investigated 
preterm infants (no 5, Figure) exhibited a pattern inconsistent with this notion. 
This patient was born at 30 gestational weeks, which is about two weeks prior to 
the time at which migrating motor complexes in the GI begin to appear [15]. It 
seems therefore possible that his inconsistent pattern of PLT 5-HT is related to an 
immature GI tract, and that such a condition may last up to 20 days after birth in 
preterm born infants. 
  In conclusion, consistent with relative gut motor quiescence we found that 
newborn PLT 5-HT is considerably lower as compared with their mothers. Early 
postnatal PLT 5-HT changes correlate with changes in feeding mode (which affect 
gut motor activity), such that institution and discontinuation of enteral feeding are 
linked to a PLT 5-HT increase and decrease, respectively. Further studies are                                                                                                                 PLATELET 5-HT AS MARKER OF GUT MOTILITY? 
- 141 - 
warranted to establish the link between PLT 5-HT and gut motor activity and the 
usefulness of PLT 5-HT in the detection and monitoring of GI pathology. 
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Abstract 
We describe a platform for the comparative profiling of urine using reversed-phase 
liquid chromatography-mass spectrometry (LC-MS) and multivariate statistical data 
analysis. Urinary compounds were separated by gradient elution and subsequently 
detected by electrospray Ion-Trap MS. The lower limit of detection (5.7-21 
nmol/L), within-day (2.9-19%) and between-day (4.8-19%) analytical variation of 
peak areas, linearity (R2: 0.918-0.999), and standard deviation for retention time 
(<0.52 min) of the method were assessed by means of addition of seven 3-8 amino 
acid peptides (0-500 nmol/L). Relating the amount of injected urine to the area 
under the curve (AUC) of the chromatographic trace at 214 nm better reduced the 
coefficient of variation (CV) of the AUC of the total ion chromatogram (CV 
=10.1%) than relating it to creatinine (CV =38.4%). LC-MS data were processed and 
the common peak matrix was analyzed by principal component analysis (PCA) after 
supervised classification by the nearest shrunken centroid algorithm. The feasibility 
of the method to discriminate urine samples of differing compositions was 
evaluated by (i) addition of seven peptides at nM concentrations to blank urine 
samples of different origin and by (ii) a study of urine from kidney patients with 
and without proteinuria. (i) The added peptides were ranked as highly 
discriminatory peaks despite significant biological variation. (ii) Ninety-two peaks 
were selected best discriminating proteinuric from non-proteinuric samples, of 
which 6 were more intense in the majority of the proteinuric samples. Two of these 
6 peaks were identified as albumin derived peptides, which is in accordance with 
the early rise of albumin during glomerular proteinuria. Interestingly, other 
albumin derived peptides were non-discriminatory indicating preferential 
proteolysis at some cleavage sites.                                                           COMPARATIVE URINE ANALYSIS BY LC-MS AND MULTIVARIATE STATISTICS 
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1. Introduction 
Biofluids such as serum, plasma, whole blood and urine are routinely used for 
diagnostic purposes and in comparative studies. Urine seems a more suitable 
biofluid than blood and its derivatives (plasma or serum), because it can be obtained 
in large quantities by non-invasive sampling. Analytical advantages of urine-
analysis are the less complex sample pretreatment due to the much lower protein 
content, the relatively small size and higher thermodynamic stability of urinary 
peptides/proteins [1], and the lower complexity and intermolecular interactions 
c o m p a r e d  t o  p r o t e i n s  i n  s e r u m  [ 2 ; 3 ] .  T h e majority of pathological changes in 
human organs may well be reflected in urine. In this way urine-analysis can aid in 
disease diagnosis, treatment monitoring and prognosis [4]. Urine, on the other 
hand, is prone to larger biological variations than the blood compartment, as it 
samples the metabolic endproducts from the organism destined for excretion. 
Factors affecting the concentrations of these products in humans, e.g. age and 
gender [5], can be controlled for by careful matching, whereas this is much harder 
to do for the influence of factors of cultural and dietary nature [6]. One of the major 
challenges in biomarker research using urine is thus the large natural variation in 
the concentration of peptides, proteins and metabolites, which requires careful 
normalization of the measurements [7]. 
  A frequently used analytical technique to profile urinary compounds for 
biomarker research is liquid chromatography – mass spectrometry (LC-MS). The 
advantages of LC-MS are high sensitivity and the feasibility of detecting 
thermolabile, water soluble compounds without the need for chemical 
derivatization. Analysis of urine by LC-MS has been applied in metabolomics [8;9], 
proteomics [4;10-15] and peptidomicstm [16-24] as well as in drug metabolism 
research. LC-MS is sensitive to matrix effects due to the interference of matrix 
components with the ionization of analytes (ion suppression) [25]. The use of 
internal standards and standardization of the injected amount are therefore 
necessary for quantitative analyses. Comparative profiling using stable isotope 
labeled standards [26] or dye-labeled proteins as internal standards [27] can 
overcome these limitations but have proven to be laborious and expensive, making 
a well-controlled label-free quantitative method as described here of particular 
interest for clinical studies, where large series of samples have to be processed. A 
quantitative method for profiling complex biological samples without the need for 
labeling or spiking with internal standards seems feasible as long as there is 
linearity of signal versus concentration and a high degree of reproducibility of 
sample processing and the LC-MS platform [28]. CHAPTER 5 
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  Comparing profiles of urinary compounds, it may be insufficient to normalize 
the data based on a single compound like creatinine, as this may not be 
representative of the wide range of molecules with different physico-chemical 
properties (e.g. molecular weight, pKa, hydrophobicity). Since the urinary 
creatinine concentration, which is widely employed to correct for concentration 
differences and to express the urinary clearance of blood components, is mainly 
determined by age, gender, muscle mass, kidney function, exercise and diet, it is 
questionable whether this should be the only standard when it comes to accurate 
data about renal clearance [5]. To base normalization on a broader molecular basis, 
we have therefore compared normalization of the injected volume of urine based 
on a fixed amount of creatinine with a multi-compound normalization strategy 
based on the area under the curve of the chromatogram at 214 nm (AUC214). 
  Data processing prior to multivariate statistical analysis is critical for 
comparing LC-MS data sets that may reach 107 to 108 data points per analysis or 
even more, in case high-resolution mass spectrometry is used. Data processing has 
the goal to correct for unwanted variations in data sets by, for example, correcting 
shifts in retention time and by discriminating meaningful data points from 
background, noise and spikes [29-31], thus generating a peak matrix suited for 
further processing by peak matching, missing peak allocation and finally statistical 
analysis. Even after data processing there is a need for a further reduction in 
dimensionality, since the complexity of biological samples like urine generates a 
great number of significant peaks that generally exceeds the number of analyzed 
samples with the inherent risk of overfitting the data. One way of further reducing 
the number of dimensions in the data is by using a regularized linear discriminant 
classifier method like the nearest shrunken centroid (NSC) algorithm [32]. Visual 
inspection of patterns in the high-dimensional data space is possible through the 
use of further dimension-reducing techniques such as principal component analysis 
(PCA) [33]. For an extensive review and references on data (pre-) processing and 
multivariate statistical methods we refer to the review of Listgarten and Emili [34]. 
  In the present work, we describe the development of a simple, rapid and 
robust reversed-phase LC electrospray (ESI) Ion Trap MS platform to reproducibly 
profile urinary compounds. The platform was evaluated using peptides, which are 
frequently present at nM concentrations in urine. Dedicated data processing and 
multivariate statistical approaches were developed and applied to the data to obtain 
proof-of-principle on several aspects of the method such as: i) the ability to 
discriminate groups of urine samples based on the absence or presence of standard 
peptides at approximately 2-10 times the lower limit of detection (LOD; nM range), 
and ii) the differentiation between the contribution of analytical and biological 
variation to the final result. Finally the platform was tested in a preliminary study                                                           COMPARATIVE URINE ANALYSIS BY LC-MS AND MULTIVARIATE STATISTICS 
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comparing urine samples from hospitalized patients with and without proteinuria. 
Using multivariate statistical analysis of LC-MS profiles of urinary compounds is 
likely to aid in diagnostics, monitoring of disease activity and therapy. It may also 
be of great value in forming new hypotheses about disease mechanisms and the 
effect of therapeutic interventions. 
2. Experimental 
Further detailed information is available under ‘Supporting Information’. 
2.1. Chemicals 
Acetonitrile (ACN) HPLC-S gradient grade), ultra pure water (18.2 MΩ.cm), 
trifluoroacetic acid (TFA) 99% spectrophotometric grade, formic acid (FA) 98-100% 
pro analysis were used for reagent preparation. A peptide stock solution [peptide, 
concentration in mmol/L; VYV, 0.29; YGGFL (leucine enkephalin), 0.20; 
DRVYIHFP (angiotensin II), 0.10; YPFPGPI (β-casomorphin 7), 0.16; YPFPG (β-
casomorphin 5), 0.21; GYPPT (gluten exorphin A5), 0.19; YGGWL (gluten 
exorphin B5), 0.20] was used for addition experiments and internal standardization. 
2.2. Sample  Preparation 
Urine samples were stored at -20˚C, thawed, mixed, acidified with 1% TFA and 
centrifuged to remove precipitate (5 min at 1500 g and 4°C). The supernatant was 
diluted 1:1 with 0.2% FA in 10% ACN and stored at 4˚C until analysis. The 
injection order on the LC-MS was randomized. A pooled urine sample was prepared 
by mixing equal volumes of urine from seven apparently healthy adults (creatinine: 
10.6 mmol/L). 
  Urinary creatinine concentration and total protein content were assayed on an 
autoanalyzer (MEGA, Merck, Darmstadt, Germany). The study protocol was in 
agreement with local ethical standards and the Helsinki declaration of 1964, as 
revised in 2004. 
2.3.  Reversed Phase HPLC-MS 
All LC-MS analyses were performed on an 1100 series capillary HPLC system 
equipped with a cooled autosampler (4°C), a UV detector (λ=214 nm) and an SL ion 
trap mass spectrometer (Agilent Technologies). Urine samples were desalted on an 
AtlantisTM dC18 precolumn (2.1 x 20 mm, 3 μm particles and 10 nm pore diameter) 
using 0.1% FA in 5% ACN at a flow rate of 50 μL/min for 16 min. Urinary 
compounds were back-flushed from the precolumn onto a thermostated (25 ºC) 
AtlantisTM dC18 analytical column (1.0 x 150 mm, 3 μm particles, 30 nm pores) and CHAPTER 5 
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separated in 90 minutes at a flow rate of 50 μL/min during which the percentage of 
s o l v e n t  B  ( 0 . 1 %  F A  i n  A C N )  i n  s o l v e n t  A  ( 0 . 1 %  F A  i n  u l t r a  p u r e  H 2O) was 
increased from 5.0 to 43.6% (0.43%/min). During these 90 minutes UV absorption 
and positive mode MS spectra were acquired. Settings for ESI and mass analysis 
were as follows: 16.0 psi N2; drying gas: 6.0 L/min N2; T: 325 °C; cap. voltage: 3.8 
kV; skimmer: 57.5 V; cap. exit: 190.7 V; oct. 1: 4.12 V; oct. 2: 2.49 V; oct. RF: 190.7 
V; lens 1: -4.9 V; lens 2: -37.7 V; trap drive: 52.5; scan speed: 5500 m/z s-1; 50 ms 
accumulation time or 30000 ions; scan range: 100-1500 m/z; Gaussian acquisition 
filter (width 0.1 m/z) of each scan; rolling average of 5 spectra. Spectra were saved 
in the centroid mode. Following the gradient, both columns were washed with 85% 
B for 5 min and equilibrated with 5% B for 10 min prior to the next injection. 
  Internal standards were injected onto the precolumn prior to injection of the 
urine samples. Between each injection the injection system was cleaned with 70% 
ACN and filled again with 0.1% FA in 5% ACN. The amount of internal standard 
(IS) peptides injected varied per experiment (see section ‘Results’ for more details). 
2.4.  Tandem mass spectrometry and database searching 
Nano-LC ESI quadrupole time-of-flight (Q-TOF) MS/MS (API QSTAR Pulsar i 
LC/MS/MS System [Applied Biosystems, MDS Sciex, Framingham, Massachusetts, 
USA]) was used in the Auto-MS2 mode (precursor ions >100 counts, 1+ to 4+ ions; 
spray voltage 2350V; varying collision energies). Using mascot.dll script-processing 
in Analyst QS 1.1, build 9865 (Applied Biosystems, MDS Sciex) MS-spectra were 
deconvoluted with respect to charge state and isotopes. The resulting spectra were 
saved in mascot (Matrix Science, London, UK) generic file format and submitted to 
an in-house version of the MASCOT [35] search engine (v1.9.05) for UniProt 
(release 7.7) queries and to a web-based version of the Phenyx [36] search engine 
(v2.1) for UniProt_Sprot (r.  48.8 of 10-Jan-2006) queries. Enzyme settings were 
based on chymotrypsin-, trypsin- and caspase-like proteolytic activity of the 26S 
proteasome in renal cells [37] allowing “half cleavages (Phenyx)” of peptide bonds. 
Search outcomes were evaluated at a significance level of a probability based 
Mowse score for MASCOT of ≥61 (P<0.001) and at an AC-score of ≥5 for Phenyx. 
The latter is the sum of the best scores per valid peptide sequence. 
  The identities of discriminatory peaks, as selected by multivariate statistics, 
from Ion-Trap and quadrupole-TOF MS data were confirmed by comparing mass 
spectra and relative retention times using bracketing between added standard 
peptides. MS/MS data from these discriminatory peaks were processed using 
MASCOT scripts to obtain a peak list of fragment ions suitable for MS/MS ion 
search. Prior to subsequent database queries these peak lists were tagged and added 
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they originated from one of the previously identified proteins. A peak was 
considered to be identified if the Phenyx z-score ≥4, P≤0.0001 and retention time of 
the peptide were within 0.05 min and 0.01 amu of the respective discriminatory 
peak. If the peak/peptide did not reach these criteria, manual conversion of the 
monoisotopic multiply-charged fragment ions to monoisotopic singly-charged 
fragment ions was performed prior to another round of searches using MASCOT 
and Phenyx. 
  Further detailed information is available under ‘Supporting Information’. 
2.5.  Data processing and analysis 
2.5.1.  Data analysis for method evaluation 
LC-MS chromatographic data were analyze d  w i t h  D a t a  A n a l y s i s  s o f t w a r e  f o r  
LC/MSD Trap, version (3.2 build 121) (Bruker Daltoniks, Bremen, Germany). Peak 
areas and intensities of the spiked peptides described were obtained from the 
respective smoothed and baseline subtracted extracted ion chromatograms (EIC). 
One cycle of smoothing with a Gaussian algorithm at a width of 1.8 points preceded 
baseline subtraction with a flatness of 1. The AUC214 was calculated between 30 and 
80 min retention time, which corresponds to 14 - 64 min for mass spectrometric 
data acquisition (MS data acquisition was started 16 min later than the gradient 
program) during gradient elution. 
  Univariate statistical analyses were performed with the Statistical Product and 
Service Solutions package version 11.5 (SPSS Inc., Chicago). 
2.5.2. Data  (pre-)processing 
For processing and multivariate statistical analysis the original Bruker Daltoniks 
LC-MS data files were converted into ASCII-format with the Bruker Data Analysis 
software. For further data analysis Matlab (version 7.0.0.19920, Mathworks, Natick, 
MA, USA) and the PLS toolbox (version 3.5.2, Eigenvector Research Inc., 
Wenatchee, WA, USA) were used. 
  Initially the nominal m/z ratios were rounded to the nearest integer to 1 amu 
bins (instead of the original 0.1 amu in the acquired data) according to Radulovic et 
al. [38], which is adapted to the accuracy of the ion trap (±0.3 amu). Binning 
reduced the amount of data by roughly a factor 10 and it also partially corrected for 
the slight shift in m/z values as a result of trap overfilling occurring during peak 
elution. For signal filtering and background reduction, data was first smoothed 
using a moving average filter (3-scan header width, 2 cycles). A modified M-N rule 
was applied for peak detection in which a pre-defined baseline T (30% of trimmed 
mean) was multiplied by M (set at 2) to set the threshold (1000 counts), which CHAPTER 5 
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should be exceeded by the peak intensity for at least N (set at 5) consecutive 
observations in the time dimension [38]. If T was lower than 1000 counts, M*1000 
was used as a threshold for that bin. For each bin we included the m/z bin value, 
intensity of the data point with the highest intensity and the mean retention time 
of the three data points with the highest intensity to generate the peak list. 
  We used a similar approach as Radulovic et al. [38] to obtain optimal settings 
for M and N. M (1.5-4) and N (4-8) were applied to two blank LC-MS runs and two 
LC-MS runs of the pooled urine sample. The settings at which the ratio between 
the number of peaks (between 30-80 min and broader than 0.3 min at baseline * N) 
in the sample and in the blank was the highest and at which a minimal number of 
peaks was extracted from the noise in the blank chromatogram were used. 
  Time alignment of the chromatograms was not needed, because the median 
(range) standard deviation of the retention time of the standard peptide peaks was 
only 0.37 (0.23-0.52) min. One-dimensional peak matching and missing peak 
allocation in different samples was realized by using a sliding windows technique in 
which similar m/z bins are evaluated for peaks proximate in time (step size 0.1 min; 
search window 1.0 min; maximal accepted difference of centroided retention time 
within a group of matched peaks 0.75 min). Missing peak allocation was performed 
by extracting the background in given m/z bins at the mean retention time of the 
other identified peaks. The generated final peak matrix, created from the peak 
matrices of the individual samples, consisted of a peak(row)-sample(column)-
intensity(value) matrix. This final peak matrix was used for multivariate statistical 
analysis. 
  All data preprocessing work was done on a personal computer equipped with a 
+3600 MHz AMD processor and with 4 GB of RAM. 
2.5.3.  Classification and multivariate statistical methods 
To select the most discriminating peaks we applied the NSC classification algorithm 
[32;39]. NSC regularizes data whereby class-specific centroids are “shrunk” toward 
the overall (nonclass-specific) centroid, which has the effect of eliminating the 
influence of the most weakly correlated peaks, thereby reducing the capacity to 
overfit [34]. This algorithm is used to select peaks that are relevant for the 
discrimination of the predefined classes in conjunction with permutation tests to 
validate the classification algorithm [40] using leave-one-out cross-validation 
(LOOCV) to avoid overfitting due to one outlier. The optimal shrinkage value was 
the value at which LOOCV showed the lowest classification error. In LOOCV one 
observation per class is iteratively omitted from the data set that is used to construct 
the classification model, which is then used to classify the omitted observation as 
case or control. Variables selected at the highest shrinkage value and lowest                                                           COMPARATIVE URINE ANALYSIS BY LC-MS AND MULTIVARIATE STATISTICS 
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LOOCV error, were employed for construction of the final classification model. 
The selected peaks were then analyzed and visualized by plotting the first two 
principal components obtained after PCA [33]. As a measure for class separation the 
Mahalanobis distance (MD), was calculated [41]. We consider a MD above the cut-
off of 6.0, corresponding to a difference of 6 sigma between the mean centroids of 
the classes [40], as indicative for significant class separation. 
3. Results 
3.1.  Method development and evaluation 
3.1.1  Optimization of RP-HPLC 
Resolution between the spiked peptides (see Experimental) was optimized by 
varying gradient steepness and flow rate in a central composite design. The goal was 
to achieve optimal resolution within a maximal runtime of 90 min and a flow-rate 
of 50 μL/min, which is adapted to the ESI-source and the column diameter of 1 
mm. Optimal resolution was obtained at a gradient steepness of 0.43% solvent 
B/min. Runs of urine samples of 6 healthy adults without the added peptides 
assured that there were no detectable peaks in the respective EIC at the retention 
times of the added peptides. A typical chromatogram of 9.6 μL urine spiked with 
0.25-0.73 pmol of standard peptides under these conditions is shown in Figure 1A. 
For two peptides (DRVYIHPF and YPFPGPI) the mono- and di-protonated ions 
were extracted and combined into one trace, whereas for the other peptides only 
the mono-protonated ions were observed and thus extracted (Figure 1B). Figure 1C 
shows the corresponding chromatographic trace at 214 nm of the in-line UV-
detector. 
3.1.2.  Normalization of injected amount of urine to creatinine or the 
AUC214 
Since ESI is sensitive to matrix effects leading to ion-suppression [25], it is 
important to standardize the injected amount of urine in comparative analyses. 
Assuming that matrix effects are proportional to the injected amount, two methods 
of normalization were investigated: i) to a given amount of creatinine (50 nmol) 
and ii) to a fixed AUC214 value (1.02x105 absorbance units [AU]; see below for the 
calculation). Creatinine was chosen, because of its frequent use in clinical chemistry 
and the UV-area at 214 nm between 30-80 minutes (AUC214) was chosen, because it 
normalizes the injected amount based on a large number of compounds, which is 
likely to be more representative of the overall sample composition. CHAPTER 5 
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Figure 1.  Analysis of a pooled urine sample spiked with nM concentrations of 
internal standard peptides. 
A.  Smoothed and baseline subtracted base peak chromatogram of a pooled urine sample (9.6 μL injected, 
equivalent to 50 nmol creatinine) co-injected with 5 μL of 1:2000 diluted peptide stock solution, after 
optimization of the resolution by varying gradient steepness in a central composite design. 
B.  Smoothed and baseline subtracted extracted ion chromatograms (EIC) of the seven peptides used for 
optimization and internal standardization (same sample as shown in panel A). Peptide peaks correspond 
to n-times the lower limit of detection (LOD): peptide (n x LOD), 1. VYV (3.9), 2. GYYPT (2.3), 3. 
YPFPG (4.6), 4. DRVYIHPF (2.2), 5. YGGFL (9.5), 6. YGGWL (3.5) and 7. YPFPGPI (7.3); the absolute 
values for the LOD can be found in Table 2. The calculated LOD for VYV appears to be lower than the 
LOD that was derived from the signal-to-noise ratio of the peak shown in Figure 1B. Peptide m/z-
values and retention times derived from the analysis of diluted stock solutions were used to extract and 
appoint peaks to the standard peptides spiked into urine. 
C.  Smoothed and baseline subtracted UV chromatogram (λ=214 nm) of the same urine sample as shown in 
panel A. 
 
Moreover, normalizing to the AUC214 rather than to the AUC of the total ion 
chromatogram (AUCTIC) avoids confounding effects resulting from ion suppression, 
since extinction coefficients are characteristic of each compound as long as the 
linear range of the UV-detector is not exceeded. By starting integration at 30 min 
we avoided the contribution of very small and very hydrophilic compounds, e.g. 
small hydrophilic organic acids, to the AUC214. 
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  To investigate which normalization method of the injected amount (injection 
volume) was preferable, ten different 24-hour urine samples of children (male: 
female / 5:5; age range 6.8 - 13.6 years) with creatinine levels ranging from 2.0 - 
10.6 mmol/L were analyzed. The initial sample volume injected onto the column 
was equivalent to 50 nmol creatinine and the AUC214 between 30 and 80 minutes 
was a measure of the overall amount of compounds injected. From this area a new 
injection volume was calculated keeping the ‘injected AUC214‘ constant at 1.02x105 
absorbance units, which corresponds to an average amount of 50 nmol creatinine 
for the ten urine samples. Five μL of the 1:500 diluted peptide stock solution (1.0-
2.9 pmol per peptide) was co-injected to evaluate which method of standardization 
resulted in the most repeatable peak areas for each peptide. 
  Overall peptide MS-signals showed less variation when the injected volume 
was normalized to a fixed AUC214 value as compared to a constant amount of 
creatinine (Table 1). Similarly, the AUCTIC between 30 and 80 minutes (dead time 
between UV detector and ion source was approximately 5 sec), which reflects all of 
the MS-detected urinary compounds, improved with respect to the coefficient of 
variation (CV) from 38% when normalized to creatinine to 10% when using the 
AUC214 value (Table 1). Generally these results indicate that adjusting the injected 
amount of urine based on the AUC214 is preferable to minimize variations in peak 
area and intensity due to matrix effects, although this seems component dependent. 
A drawback of using the UV-area is that one compound eluting at 35.0 min 
retention time determined a large portion (median [range]; 44% [14-62%]) of the 
total AUC214. 
 
Table 1.  Peak area and intensity variation of peptides added to urine after 
normalization of the injected amount to creatinine or UV-area 
 
a  Area under the curve of the UV-
chromatogram (λ=214 nm) between 30 and 
80 min retention time; 
b Coefficient of variation; 
c Area under the curve of the total ion 
chromatogram between 30 and 80 min 
retention time. 
 
 
 
 
 
 
Peptide 
(sequence) 
Creatinine 
[CV b (%)] 
AUC214 a 
[CV b (%)] 
  Area Intensity Area Intensity 
1  VYV  30.1 22.2 23.3 20.7 
2  GYYPT 19.3 16.2 13.2 11.9 
3 YPFPG 19.2 15.1 11.3 11.6 
4  DRVYIHPF  13.7 13.3 25.6 23.3 
5 YGGFL 21.5  16.3  5.9  6.1 
6 YGGWL 11.5  11.1  7.1  9.7 
7  YPFPGPI  20.4 20.1 15.4 17.6 
       AUCTIC c 38.4  10.1 CHAPTER 5 
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3.1.3. Method  evaluation 
The linearity and lower limit of detection (LOD) of the optimized LC-MS method 
were determined by duplicate analyses of pooled urine samples spiked with 
peptides at concentrations of 0 (n=5); 10; 25; 50; 100; 150; 250 and 500 nmol/L 
(calculated for YGGFL). Calibration curves were based on the respective smoothed 
and baseline subtracted EIC. Least squares linear regression analysis was employed. 
The LOD is calculated from the intercept of the y-axis with the upper limit of the 
95% confidence interval of the calibration curve [42]. 
  The method exhibited good linearity (all curves P<0.001) with R2 values 
ranging from 0.918–0.999 for peak area and intensity over the concentration range 
(data not shown). The LOD ranged from 5.7-21 nmol/L, depending on the peptide 
(Table 2). This corresponds to an injected amount of 54-204 fmol per peptide (Table 
2). Figure 1B shows the EIC of the respective peptides at the calculated 2-10 times 
their LOD (i.e. 0.25-0.73 pmol injected or 50-145 nmol/L). The calculated LOD for 
VYV appears to be lower than the LOD that was derived from the signal-to-noise 
ratio of the peak shown in Figure 1B. 
 
Table 2. Lower limits of detection (LOD) of seven peptides used as internal standards 
 
No.  Peptide  m/z values of EICsa  LOD (concentration)  LOD (amount) 
  (sequence) ([M+H]1+, [M+2H]2+) (nmol/L) (fmol  injected) 
1 VYV  380.2  19b  186b 
2 GYYPT  600.3  21  204 
3 YPFPG  580.3  12  113 
4 DRVYIHPF  1046.5,  523.8  12  114 
5 YGGFL  556.3  5.7  54 
6 YGGWL  595.3  15  143 
7 YPFPGPI  790.4,  395.7  5.7  55 
 
a Extracted ion chromatogram. 
b The reported LOD, calculated from the intercept of the y-axis with the upper limit of the 95% confidence 
interval of the calibration curve, appears to be lower than the LOD derived from the signal-to-noise ratio of 
peak VYV depicted in Figure 1B. 
 
 
The within-day and between-day analytical variation of the method were 
determined by repetitive analyses (n=5) of the pooled urine sample (equivalent to 
50 nmol creatinine) injected together with 5 μL of a low (1:2000 diluted peptide 
stock solution, 0.25–0.73 pmol) and a high (1:500 diluted peptide stock solution, 
1.0–2.9 pmol) amount of added peptides on the same day and on five consecutive 
days, respectively. Outliers were removed (α=0.05) using the Dixon test [43] and 
Cochran’s maximum variance test [44]. Overall, the within-day and between-day 
variation ranged between 2.9 and 19% for the various peptides (Table 3).                                                           COMPARATIVE URINE ANALYSIS BY LC-MS AND MULTIVARIATE STATISTICS 
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Table 3.  Within-day (n=5) and between-day (5 days, n=5) variation of internal 
standard peptides added to a pooled urine sample 
 
 within-day  between-day 
peptide amount  injected area intensity  RT  a area  intensity  RT 
(sequence) (pmol)  CV  b (%)  CV (%)  SD c (min)  CV (%)  CV (%)  SD (min) 
VYV 
0.73 12  11 
0.36 
18 14 
0.48 
2.9 6.0  12  7.2  9.5 
GYYPT 
0.48 16  11 
0.43 
19 17 
0.35 
1.9 7.2  9.3  12  14 
YPFPG 
0.53 12  7.3 
0.25 
13 10 
0.37 
2.1 3.2  4.4  6.5  8.7 
DRVYIHPF 
0.25 19  12 
0.23 
5.3 6.0 
0.43 
1.0 7.4  13  8.1  9.1 
YGGFL 
0.50 6.2  5.8 
0.26 
6.2 8.3 
0.44 
2.0 2.9  3.1  7.3  7.8 
YGGWL 
0.50 3.0  4.5 
0.27 
4.8 5.3 
0.47 
2.0 3.5  3.6  6.6  6.8 
YPFPGPI 
0.40 6.5  8.3 
0.29 
8.5 6.6 
0.52 
1.6 2.9  4.4  5.2  7.0 
 
a RT, retention time; b CV, coefficient of variation; c SD, standard deviation. 
 
3.2.  Data processing and multivariate statistical analysis of LC-
MS profiles of urinary compounds 
3.2.1.  Data processing and analysis 
Binning from an instrumental resolution of 0.1 amu to 1 amu reduced the size of 
the dataset to reach an acceptable data processing and analysis time on a normal 
desktop computer (see ‘Experimental’ for specifications). The M-N rule proved to 
be a simple, fast and robust peak picking algorithm, which generated a peak list 
within one hour per sample. The input, i.e. the number of samples, determined the 
time required for peak matching, missing peak allocation and for construction of 
the final peak matrix (see ‘Experimental’ for details). 
3.2.2.  Multivariate statistical comparison of pooled urine samples to 
assess the effect of analytical variation 
LC-MS data from repetitive analyses (n=6) of 11.1 μL injections of blank pooled 
urine (AUC214= 1.02x105 AU) and of the same urine spiked at 2-10 times the LOD 
(n=6) were processed as described before to obtain a final matrix containing 10029 
peaks. This peak matrix was used to construct a PC score plot of the two first 
principal components (PC 1 and PC 2) best explaining the total variance of the data CHAPTER 5 
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(Figure 2A). Using all 10029 peaks, the plot showed a strong overlap between the 
blank (¡) and spiked (Ì) group, which was confirmed by a MD of 0.43 (non-
significant). 
 
 
 
-60 -40 -20 0 20 40 60 80
-80
-60
-40
-20
0
20
40
60
Scores on PC 1 (17.17%)
S
c
o
r
e
s
 
o
n
 
P
C
 
2
 
(
1
3
.
2
2
%
)
 
 
 
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
-60 -40 -20 0 20 40 60 80
-80
-60
-40
-20
0
20
40
60
Scores on PC 1 (17.17%)
S
c
o
r
e
s
 
o
n
 
P
C
 
2
 
(
1
3
.
2
2
%
)
 
 
 
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
A 
-0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
PC 1 (76.15%)
P
C
 
2
 
(
9
.
5
0
%
)
 
 
 
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
17 peaks selected by NSC best discriminating the groups
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
17 peaks selected by NSC best discriminating the groups
-0.4 -0.3 -0.2 -0.1 0 0.1 0.2 0.3 0.4
-0.8
-0.6
-0.4
-0.2
0
0.2
0.4
0.6
PC 1 (76.15%)
P
C
 
2
 
(
9
.
5
0
%
)
 
 
 
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
17 peaks selected by NSC best discriminating the groups
6 repetitions of a spiked (2-10x LOD) pooled urine sample
6 repetitions of a blank pooled urine sample
17 peaks selected by NSC best discriminating the groups
B 
 
 
Figure 2.  Description of the analytical variation in urine profiles from a pooled urine 
sample analyzed six times. 
A.  The principal component (PC) analysis plot using the complete peak matrix of 10029 peaks shows 
overlap between repetitions of the blank (¡) and spiked (Ì; 2-10 times lower limit of detection of 
standard peptides) pooled urine sample. Together PC 1 and PC 2 explain only 30.39% of the variation 
between the samples. 
B.  The biplot depicts the same blank (¡) and spiked (Ì) samples as in panel A together with 17 of the 
10029 most discriminating peaks (T) selected by the nearest shrunken centroid classification method at 
a leave-one-out cross-validation error of 0. Arrows indicate peaks that do not belong to the added 
peptides. In contrast to Figure 2A, PC 1 and PC 2 now explain a much larger portion (85.65%) of the 
variation between the samples. Ellipses circle groups of samples belonging to the same class, i.e. blank 
and spiked. 
 
Application of the NSC classification method yielded 17 highly discriminatory 
peaks (T) out of the original peak matrix at a shrinkage value of 3.0 with a LOOCV 
(see ‘Experimental’) error of 0 (Figure 2B). Fourteen (82%) of these 17 peaks could 
be traced back to the added standard peptides based on m/z-values and retention 
times. These 14 peaks were elevated in the spiked group as expected (data not 
shown). Of the remaining three peaks (arrows), two were located in the region of 
the blank urine sample and one was located in the spiked samples area. Univariate 
comparison revealed no significant difference between peak areas (P>0.5) indicating 
that these peaks were selected by chance. The higher number of selected peaks 
relative to the number of spiked peptides is due to the fact that the original data 
were not deconvoluted with respect to charge state or isotopic distribution. This 
did, however, not affect the classification of samples. The PCA biplot, based on the 
17 selected peaks, showed clear discrimination between the blank and the spiked 
samples, which was confirmed by a MD of 9.91 (significant). Urine samples spiked                                                           COMPARATIVE URINE ANALYSIS BY LC-MS AND MULTIVARIATE STATISTICS 
- 159 - 
at nM concentrations with peptides can thus be discriminated using the developed 
LC-MS method followed by supervised peak selection with cross-validation and 
visualization of the first two principal components. 
3.2.3.  Multivariate statistical comparison of urine samples from different 
individuals to assess the effect of biological variation 
LC-MS data obtained from the analysis of blank and spiked (2-10 times LOD) urine 
samples (6.6-19.8 μL injected; AUC214 = 1.02x105 AU) of six healthy individuals 
(male: female / 3:3; median age [range] 27 years [25-30]) yielded a matrix 
containing 14234 peaks. To relate analytical variation to biological variation, we 
generated a common matrix of 14234 peaks including the samples described under 
section 3.2.2, which reflect analytical variation only. 
 Figure  3A shows a PC score plot generated with the entire peak matrix. Blank 
(z) and spiked () samples of the same individual co-localized in 5 out of 6 cases. 
This indicates that the analytical variation is much smaller than the biological 
variation between different healthy individuals. Co-localization of the data points 
from the repetitive analyses of blank (¡) and spiked (Ì) pooled urine samples 
(analytical variation only) emphasizes the importance of biological variation 
relative to analytical variation further. Moreover, pooling the urine of these six 
healthy individuals averaged the explained variation represented by PC 1 and PC 2 
(both around 0) out. 
  It was thus of importance to assess whether spiking of the seven standard 
peptides at 2-10 times the LOD could still be discriminated despite the observed 
biological variation. The NSC algorithm yielded 16 discriminatory peaks (T) from 
the original peak matrix at a shrinkage value of 1.85 with an LOOCV error of 0. 
Fourteen (88%) of these 16 peaks could again be related to 6 of the 7 added peptides 
based on m/z-values and retention times (Figure 3B). 
  Peak areas and intensities, derived from the EIC of the first two isotopic peaks 
of the NSC-selected peptide peaks, were compared by univariate statistics (Figure 
4). P-values were less than 0.001 for area (Figure 4A) and intensity (Figure 4B) for 5 
out of the 7 spiked peptides, whereas no significant difference was found for the 
two other peaks that the NSC algorithm had selected as being discriminatory. One 
of these peaks (peak X in Figure 3B; 694.6 m/z) co-eluted with one of the spiked 
peptides (YPFPGPI; [M+H]+=790.4 m/z). The non-significant decrease in peak area 
and intensity of this signal after spiking suggests an ion-suppression effect. We 
could not clarify the reason why the peak at 80.85 min (peak Y in Figure 3B; m/z = 
356.5) was selected as being discriminatory by the NSC algorithm. CHAPTER 5 
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Figure 3.  Description of the analytical and biological variation in urine profiles from 
six healthy individuals. 
A.  The principal component (PC) analysis plot using the complete peak matrix of 14234 peaks shows 
overlap between the blank (z) and spiked (; 2-10 times lower limit of detection of standard peptides) 
urine samples of six apparently healthy adults, and six repetitive analysis of a blank (n=6; ¡) and a 
spiked (n=6; Ì) pooled urine sample. Co-localization (red ellipses) of the blank and spiked samples from 
the same individual (for 5 out of 6 individuals) and the pool, suggests biological variation to be the main 
determinant of the observed variation between samples. Unsupervised PC analysis obviously provides 
insufficient discriminatory power to detect the variation caused by spiking. Together PC 1 and PC 2 
explain 45.74% of the variation between the samples. 
B.  The biplot depicts the same blank (z) and spiked () samples as in panel A together with 16 of the 
14234 most discriminating peaks (T) selected by the nearest shrunken centroid classification method at 
a leave-one-out cross-validation error of 0. PC 1 in the biplot explains 78.51% of the variation between 
blank (z) and spiked () samples. Two peaks (X and Y) could not be related to the added peptides. 
 
 
The NSC algorithm missed the added peptide GYYPT as being discriminatory 
probably because it eluted early in the gradient and was added to the urine at a 
concentration equivalent to 2.2 times the LOD. Despite this fact, it was clearly 
possible to discriminate the two groups of samples based on a PCA score plot, 
explaining 89.6% of the variation between blank and spiked samples, using the 16 
selected peaks (MD of 9.10) in the presence of the observed biological variation. 
Classification of the repetitions of the blank and spiked pooled urine samples, using 
the 16 peaks selected by the NSC algorithm, r e s ul t e d  al s o  i n  a s s i g n me n t  o f t h e 
samples to the appropriate classes (MD of 8.04; not shown). 
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Figure 4.   Univariate comparison of peak areas and intensities of peptides/peaks 
discriminating blank from spiked urine samples from different individuals. 
Graphs represent univariate paired comparisons (P-values) of peak area (A) and intensity (B) of smoothed and 
baseline subtracted extracted ion chromatograms from raw LC-MS data of the peptides/peaks selected by the 
nearest shrunken centroid classification method. Bars represent the mean values (error bars: +/- 1 x SD). The 
median (error bars: minimum-maximum) is presented for the area of 356.5 m/z and the intensity of peptide 
VYV. Comparison was performed with the Wilcoxon signed ranks test (non-parametric) and the paired 
Student’s T-test (parametric) dependant on the normality of the distribution (Shapiro-Wilk’s test). 
 
3.2.4.  Application of the developed methodology to urine from patients 
with and without proteinuria 
In order to evaluate the applicability of the described methodology, we studied 
urine of hospitalized patients with established proteinuria (P; male: female / 5:1; 
median age 60 years [60-75]; median (range) total protein concentration in a 
random portion of urine: 7.6 g/L [6.5-10]) due to primary or secondary renal 
morbidity, and we studied urine of hospitalized patients with a medical history of 
renal morbidity but without proteinuria at the time of sampling (NP; male: female / 
5:1; median age 63 years [56-72]; total protein concentration in portion urine: 0.1 
g/L [0.0-0.2]). Proteinuria was defined as having a total urinary protein 
concentration above 1 g/L in a random portion. The total peak matrix contained 
11867 peaks and did not allow discrimination between the proteinuric and non-
proteinuric samples (MD=1.84) without supervised classification. 
  The NSC classifier yielded 92 discriminatory peaks at a shrinkage value of 1.88 
with a LOOCV error of 0. The urine samples with and without proteinuria were 
discriminated (MD = 6.95) in the PC 1 dimension of the biplot (Figure 5A). Ninety-
one out of 92 discriminatory peaks (T) increased in intensity in proteinuria (), 
whereas one peak seemed to be increased (arrow) in the samples without 
proteinuria (z). Classification of the urine samples from six healthy individuals 
described in sections 3.2.2 and 3.2.3 (spiked or blank; total of 24 samples; ¡) using 
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the model generated with the variables selected from the 12 chromatograms 
described in this section, resulted in the formation of a dense cluster close to the 
non-proteinuric samples (Figure 5B), discriminating them even more strongly from 
the proteinuric samples (MD =15.40) notwithstanding the fact that some of them 
contained spiked peptides. Most remarkable was the difference (MD =3.39) 
between the urine samples of apparently healthy individuals without known renal 
morbidity used for spiking experiments and the patients with (a history of) renal 
morbidity but without proteinuria. A trend of progressing renal disease may be 
implied, as patients shift to the right along the PC 1-axis. 
 
 
Figure 5.   Comparison of urine samples from proteinuric and non-proteinuric patients 
with renal disorders. 
The biplot (A) shows the urine samples from 6 patients with proteinuria (;  ≥1 g/L total protein 
concentration in a random portion of urine) and from 6 patients without proteinuria (z; ≤0.1 g/L) but with a 
medical history of renal morbidity. 92 peaks (T) out of 11867 were selected for their discriminatory 
properties by the nearest shrunken centroid classification method at a leave-one-out cross-validation error of 
0. The arrow indicates an upregulated peak in the non-proteinuria group. Using this model, classification of 
24 samples from apparently healthy individuals (¡) resulted in a dense cluster (purple ellipse) that was 
separated from the non-proteinuric patients (B) implying large differences in the composition of urine 
between healthy individuals and hospitalized patients with or without proteinuria. The enlarged area in panel 
B shows that some patients without overt proteinuria show a trend in PC 1 placing them at various levels 
towards overt proteinuria. 
 
3.2.5.  Selection of discriminatory peaks and identification by tandem 
mass spectrometry 
The 92 discriminatory peaks obtained by NSC from the total peak matrix were 
curated by manual de-isotoping and charge deconvolution. From the resulting 54 
curated peaks we selected 6 peaks for further univariate statistical comparison, 
based on their elevated levels in the majority of the proteinuric samples. Figure 6 
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shows the box and whisker plots and corresponding P-values for univariate 
comparison of the peak areas (A) and intensities (B) of these 6 peaks for the two 
patient groups. The overlaid EIC of 2 of the 6 peaks (Figure 6C) showed that both of 
these peaks were increased in 3 out of 6 proteinuric urine samples, but not in the 
non-proteinuric samples. This indicates a considerable variability in the proteinuric 
patient group, which is also evident from the PCA score plot (see Figure 5), relative 
to patients with kidney disease but no proteinuria. Interestingly, there was no 
correlation (P>0.05, R2≤0.0276) between total protein content in urine and peak 
area or intensity of these 6 peaks in patients with proteinuria, suggesting that the 
selected peaks discriminate patients not simply based on the total protein 
concentration in urine. Remarkably, most of the selected peaks did not reach 
statistical significance (P<0.05) on their own when comparing proteinuric and non-
proteinuric patient samples due to the large variation in the proteinuric patient 
group. This adds further support to the value of a multivariate statistical comparison 
for discrimination between complex samples. 
 
 
Figure 6.   Univariate comparison of peak area and intensity of 6 peaks discriminating 
proteinuria from non-proteinuria. 
Represented are box and whisker plots and the corresponding P-values for univariate comparisons of peak 
area (A) and intensity (B) of smoothed and baseline subtracted extracted ion chromatograms (EIC) from raw 
LC-MS data of 6 discriminating peaks selected by the nearest shrunken centroid (NSC) classification method. 
Comparison was performed with the Mann-Whitney U test (non-parametric) and the Student’s T-test 
(parametric) dependant on the normality of the distribution (Shapiro-Wilk’s test). Panel (C, next page) shows 
the EIC of two discriminatory peaks selected by the NSC algorithm for the proteinuric (blue) and non-
proteinuric (red) samples. 
 
 
 
 
 
 
NSC selected peaks
736.5 m/z
712.6 m/z
694.7 m/z
690.4 m/z
573.5 m/z
528.7 m/z
A
r
e
a
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
4
3
2
1
0
-1
No Proteinuria
Proteinuria
P=0.13
P=0.083
P=0.16
P=0.083
P=0.072
P=0.015
x
 
1
0
9
NSC selected peaks
736.5 m/z
712.6 m/z
694.7 m/z
690.4 m/z
573.5 m/z
528.7 m/z
A
r
e
a
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
4
3
2
1
0
-1
No Proteinuria
Proteinuria
P=0.13
P=0.083
P=0.16
P=0.083
P=0.072
P=0.015
x
 
1
0
9
A 
NSC selected peaks
736.5 m/z
712.6 m/z
694.7 m/z
690.4 m/z
573.5 m/z
528.7 m/z
I
n
t
e
n
s
i
t
y
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
10
8
6
4
2
0
-2
No Proteinuria
Proteinuria
P=0.10
P=0.34
P=0.16
P=0.10
P=0.064 P=0.016
x
 
1
0
7
NSC selected peaks
736.5 m/z
712.6 m/z
694.7 m/z
690.4 m/z
573.5 m/z
528.7 m/z
I
n
t
e
n
s
i
t
y
 
(
a
r
b
i
t
r
a
r
y
 
u
n
i
t
s
)
10
8
6
4
2
0
-2
No Proteinuria
Proteinuria
P=0.10
P=0.34
P=0.16
P=0.10
P=0.064 P=0.016
x
 
1
0
7
B 
 CHAPTER 5 
- 164 - 
 
 
 
 
 
 
The proteinuric urine sample containing the 
highest level of these six peaks was analyzed 
in duplicate by nanoLC ESI-Q-TOF MS/MS 
to identify the parent protein(s) from which 
the discriminating peaks were derived. LC-
MS data were processed as described under 
‘Experimental’.  Table 4 and 5 list the most 
significant hits of identified proteins for 
MASCOT- and Phenyx-algorithm based 
Uniprot/SwissProt database searches, 
respectively. Most of the identified proteins 
are derived from blood. 
 
 
Table 4.    Proteins in a proteinuric urine sample identified by LC-MS/MS and 
subsequent UniProt database search by the MASCOT algorithm  
 
Protein Accession  no.  Score  a Cov.(%)  b #  Peptides  c 
α-1-antitrypsin precursor d  P01009 1090  43 16/35 
serum albumin precursor d  P02768 445  11 4/19 
haptoglobin precursor d P00738  173  14  1/9 
serotransferrin precursord  P02787 153  7 2/7 
α-1-acid glycoprotein 1 precursor d  P02763 117  12 1/7 
apolipoprotein A-I precursor d  P12270 103  9 1/3 
hemoglobin β-subunit d P68871  102  21  2/3 
α-1-antichymotrypsin precursor d P01011 99 10  1/5 
transthyretin precursor (prealbumin) d  P02766 96  28 2/5 
Collagen α-1 (XIV) chain precursor  P02766  73  1 1/5 
 
a Listed are proteins associated with the ten highest probability based Mowse scores (remaining identified 
proteins with a Mowse score ≥61 (P<0.001) are listed under ‘Supporting Information’). An in-house version of 
the Mascot search engine (v1.9.05) was used to search the UniProt (release 7.7) database. Enzyme ‘none’ was 
specified for the search. b Percent ratio of all amino acids from valid peptide matches to the total number of 
amino acids in the protein. c Number of unique peptide matches (ion score >34 [P<0.05] was considered 
significant) followed by the total number of peptide matches found for the given protein. d Proteins were also 
identified by Phenyx (Table 5). Further detailed information is available under ‘Supporting Information’. 
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Table 5.    Proteins in a proteinuric urine sample identified by LC-MS/MS and 
subsequent UniProt/SwissProt databases search by the Phenyx algorithm 
 
Protein Accession  no.  Score  a Cov.  (%)  b #  Peptides  c 
α-1-antitrypsin precursor d P01009_WOSIG0  187.8  35  39/57 
serum albumin precursor d P02768_WOSIG0  47.43  4  9/21 
haptoglobin-related protein precursor d P00739_WOSIG0  40.49  12  8/10 
α-1-acid glycoprotein 1 precursor d P02763_WOSIG0  28.28  14  6/10 
hemoglobin β-subunit d P68871  25.33  16  4/6 
serotransferrin precursor d P02787_WOSIG0  24 3  4/9 
α-1-acid glycoprotein 2 precursor  P19652_WOSIG0  14.95  9  3/3 
apolipoprotein A-I precursor d P02647_WOSIG0  13.93  8  2/5 
α-1b-glycoprotein precursor  P04217_WOSIG0  9.33  2  1/3 
zinc-α-2-glycoprotein precursor  P25311_WOSIG0  8.87  3  3/3 
transthyretin precursor (prealbumin) d P02766_WOSIG0  8.82  8  1/4 
α-1-antichymotrypsin precursor d P01011_WOSIG0  8.37  3  2/7 
angiotensinogen precursor e P01019_PEPT0  8.29  80  1/1 
 
a Listed are the proteins with AC-scores ≥8 (remaining identified proteins with an AC-score ≥5 are listed 
under ‘Supporting Information’). A web-based version of the Phenyx search engine (v2.1) was used to search 
the UniProt_Sprot (r. 48.8 of 10-Jan-2006) at AC-scores ≥5. Enzyme ‘Chymotrypsin (FYL)’ was specified for 
the search. b Percent ratio of all amino acids from valid peptide matches to the total number of amino acids in 
the protein. c Number of valid peptide matches followed by the total number of peptide matches found for the 
given protein. Further detailed information is available under ‘Supporting Information’. d Proteins were also 
identified by MASCOT (Table 4). e Angiotensin II was spiked into the urine sample at a concentration of 0.5 
μM (2.5 pmol). 
 
 
Two of the peaks selected by the NSC algorithm to be elevated in proteinuric urine 
samples (Ion-Trap 573.0 m/z, 3+ and 712.3 m/z, 1+ Figure 6C) were identified as 
possible breakdown products of human serum albumin by both algorithms (Figure 
7A: serum albumin precursor protein, P02768-CHAIN0 in uniprot_sprot, 
L.VRYTKKVPQVSTPTL.V, and L.IAFAQY.L position 31-36; Table 6), a protein 
that is known to be increased in concentration in glomerular proteinuria [5]. 
Manual conversion of the monoisotopic multiply-charged fragment ions to 
monoisotopic singly-charged fragment ions confirmed the identity of one peptide 
with a higher score (Table 6). To evaluate peak selection by the NSC algorithm, we 
compared the respective EIC of two other albumin-derived peptides that were not 
selected by the NSC algorithm (Table 6 and Figure 7B). The levels of the two 
discriminatory peptides were elevated in at least 3 out of 6 proteinuric patients (for 
both peptides; P>0.05), while the other two non-discriminatory peptides showed 
increased intensities in only 2 out of 6 patients (for both peptides; P>0.05). The fact 
that the NSC algorithm did not select these two peptides indicates that it was not 
able to detect them as discriminatory due to the large biological variability in the CHAPTER 5 
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proteinuric patient group. The observation that there are proteolytic fragments of 
albumin with a higher discriminatory value than others points towards the 
existence of ‘disease-specific’ proteolytic degradation of albumin and urinary 
excretion of its fragments. This idea is s u p p o r t e d  b y  r e c e n t  d a t a  o f  O s i c k a  a n d  
Comper [45] and Villanueva et al. [46]. 
 
  1 DAHKSEVAHR FKDLGEENFK ALVLIAFA Q Y LQQCPFEDHV KLVNEVTEFA KTCVADESAE
61 NCDKSLHTLF GDKLCTVATL RETYGEMADC CAKQEPERNE CFLQHKDDNP NLPRLVRPEV
121 DVMCTAFHDN EETFLKKYLY E I ARRHPYFY APELLFFAKR YKAAFTECCQ AADKAACLLP
181 KLDELRDEGK ASSAKQRLKC ASLQKFGERA FKAWAVARLS QRFPKAEFAE VSKLVTDLTK
241 VHTECCHGDL LECADDRADL AKY ICENQDS ISSKLKECCE KPLLEKSHCI AEVENDEMPA
301 DLPSLAADFV ESKDVCKNYA EAKDVFLGMF LYEYARRHPD YSVVLLLRLA KTYETTLEKC
361 CAAADPHECY AKVFDEFKPL VEEPQNL I KQ NCELFEQLGE YKFQNALLVR YTKKVPQVST
421 PTLVEVSRNL GKVGSKCCKH PEAKRMPCAE DYLSVVLNQL CVLHEKTPVS DRVTKCCTES
481 LVNRRPCFSA LEVDETYVPK EFNAETFTFH ADICTLSEKE RQIKKQTALV ELVKHKPKAT
541 KEQLKAVMDD FAAFVEKCCK ADDKETCFAE EGKKLVAASQ AALGL  
 
 
Figure 7.  Serum albumin peptides 
identified by LC-MS/MS 
The amino acid sequence of serum albumin 
precursor (Uniprot_Sprot AC no. P02768-
CHAIN0) is shown (A). Peptide matches are 
listed and highlighted in colored boxes (green for 
valid peptides, red for invalid peptides, and 
orange for valid half cleaved peptides). Two of 
the serum albumin precursor peptides (boxed, 
amino acids in italic and bold) were selected by 
nearest shrunken centroid (NSC) classification to 
be discriminatory between proteinuria and non-
proteinuria, whereas two (boxed, amino acids in 
bold) of the other albumin peptides were not 
selected by NSC. Panel (B) depicts the extracted 
ion chromatograms of these two non-
discriminatory albumin peptides for the 
proteinuric (blue) and non-proteinuric (red) 
samples indicating that also these peptides are 
elevated in some proteinuric patients (see Fig. 6C 
for discriminatory peptides). 
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Table 6. Peaks identified by LC-MS/MS as serum albumin derived peptides 
 
sequence cleavage 
specificity 
modifications precursor 
mass  
(Da) 
charge mass 
error 
(Da) 
score position 
selected by NSC a 
L.VRYTKKVPQVSTPTL.V b 1  MC  c none  1715.99  3+  0.02  40d 415-429 
L.IAFAQY.L e 1  MC  none  711.359  1+  0.036  4.99  f 31-36 
not selected by NSC 
L.GEENFKALVL.I e  2 MC  none  1118.597  2+  0.014  5.1 f  21-30 
L.PSLAADF.V e  half none  719.349  1+  0.03  4.73  f  303-309 
 
a Peptides selected by nearest shrunken centroid (NSC) classifier. b Peptide identified using MASCOT. c MC, 
missed cleavage; d Individual ion score >33 indicates identity or extensive homology (p<0.05); e Peptides 
identified using Phenyx. f Peptides with z-scores ≥4 and p<0.0001 were considered significant. Further 
detailed information is available under ‘Supporting Information’. 
 
4.  Discussion and conclusion 
The aim of this work was to develop a platform for the comparative profiling of 
urine by microbore, reversed-phase HPLC coupled on-line to ESI-Ion Trap MS. 
Dedicated data preprocessing followed by statistical classification (with cross-
validation) and PCA were used to assess the relative contributions of analytical and 
biological variation to the obtained results as well as to apply the methodology to a 
sample set of kidney patients with and without proteinuria. 
4.1.  Method development and evaluation 
Urine has been the biofluid of choice in many clinical and pharmacological studies 
focusing on diseases of the genitourinary tract [47-50]. Profiling urinary (trypsin-
digested) proteins and peptides, usually starts with prefractionation or (affinity-) 
enrichment followed by separation based on physico-chemical properties (e.g. by 
HPLC and/or 1D/2D electrophoresis [1DE/2DE]) and detection/identification by 
mass spectrometry [18;51-53]. While 1DE/2DE are often used in urinary 
proteomics, their application is limited by poor coverage of proteins with extreme 
properties (e.g. low molecular weight; high isoelectric point) or low concentration, 
a relatively low sample throughput and the difficulty to automate handling of large 
numbers of clinical samples [51]. Profiling by LC-MS provides an alternative with 
advantages in areas where 1DE/2DE is weak, notably the low-molecular weight 
region of the proteome also termed the peptidome. The urinary peptidome can be 
considered complementary to the urinary proteome, since most peptides are 
derived from higher molecular weight proteins through proteolytic cleavage [18]. 
Since there is evidence that the “degradome” of high molecular weight proteins 
may give insights into disease mechanisms and provide new diagnostic biomarkers 
[46;54], we have developed a simple, rapid and robust on-line reversed phase LC CHAPTER 5 
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ESI Ion Trap MS-based profiling method with minimal sample pretreatment 
directed at low-molecular weight compounds in urine. 
  Validation parameters such as the LOD, linearity, within- and between-day 
analytical variation and standard deviation for retention time and peak area were 
used to characterize the method. Sensitivity for peptides (3-8 amino acids) is 
comparable to what can be routinely attained with a microbore-LC ESI-Ion Trap 
MS configuration, i.e. detection of low nM (<25 nmol/L) concentrations and 
femtomole quantities (<250 fmole) of peptides [55]. However, it must be remarked 
that small peptides, such as one of the standard peptides VYV, that elute at the 
beginning of the gradient are prone to higher analytical variation in terms of peak 
area and retention time, especially at low concentrations. This is likely due to some 
chromatographic migration under the isocratic sample loading conditions affecting 
retention time and possibly small losses during loading of the trap column. Very 
small peptides, however, tend to be less disease-specific, as they may be derived 
from a wide range of precursor proteins. Since our method does not rely on stable 
isotope labeled internal standards, it was critical to evaluate its linearity, which was 
larger than R2 = 0.9 for each of the 7 added peptides tested over a concentration 
range from 10 to 500 nM supporting the presumed linear relationship between 
peptide concentration and MS response [28]. A linear correlation between peptide 
concentration and detected signal allows compositional analyses not only from a 
qualitative but also from a quantitative point of view enabling us to address changes 
in concentrations of the detected compounds [56]. Randomization of the order of 
analysis was used to level out systematic errors due to unavoidable between-day 
and within-day analytical variation, which might otherwise confound the ensuing 
statistical analysis. Together, these performance characteristics can be used for 
power calculations when setting up biomarker discovery projects [18]. Guidelines 
for power calculations in LC-MS driven biomarker research are lacking. However, 
experimental data from microarray studies provide some guidelines with respect to 
power calculations, i.e. sample size, variability of the population, desired detectable 
differences, acceptable error rate, experimental design, technical variability and 
data pre-processing [57;58]. 
  In contrast to most published studies, we opted for preanalytical normalization 
of the amount of injected sample as compared to post-analytical data normalization, 
since post-analysis normalization cannot account for non-linear effects such as ion 
suppression. There are still many issues to address in post-analysis data 
normalization like global vs. local normalization, replicate filtering and averaging 
[34;38;59]. The urinary creatinine concentration is generally used as normalization 
factor in comparative studies [17;18]. Normalization based on creatinine was 
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the chromatographic region of interest (excluding amino acids, small hydrophilic 
peptides and other early-eluting UV-absorbing compounds). The latter approach 
seems better adapted to normalizing the amount of urine over a wide range of 
compounds, as was supported by the lower CV of the AUCTIC and the peak areas of 
the added peptides. The drawback of this approach is that duplicate analyses are 
required and that the relatively large contribution of one peak/compound to the 
total UV-area suggests in essence normalization to only a few high abundant UV-
absorbing compounds. Development and evaluation of other preanalytical multi-
compound normalization strategies for the comparative profiling of urine remains 
therefore an issue. 
4.2.  Data (pre-)processing and multivariate statistical comparison 
of LC-MS profiles of urinary compounds in different 
experimental settings 
The performance of the developed analytical platform was evaluated by (i) assessing 
the effect of analytical and biological variation on the comparison of urine samples 
spiked with exogenous peptides and (ii) by a preliminary study comparing urine 
samples of hospitalized patients with and without proteinuria due to various causes. 
  Unsupervised multivariate statistical analysis by PCA using the complete peak 
matrix of about 14000 peaks was unable to discriminate blank from spiked pooled 
urine samples. The observed variation between the samples is in this case composed 
of analytical variation and variation introduced by the added peptides (low nM 
concentrations). Our results suggest that spiking affects the linear combination of 
all elements composing the data vectors in an unsupervised setting only minimally. 
It is therefore necessary to apply a supervised classification algorithm (the NSC 
with permutation-based cross-validation in our case) to select discriminating 
elements prior to PCA, which resulted in clear separation between spiked and 
blank samples in the PC 1 dimension. We employed the NSC classifier, because of 
its simplicity and the fact that Tibshirani et al. [39] found it to perform as well or 
even better than several other classifiers. The validity of the described approach 
was shown by the fact that the NSC algorithm was capable of extracting the added 
peptides as discriminatory peaks out of the 14000 feature containing peak matrix. 
However, 3 peaks selected by the classifier could not be related to the added 
peptides through possible ion-suppression due to or in-source fragmentation 
products of the added peptides. Analytical artifacts and suboptimal data-processing 
issues, e.g. binning [56], might have played a role. These issues are presently being 
addressed. 
  Comparing blank and spiked urine samples of different healthy individuals by 
unsupervised PCA proved that variation in urinary peptide profiles between-CHAPTER 5 
- 170 - 
subjects (i.e. biological variation) was much larger than within-subjects (i.e. 
analytical variation), irrespective of spiking. However, the correct classification of 
blank versus spiked urine samples from different individuals using the NSC-selected 
peaks (14 out of 16 were related to the spiked peptides) emphasizes the applicability 
of the platform also in the presence of considerable biological variation. 
Nevertheless some issues, e.g. the selection of false-positive discriminatory peaks, 
remain to be addressed. 
  Our preliminary study comparing urine samples from hospitalized patients 
with a normal and high protein content resembled a study of Jurgens et al. [18]. 
Using LC combined with off-line MALDI-TOF MS detection and differential 
peptide display to compare pathological with healthy urines, they observed a 
substantial number of peptides in post-renal disease, which are absent in normal 
urine. Ninety-two peaks were selected from the LC-MS data to obtain a zero 
classification error. The larger portion (75%) of these peaks eluted late in the 
gradient, which suggests that they are rather hydrophobic. Clustering of the non-
proteinuric samples from healthy individuals apart from the non-proteinuric 
samples from hospitalized patients, indicates that there is a trend of increased renal 
dysfunction in these patients as visualized by a right-shift in PC 1. Our current 
platform appears to be suitable in the study of early-stage renal disease but larger 
sets of samples need to be analyzed to substantiate these findings. The identified 
precursor proteins in the proteinuric urine samples are in good agreement with 
other studies profiling the urinary proteome [3;10;16;51] and peptidome [18]. The 
identification of two discriminatory peaks as serum albumin derived peptides is in 
accordance with the expected rise of albumin during glomerular proteinuria. 
Albumin is the first protein to rise in proteinuria and is degraded intracellular in 
the lysosomes after which the fragments are being exocytosed to the apical and 
basolateral sides of the renal tubular cells [60]. Recently it has also been suggested 
that significant amounts of albumin fragments are excreted in urine, possibly 
resulting from tubular degradation of filtered albumin, followed by luminal 
secretion of its fragments [61;62]. Disease-specific proteolytic degradation products 
of tissue or biofluid proteins are possible biomarker candidates [46]. However, most 
discriminatory peaks, including the albumin-derived peptide peak, were not 
significantly elevated in proteinuria when analyzed by univariate statistics due to a 
very large biological variation amongst the proteinuric patient group. The use of 
higher-order interactions between features in multivariate statistical analysis thus 
provides more discriminative power than univariate statistics. Manual univariate 
comparison of selected peaks remains, however, imperative for biomarker selection 
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  In summary, we have developed an analytical platform for the comparative 
analysis of urine samples by LC-MS followed by dedicated data preprocessing and 
multivariate statistical analysis of the obtained profiles. The analytical and 
biological variation did not adversely affect the performance of the method with 
respect to the classification of blank and spiked samples of different origin. The 
preliminary study of pathological and healthy urine samples emphasizes the 
potential of the platform not only for patient classification but also for detecting 
trends. However, some issues remain to be addressed and improved to enhance the 
performance of the platform. Currently we are implementing more advanced data 
processing and multivariate statistical analysis approaches such as: data meshing 
instead of binning, optimized M-N rule filtering for peak detection and improved 
peak matching methods together with de-isotoping and charge-deconvolution. 
Advanced retention time alignment and possibly m/z alignment algorithms are also 
being considered as well as other classifying algorithms and methods. Combined 
with larger and better defined urine sample sets this will allow us to do advanced 
proof-of-principle studies towards the goal of defining reliable biomarkers suitable 
for clinical validation. 
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Abstract 
 
Introduction: This paper describes the application and evaluation of a comparative 
urine analysis platform employing reversed-phase liquid chromatography-mass 
spectrometry (LC-MS) and multivariate statistical data analysis for the discovery of 
low-molecular weight (LMW) urinary compounds that are differentially excreted 
in human pregnancy. Methods and materials: Urinary compounds were separated 
by gradient elution and subsequently detected by electrospray ionization (ESI) Ion-
Trap mass spectrometry. Normalization of the injected amount was based on the 
creatinine concentration and on the area under the curve of the UV-chromatogram 
at 214nm (AUC214). Data processing included 2-dimensional smoothing (meshing), 
peak detection with a geometrical algorithm based on local slope, and time 
alignment of the peaks using correlation optimized warping with a two-
dimensional correlation signal based on the peaks themselves. Discriminatory peaks 
were selected from the final peak matrix by supervised classification using the 
nearest shrunken centroid (NSC) algorithm. Final dimensionality reduction and 
visualization were performed using principal component analysis (PCA). Using this 
methodology, urine samples from 7-16 weeks pregnant females (n=25) and age-
matched controls (n=25) were comparatively analyzed. Results: Sample 
classification using all peaks (15876) already showed clear separation of the 
pregnant group from the control group with a sensitivity of 96% and a specificity of 
100%. At a shrinkage of 3.11 (186 discriminatory peaks) sensitivity and specificity 
were 100%. When increasing the shrinkage further to 7.52 (10 discriminatory 
peaks) and to 12.55 (1 discriminatory peak), the sensitivity decreased from 96% to 
92%, respectively, while the specificity remained 100%. Deconvolution of multiple 
charge states and isotopic distributions of the 186 discriminatory peaks resulted in a 
list of 38 discriminatory peaks that also contained the discriminatory peaks from 
higher shrinkage values. Discussion: The current method is capable of 
discriminating urine samples from pregnant and non-pregnant females. 
Optimization of data-processing improved the quality of the selected peaks, 
although a minor number of noisy peaks and redundancy in the peak list of 
discriminatory peaks at low shrinkage values remained. Other classification 
algorithms will be explored as well as improving the currently used NSC, to address 
this problem. Relating sensitivity and specificity to shrinkage value can assist in 
determining the most discriminatory biomarker candidates. Efforts are presently 
directed at identifying discriminatory compounds and at validating the 
classification model in an independent test-set.                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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1. Introduction 
At least some of the pathological changes in human organs are reflected in urine. 
Thus urine-analysis can aid in diagnosis, treatment monitoring and prognosis of 
notably diseases of the genitourinary tract [1]. Biomarker discovery studies have 
used urine as sample matrix, because it can be obtained in large quantities by non-
invasive sampling, it is less complex than blood, and urinary peptides/proteins tend 
to be relatively small in size, water-soluble and rather stable. Compounds in urine 
show furthermore fewer intermolecular interactions than blood compounds [2], 
making their separation, and thus detection and quantification, more easy. 
However, the composition of urine varies greatly between and within individuals 
because of differences in age and gender [3] as well as factors of cultural and dietary 
nature [4]. If possible, these factors should be controlled for by careful matching of 
patients and controls. Recent reviews emphasize important aspects regarding 
urinary biomarker discovery studies and achievements [5;6]. A recent viewpoint 
paper defines some essential factors that should be considered in the design and 
execution of biomarker discovery studies including study group selection, sample 
collection, choice of technology and quality control [7]. This requires close 
interdisciplinary collaboration. 
  Compositional analysis of urine can be done using numerous analytical 
techniques [8] (e.g. 2D gel electrophoresis, separation techniques hyphenated to 
mass spectrometry (MS) and their off-line variants. Liquid chromatography (LC) 
coupled to MS using electrospray ionization (ESI) is a frequently used analytical 
technique to profile urinary compounds for biomarker research, which has the 
advantages of automation, high sensitivity, high resolution and the feasibility of 
detecting thermolabile, water-soluble compounds without the need for chemical 
derivatization. LC-MS is, however, time-consuming and suffers from ion-
suppression effects of interfering compounds. Urine analysis by LC-MS has been 
applied in many fields: peptidomics [9-19], proteomics [1;20-26], metabolomics [27-
29] as well as in drug metabolism research. The use of internal standards and/or 
standardization of the injected amount is necessary in order to correct for possible 
interferences of matrix components with the ionization of compounds of interest in 
quantitative studies to generate comparable LC-MS data [30]. A quantitative label-
free profiling method of complex biological samples seems feasible as long as there 
is linearity of signal versus concentration and a high degree of reproducibility of 
sample processing (i.e. pre-analytical phase) and the LC-MS method (i.e. analytical 
phase) itself [31;32]. 
  In a previous paper [33] we have described the development, evaluation and 
application of a comparative urine analysis platform for the discovery of low-CHAPTER 6 
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molecular weight (LMW) urinary biomarkers using LC-MS and multivariate 
statistical data analysis. We observed that normalization of the injected amount to 
the area under the curve (AUC) of the chromatogram at 214 nm (AUC214) instead of 
creatinine levels was better adapted to the profiling of a wide range of molecules 
with different physico-chemical properties (e.g. molecular weight, pKa, 
hydrophobicity), which was reflected in the lower relative standard deviation 
(RSD) of individual peaks and the total chromatographic peak area. Processing of 
LC-MS data prior to multivariate statistical analysis was implemented in the 
workflow, because this is critical when comparing LC-MS data sets that may reach 
107 to 108 d a t a  p o i n t s  p e r  a n a l y s i s .  D a t a  p r o c e s s i n g  h a s  t h e  g o a l  t o  c o r r e c t  f o r  
unwanted variations (analytical noise) in data sets [34-36], thus generating a peak 
matrix that contains only relevant information that is comparable. This peak matrix 
is obtained by matching common peaks in different samples and by filling locations 
that ‘miss’ peaks with background subtracted local data. After data processing the 
nearest shrunken centroid (NSC) classification algorithm [37] is used to reduce the 
dimensionality and to select discriminatory peaks. Visual inspection of patterns in 
the high-dimensional data space was done using principal component analysis 
(PCA), a technique that further reduces dimensionality to two dimensions [38]. 
Using this methodology we were able to extract discriminatory peaks from the LC-
MS data of spiking-experiments despite biological and analytical variation down to 
the low nM concentration range. The methodology was applied to identify 
differences in the urinary composition of patients with kidney disease that is 
accompanied by normal protein excretion or proteinuria. This resulted in the 
identification of differentially excreted albumin-derived peptides amongst other 
compounds that allowed discrimination. 
  In this paper we describe the application and evaluation of this comparative 
urine analysis platform for the discovery of LMW biomarkers that are differentially 
excreted in urine from pregnant as compared to non-pregnant females. The 
methodology was improved with respect to data processing and data analysis 
compared to our previous work [33]. The discriminatory peaks that were selected 
by the classification model were evaluated for their discriminatory properties in 
terms of sensitivity and specificity.                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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2. Experimental 
2.1. Subjects:  pregnant  and non-pregnant females 
Urine samples from 25 pregnant females [median (range) age 38.7 years (29.2-41.3)] 
were retrieved from a biobank of frozen (-20 °C) urine samples from the 
department of Obstetrics and Gynecology of the University Medical Center in 
Groningen (The Netherlands). Urine samples in this biobank originated from 
pregnant females that attended the clinic for prenatal screening because of their 
age. The median (range) duration of gestation of the 25 pregnant females was 9.8 
weeks (7.6-15.7). Samples of first-void midstream morning urines that were 
brought to the hospital, were aliquoted and stored at -20 °C for a median (range) 
period of 7.1 years (7.1-7.2) before analysis by LC-MS. We prospectively collected 
first-void midstream morning urine samples from 25 non-pregnant females [median 
(range) age 27.4 years (21.0-45.5)], notably colleagues and friends. The median 
(range) storage time at -20 °C for the samples from non-pregnant females was 11 
days (3-30) before analysis by LC-MS. 
  Pregnancy was established by measurement of urinary free beta subunits of the 
human chorionic gonadotropin (β-hCG). Urine samples of 25 pregnant females had 
a median (range) β-hCG of 16396 mIU/mL (2713-62103). For 24 controls β-hCG 
levels were below the lower detection limit of 1.2 mIU/mL with one non-pregnant 
control showing a β-hCG level of 22 mIU/mL, because she gave birth 18 days before 
the date of urine collection. All samples were collected in polypropylene containers 
(Sarstedt, Nümbrecht, Germany) and kept at 4 °C for a maximum of 1 day, after 
which they were aliquoted in 10 mL polypropylene tubes (Becton Dickinson, 
Heidelberg, Germany) and stored at -20 °C. None of the subjects was fasting at time 
of urine collection. 
  All subjects that participated in this study gave their oral and/or written 
informed consent. The study protocol was in agreement with local ethical standards 
and the Helsinki declaration of 1964, as revised in 2004. 
2.2. Chemicals 
Acetonitrile (ACN) HPLC-S gradient grade (Biosolve; Valkenswaard, The 
Netherlands), ultra pure water (18.2 MΩ/cm), trifluoroacetic acid (TFA) 99% 
spectrophotometric grade (Aldrich; Milwaukee, USA), formic acid (FA) 98-100% 
pro analysis (Merck; Darmstadt, Germany) were used for reagent preparation. A 
peptide stock solution [peptide, concentration in mmol/L; VYV, 0.29; YGGFL 
(leucine enkephalin), 0.20; DRVYIHFP (angiotensin II), 0.10; YPFPGPI (β-
casomorphin 7), 0.16; YPFPG (β-casomorphin 5), 0.21; GYPPT (gluten exorphin CHAPTER 6 
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A5), 0.19; YGGWL (gluten exorphin B5), 0.20] was used to evaluate the 
repeatability of the analytical LC-MS system. The first five peptides were obtained 
from Sigma (Zwijndrecht, The Netherlands) and the latter two from PepScan 
(Lelystad, The Netherlands). 
2.3. Sample  Preparation 
Urine samples were thawed resulting in a minimum of 1 and maximum of 3 freeze-
thaw cycles, then they were mixed, acidified with 1% TFA, stored overnight on 
melting ice, and centrifuged to remove precipitate (10 min at 1500 g and 4 °C). The 
supernatant was diluted 1:1 with 0.2% FA in 10% ACN and stored at 4 °C until 
analysis. 
  Urinary creatinine concentrations were assayed on a Merck MEGA (Merck, 
Darmstadt, Germany) and on a Roche/Hitachi Modular P (Roche Diagnostics, Basel, 
Switzerland) analyzer using the alkaline picrate (Jaffe) and enzymatic creatinine 
(creatinine plus) assay, respectively. Urinary levels of β-hCG were measured on an 
AutoDELFIA (Wallac Oy, Germany) with a solid-phase, two-site 
fluoroimmunometric assay. 
2.4.  Reversed Phase LC-MS analysis 
The injection order of the urine samples was randomized. Five μL of the 500-times 
diluted peptide stock solution (in 0.1% FA and 5% ACN) were injected onto the 
precolumn prior to injection of each urine sample. Between each injection the 
injection system was cleaned by rinsing with 70% ACN and filled again with 0.1% 
FA in 5% ACN. System stability was monitored and evaluated by 5 μL injections of 
the 500-times diluted peptide stock solution before and after each series of 10 urine 
samples. An equivalent of each urine sample corresponding to 50 nmol creatinine 
was injected in a first instance (creatinine-batch). In second instance, we calculated 
a median AUC214 and normalized all AUC214-based injection volumes to this value 
(AUC214-batch). The AUC214 was calculated between 20 and 80 min retention time, 
which corresponds to 4 - 64 min for mass spectrometric data acquisition (MS data 
acquisition was started 16 min later than the gradient program). The majority of 
UV-absorbing compounds eluted in between 20 and 80 min retention times [33]. 
  All LC-MS analyses were performed on an 1100 series capillary HPLC system 
equipped with a cooled autosampler (4 °C), a UV detector (λ=214 nm) and an SL Ion 
Trap mass spectrometer (Agilent Technologies). A urine volume equivalent to 50 
nmol of creatinine or the median AUC214 was desalted on an AtlantisTM dC18 
precolumn (2.1 × 20 mm, 3 μm particles and 10 nm pore diameter; Waters, Milford, 
Massachusetts, USA) using 0.1% FA in 5% ACN at a flow rate of 50 μL/min for 16 
min. Urinary compounds were back-flushed from the precolumn onto a                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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thermostated (25 °C) AtlantisTM dC18 analytical column (1.0 × 150 mm, 3 μm 
particles, 30 nm pores; Waters) and separated in 90 minutes at a flow rate of 50 
μL/min during which the percentage of solvent B (0.1% FA in ACN) in solvent A 
(0.1% FA in ultra pure H2O) was increased from 5.0 to 43.6% (0.43%/min). During 
these 90 minutes UV absorption and positive mode ESI-MS spectra were acquired. 
Settings for ESI and MS were as follows: 16.0 psi N2; drying gas: 6.0 L/min N2; T: 
325 °C; cap. voltage: 3.8 kV; skimmer: 57.5 V; cap. exit: 190.7 V; oct. 1: 4.12 V; oct. 
2: 2.49 V; oct. RF: 190.7 V; lens 1: -4.9 V; lens 2: -37.7 V; trap drive: 52.5; scan 
speed: 5500 m/z s-1; trap loading: 50 ms accumulation time or 30000 ions; scan 
range: 100-1500 m/z; Gaussian acquisition  f i l t e r  ( w i d t h  0 . 1  m / z )  o f  e a c h  s c a n ;  
rolling average of 5 spectra. Spectra were saved in the centroid/line mode. 
Following each gradient, both columns were washed with 95% B for 5 min and 
equilibrated with 5% B for at least 10 min prior to the next injection. 
2.5.  Data processing and analysis 
2.5.1.  Data analysis for method evaluation 
LC-MS chromatographic data were analyzed with the Data Analysis software 
provided with the LC/MSD Trap (version 3.4 build 181) (Bruker Daltoniks, Bremen, 
Germany). For raw (unprocessed) LC-MS data, peak areas, intensities and retention 
times were obtained from the respective smoothed and baseline subtracted 
extracted ion chromatograms (EIC). One cycle of smoothing with a Gaussian filter 
at a width of 1 sec (± 1.8 points) preceded baseline subtraction with a flatness of 1. 
  Univariate statistical analyses were performed with the Statistical Product and 
Service Solutions package version 14.0 (SPSS Inc., Chicago, IL, USA). 
2.5.2. Data  processing 
For processing and multivariate statistical analysis the original Bruker Daltoniks 
line-mode LC-MS data files were converted into ASCII-format with the Bruker 
Data Analysis software using an in-house developed visual basic script. The data 
processing workflow was developed and compiled using Visual Studio 2005, version 
8.0.50727.762 (SP.050727-7600, Microsoft Corp, Redmond, WA, USA). For further 
data analysis Matlab [version 7.3.0.267 (R2006b) Mathworks, Natick, MA, USA] 
and the PLS toolbox (version 4.0, Eigenvector Research Inc., Wenatchee, WA, 
USA) were used. 
  Initially the m/z ratios were meshed using a 2-dimensional (2D) Gaussian filter 
with sigma values of 0.05 min and 0.25 amu for the retention time and m/z 
dimension, respectively. Meshing partially compensated for the slight shift in m/z 
values as a result of trap overfilling that occurred during elution of abundant CHAPTER 6 
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compounds [39] and was used to smooth and fit deficient line data into a regular 
grid. Peak picking was performed using a geometrical algorithm based on local 
slope. The algorithm scans the mesh for local maxima. Starting at and descending 
from the peak maximum the algorithm then detected changes in the slope (from 
negative to positive) of the path of connected points thereby assigning the 
end/border of the peak. Connected points for one maximum were then considered 
to belong to one peak and the connected points in the perimeter of the peak were 
determined. This algorithm enabled the separation of overlapping peaks in 
particular shoulder peaks. After the algorithm has completed for a mesh, all peaks 
are output along with their height, width, volume, and extents in both m/z and 
retention time. Furthermore, each peak has a local estimate of the background 
value. In this work, the peak height was used for all analysis. Figure 1 shows a 
typical 3-dimensional plot of LC-MS data after the data processing. 
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Figure 1. 
Example of a bird’s view (3-dimensional plot) of typical LC-MS data after data processing. Data were 
processed using 2-dimensional meshing without data reduction and peak picking using a geometrical 
algorithm based on local slope. 
 
After having defined all peaks accurately, time alignment was performed using 2D 
correlation optimized warping (COW) of peak locations stored in the peak list of 
each chromatogram [40]. Then the full set of peaks from all samples was searched 
for local clusters of peaks, referred to as “MetaPeaks.” The generated final peak 
matrix of the complete study consisted of an index(row)-sample(column)-
height(value) matrix. The index corresponds to one unique combination of a 
retention time and m/z value from a particular metapeak. This final peak matrix 
was used for multivariate statistical analysis by NSC and PCA. 
  All data processing was done on a personal computer equipped with a +3800 
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2.5.3.  Classification and multivariate statistical methods  
To select the most discriminating peaks, we applied the NSC classification 
algorithm [37;41]. NSC regularizes data whereby class-specific centroids are 
“shrunk” toward the overall (nonclass-specific) centroid, which has the effect of 
eliminating the influence of the most weakly correlated peaks, thereby reducing 
the capacity to overfit [42]. This algorithm is used to select peaks that are relevant 
for the discrimination of the predefined classes in conjunction with permutation 
tests to validate the classification algorithm [43] using leave-one-out cross-
validation (LOOCV) to avoid overfitting due to single outliers. The optimal 
shrinkage value was the value at which LOOCV showed the lowest classification 
error. In LOOCV one observation per class is iteratively omitted from the data set 
that is used to construct the classification model, which is then used to classify the 
omitted observation as case or control (e.g. pregnant or non-pregnant in this study). 
Variables selected at the highest shrinkage value (lowest number of peaks) and 
lowest LOOCV error, were employed for construction of the final classification 
model. The selected peaks were then analyzed and visualized by plotting the first 
two principal components obtained after PCA [38]. As a measure for class 
separation the Mahalanobis distance (MD) was calculated [44]. We consider an MD 
above 4.0, corresponding to a difference of 4 sigma between the mean centroids of 
the classes [43], as indicative for significant class separation. 
3. Results 
3.1.  Evaluation of the normalization strategy and LC-MS system 
In pregnant females the urine volume equivalent to 50 nmol creatinine 
corresponded to a higher mean (±SD) of the AUC of the total chromatogram (TIC) 
between 20 and 105 min retention time than in non-pregnant female controls: 5.4 
(±0.8) *109 arbitrary units (AU) vs. 4.7 (±0.6) *109 AU, respectively (p<0.001). There 
was no significant difference (p>0.2) between the median (range) AUCTIC of the 
creatinine- (4.9 (3.7-7.4) *109 AU ) and the AUC214-normalized (4.7 AU (3.2-8.1) 
*109 AU) batches. The RSD of the AUCTIC was lower for the AUC214-normalized 
data than for creatinine-normalized data, 15 vs. 24%, respectively. Figure 2 shows 
histograms of the RSD for all peak intensities in the final peak matrix of the 
creatinine- and AUC214-normalized data. The AUC214-normalized LC-MS data 
(11639 peaks; median RSD 96.0%) had a higher (p<0.001) median RSD of peak 
height than the creatinine-normalized LC-MS data (12233 peaks; median RSD 
91.8%). 
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Figure 2. 
Histogram of the relative standard deviation (RSD) of peaks in the final peak matrix from the batch that was 
normalized to creatinine (a urine volume corresponding to 50 nmol creatinine was injected; 12233 peaks; 
filled line) and the batch that was normalized to the area under the curve at 214 nm between 20 and 80 min 
retention time (AUC214; 11639 peaks; striped line). Each batch consisted of urine samples from 25 pregnant 
females and from 25 apparently healthy non-pregnant females. 
 
Normalization to creatinine (median RSD 88.7%) better reduced the variation in 
the pregnant group (p<0.001) than normalization to AUC214 (median RSD 92.3%). 
Also in the non-pregnant group, normalization to creatinine (median RSD 90.1%) 
better reduced the variation (p<0.001) than normalization to AUC214 (median RSD 
95.3%). Normalization of the injection volume to the AUC214 better reduced the 
RSD of the AUCTIC compared to normalization to the creatinine concentration. 
Remarkably, creatinine-normalization resulted in a lower median RSD of peak 
heights in each group (pregnant/non-pregnant) than AUC214-normalization. 
  System-stability was evaluated by calculating the within-series correlation of 
six 5 μL injections of the 500-times in 0.1% FA and 5% ACN diluted peptide stock 
solution (IS) before and after each series of 10 urine samples. Figure 3 shows a high 
correlation (R2 > 0.95) of peak intensities for creatinine-normalized samples as well 
as for AUC214-normalized samples (R2 > 0.9), between the six individual samples, 
except for the first file in the creatinine-batch (absence of peak for peptide VYV 
from the peak list) and the last file in the AUC214-batch (absence of peak for peptide 
YGGWL from the peak list). The latter finding is remarkable, because the peak is 
clearly visible in the raw LC-MS data, which suggests a data processing error. This 
reasoning is not valid for the missing VYV peak, because the raw MS data lacks this 
peak at the expected retention time. 
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Figure 3 
Correlation map of the final peak matrix (obtained as described in ‘Experimental’) from six 5 μL injections of 
500-fold diluted peptide stock solution (1.0-2.9 pmol injected). These samples were analyzed before and after 
each series of 10 samples (equivalent to ±24h of analysis time) of the creatinine-normalized batch (A) and the 
batch of samples that was normalized to the area under the curve at 214 nm (B). Samples are regrouped by 
similarity. The numbers correspond to the order of analysis (e.g. 23 means that this sample was the 23rd 
sample that was analyzed in this batch. 
 
3.2.  Data processing and multivariate statistical analysis of LC-
MS profiles 
3.2.1.  Data processing and analysis 
The data processing workflow was significantly improved in comparison to our 
previous report (33). The previous workflow included binning from an 
instrumental resolution of 0.1 amu to 1 amu. This was done to reduce the size of the 
datasets (approximately by a factor 10) to reach an acceptable data processing and 
analysis time with Matlab on a desktop computer (see ‘Experimental’ for 
specifications). The new data processing workflow (C++) compared to the old data 
analysis processing ((33); Matlab) is improved by the following: (i) C++ provides 
much greater performance, particularly with large spectral datasets. (ii) Data 
meshing is used to address the problem of the irregular distribution of peak 
intensities of line data, and to detect peaks by assigning the top of a peak. (iii) 
Higher performance when working with regular, meshed data rather than irregular 
points. (iv) Calculation of peak parameters (height, volume, extent, background) 
along with the separation of overlapping peaks. (v) Finally, the peak picking 
algorithm is better capable of detecting and accurately quantifying relatively small 
peaks (low S/N), thus enlarging the dynamic range. 
  The most important improvement is, however, the inclusion of 2D alignment 
(retention time and m/z) in the workflow. In the previous study the SD for 
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retention time was ≤0.52 min (33). Comparing peak heights of batches (e.g. a 
training-set and a test-set) that are analyzed interspaced in time (e.g. months to 
years between analyses) requires proper peak matching in both the time- and m/z-
dimension. First, COW (42) was applied to align the TIC of different samples. COW 
is suitable for single signal detectors (e.g. UV, fluorescence, flame-ionization etc.) 
and for samples that contain low numbers of peaks. We adapted the COW 
algorithm to calculate the correlation between the TIC (hereafter referred to as the 
‘COW-TIC’) of different samples in a similar manner as for single signal detectors. 
However, urine is a complex biological sample and its composition is highly 
variable, qualitatively and quantitatively. The biological variance of the 
concentration of individual compounds is high, resulting in markedly different TIC 
of samples from different individuals. Therefore, the COW-TIC algorithm, a 1-
dimensional alignment algorithm, was not able to align the 50 chromatograms, 
because retention time shifts within-batch and biological variation led to dissimilar 
TIC. 
  The time alignment algorithm was then changed to calculate correlations 
based on the peak list of each chromatogram. By doing this, 2 dimensions (2D: 
retention time and the mean m/z-value of the intensity distribution, including the 
measured widths of each peak in m/z and retention time) are taken into account in 
contrast to the COW-TIC, that uses only 1 dimension (1D; the TIC is a summed 
intensity) for COW. The new 2D-alignment algorithm corrects for large time shifts. 
In addition, inclusion of peak matching using metapeak clusters, and 
implementation of a 2D ‘shift-area’ to compensate for shifts in retention time and 
m/z decreases the probability of peak mismatching compared to the 1D sliding 
windows peak matching algorithm used previously (33). In summary the new data 
processing workflow resulted in a well-aligned peak matrix with a more accurate 
measure for peak intensity – all with significantly improved performance. 
  To evaluate whether data processing reduced the variation in retention time 
between the different chromatograms, the TIC was divided into 10 segments of 8 
min between 25 and 105 min retention time. This is the region where the majority 
of peaks detected by MS elute (see example of TIC in (33)). From each of these 
segments, the four highest peaks were extracted from the final peak matrix of the 
AUC214-batch. From these four highest peaks, the extracted ion chromatogram 
(EIC) of the peak with the ‘poorest’ alignment before and after 2D-alignment is 
depicted in Figure 4.                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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Figure 4. 
Each panel represents an extracted ion chromatogram (EIC) of the peak with the ‘poorest’ time alignment 
derived from the four highest peaks in each of the ten 8 minute segments between 25 and 105 minutes 
retention time. The upper trace in each panel represents meshed LC-MS data before 2-dimensional (2D: 
retention time and m/z) alignment using correlation-optimized warping, while the lower trace represents 
meshed data after 2D-alignment. The final peak matrix from the analysis 50 urine samples (25 pregnant 
females; 25 non-pregnant females) that were normalized to the area under the curve at 214 nm was used. 
 
3.2.2.  Multivariate statistical comparison of urine from pregnant and 
non-pregnant females 
The final peak matrix of the AUC214-batch contained 15876 peaks. By varying the 
shrinkage value of the NSC classifier and following the LOOCV error, we obtained 
a region with zero cross-validation error (Figure 5A). The plot of all 15786 peaks in 
the final peak matrix explains only 11.5% of the variance on principal component 
(PC) 1 and PC 2 (Figure 5B), although there was little overlap between the 
pregnant and non-pregnant groups (MD of 2.45). This resulted in a sensitivity of 
96% and a specificity of 100% when using all peaks in the peak matrix for sample 
classification. 
  The NSC algorithm selected 186/15876 (1.2%) peaks at a shrinkage of 3.11 that 
separated (MD is 5.39) the two classes without any LOOCV error (specificity and 
sensitivity of 100%) (Figure 5A and 5C). Using these 186 discriminatory peaks, PC 1 
and PC 2 explain 52.1% of the variance in the data (Figure 5C). Increasing the 
shrinkage to 7.52 resulted in the selection of 10/15876 (0.063%) discriminatory 
peaks that explained 90.6% of the variance in the data through PC 1 and PC 2 
(Figure 6A). The MD was 4.16, which indicates significant separation of the classes, 
with a sensitivity of 96% and specificity of 100%. Figure 6B shows the individual 
values in a Box-Whisker plot for the only peak (514.6 m/z, 95.65 min; p=6.8*10-10) 
that remains at a shrinkage value of 12.55 (92% sensitivity, 100% specificity). 
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Figure 5. 
Leave-one-out cross validation (LOOCV) error plot (panel A) of the classification model derived from the 
analysis of the final peak matrix (15876 peaks) from data of 50 urine samples (25 pregnant females; 25 non-
pregnant females) that were normalized to the area under the curve at 214 nm. Cross-validation error (Y) was 
calculated at each shrinkage value (X) using the nearest shrunken centroid algorithm. The inserted table 
reports the number of discriminatory peaks, sensitivity and specificity of the classification model at three 
shrinkage values. Plot of principal component (PC) 1 and PC 2 using all peaks (15876) in the final peak matrix 
(panel B). Plot of PC 1 and PC 2 using 186/15876 peaks (1.2%) that were selected by the nearest shrunken 
centroid (NSC) algorithm at a shrinkage value of 3.11 (panel C). Pregnant females (T), non-pregnant females 
(z), discriminatory peaks (Ä). 
 
 
We used the list of 186 discriminatory peaks that was obtained at a shrinkage value 
of 3.11 (sensitivity 100%, specificity 100%) as starting point to select biomarker 
candidates. A histogram of the 10log of the p-values from the non-parametric 
comparison (Mann-Whitney U test; MWU-test) of discriminatory peak heights in 
the final peak matrix between pregnant and non-pregnant females is depicted in 
Figure 7. All selected peaks had p-values < 0.01 with some p-values reaching down 
to 10-10. One selected peak had a p-value of 0.4 and was, according to the MWU-
test, not significantly different between pregnant and non-pregnant females. This 
peak was probably selected because it is a Na+-adduct (81.25 min, 722.7 m/z) of a 
highly discriminatory peak (81.26 min, 700.6 m/z; p= 3.17*10-07).                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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Figure 6. 
Plot of principal component (PC) 1 and PC 2 using 10/15876 peaks (0.063%) that were selected by the nearest 
shrunken centroid (NSC) algorithm at a shrinkage value of 7.52 from the final peak matrix (15876 peaks) from 
data of 50 urine samples (25 pregnant females; 25 non-pregnant females) that were normalized to the area 
under the curve at 214 nm (panel A). Box-and-Whisker plot (panel B) of the only peak (514.6 m/z; 96.7 min) 
that was selected by the nearest shrunken centroid algorithm at a shrinkage value of 12.55 (p-value = 6.18 × 
10-10; see Table 1). Pregnant females (T), non-pregnant females (z), discriminatory peaks (Ä). 
 
 
In addition, the use of a non-parametric test like the MWU-test, which compares 
mean ranks, may be less appropriate when many values in both groups are set at 0 
(equal ranks). Visual inspection of both the raw and processed data show a clear 
difference in peak height of this peak, and a Student’s t-test of the non-Gaussian 
distributed data resulted in p=3.95*10-4. Interestingly, in the urine of pregnant 
females we found 12/186 (6.5%) discriminatory peaks to correlate (p<0.05; 5 
negatively, 7 positively) with free β-hCG subunit levels. The free β-hCG 
concentration in the urine samples of pregnant females ranged between 0.12 and 
2.8 μmol/L, which would be equivalent to 0.36 to 17 pmol on-column, based on the 
conversion table of the WHO of 1975 (1 IU = 0.045 nmol free β-hCG). The β-hCG 
subunit, however, was not identified by LC-MS/MS (unpublished observation). 
  Redundancy in the peak list was explored and reduced by manual deisotoping 
and charge-state deconvolution. Plotting the raw m/z values against retention time 
revealed furthermore Na+ adducts and H2O-loss due to “in-source” fragmentation of 
certain discriminatory peaks. Correlation analysis of the intensity of discriminatory 
peaks showed that some are quantitatively related (unpublished observations), 
implying structural or functional similarities. The curated peak list contained 
38/186 (20.4%) peaks with most of these peaks being related to a different 
compound. 
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Figure 7. 
Histogram of the 10log plot of p-values obtained 
by non-parametric comparison of the peak-
volumes of 186 peaks that discriminate urine of 
25 pregnant females from urine of 25 non-
pregnant females with 100% sensitivity and 100% 
specificity. One peak was not statistically 
significant at α=0.05 (arrow). 
 
 
 
 
 
 
 
 
 
Ten of these 38 peaks were the principal discriminatory peaks at a shrinkage level 
of 7.52 (sensitivity 96%, specificity 100%) (Table 1). Univariate statistical 
comparison (Table 1) and EIC (Figure 8) of these discriminatory peaks revealed 
strongly elevated levels in the majority of the urine samples from pregnant females 
making them candidate biomarkers for pregnancy. 
 
Table 1.  Characteristics of 10 peaks that discriminate between urine samples from 
pregnant and non-pregnant females at a shrinkage value of 7.52 (sensitivity 
96%, specificity 100%). 
 
Peak #  RT a m/z  b  Peak height pregnancy (P) c  Peak height controls (NP) d  p-value e 
 (min)  (M+1H)1+  Arbitrary units  Arbitrary units   
1  78.3  604.6  1390000 (0-3100000)  34549 (0-192143)  1,79E-008 
2  95.6  285.4  1140000 (353106-2730000)  0 (0-324000)  3,68E-010 
3  95.6 1015.9f  903843 (0-2220000)  7364 (0-246307)  2,24E-007 
4  95.7  203.4  44150 (14448-95888)  3996 (0-17652)  1,35E-009 
5  95.7  514.6  719223 (216616-1410000)  0 (0-213025)  6,18E-010 
6  95.7  519.7  432093 (0-533025)  64568 (0-259183)  2,29E-008 
7  97.0  519.7  180159 (0-347504)  8948 (0-35279)  1,79E-007 
8  98.3  301.6  223725 (0-392491)  4459 (0-35978)  6,42E-006 
9  98.3  477.7  221690 (0-379820)  7231 (0-52876)  2,23E-006 
10  98.3  517.6  246524 (91532-559978)  9057 (0-78090)  1,23E-009 
 
Data represent median values (minimum-maximum). Figure 8 depicts the extracted ion chromatograms of the 
discriminatory peaks. a RT, retention time; b Mass-to-charge ratio derived from final peak matrix generated as 
described under ‘Experimental’; c Peak height derived from the final peak matrix of AUC214-normalized LC-
MS data of 25 pregnant females (P); d Peak height derived from the final peak matrix of AUC214-normalized 
LC-MS data of 25 female controls (C); e  p-value derived from Mann-Whitney U tests for non-Gaussian 
distributed data (tested with the Shapiro-Wilk test and normality plots); f z=2.                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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Figure 8. 
Overlaid extracted ion chromatograms (EIC) of 10 peaks that discriminate between urine samples from 
pregnant and non-pregnant females with a sensitivity of 96% and specificity of 100%. The upper panel shows 
EICs of peaks from 25 pregnant females. The lower panel shows EICs of peaks from 25 non-pregnant females. 
The data is derived from the final peak matrix of the AUC214-normalized batch. Table 1 reports the 
characteristics of the discriminatory peaks. In most panels additional peaks are present with similar m/z-
values but different retention times than the discriminatory peaks (centered peak in each panel). These 
additional peaks also differentiate between the samples of pregnant and non-pregnant females. More than 
95% of these additional peaks have discriminatory properties (included in list of 186 discriminatory peaks at a 
shrinkage of 3.11), but they are not selected at the shrinkage level of 7.52. 
 
4.  Discussion and conclusion 
The aim of this work was to evaluate our comparative urine analysis platform for its 
potential to differentiate between two physiological states. For this we have used 
profiling of LMW urinary compounds from pregnant and non-pregnant females by 
LC-MS and subsequent multivariate statistical analysis of processed data. 
  Normalization of the injected amount to the AUC214 did not result in a 
lowering of the peak height variance compared to normalization of creatinine, 
although this did reduce the variance in the AUCTIC. This suggests that biological 
variation is not compromised by normalization to the AUC214. Moreover, AUC214-
normalization better normalizes the injected amount if the AUCTIC is considered to 
be representative for this. It should, however, be remarked that the peaks in the 
peak matrix of the AUC214-batch were not matched to those of the creatinine-batch. 
An alternative, and even better approach is to run quality control (QC) samples 
(e.g. a pooled urine sample) before and after a predefined number of samples (e.g. 
10). These QC could be analyzed at different creatinine concentrations (e.g. 25, 50 
and 75 nmol creatinine) to evaluate the biological and analytical variation of the 
method and its quantitative properties. Furthermore, it can be questioned whether 
normalization to the AUC214 is appropriate in case of renal dysfunction. Large 
amounts of UV-absorbing compounds are excreted during renal pathology which 
will then lead to erroneous normalization if compared to urine samples from CHAPTER 6 
- 192 - 
controls with normal renal function. Thus, in each biomarker discovery study for 
disorders of the genitourinary tract the normalization strategy should be dependent 
on the disease under study. 
  Our new data processing workflow improved the quality of the final peak 
matrix with respect to the comparability and accuracy. Respectively, this was done 
by geometrical peak picking and peak measurement, and COW in 2D (retention 
time and m/z). In addition, full-resolution Ion-Trap MS data was used instead of 
binned Ion-Trap MS data to avoid loss of information during data processing. 
However, some peaks were not properly aligned (Figure 3) and peaks with low S/N 
were not properly picked and thus not included in the peak matrix. Adaptation of 
certain settings, e.g. 2D peak detection window, 2D alignment algorithm window, 
to the quality of the data is needed to optimize the output of the algorithms. 
  By assessing the relation between shrinkage value, cross-validation error, 
sensitivity, specificity and the number of discriminatory peaks we were able to 
optimize and improve the selection of discriminatory peaks, notably by reduction 
of the number of candidate biomarkers. Manual univariate comparison and 
visualization of selected peaks for both classes aided also in biomarker selection. In 
addition, we observed that the model at a shrinkage value of 3.11 (186 peaks) with 
both a specificity and sensitivity of 100% contained many ‘noisy’ and redundant 
peaks which might be caused by the narrow window that was used to match peaks 
to the metapeaks. The trade-off between a decrease in sensitivity and an increase in 
number of discriminatory peaks, might be a good strategy for selecting ‘real’ 
candidate biomarkers that are characterized by a strong discriminatory capacity. 
Implementing sensitivity, specificity and MD as measures for proper sample 
classification should improve the statistical evaluation and thus the quality of the 
selected biomarker candidates. The next step is to test the performance of the final 
classification model and the associated candidate biomarkers in larger independent 
test sets that include related ‘disorders’ such as extra-uterine pregnancies and testis 
carcinoma. We will also investigate the effects of short- and long-term storage (-20 
°C) of urine samples from pregnant and non-pregnant females on the classification. 
However, the aim of this study was not to find a biomarker for pregnancy, but 
merely to obtain an advanced-proof-of principle and to optimize the comparative 
analysis platform. 
 
At present we are trying to identify the discriminatory peaks by LC-MS/MS. The 
majority of the discriminatory peaks (independent of the shrinkage value) eluted 
late in the gradient, which suggests that they are rather hydrophobic. In addition, 
the low molecular masses of the discriminatory peaks and their non-peptide like 
fragmentation in MS/MS experiments (unpublished observations) suggests that we                         BIOMARKER DISCOVERY IN HUMAN PREGNANCY BY LC-MS AND MULTIVARIATE STATISTICS 
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are dealing with metabolites of pregnancy-related hormones and possibly post-
translationally modified proteins (e.g. glycoproteins). The anticipated variation in 
the concentration of these discriminatory peaks because of the large variation in 
gestational age, is clearly exemplified by the larger distribution of the samples in 
the ‘pregnancy’ cluster compared to the ‘non-pregnant’ cluster (Figure 6A). 
  Pregnancy is a physiological condition in which modified immune responses 
allow a semi-allogenic fetus to survive within the uterine environment. The 
gestational tissues, including the uterine myometrium, the decidua, the placenta 
and fetal membranes, allow the fetus to survive and considerably modify the 
composition of blood, urine, amniotic fluid, cervicovaginal fluid etc. during 
gestation [45]. These biofuids are increasingly investigated for early diagnostic 
markers of preterm labor, pre-eclampsia and fetal growth restriction [46-48]. 
Compounds that are differentially expressed in pregnancy and of which some are 
even pregnancy specific are placental lactogen, chorionic gonadotropin (of which β-
hCG is a subunit), fetal fibronectin, α-fetoprotein, dimeric inhibin A, unconjugated 
estriol, placental peptides, pregnancy-associated placental protein-A [3]. In our 
group of pregnant females the gestation duration ranged from 7.6-15.7 weeks, 
which leads to a considerable variation in the concentrations of these pregnancy 
specific compounds in blood. This concentration variation of hormones, proteins, 
their proteolytic fragments or conjugates is probably reflected in the composition of 
urine. Comparing the urinary composition of pregnant with non-pregnant females 
we expected on forehand to find clear differences, because the analytical method 
(reversed phase LC – positive mode MS) is capable of detecting those compounds. 
  The finding of correlations between β-hCG in urine and peak heights of 
certain discriminatory peaks in the urine of pregnant females suggests that some of 
the selected peaks discriminate patients based on an indirect relationship, either 
metabolic, functional or structural, with the total content of free β-hCG in urine. 
However, some correlations may be false because of a type-II error. The sample 
pretreatment procedure that consisted of at least 1 freeze-thaw cycle and sample 
acidification for mild protein precipitation could have removed pregnancy-related 
proteins or their fragments. Also, most pregnancy-related proteins are 
glycoproteins, which may have hampered the identification of these proteins by 
‘routine’ proteomics, i.e. analysis by LC-MS/MS and protein database queries. 
 
In summary the comparative urine analysis method has benefited from 
improvements in the data processing workflow. It was possible to discriminate 
urine samples of pregnant females from those of non-pregnant females with a 
sensitivity of 96% and specificity of 100% using only 10 discriminatory peaks. CHAPTER 6 
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Identification of the discriminatory peaks and validation of the classification model 
in an independent test-set is imperative. 
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Summary and Future Perspectives 
In the Introduction I give a description of the burden, epidemiology, classification 
and implicated causes of psychiatric disorders such as schizophrenia and autism. 
The etiology of these disorders is complex and only partially understood. At the 
same time mental disorders contribute enormously to psychological, social and 
economic suffering, on a global and individual level. Having an affected relative can 
have detrimental effects on future perspectives of a family, notably in third-world 
countries, because most disorders are characterized by early onset and chronicity 
with little hope of full recovery. The predicted rise in prevalence of certain 
psychiatric disorders by the WHO is worrying. Despite the relatively wide 
availability of psychiatric services and psychiatrists in Western countries, under-
diagnosis and under-treatment are still common. Currently available diagnostic and 
treatment (psychosocial and/or medication) modalities are not perfect. Diagnostic 
modalities have poor consistency in the short-term, while treatment modalities 
have poor efficacy and significant side-effects. Metabolic side-effects burden the 
lives of patients with psychiatric disorders extra, because they are associated with 
increased risk of cardiovascular disease (CVD) in a population that is already at risk. 
Risk factors for CVD are difficult to treat in patients with schizophrenia, because of 
substance abuse and self-neglect. Few patients with schizophrenia recover 
sufficiently to have a normal societal life. The largely unknown disease etiology and 
a diagnostic system that is solely based on observations of symptom clusters seem to 
be responsible for a poor prognosis of patients with psychiatric disorder. It is 
surprising, in this context, that the many epidemiological studies and the studies of 
animal models (e.g. for anxiety, depression and addiction) have not resulted in 
drugs other than those that were discovered by serendipity. These drugs have, 
however, increased our knowledge about mental disorders on a molecular and 
cellular level with respect to neuronal signaling, and insight into their modes of 
action is increasing. So far, it seems that hypothesis-driven research has failed to 
provide novel solutions for psychiatric disorders, while identifying many risk 
factors related to psychosocial, cultural, and early-life events. While genetic studies 
have uncovered predisposing gene candidates (many of which could not be 
replicated in subsequent studies), their overall contribution to the susceptibility to 
mental disorders appears to be small or negligible compared to the contribution of 
non-genetic risk factors. Despite these efforts in fundamental research, no single 
gene has been identified that explains the complex etiology of mental disorders and 
that might function as a lead towards more effective therapies.  
  More recently altered gene expression due to epigenetic regulation has been 
implicated in the development of mental disorders. Our environment (e.g.  
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nutrition), and even some of the putatively involved mutations (e.g. MECP2) and 
polymorphisms (e.g. MTHFR), can affect gene expression via epigenetic 
mechanisms. This partly explains why genetic findings are not easily replicated and 
possibly also the way psychosocial and cultural factors increase the risk for the 
development of a psychiatric disorder. Therefore, it seems to make more sense to 
study health and disease at the ‘executive’ level of a cell or organism, i.e. 
quantitative and qualitative changes at the protein level are likely to better reflect 
the dynamic processes that are characteristic for health and disease than is done by 
our ‘static’ genome. The same reasoning is valid if we are trying to increase insight 
into the process(es) that lead(s) to the development of a mental disorder. 
  Modern non-hypothesis driven technologies, such as genomics, 
transcriptomics, proteomics and metabolomics, are likely to increase our 
comprehension of mental disorders through the (expression-) profiling of hundreds 
to thousands of genes, gene-transcripts (mRNA), proteins and metabolites, 
respectively. Powerful bioinformatics approaches are essential for the integration of 
these results in functional correlation networks, thereby offering the possibility to 
study mental disorders in a systems biology approach. If non-hypothesis driven 
research is used in such a way that it complements hypothesis driven studies, it can 
be expected that in the near future new prognostic, diagnostic and therapeutic 
biological markers (biomarkers) or panels of markers for mental disorders will be 
discovered. These markers should have superior sensitivity and specificity and 
relate in a causative manner to the organ, tissue, cell or molecular pathway that is 
part of the pathophysiology. In the end it may even be possible to make mental 
disorders run a less severe course, to prevent or delay the onset in susceptible 
individuals, to decrease the presence or effect of environmental risk-factors, to 
identify highly-susceptible individuals, and to prevent or even cure mental 
disorders in generations to come. The latter is a utopia if we appreciate the thought 
that psychiatric disorders are a an inseparable part of the spectrum of humanity. 
 
In Chapter 1 we elude on the role of folate, notably its role in carbon-1 metabolism 
and epigenetics, and long-chain polyunsaturated fatty acids (LCPUFA) in 
schizophrenia, autism and depression. As described in the Introduction, these 
complex disorders do not inherit by Mendel’s law and the search for a genetic basis 
has remained unsuccessful. The relation of low birth weight and pregnancy 
complications with schizophrenia and autism suggests developmental adaptations 
by fetal ‘programming’. Epigenetics might constitute the basis of such programming 
and depends on folate status and carbon-1 metabolism in general. In key animal 
experiments dietary carbon-1 substrate availability during pregnancy was found to 
affect gene expression in the offspring. This led to the idea that early folate status of                          SUMMARY AND FUTURE PERSPECTIVES 
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patients with schizophrenia might be compromised, which is supported by (i) 
coinciding incidences of schizophrenia and neural tube defects (NTDs) during the 
Dutch hunger winter of 1944-1945, (ii) coinciding seasonal fluctuations in birth of 
patients with schizophrenia and NTDs, and higher schizophrenia incidence in (iii) 
immigrants and (iv) methylene tetrahydrofolate reductase 677C→T homozygotes. 
Recent studies in schizophrenia and autism point at epigenetic silencing of genes 
(e.g. reelin) or chromosomal loci that are crucial for e.g. brain development. The 
product of the reelin gene, for example, is involved in neural plasticity and 
neurodevelopment. Findings of a low status of carbon-1 substrates in adults with 
schizophrenia with DNA hypomethylation and altered gene expression as possible 
consequences, add to the idea of aberrant carbon-1 metabolism in certain 
psychiatric disorders. Low folate status is also associated with the severity of the 
negative symptoms of schizophrenia. The same has been suggested for the 
LCPUFAs arachidonic (AA, from meat) and docosahexaenoic (DHA, from fish) acid, 
which are components of brain phospholipids, and modulators of signal 
transduction and gene expression. Patients with schizophrenia and possibly autism, 
exhibit abnormal phospholipid metabolism that might cause local depletion of AA 
and impaired eicosanoid-mediated neuronal signal transduction. National fish 
intakes relate inversely with major and postpartum depressions, which suggests a 
relation between the intake of the LCPUFA eicosapentaenoic acid (EPA, from fish) 
and the incidence of depression. Five out of six randomized controlled trials with 
add-on EPA have shown positive effects in schizophrenia and four out of six were 
favorable in depression and bipolar disorders. From the presented evidence we 
conclude that folate and LCPUFAs may be important in both the etiology and 
severity of at least some psychiatric diseases. These findings together with the fact 
that low status of B-vitamins and LCPUFA are associated with increased risk of 
cardiovascular disease, led to the study described in Chapter 2. 
 In  Chapter 2 we assessed the essential fatty acid (EFA) and B-vitamin status, 
together with their anthropometrical, lifestyle and biochemical determinants, in 61 
patients with schizophrenia and established whether those with a very poor status 
of these important nutritional constituents respond biochemically to the 
appropriate dietary supplements. This study also aimed to test the membrane-
phospholipid hypothesis in schizophrenia, which suggests altered rates of 
incorporation and removal of EFA from phospholipids in neural cell membranes. 
The fatty acid composition of erythrocytes (peripheral) was assumed to reflect the 
fatty acid composition of neurons (central) according to results from previous 
studies. We found that as a group, patients had high erythrocyte saturated fatty acid 
(FA) and monounsaturated FA levels but low levels of the important 
polyunsaturated FAs of the ω3 and ω6 series. Patients reporting not to take vitamin  
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supplements had low concentrations of serum vitamin B12 and high plasma 
homocysteine (Hcy). In a multivariate analysis Hcy variance proved best explained 
by serum folate in both the total group and in male patients, and by vitamin B12- 
and B6-blood levels in female patients. Alcohol consumption and duration of illness 
were found to be risk factors for low polyunsaturated FA status (<2.5th percentile of 
the reference range), while male gender and absence of fish consumption predicted 
hyperhomocysteinemia (>97.5th percentile of the reference range). To our 
astonishment we found two patients exhibiting biochemical EFA deficiency 
(20:3ω9 above the cut-off value), while 7 patients had biochemical signs of 
ω3/DHA marginality, which was defined as moderately increased 22:5ω6/DHA 
ratio. In addition, four patients exhibited intermediate hyperhomocysteinemia (30-
100  μmol/L) with plasma values ranging from 57.5-74.8 μmol/L. Such severe 
abnormalities are rare in the general population suggesting a metabolic origin or the 
long-term consumption (many years) of a diet deficient in these essential nutrients. 
The fact that none of these 5 patients, with either intermediate 
hyperhomocysteinemia, biochemical EFA deficiency, or both, was assessed by their 
clinicians to have a poor diet, is worrying and indicative of suboptimal risk factor 
assessment and treatment in patients with schizophrenia. That diet was at the basis 
of these abnormalities was confirmed after supplementing 4 of these 5 patients with 
B-vitamins and with soybean and fish oils. Although, we did not measure 
psychiatric symptoms during supplementation, in the long-term the treating 
psychiatrist noticed some improvements. We concluded that a subgroup of patients 
with schizophrenia suffers from biochemical EFA deficiency, ω3/DHA marginality, 
moderate hyperhomocysteinemia, or combinations thereof. Correction is indicated 
in view of the possible relation of poor EFA and B-vitamin status with psychiatric 
symptoms, but notably to reduce their high risk of cardiovascular disease. 
 In  Chapter 3 we describe a study on the relationship between platelet (PLT) 
serotonin (5-HT) and intestinal permeability in children with pervasive 
developmental disorders (PDD) in Curaçao. Platelet hyperserotonemia is observed 
in 30-40% of patients with PDD, and we hypothesized that PLT 5-HT levels in 
PDD are mainly determined by intestinal motility (see Chapter 4), for which 
increased intestinal permeability might be a proxy. Previous studies reporting 
increased intestinal permeability in approximately half of the patients with PDD, 
are in support of the existence of a ‘leaky gut syndrome’ in a subgroup of children 
with PDD. The aim of this study was to assess whether a leaky gut is related to 
increased PLT 5-HT contents. For this, differential sugar absorption and PLT 5-HT 
were determined in 23 children with PDD. Platelet 5-HT (2.0-7.1 nmol/109 PLT) 
was elevated in 4 or 6 out of 23 patients, depending on the employed cut-off value. 
Two cut-off values were used: 5.4 nmol/109 P L T ,  i s  u s e d  i n  t h e  d i a g n o s i s  o f                           SUMMARY AND FUTURE PERSPECTIVES 
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carcinoid tumors; and 4.55 nmol/109 PLT, is used to classify patients with PDD as 
being normo- or hyperserotonemic. Remarkably, none of the patients exhibited 
elevated intestinal permeability (urinary lactulose/mannitol ratio: 0.008-0.035 
mol/mol). Also, no correlation between PLT 5-HT and intestinal permeability or GI 
tract complaints was observed, which led us to reject our initial hypothesis. PLT 5-
HT correlated with 24h urinary 5-hydroxyindoleacetic acid (5-HIAA; p=0.034), 
which is the principal metabolite of 5-HT. Also urinary 5-HIAA and urinary 5-HT 
were interrelated (p=0.005) suggesting increased production of 5-HT to be 
responsible for PLT hyperserotonemia in a subgroup of children with PDD. To 
study the (in)consistency of intestinal permeability and PLT 5-HT, we suggest 
monthly monitoring in a well-defined patient and control group, notably to 
confirm or reject the presence of increased intestinal permeability in this group. 
  The usefulness of PLT 5-HT as a marker of intestinal motility is the topic of 
Chapter 4. To study the effects of intestinal motility on PLT 5-HT in a non-invasive 
indirect manner, we determined whether PLT 5-HT is lower at a condition of 
relative gut motor activity quiescence (i.e. in newborns at birth) compared with a 
condition of normal gut motor activity (i.e. in their mothers at birth), and whether 
in newborns institution and discontinuation of enteral feeding coincide with 
increases and decreases of PLT 5-HT, respectively. For this PLT 5-HT was 
determined in 17 mothers and their 18 healthy full-term newborns at birth in 
Curaçao. To support a role of intestinal motility as determinant of PLT 5-HT, 
longitudinal PLT 5-HT data and data of feeding modes (enteral or parenteral) in 5 
out of 20 included preterm-born infants were evaluated. We replicated the findings 
from previous studies that newborns exhibit about two-fold lower PLT 5-HT 
compared with their mothers (medians: 1.5 and 2.9 nmol/109 PLT, respectively). In 
a multivariate analysis we found newborn PLT 5-HT to be positively related with 
maternal PLT 5-HT and newborn mean PLT volume, and negatively with newborn 
whole blood tryptophan. We have no explanation for the relation between 
newborn and mother PLT 5-HT. The negative correlation of newborn PLT 5-HT 
with newborn tryptophan suggests that PLT 5-HT is largely independent of 
tryptophan-availability. In the longitudinally investigated preterm-born infants we 
observed 7 increases and 1 decrease of PLT 5-HT during institution of enteral 
feeding (observed in 5/5 infants), and 2 decreases and 1 increase of PLT 5-HT 
during parenteral feeding (observed in 3/5 infants). Despite the low number of 
included newborns in the longitudinal study we expect that the lower PLT 5-HT at 
birth, and its change in response to the institution or discontinuation of enteral 
feeding, is related to the relatively gut motor quiescence at birth, and the 
increase/decrease of intestinal motility as reaction to the institution/discontinuation 
of enteral feeding, respectively. These results suggest gut motor activity to be an  
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important determinant of PLT 5-HT in early postnatal life. However, to support 
this notion, in vivo intestinal motility measurements should be correlated with 
changes in PLT 5-HT over time (e.g. some months). 
 
In  Chapter 5 we describe the development, evaluation and application of a 
biomarker discovery platform for urine as a non-hypothesis driven approach. Low-
molecular weight urinary compounds were analyzed by reversed-phase liquid 
chromatography coupled to mass spectrometry (LC-MS) and data were compared 
using multivariate statistical data analysis. More specifically, separation by gradient 
elution with acetonitrile and subsequent detection by UV-absorbance at 214nm in-
line with electrospray Ion-Trap MS was employed. Using this technique we were 
able to resolve thousands of compounds with good sensitivity and selectivity. The 
method was evaluated for its lower limit of detection (5.7-21 nmol/L), within-day 
(2.9-19%) and between-day (4.8-19%) analytical variation of peak areas, linearity 
(R2: 0.918-0.999), and standard deviation for retention time (<0.52 min) by means 
of addition of seven 3-8 amino acid peptides (0-500 nmol/L) to determine the 
possibilities and limitations of this biomarker discovery platform. Relating the 
amount of injected urine to the area under the curve (AUC) of the chromatographic 
trace at 214 nm better reduced the coefficient of variation (CV) of the AUC of the 
total ion chromatogram (CV =10.1%) than relating it to creatinine (CV =38.4%). 
This suggests that for specific biomarker discovery studies in urine from patients 
with normal renal function, a multi-compound normalization strategy is preferred 
over a single-compound normalization strategy. LC-MS data (retention time; mass-
to-charge ratio; peak intensity) were subsequently preprocessed to improve data-
handling (data reduction) and to render data comparable (peak matching) and free 
of noise (peak selection). The common peak matrix, containing all peaks for all 
samples, was analyzed by dimension-reducing principal component analysis (PCA) 
after supervised classification and variable selection by the nearest shrunken 
centroid (NSC) algorithm. The NSC algorithm removes peaks from the peak matrix 
that do not contribute significantly to the separation of groups of samples (e.g. 
spiked and non-spiked) with simultaneous control for classification errors by leave-
one-out cross-validation. The feasibility of the method to discriminate urine 
samples of differing compositions was evaluated by (i) addition of seven peptides at 
nM concentrations to blank urine samples of different origin and by (ii) a study of 
urine from kidney patients with and without proteinuria. (i) The added peptides 
were ranked as highly discriminatory peaks despite significant biological variation. 
(ii) Ninety-two peaks were selected as discriminating proteinuric from non-
proteinuric samples. Removal of redundant peaks from the peak list of 92 
discriminatory peaks resulted in a list of 54 peaks of which 6 were more intense in                          SUMMARY AND FUTURE PERSPECTIVES 
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the majority of the proteinuric samples. Two of these 6 peaks were identified as 
albumin derived peptides by LC-MS/MS. This was expected, because of the early 
rise of albumin during the onset of glomerular proteinuria. Interestingly, other 
albumin derived peptides were non-discriminatory indicating the possibility of 
preferential proteolysis at certain cleavage sites. An advanced proof-of-principle of 
the comparative urine analysis platform was obtained by the study of urine samples 
from pregnant and non-pregnant females, as described in Chapter 6. 
 Chapter  6 is a sequel of Chapter 5. In this chapter we describe the application 
and evaluation of our non-hypothesis-driven comparative urine analysis platform 
to select urinary compounds that are differentially excreted in human pregnancy. A 
somewhat similar method to that described in Chapter 5 was used. Data processing, 
however, was optimized and included peak meshing, peak detection using a 
geometrical algorithm, and peak-alignment in the 2-dimensions (retention time and 
m/z) through correlation optimized warping. This resulted in better comparable 
and more accurate data that were almost devoid of irrelevant peaks coming from 
analytical noise. Discriminatory peaks were selected by supervised classification 
with the leave-one-out cross-validated NSC algorithm and visualized by PCA. 
Urine samples of 7.6-15.7 weeks pregnant females (n=25) and non-pregnant females 
(n=25) were comparatively analyzed. Sample classification using all peaks (15876) 
i n  t h e  f i n a l  p e a k  m a t r i x  s h o w e d  o n l y  little overlap of the pregnant and non-
pregnant group (sensitivity 96%, specificity 100%). Using the NSC algorithm 186 
discriminatory peaks were selected at a s h r i n k a g e  o f  3 . 1 1  t o  f u l l y  s e p a r a t e  t h e  
pregnant from non-pregnant samples (sensitivity and specificity of 100%). 
Increasing the shrinkage value to 7.52 (10 discriminatory peaks) and 12.55 (1 
discriminatory peak) decreased the sensitivity only slightly to 96% and 92%, 
respectively, while the specificity remained 100%. The 186 selected peaks were 
evaluated by univariate comparison, visual inspection and deconvoluted for 
multiple charge-states and isotopic distribution to reduce redundancy. Results from 
correlation analysis of discriminatory peaks suggest structural and/or functional 
similarities. Relating specificity, sensitivity and additional measures for class 
separation to the shrinkage value and the number of discriminatory peaks can aid in 
improving the quality (i.e. discriminatory power) of the selected biomarker 
candidates. Work along these lines is in progress. The comparative analytical 
platform was able to discriminate urine samples from pregnant and non-pregnant 
females with an acceptable sensitivity and specificity using only a few peaks (10). 
Efforts now focus on the identification of discriminatory peaks and validation of the 
classification model using an independent test-set. The method will be applied to 
the discovery of markers related to diseases of the genitourinary tract and adverse  
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pregnancy outcomes, but it may also prove useful in studies related to mental 
disorders, especially those where a nutritional component is suspected. 
 
In conclusion, this thesis aimed to evaluate certain biochemical markers of 
nutrition and presumably of intestinal permeability and motility in schizophrenia 
and autism, respectively (Chapters 2 and 3). Further in-depth analysis of fatty acid 
and carbon-1 metabolism in schizophrenia and autism (Chapter 1) is warranted, 
and so are studies to the role of the intestine and its biochemistry in autism. These 
studies should be complemented by symptom ratings. It is worrying that low 
s t a t u s e s  o f  L C P U F A  a n d  B - v i t a m i n s  i n  patients with schizophrenia go largely 
undetected and untreated, because these low statuses are easily correctable by 
nutritional supplementation. The monitoring and treatment of comorbidity in 
psychiatric patients is of special importance, because comorbidity adds to the 
existing heavy disease burden. 
  To determine the meaning and usefulness of certain markers (e.g. PLT 5-HT), 
and to determine the role of factors that are likely to affect the concentration of 
these markers (e.g. intestinal motility) in autism, other groups of subjects were 
studied such as newborns and their mothers (Chapter 4). The study of other groups 
of subjects that are characterized by a greater homogeneity, absence of confounding 
co-morbidity, and the presence of the physiological condition of interest (e.g. 
normal or sub-normal intestinal motility) can facilitate the interpretation of 
phenomena observed in mental disorders. 
  Probably none of the investigated biochemical parameters are specific for a 
diagnostic psychiatric entity, and it seems that we are only able to (biochemically) 
characterize subgroups of patients. Present psychiatric nosology is not based on 
etiology, and until now no marker, mechanism or risk factor is able to explain the 
onset and development of psychiatric disorders. This fact, together with the 
enormous socioeconomic and psychological burden of psychiatric disorders, the 
predicted rise in prevalence, and availability of rather suboptimal diagnostic and 
therapeutic modalities calls for another view of researchers on research of complex 
diseases such as mental disorders (Introduction). Alternative approaches using non-
hypothesis driven methods that have a valid underlying clinical question are 
therefore welcome to complement hypothesis driven research, although their 
potential should not be overestimated until proven otherwise. 
  Modern ‘-omics’ technologies that enable the unbiased, comprehensive and 
simultaneous study of large numbers of genes, mRNA (gene-transcripts), proteins 
and metabolites in a systems biology approach, will certainly influence the way 
mental disorder research is conducted. The development, evaluation and 
application of an ‘-omics’ technique for biomarker discovery in urine is described in                          SUMMARY AND FUTURE PERSPECTIVES 
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Chapter 5. Comparative analysis of low-molecular weight urinary compounds using 
state-of-the-art separation (liquid chromatography; LC) and detection (mass 
spectrometry; MS) techniques followed by tailored multivariate analysis of LC-MS 
data that contain thousands of compounds, is a good example of how non-
hypothesis driven research can be performed. Optimization and further evaluation 
of this method in a group of pregnant and non-pregnant females exemplifies the 
possibilities and pitfalls of this methodology (Chapter 6). A stepwise approach in 
the development, evaluation and application of these ‘-omics’ methods to more 
complex clinical research questions is necessary to convince the end-users of their 
potential and validity. Going down in concentration sensitivity (by e.g. 
prefractionation, affinity extraction), the application of more selective detectors, 
and the use of optimized algorithms for data-processing and -analysis are ways to 
improve the success rate of cross-sectional and longitudinal biomarker discovery 
studies. If these studies are complemented and integrated with results from 
hypothesis-driven research we might be able to unravel some of the mysteries of 
complex diseases including mental disorders such as autism and schizophrenia.
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Samenvatting en Toekomstperspectief 
In de Inleiding beschrijf ik de ziektelast en -kosten, de epidemiologie, diagnostiek 
en mogelijke oorzaken van psychiatrische stoornissen zoals schizofrenie en autisme. 
De etiologie van deze stoornissen is complex en wordt slechts deels begrepen. 
Tegelijkertijd dragen psychiatrische stoornissen enorm bij aan het lijden in 
psychologisch, sociaal en economisch opzicht, op een mondiaal en individueel 
niveau. Het hebben van een familielid met een psychiatrische stoornis kan een 
negatieve invloed hebben op het toekomstperspectief van een familie, voornamelijk 
in de derde wereld, omdat de meeste stoornissen zich openbaren in de jeugd of 
adolescentie, chronisch van aard zijn en er een weinig hoop op volledig herstel is. 
De door de Wereldgezondheidsorganisatie voorspelde stijging van het aantal 
personen dat op een bepaald moment lijdt aan een psychiatrische stoornis is 
zorgwekkend. Ondanks de relatief goede beschikbaarheid van psychiatrische zorg 
en psychiaters in de westerse wereld, zijn er nog steeds veel patiënten die niet 
gediagnosticeerd zijn of suboptimaal behandeld worden. De opties die op dit 
moment beschikbaar zijn voor de diagnostiek en behandeling (psycho-
/gedragstherapie en/of medicamenteus) lijken niet optimaal. Zo wordt op de korte 
termijn de gestelde diagnose frequent gewijzigd en daarnaast is medicamenteuze 
therapie maar matig effectief en gaat deze gepaard met vervelende bijwerkingen. 
De metabole bijwerkingen zijn extra belastend voor patiënten met psychiatrische 
stoornissen, omdat deze een haast onvermijdelijk verhoogd risico op het 
ontwikkelen van cardiovasculaire aandoeningen met zich meebrengen in groep die 
al een verhoogd risico heeft. Cardiovasculaire risicofactoren zijn moeilijk te 
behandelen in patiënten met schizofrenie, vanwege middelenmisbruik en 
zelfverwaarlozing. Compleet herstel dat leidt tot normaal maatschappelijk 
functioneren is dan ook voor maar weinig patiënten weggelegd. De onbekende 
etiologie en de enkel en alleen op observaties van symptoomclusters gebaseerde 
diagnostiek lijken deels debet aan de slechte prognose van psychiatrische patiënten. 
  Het is verrassend dat de vele epidemiologische studies en studies van 
diermodellen (bijvoorbeeld voor angst, depressie en verslaving) nog niet geleid 
hebben tot de ontdekking van geneesmiddelen anders dan door serendipiteit en 
verbetering van de bestaande middelen. Geneesmiddelen, echter, hebben onze 
kennis over zenuwprikkeloverdracht op een moleculair en cellulair niveau 
vergroot, en het begrip van het werkingsmechanisme van deze geneesmiddelen 
groeit. Tot dusver lijkt het erop dat hypothesegedreven onderzoek er niet in 
geslaagd is om met nieuwe antwoorden te komen voor psychiatrische stoornissen, 
ondanks dat dit soort onderzoek geleid heeft tot de ontdekking van vele 
risicofactoren die psychosociaal of cultureel van aard zijn of verband houden met     
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gebeurtenissen in het vroege leven. Genetisch onderzoek heeft vele genen 
opgeleverd die predisponeren voor het ontstaan van psychiatrische stoornissen (in 
vervolgstudies, echter, kon van vele genen de betrokkenheid niet gerepliceerd 
worden). Globaal genomen lijkt de bijdrage die ‘foute’ genen leveren aan de kans op 
het ontwikkelen van een psychiatrische stoornis klein of verwaarloosbaar in 
vergelijking met de bijdrage van andere niet-genetische risicofactoren. Ondanks 
deze inspanningen op het gebied van fundamenteel onderzoek is er geen enkel gen 
gevonden welke de complexe etiologie van psychiatrische stoornissen verklaart en 
die kan dienen als aanknopingspunt voor de ontwikkeling van meer werkzame 
therapieën.  
  Recentelijk is gesuggereerd dat veranderde expressie van genen door 
epigenetische regelmechanismen een rol zou kunnen spelen bij het ontstaan van 
een psychiatrische stoornis. Onze omgeving (vb. voeding) en zelfs enkele 
‘verdachte’ genmutaties (vb. MECP2) en genpolymorfismen (vb. MTHFR) kunnen 
genexpressie beïnvloeden door middel van epigenetische mechanismen. Dit 
verklaart gedeeltelijk waarom bevindingen van genetisch onderzoek moeilijk te 
repliceren zijn en eventueel ook hoe psychosociale en culturele factoren het risico 
vergroten op het ontwikkelen van een psychiatrische stoornis. Het lijkt dan ook 
verstandiger om gezondheid en ziekte te bestuderen op het ‘uitvoerende’ niveau 
van een cel of organisme, met andere woorden kwalitatieve en kwantitatieve 
veranderingen op eiwitniveau lijken een betere afspiegeling van de dynamische 
processen die kenmerkend zijn voor gezondheid en ziekte dan gedaan wordt door 
ons ‘statische’ genoom. Dezelfde redenering gaat op als we trachten ons inzicht te 
vergroten in het traject dat leidt tot het ontstaan van een psychiatrische stoornis. 
  Moderne technologieën, zoals (epi-)genomics, transcriptomics, proteomics en 
metabolomics die vaak op een niet hypothese gedreven wijze gebruikt worden 
zullen ons begrip van psychiatrische stoornissen verbeteren door het respectievelijk 
in kaart brengen van honderden tot duizenden genen, gen-transcripten (mRNA), 
eiwitten en metabolieten. Het gebruik van geavanceerde bio-informatica is 
essentieel voor integreren van deze resultaten in functionele correlatienetwerken, 
waardoor de mogelijkheid ontstaat om psychiatrische stoornissen vanuit de 
systeembiologie te benaderen. Wanneer de kennis die voortvloeit uit niet-
hypothese gedreven onderzoek gecomplementeerd wordt met resultaten van 
hypothese gedreven onderzoek, dan mag verwacht worden dat in de nabije 
toekomst prognostische, diagnostische en therapeutische biologische markers 
(biomarkers) of combinaties daarvan voor psychiatrische stoornissen ontdekt zullen 
worden. Deze markers dienen wel superieure sensitiviteit en specificiteit te hebben 
en dienen bij voorkeur gerelateerd te kunnen worden aan het orgaan, het weefsel, 
de cel of moleculaire cascade die onderdeel is van het pathofysiologisch proces. Op                SAMENVATTING EN TOEKOMSTPERSPECTIEF 
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de lange termijn is het misschien zelfs mogelijk om de ernst van het verloop van 
psychiatrische stoornissen te verminderen, om het ontstaan ervan in individuen die 
verhoogd vatbaar zijn voor het ontwikkelen van een psychiatrische stoornis te 
voorkomen of te vertragen, om de aanwezigheid van risicofactoren in de omgeving 
te verminderen of hun impact te reduceren, om vatbare/gevoelige individuen te 
identificeren, en om het ontstaan van psychiatrische stoornissen in latere generaties 
te voorkomen of zelfs te genezen. Dit laatste is een utopie als we psychiatrische 
stoornissen beschouwen als een onlosmakelijk deel van het spectrum van 
menselijkheid. 
 
In Hoofdstuk 1 wordt uitgewijd over de rol van folaat als substraat in het koolstof-1 
metabolisme en epigenetica, en over langeketen meervoudig onverzadigde vetzuren 
(LCPUFA) in schizofrenie, autisme en depressie. Zoals beschreven wordt in de 
Inleiding, worden complexe stoornissen zoals schizofrenie niet overgeërfd volgens 
de wet van Mendel, en het onderzoek naar een genetische basis is niet succesvol 
gebleven. De relatie van een laag geboortegewicht en zwangerschapscomplicaties 
met schizofrenie en autisme veronderstelt aanpassingen van de ontwikkeling van 
de foetus door `programmering'. Epigenetica staat mogelijk aan de basis van dit 
zogenaamde ‘programmeren’ en lijkt nauw verbonden met de folaat-status en het 
koolstof-1 metabolisme in het algemeen. In begripsbepalende proeven in zwangere 
ratten werd gevonden dat de beschikbare hoeveelheid koolstof-1 substraat 
(bijvoorbeeld folaat) in de voeding expressie van genen in het nageslacht kan 
beïnvloeden. Dit leidde tot de gedachte dat de folaat-status van patiënten met 
schizofrenie in hun perinatale leven gecompromitteerd zou kunnen zijn, wat 
ondersteund wordt door (i) samenvallende pieken in de incidentie van schizofrenie 
en neurale buisdefecten (NBD) na de Nederlandse Hongerwinter van 1944-1945, 
(ii) samenvallende seizoensgebonden schommelingen van het aantal geboortes van 
patiënten met schizofrenie en NBD, en een hogere incidentie van schizofrenie in 
(iii) immigranten en (iv) in mensen die homozygoot zijn voor het gen methyleen 
tetrahydrofolaat reductase 677C→T. Recente studies in patiënten met schizofrenie 
en autisme laten zien dat expressie van genen (vb. reeline) of chromosomale loci die 
cruciaal zijn voor bijvoorbeeld de ontwikkeling van de hersenen, gedereguleerd 
worden door epigenetische processen. Zo is het product van het reeline-gen 
betrokken bij het tot stand brengen van neurale plasticiteit en de neuro-
ontwikkeling. Het feit dat in volwassen patiënten met schizofrenie een lage status 
van koolstof-1 substraten gevonden wordt, welke als mogelijke consequenties DNA 
hypomethylering en veranderde genexpressie heeft, versterkt het idee van een 
afwijkend koolstof-1 metabolisme in bepaalde psychiatrische stoornissen. Een lage 
folaat-status wordt ook geassocieerd met de ernst van negatieve symptomen in     
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schizofrenie. Een zelfde effect is voorgesteld voor een lage status van de LCPUFA 
arachidonzuur (AA, uit vlees) en docosahexaeenzuur (DHA, uit vis). Deze vetzuren 
maken deel uit van hersenfosfolipiden en modulatoren van signaaltransductie en 
genexpressie. Patiënten met schizofrenie, en mogelijk ook patiënten met autisme, 
vertonen een abnormaal fosfolipidenmetabolisme, wat lokaal uitputting van AA 
kan geven en een verslechterde eicosanoïd-gemedieerde zenuwprikkeloverdracht 
zou kunnen veroorzaken. Verder blijkt dat de inname van vis op nationaal niveau 
omgekeerd evenredig gerelateerd is aan de incidentie van postpartum-depressies en 
depressies in engere zin, wat een relatie suggereert tussen de inname van de ω3-
LCPUFA eicosapentaeenzuur (EPA, uit vis) en de incidentie van depressie. Vijf van 
de 6 gerandomiseerde gecontroleerde studies naar de effecten van suppletie met 
EPA naast het gebruik van antipsychotica in patiënten met schizofrenie lieten 
positieve effecten zien, en 4 van de 6 studies toonden gunstige effecten voor 
patiënten met een depressie en/of bipolaire stoornis. Uit het hiervoor vermelde, kan 
men concluderen dat folaat en LCPUFA een belangrijk rol zouden kunnen spelen in 
zowel de etiologie als ernst van in ieder geval enkele psychiatrische ziekten. Deze 
bevindingen samen met het feit dat een lage status van B-vitaminen en LCPUFA 
geassocieerd wordt met een verhoogd risico op cardiovasculaire ziekten, leidde tot 
de uitvoering van de studie die beschreven wordt in Hoofdstuk 2 van dit 
proefschrift. 
 In  Hoofdstuk 2 onderzochten we de status van essentiële vetzuren (EFA) en B-
vitaminen en hun anthropometrische, leefstijl en biochemische determinanten in 
61 patiënten met schizofrenie. We stelden vast of die patiënten met slechte status 
van deze belangrijke voedingsbestanddelen in biochemisch opzicht verbeterden na 
inname van de juiste voedingssupplementen. Daarnaast werd deze studie 
uitgevoerd om de membraanfosfolipiden-hypothese van schizofrenie te testen, 
welke stelt dat de inbouw en verwijdering van EFA-bevattende fosfolipiden uit 
neuronale celmembranen veranderd is in patiënten met schizofrenie. De 
vetzuursamenstelling van erytrocyten (perifeer) zou volgens eerder onderzoek een 
afspiegeling zijn van de vetzuursamenstelling van neuronen (centraal). Wij vonden 
dat in de groep patiënten als geheel hun erytrocyten veel verzadigde vetzuren (FA) 
en mono-onverzadigde FA bevatten en weinig LCPUFA van de ω3 en ω6 reeksen. 
De patiënten die geen vitaminesupplementen-gebruik meldden, hadden lage serum 
vitamine B12 en hoge plasma homocysteine (Hcy) spiegels. Uit een multivariate 
analyse bleek dat de variantie in Hcy het best verklaard werd door serum folaat in 
zowel de gehele groep patiënten als de mannelijke patiënten. De variantie van Hcy 
in vrouwelijke patiënten werd het best verklaard door vitamine B12 en B6. 
Alcoholconsumptie en ziekteduur werden gevonden als risicofactoren voor het 
hebben van een lage status van meervoudig onverzadigde FA (<2.5 percentiel van                SAMENVATTING EN TOEKOMSTPERSPECTIEF 
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de referentiewaarden), terwijl “man-zijn” en de afwezigheid van vis in de voeding 
hyperhomocysteïnemie (>97.5 percentiel van de referentiewaarden) voorspelden. 
Tot onze verbazing vonden wij twee patiënten die biochemische EFA-deficiëntie 
(20:3ω9 boven de afkapwaarde) vertoonden en 7 waren biochemisch ω3/DHA 
marginaal, wat gedefinieerd was als een matig verhoogde 22:5ω6/DHA ratio. 
Bovendien vonden we vier patiënten met matig verhoogde Hcy-concentraties (30-
100 μmol/L) met plasmawaarden die zich bevonden tussen 57.5-74.8 μmol/L. Zulke 
bevindingen zijn zeldzaam in de doorsnee bevolking. Dit suggereert dat deze 
bevindingen een metabole oorzaak hebben, en/of dat deze te wijten zijn aan de 
langdurige inname (vele jaren) van voeding die ontoereikende hoeveelheden B-
vitaminen en LCPUFA bevat. Het feit dat geen van deze 5 patiënten met hun matig 
verhoogde Hcy, biochemische EFA-deficiëntie, of beiden, door hun behandelaren 
aangemerkt werd als een patiënt met een slechte voeding, is zorgwekkend, en wijst 
op suboptimaal monitoren van risicofactoren en de behandeling daarvan in 
patiënten met schizofrenie. Dat voeding aan de basis lag van deze afwijkende 
bevindingen werd bevestigd nadat vier van de vijf patiënten werden behandeld met 
B-vitaminen en met sojaboon- en visoliën. Hoewel psychiatrische symptomen niet 
gemeten werden tijdens de suppletie, bemerkte de behandelende psychiater wel 
verbetering op de lange termijn. Concluderend kan gesteld worden dat een 
subgroep van patiënten met schizofrenie lijdt aan biochemische EFA-deficiëntie, 
ω3/DHA marginaliteit, matig verhoogde Hcy, of combinaties daarvan. Behandeling 
van deze biochemische afwijkingen is geïndiceerd vanwege de mogelijke relatie van 
slechte EFA en B-vitamine status met psychiatrische symptomen, maar in het 
bijzonder om hun verhoogd risico op hart- en vaatziekten te verminderen. 
 In  Hoofdstuk 3 wordt een onderzoek beschreven naar het verband tussen het 
trombocyten (PLT) serotonine (5-HT) en de darmdoorlaatbaarheid in kinderen met 
pervasieve ontwikkelingsstoornissen (PDD) op Curaçao. Een verhoogde 
hoeveelheid 5-HT in de PLT wordt gevonden in 30-40% van kinderen met PDD. 
Onze hypothese was dat PLT 5-HT in PDD hoofdzakelijk bepaald wordt door 
darmmotiliteit (zie ook Hoofdstuk 4) en dat een verhoogde darmdoorlaatbaarheid 
hiervoor een proxy kan zijn. In eerdere studies werd gevonden dat ongeveer de 
helft van de patiënten met PDD een verhoogde darmdoorlaatbaarheid heeft, wat 
een argument is voor de aanwezigheid van het `lekke darmsyndroom' in een 
subgroep van kinderen met PDD. Het doel van deze studie was te beoordelen of er 
een verband bestaat tussen een ‘lekke’ darm en een verhoogde hoeveelheid 5-HT in 
PLT. Om dit te onderzoeken, werden de differentiële suikerabsorptie en het PLT 5-
HT bepaald in 23 kinderen met PDD. Trombocyten 5-HT (2.0-7.1 nmol/109 PLT) 
was, afhankelijk van de gebruikte afkapwaarde, verhoogd in 4 of 6 van de 23 
patiënten. Twee afkapwaarden werden gebruikt: 5.4 nmol/109 PLT, wordt gebruikt     
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voor diagnostiek van carcinoïdtumoren; en 4.55 nmol/109 PLT, wordt gebruikt om 
kinderen met PDD te classificeren als normo- of hyperserotonemisch. Het was 
opmerkelijk dat geen van de onderzochte patiënten een verhoogde 
darmdoorlaatbaarheid bleek te hebben (lactulose/mannitol ratio in urine: 0.008-
0.035 mol/mol). Tevens werden er geen correlaties gevonden tussen het PLT 5-HT, 
de darmdoorlaatbaarheid en maag-darmklachten. Dit leidde tot het verwerpen van 
onze eerste hypothese. Trombocyten 5-HT correleerde met 5-
hydroxyindoleazijnzuur (5-HIAA) in 24-uurs urine (p=0.034). 5-HIAA is een 
voornaamste metaboliet van 5-HT. Ook waren 5-HIAA in de urine en 5-HT in de 
urine aan elkaar gerelateerd (p=0.005), wat suggereert dat een verhoogde aanmaak 
van 5-HT verantwoordelijk is voor de verhoging van 5-HT in de PLT in een 
subgroep van kinderen met PDD. Om de (in)consistentie van darmdoorlaatbaarheid 
en PLT 5-HT te bestuderen, stellen we voor om deze maandelijks te meten in een 
goed gedefinieerde groep patiënten en controles, in het bijzonder om de 
aanwezigheid van een ‘lekke’ darm in deze groep te bevestigen of te verwerpen. 
  De bruikbaarheid van PLT 5-HT als parameter voor darmmotiliteit is het 
onderwerp van de studie die beschreven wordt in Hoofdstuk 4. Om de invloed te 
bestuderen van darmmotiliteit op PLT 5-HT op een niet-invasieve, indirecte 
manier, bepaalden wij of PLT 5-HT lager is in een toestand van relatief lage 
darmmotiliteit (d.w.z. in pasgeborenen bij de geboorte) in vergelijking tot een 
toestand van normale darmactiviteit (d.w.z. in hun moeders). Daarnaast bepaalden 
we of het starten of stoppen met enteraal voeden gepaard gaat met respectievelijk 
een stijging of daling van PLT 5-HT. Trombocyten 5-HT werd bepaald in 17 
moeders en in hun 18 gezonde, a-term geboren kinderen bij de geboorte op 
Curaçao. Om de rol van darmmotiliteit als determinant van PLT 5-HT te 
ondersteunen, werd van 20 vroegtijdige geboren zuigelingen longitudinaal 
informatie verzameld over de voedingsroute (enteraal of parenteraal) en het PLT 5-
HT. In 5 van de 20 zuigelingen was longitudinale informatie beschikbaar. Evenals 
eerdere studies vonden we dat pasgeborenen twee maal lagere PLT 5-HT waarden 
hebben in vergelijking tot hun moeders (medianen: 1.5 en 2.9 nmol/109 PLT, 
respectievelijk). Multivariate analyse liet zien dat PLT 5-HT van pasgeboren positief 
gerelateerd is aan het PLT 5-HT van de moeder en het gemiddelde PLT-volume van 
pasgeborenen, en negatief gerelateerd aan de tryptofaan concentratie in bloed van 
pasgeborenen. Wij hebben geen verklaring voor de relatie tussen het PLT 5-HT van 
pasgeborenen en hun moeders. De negatieve correlatie van PLT 5-HT met 
tryptofaan in pasgeborenen suggereert een tryptofaanonafhankelijkheid van PLT 5-
HT in het vroege leven. In de longitudinaal onderzochte prematuur geboren 
zuigelingen vonden wij 7 verhogingen en 1 vermindering van het PLT 5-HT tijdens 
het starten van het enteraal voeden (in 5/5 zuigelingen), en 2 verminderingen en 1                SAMENVATTING EN TOEKOMSTPERSPECTIEF 
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verhoging van PLT 5-HT tijdens het stoppen van enteraal voeden (starten van 
parenteraal voeden) in 3/5 zuigelingen. Ondanks het kleine aantal bestudeerde 
pasgeborenen in de longitudinale studie verwachten we dat het lagere PLT 5-HT bij 
de geboorte en de verandering hiervan bij het starten en/of stoppen met enteraal 
voeden verband houdt met respectievelijk de relatief lage darmmotiliteit bij de 
geboorte, en de verhoging/vermindering van de darmmotiliteit als reactie op het 
starten/stoppen met enteraal voeden. Het lijkt erop dat darmmotiliteit een 
belangrijke determinant is van PLT 5-HT in het vroege postnatale leven. Echter, 
om dit idee te ondersteunen dienen in vivo metingen van de darmmotiliteit 
verricht te worden en deze dienen gerelateerd te worden aan veranderingen in PLT 
5-HT in de tijd (bijvoorbeeld enkele maanden). 
 
In Hoofdstuk 5 beschrijven wij de ontwikkeling, de evaluatie en de toepassing van 
een platform voor de ontdekking van biomarkers in urine. Laag-moleculaire stoffen 
in urine werden geanalyseerd door middel van reversed-phase 
vloeistofchromatografie, gekoppeld aan massaspectrometrie (LC-MS) en data 
werden geanalyseerd door middel van multivariate statistische analyse van de van 
ruis ‘gezuiverde’ data. Specifieker, stoffen in urine werden gescheiden door middel 
van gradiënt-elutie met acetonitrile en detectie vond vervolgens plaats met UV-
absorptie bij 214nm en elektrospray ionisatie Ion-Trap MS. Door gebruik te maken 
van deze techniek konden we duizenden stoffen scheiden met een goede 
gevoeligheid en selectiviteit. De methode werd geëvalueerd door middel van 
toevoeging van zeven 3-8 aminozuur lange peptides (0-500 nmol/L). Prestatie-
indicatoren waren: detectielimiet (5.7-21 nmol/L), binnen-dag (2.9-19%) en tussen-
dag (4.8-19%) analytische variatie van piekoppervlakten, lineariteit (R2: 0.918-
0.999) en standaarddeviatie van retentietijd (<0.52 min). Deze prestatie-indicatoren 
bepalen de (on)mogelijkheden van dit platform voor de ontdekking van biomarkers 
in urine. Het aanpassen van het (op de chromatografische kolom geïnjecteerde) 
urine volume aan het oppervlakte onder de curve (AUC) van het UV-
chromatogram bij 214nm, verlaagde de variatiecoëfficiënt (CV) van de AUC van het 
chromatogram van de totale hoeveelheid ionen (CV =10.1%) meer dan wanneer het 
urine volume aangepast werd aan de creatinine concentratie (CV =38.4%). Dit 
suggereert dat voor specifieke studies naar de ontdekking van biomarkers in de 
urine van patiënten met een normale nierfunctie, aanpassing/normalisering van het 
urine volume op basis van meerdere stoffen te verkiezen is boven de 
aanpassing/normalisering op basis van één stof. LC-MS data, bestaande uit 
retentietijden, massa-lading (m/z) ratios en piekintensiteiten, werden vervolgens 
voorbewerkt met algoritmen om de verwerking van de data te verbeteren (data-
reductie), en om ruis te verwijderen (piekselectie) en data vergelijkbaar te maken     
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(piekgroepering/-clustering). De uiteindelijke, gemeenschappelijke piekenmatrix 
die alle pieken van alle urinemonsters bevatte, werd geanalyseerd met principale 
componentenanalyse (PCA) na gesuperviseerde classificatie en piekenselectie door 
het “nearest shrunken centroid” (NSC) algoritme. Principale component analyse 
vermindert de dimensionaliteit van de data zodat visualisatie mogelijk is. Het NSC 
algoritme verwijdert die pieken uit de piekenmatrix die niet significant bijdragen 
aan de scheiding/classificatie van de gedefinieerde groepen monsters (vb. ‘spiked’ 
vs. blanco) en tegelijkertijd corrigeert dit algoritme voor classificatiefouten door een 
laat-er-één-uit kruisvalidatie. De haalbaarheid van de methode om urinemonsters 
van verschillende samenstellingen te onderscheiden werd onderzocht door (i) 
toevoeging van zeven peptiden (nM concentraties) aan blanco urinemonsters van 
verschillende individuen en een urine-‘pool’, en door (ii) een studie naar de urine 
samenstelling van nierpatiënten met en zonder proteïnurie. We vonden dat de 
methode (i) de toegevoegde peptiden rangschikte als sterkst onderscheidende 
pieken ondanks de grote biologische variatie die aanwezig is in de samenstelling 
van urine. (ii) Tweeënnegentig pieken werden geselecteerd met de methode als 
zijnde het meest onderscheidend tussen nierpatiënten met en zonder proteïnurie. 
Het opschonen van de piekenlijst met 92 onderscheidende pieken resulteerde in 
een lijst van 54 pieken waarvan er 6 intenser waren in de meerderheid van de 
urinemonsters die afkomstig waren van nierpatiënten met proteïnurie. Twee van 
deze 6 pieken werden geïdentificeerd met LC-MS/MS als peptiden die afkomstig 
waren van albumine. Dit is in overeenstemming met de verwachte vroege stijging 
van albumine tijdens glomerulaire proteïnurie. Het was opmerkelijk dat andere van 
albumine afkomstige peptiden niet onderscheidend waren, wat kan duiden op 
ziektespecifieke eiwitafbraak. De ontwikkelde methode werd vervolgens toegepast 
op een enigszins complexere vraagstelling waarbij de verschillen in samenstelling 
van de urinemonsters van zwangere en niet-zwangere vrouwen onderwerp van 
studie was (Hoofdstuk 6). 
 In  Hoofdstuk 6 beschrijven wij de toepassing en de evaluatie van ons niet- 
hypothesegedreven platform voor de vergelijking van urinemonsters, en de selectie 
van onderscheidende pieken, van zwangere en niet-zwangere vrouwen. Op enkele 
summiere veranderingen van het LC-MS systeem na werden de urinemonsters 
geanalyseerd zoals beschreven in Hoofdstuk 5. De verwerking van de LC-MS data, 
echter, werd geoptimaliseerd en bestond uit piekenschakeling (‘meshing’), 
piekdetectie met een geometrisch algoritme, en 2-dimensionale (retentietijd en 
m/z) piekgroepering/-clustering door correlatiegeoptimaliseerd clusteren. Dit 
resulteerde in beter vergelijkbare, meer precieze en juiste data met minder pieken 
die afkomstig waren van analytische ruis. De onderscheidende pieken werden 
vervolgens geselecteerd met behulp van gesuperviseerde classificatie door het NSC                SAMENVATTING EN TOEKOMSTPERSPECTIEF 
- 217 - 
algoritme en laat-er-één-uit kruisvalidatie. De resultaten hiervan werden 
gevisualiseerd door middel van PCA. Urinemonsters van 7.6-15.7 weken zwangere 
vrouwen (n=25) en niet-zwangere vrouwen (n=25) werden geanalyseerd en 
vergeleken. Bij het gebruik van alle pieken in de uiteindelijke piekenmatrix (15876) 
voor de classificatie van de urinemonsters vonden we nauwelijks overlap tussen 
zwangere en niet-zwangere groep (sensitiviteit 96%, specificiteit 100%). Door 
gebruik te maken van het NSC algoritme werd een optimale shrinkage-waarde van 
3.11 gevonden waarbij het aantal pieken in het classificatiemodel teruggebracht 
werd tot 186 (1.2%). Dit model had geen kruisvalidatie-fout, en een sensitiviteit en 
specificiteit van 100%. Het vergroten van de shrinkage-waarde tot 7.52 (10 
onderscheidende pieken in het model) en 12.55 (1 onderscheidende piek in het 
model) leidde slechts tot een afname van de sensitiviteit tot respectievelijk 96% en 
92%, terwijl de specificiteit 100% bleef. De lijst met 186 onderscheidende pieken 
werd geëvalueerd door middel van univariate toetsing en visuele inspectie, en 
opgeschoond voor wat betreft meerdere ladingstoestanden van 1 onderscheidende 
piek en isotopen-verdeling om het aantal mogelijke biomarker kandidaten te 
verminderen. Resultaten van de analyse van correlaties tussen onderscheidende 
pieken suggereren structurele en/of functionele relaties. Het relateren van de 
specificiteit, de sensitiviteit of andere maten voor het onderscheid tussen groepen 
aan de shrinkage-waarde en het aantal onderscheidende pieken, kan helpen bij het 
verbeteren van de kwaliteit (onderscheidend vermogen) van de geselecteerde 
biomarker-kandidaten. Hier wordt aan gewerkt. Het vergelijkende urineanalyse 
platform kon urinemonsters van zwangere en niet-zwangere vrouwen 
onderscheiden met een acceptabele sensitiviteit en specificiteit op basis van slechts 
een klein aantal pieken (10). Momenteel wordt gewerkt aan de identificatie van de 
onderscheidende stoffen en aan het valideren van het classificatiemodel met een 
onafhankelijke test-set. De uiteindelijke methode zal verder geoptimaliseerd 
worden en worden ingezet voor de ontdekking van biomarkers voor ziekten van de 
urogenitale tractus en ongunstige zwangerschapsuitkomsten, maar de methode zou 
ook bruikbaar kunnen zijn voor de bestudering van psychiatrische stoornissen 
waarbij een voedingscomponenten mogelijk een rol spelen. 
 
Samenvattend, het doel van dit proefschrift was om markers van micronutriënten-
status en darmmotiliteit te bestuderen in patiënten met schizofrenie en autisme 
(Hoofdstukken 2 en 3). Meer gedetailleerde studies naar het vetzuur- en koolstof-1 
metabolisme in schizofrenie en autisme (Hoofdstuk 1) zijn gewenst, evenals studies 
naar de rol van de biochemie van de darm in autisme. Deze studies dienen bij 
voorkeur gecomplementeerd te worden met maten/scores van de psychiatrische 
symptomatologie. Het is zorgelijk dat lage statussen van zowel LCPUFA als B-    
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vitaminen in patiënten met schizofrenie grotendeels niet onderkend en dus 
onbehandeld worden, omdat deze lage statussen makkelijk corrigeerbaar zijn door 
middel van suppletie. Het monitoren en behandelen van co-morbiditeit in 
psychiatrische patiënten is van wezenlijk belang, omdat co-morbiditeit bovenop de 
reeds bestaande hoge ziektelast komt. 
  Om in autisme de betekenis en bruikbaarheid van bepaalde markers (vb. PLT 
5-HT) te bepalen, en om de rol van factoren die de concentratie van deze markers 
waarschijnlijk beïnvloeden (vb. darmmotiliteit) te bepalen, werden andere groepen 
proefpersonen bestudeerd, zoals pasgeborenen en hun moeders (Hoofdstuk 4). Het 
bestuderen van andere groepen proefpersonen die gekenmerkt worden door een 
grotere homogeniteit, door afwezigheid van storende co-morbiditeit, en door de 
aanwezigheid van de te onderzoeken fysiologische toestand (vb. normale of sub-
normale darmmotiliteit), kan de interpretatie van (epi-)fenomenen die 
waargenomen worden in psychiatrische ziekten vergemakkelijken. 
  Waarschijnlijk is geen van de door ons onderzochte stoffen/markers specifiek 
voor een psychiatrische diagnostische entiteit, en het lijkt er op dat we slechts in 
staat zijn om subgroepen van patiënten (biochemisch) te karakteriseren. De 
hedendaagse psychiatrische nosologie is niet gebaseerd op de etiologie, en tot nu toe 
is geen enkele marker, mechanisme of risicofactor in staat om het ontstaan en de 
ontwikkeling van deze aandoeningen te verklaren. Dit feit, samen met de grote 
socio-economische en psychologische last van psychiatrische stoornissen, de 
voorspelde stijging van de prevalentie, en de beschikbaarheid van suboptimale 
diagnostische en therapeutische modaliteiten, vraagt om een andere blik van 
onderzoekers op hypothesegedreven onderzoek van complexe ziekten zoals 
psychiatrische ziekten (Inleiding). Alternatieve onderzoekstrategieën die niet-
hypothesegedreven zijn en een valide klinische vraagstelling hebben, zijn een 
welkome aanvulling op hypothesegedreven onderzoek, hoewel de mogelijkheden 
van niet-hypothese gedreven onderzoek niet overschat dienen te worden tot het 
tegendeel bewezen is. 
  Moderne ‘-omics’ technologieën die de gelijktijdige en onbevooroordeelde 
bestudering (kwalitatief en kwantitatief) van zeer grote aantallen genen, mRNA 
(gen-transcripten), eiwitten en metabolieten mogelijk maken in een 
systeembiologie georiënteerde aanpak, zullen zeker de manier waarop onderzoek 
naar psychiatrische ziekten gedaan wordt, beïnvloeden. De ontwikkeling, de 
evaluatie en de toepassing van een ‘-omics' techniek voor de ontdekking van 
biomarkers in urine wordt beschreven in Hoofdstuk 5. Vergelijkende analyse van 
urinemonsters met state-of-the-art technieken voor het scheiden 
(vloeistofchromatografie; LC) en detecteren (massaspectrometrie; MS) van laag-
moleculaire stoffen gevolgd door multivariate analyse van LC-MS data die                SAMENVATTING EN TOEKOMSTPERSPECTIEF 
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tienduizenden pieken bevat, is een goed voorbeeld van hoe niet-hypothesegedreven 
onderzoek zou kunnen worden uitgevoerd. Bij de optimalisering en verdere 
evaluatie van deze methode in zwangere en niet-zwangere vrouwen zullen de 
verdere mogelijkheden en problemen van dit soort methodes duidelijk worden 
(Hoofdstuk 6). Nochtans, is de stapsgewijze ontwikkeling, evaluatie, en toepassing 
van deze ‘-omics’ methodologie op complexere klinische onderzoekvragen 
noodzakelijk om de eindgebruiker te overtuigen van de mogelijkheden en 
betrouwbaarheid. Het vergroten van de concentratiegevoeligheid (door vb. 
prefractionering, affiniteitextractie), de toepassing van meer selectieve detectors, en 
het gebruik van geoptimaliseerde algoritmen voor de dataverwerking en –analyse 
zijn manieren om het succes van cross-sectionele en longitudinale studies voor de 
ontdekking van biomarkers te vergroten. Als deze studies gecomplementeerd en 
geïntegreerd worden met resultaten van hypothesegedreven onderzoek, dan 
zouden wij misschien in staat zijn een deel van de mysteries te kunnen ophelderen 
van complexe ziekten waaronder psychiatrische stoornissen zoals autisme en 
schizofrenie.
  
                                         SAMENVATTING VOOR DE LEEK 
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Samenvatting voor de Leek 
Voordat ik begin met iedereen te bedanken voor de spreekwoordelijke bijgedragen 
steentjes en pallets met stenen lijkt dit me dè plaats om iets over mijn onderzoek te 
schrijven. 
 
Ik heb dus onderzoek gedaan naar de rol van voeding en biomarkers binnen de 
psychiatrie en dan met name bij autisme en schizofrenie. De oorzaken van deze 
psychiatrische ziekten zijn onbekend. Er zijn geen laboratoriumtesten om autisme 
of schizofrenie mee aan te tonen en de huidige behandelingsmogelijkheden zijn 
beperkt effectief. Patiënten met een psychiatrische ziekte en hun familie hebben 
vaak psychosociale en/of financiële problemen. Om psychiatrische patiënten beter 
te kunnen helpen is er meer onderzoek nodig naar de oorzaken en het verloop van 
deze ziektes, en naar betere therapieën. Dit onderzoek kan zowel hypothese 
gedreven (deel I van mijn proefschrift) als niet-hypothese gedreven (deel II van 
mijn proefschrift) gedaan worden. Bij hypothese gedreven onderzoek is er 
voorafgaand aan het onderzoek een duidelijke vraagstelling/idee, terwijl dit bij niet-
hypothese gedreven onderzoek niet het geval is. 
  Een voorbeeld van een hypothese gedreven onderzoek is ons onderzoek naar 
langeketen meervoudig onverzadigde ω3- en ω6-vetzuren (belangrijk voor de 
opbouw van de hersenen en zenuwprikkeloverdracht) en B-vitaminen (foliumzuur, 
B6 en B12; belangrijk voor celgroei in de hersenen) bij patiënten met schizofrenie. 
Het bleek dat veel patiënten met schizofrenie milde tot ernstige tekorten hebben 
van deze micronutriënten. Deze tekorten worden in verband gebracht met meer 
symptomen van schizofrenie en met een verhoogd risico op het krijgen van hart- en 
vaatziekten. Een klein groepje patiënten met ernstige tekorten kreeg vis- en slaolie, 
en B-vitamine-tabletten. Hiermee konden we hun tekorten aanvullen. Of de 
psychiatrische symptomen verbeterden, weten we niet, omdat deze destijds niet 
gemeten werden. Ook blijkt uit literatuuronderzoek dat tekorten van ω3-vetzuren 
en B-vitaminen in verband gebracht worden met autisme en depressie en dat 
toediening van deze micronutriënten meestal positieve effecten laat zien op de 
symptomen van patiënten met een depressie en schizofrenie. 
  Op Curaçao heb ik onderzoek gedaan naar de relatie tussen de 
darmdoorlaatbaarheid en de hoeveelheid serotonine (een stof die o.a. de darm 
prikkelt om te bewegen) in bloedplaatjes bij kinderen met autisme, vanwege de 
‘lekke darm’-hypothese van autisme. Ons idee was dat een meer doorlaatbare 
(‘lekke’) darm meer serotonine in de bloedbaan uitscheidt, waardoor het 
bloedplaatjes-serotonine verhoogd wordt. Echter, alle onderzochte kinderen 
hadden een normale darmdoorlaatbaarheid, maar 25% had wel een verhoogd  
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bloedplaatjes-serotonine. Ook dachten we dat naarmate de darm meer beweegt 
(darmmotiliteit) het bloedplaatjes-serotonine stijgt. Daarom deden we onderzoek 
bij pasgeborenen (relatief weinig darmmotiliteit) en hun moeders (normale 
darmmotiliteit), en deden we onderzoek naar het effect van infuusvoeding 
(parenteraal) en voeding via de mond (enteraal) op het bloedplaatjes-serotonine in 
te vroeg geborenen. Moeders hadden een tweemaal zo hoog bloedplaatjes-
serotonine als hun pasgeborenen. Daarnaast zagen we dat het bloedplaatjes-
serotonine hoger wordt als pasgeborenen enteraal gevoed worden en dat dit lager 
wordt als hiermee gestopt wordt en overgegaan wordt op parenterale voeding. We 
denken dus dat darmmotiliteit gestimuleerd wordt in pasgeborenen door enterale 
voeding en dat de serotonine die vrijkomt door en tijdens de vertering van voeding 
een belangrijke bijdrage levert aan de hoeveelheid serotonine in de bloedplaatjes. 
  Het tweede deel van dit proefschrift gaat over een methode die gebruikt wordt 
voor het op een niet-hypothese gedreven manier ontdekken van biomarkers in 
urine. Biomarkers zijn stoffen die gebruikt kunnen worden om aan te tonen of 
iemand ziek zal worden, ziek is, of beter wordt. We maakten gebruik van 
vloeistofchromatografie gekoppeld aan massaspectrometrie voor het resp. scheiden 
en zichtbaar maken van stoffen in urine als pieken (± 5-15 duizend!). Om te zien 
welke pieken afwezig/aanwezig zijn of een lagere/hogere concentratie hebben in de 
urine van iemand die ziek is, analyseerden we urinemonsters van zieke en gezonde 
mensen. Vervolgens vergeleken we de hoogtes van alle pieken van gezonden met 
die van zieken, natuurlijk met de computer. De pieken werden daarvoor eerst 
voorbewerkt om ruis te verminderen en de pieken vergelijkbaar te maken. Daarna 
zochten we met diverse wiskundige methoden naar pieken die sterk verschillen 
tussen ziek en gezond. Om onze methode te testen, hebben we bijvoorbeeld urine 
met en zonder toegevoegde peptiden (stukjes eiwit) geanalyseerd om te zien of onze 
methode de peptiden die we toegevoegd hadden eruit kon vissen als die pieken die 
het belangrijkste verschil maken. Ook hebben we de methode toegepast op 
urinemonsters van zwangere en niet-zwangere vrouwen, om te zien of we deze 
twee groepen van elkaar konden onderscheiden op basis van de stoffen in hun 
urine. Met 10 van de ±15.000 pieken konden we bepalen of een vrouw zwanger 
was. Nu willen we nog weten wat deze 10 pieken zijn, met andere woorden: welke 
stoffen (vb. zwangerschapshormoon) passen bij die 10 pieken? Ons doel was 
natuurlijk niet om een zwangerschapstest te ontwikkelen, maar om te zien of onze 
niet-hypothese gedreven methode werkt. Het uiteindelijke doel is om met deze 
methoden meer inzicht te krijgen in ziekteprocessen, en om laboratoriumtesten 
(biomarker-testen) voor ziektes te ontwikkelen, vb. voor vroeggeboorte. Een 
dergelijke methode kan natuurlijk ook gebruikt worden om psychiatrische ziekten 
mee te onderzoeken.                                                                          DANKWOORD 
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Dankwoord 
Hatsikidee, ik stop ermee. Het einde is in zicht, maar ik kan natuurlijk niet afsluiten 
met een simpel ‘Iedereen bedankt!’, alhoewel dit wel een aantrekkelijke optie is. 
Een groot aantal mensen verdient het om persoonlijk bedankt te worden en 
degenen die ik hierbij vergeet alvast een welgemeend ‘ut spiet mie donders’. Het is 
misschien raar om mezelf te bedanken, maar ik doe het toch, omdat ik het bijltje er 
op sommige momenten niet bij neergegooid heb. Ramses, bedankt! 
 
Allereest wil ik mijn ‘promotievaders’ Prof. Dr. Frits Muskiet, Prof. Dr. Rainer 
Bischoff en Dr. Ido Kema bedanken voor hun inzet om mijn promotie tot een goed 
einde te brengen. 
  Beste Frits, dankzij jou heeft mijn proefschrift de focus gekregen die het nu 
heeft. Het afbakenen van onderzoek heeft je nooit echt gelegen en daarvoor ben ik 
je oprecht dankbaar evenals voor de mogelijkheid die je me bood om te proeven 
van onderzoek doen in de Cariben. Ik heb veel geleerd van je patiënt-georiënteerde 
manier van onderzoek doen. Je bent een echte leermeester voor me geweest en ik 
hoop dat we zo nu en dan nog eens van gedachten kunnen wisselen over de 
klinische chemie en de andere zaken des levens. 
  Beste Rainer, ook al hebben we de lekke-darm en ‘opioid-excess’ hypothese in 
autisme niet kunnen bevestigen, ik ben blij dat je nog zo’n gunstige ‘twist’ aan de 
urine-analyse methode hebt weten te geven. Ik heb veel bewondering voor de 
manier waarop jij en Diane blijven werken aan FAS. Je bent een uitstekend 
wetenschapper van wie ik veel geleerd heb op velerlei vlakken. Het zit wel snor (oh 
nee, niet meer) met onze samenwerking. 
  Beste Ido, helaas hebben we elkaar door je drukke werkzaamheden en hectiek 
van het LC minder gesproken dan in beginsel bedoeld was. Ik zie er naar uit om de 
schade de komende jaren in te halen en ik heb zin om te starten met de opleiding. 
Bedankt voor je vertrouwen en voor mijn 3-maanden door het CWI-gesponsorde 
‘vakantie’. 
 
De leden van de beoordelingscommissie Prof. Dr. Hubertus Irth, Prof. Dr. Jaap Korf 
en Prof. Dr. Ben Westerink wil ik bedanken voor het kritisch en tijdig doornemen 
van mijn toch wel lange manuscript. 
 
Door de samenwerking met studenten kon ik me enerzijds nog één van hen voelen 
(geestelijke verjongingskuur) en anderzijds kon ik mijn didactische experimenten 
op ze uitoefenen. Jullie hebben me scherp gehouden en ik durf dan ook wel te  
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stellen dat voor het gereedkomen van mijn proefschrift jullie bijdrage onontbeerlijk 
was, gezien het aantal coauteurschappen. 
  Mijn dank gaat uit naar mijn bijvakkers (in chronologische volgorde): Marieke, 
Berend, Marianne en Bernadine. Ik heb het erg gezellig met jullie gehad, alhoewel 
we vaker een borrel hadden moeten drinken (7 december dan maar?). Marieke en 
Bernadine, veel succes met de farmaceutische carrière en ik hoop dat jullie met 
plezier terugdenken aan de tijd in het lab en de psychosen-poli. Marianne …-
Wilkens, hou je de knakworsten warm? Berend (allemaal het raam uit!), ik ben blij 
dat jij het stokje van me overneemt en de vakgroep komt versterken/verNL-en. 
  Zonder de goede samenwerking met de afdeling Psychiatrie van het UMCG 
was de titel van dit proefschrift anders geweest. Ik wil Dr. Rikus Knegtering en Dr. 
Richard Bruggeman hiervoor bedanken en ik verwacht dat we nog meer klinisch-
chemisch onderzoek naar schizofrenie gaan doen als jullie er tenminste nog niet 
‘vet zuur’ van zijn. Prof. Dr. Jaap Korf wil ik bedanken voor zijn input tijdens het 
VIS-onderzoek. Voor het in goede banen leiden van het onderzoek, de prettige 
contacten met patiënten en medewerkers, en het welkom heten van mijn 
bijvakkers, bedank ik Nynke van der Wal, Yfne Hoekstra en Mike Vervoort. Asmar 
en de SFF-ers, ik hoop dat jullie PHASTER PHAMOUS worden, bedankt voor de 
goede samenwerking. 
  Voor het opzetten van het onderzoek naar autisme, bloedplaatjes-serotonine 
en darmdoorlaatbaarheid wil ik Prof. Dr. Ruud Minderaa en Dr. Erik Mulder van 
de afdeling Kinder- en Jeugdpsychiatrie van het UMCG bedanken. Dit onderzoek 
werd uiteindelijk in gewijzigde vorm uitgevoerd op Curaçao. De uitvoering aldaar 
was alleen mogelijk dankzij de inspanningen van Fred Muskiet en Inge Boutier. 
Fred, bedankt voor je droge humor en doortastendheid bij het includeren van 
patiëntjes. Inge, enorm bedankt voor je bereidheid om ons te helpen bij ‘weer een 
onderzoek’ bij kinderen met autisme. Je bent een warm persoon waardoor ik 
begrijp dat je veel betekent voor de autisme-gemeenschap op Curaçao. 
  In het rijte van permanente en tijdelijke Curaçao-bewoners wil ik ook Sanne, 
Jeroen en Yke bedanken. Sanne en Igor, bedankt voor de koude Polars (ze hebben 
goed gesmaakt) en de welkome ontspanning buiten het werk om. Jeroen en Yke, 
bedankt voor het verzamelen van de bloedmonsters en patiënteninfo in het Sint 
Elisabeth Ziekenhuis en de Klinika Capriles. 
  Het werk op Curaçao was niet mogelijk zonder de hulp van Dr. Fey van der 
Dijs en Dr. Hans Landman. Daarnaast wil ik Dr. Pytha Jessurun, Dr. Petra Gelan, 
Francis van Eijndhoven en Arlene Daal bedanken voor de interessante en nuttige 3 
weken in de Klinika Capriles. Mijn labwerk in Curaçao was niet mogelijk zonder de 
uitstekend uitgeruste laboratoria van de Rode Kruis Bloedbank (Dr. Ashley Duits)                                                                          DANKWOORD 
- 225 - 
en Medical Laboratory Services (Dhr. Helfrick Genaro). Bedankt voor het gastvrije 
ontvangst en de gezelligheid. Carmabi, bedankt voor de woonruimte aan het strand. 
  Dr. Jan-Jaap Erwich en Esther Streefland van Obstetrie en Gynaecologie van 
het UMCG ben ik erkentelijk voor resp. het pilot-werk naar bloedplaatjes-
serotonine in pasgeborenen en de bijdrage aan de studie naar biomarkers van 
zwangerschap. 
 
Veel bepalingen die beschreven worden in dit proefschrift werden uitgevoerd door 
de toegewijde medewerkers van het LC. In het bijzonder wil de volgende personen 
bedanken: Ina en Hilda (suikers), Dineke en Enge (indolen), Claude en Paul 
(catecholaminen), Jasper voor de hulp bij HPLC-opstellingen, chemicaliën en 
andere dingen, Ingrid en Marchien (vetzuren), Herman (B-vitaminen en de 
vetzuurstudie op Curaçao). Voor het inwerken op de LC-MS wil ik Jan van der 
Molen bedanken. Ik weet zeker dat ik een aantal personen vergeten ben en 
daarvoor dan ook: “Sorry!” Ik heb het in ieder geval erg naar mijn zin gehad bij de 
jullie LHGV-ers. Van het lab bindingsanalyse wil ik Robert de Vrij bedanken. 
Iedereen ook hartelijk bedankt voor de opvang van ‘mijn’ studenten. 
  Mijn andere collega’s van het LC bedank ik hierbij voor de gezellige en 
interessante tijd. Rebecca, bedankt voor je tips met betrekking tot statistiek, KCIO 
worden en het promoveren bij Frits. Janneke, bedankt voor de gezelligheid op 
Curaçao. Francien, dit jaar weer naar de NVKC-Chinees? 
 
Mijn medepromovendi en Y3.181-kamergenoten van het eerste uur, Hylco, Saskia 
en Remko, dank voor het koffieleuten. Dr. Hylco, succes met je carrière in de 
medische wetenschap, de veeteelt of uitvindersbusiness. Saskia, je hebt altijd een 
nuchtere kijk op dingen en ik kan goed met je lachen. Remko, altijd maar weer 
weg, Tanzania (rimboe en savanne), Curaçao en …? Je lust er wel melk van. 
  Anne Marie. Jij bent een soort ‘promotiemoeder’ geweest voor me. Bedankt 
voor ‘de catering’, en je ondersteuning op zowel professioneel als persoonlijk vlak. 
Het is altijd gezellig met jou en dan zeg ik niks teveel. 
 
Zonder de onbaatzuchtige deelname van alle volwassen patiënten in Nederland, de 
patientjes en hun ouders/verzorgers in Curaçao, en alle andere ‘vrijwilligers’ zou ik 
mijn proefschrift nooit hebben kunnen afronden. Heel erg bedankt en masha, 
masha danki! 
 
In het voorgaand schrijven lijkt het er op dat mijn onderzoek werd uitgevoerd in 
het UMCG en op Curaçao. Niets is minder waar. Het voordeel van een tweede 
promotor hebben, is dat je ook in een andere groep mag ‘wonen’ gedurende bijna  
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vijf jaar. Mijn 2de honk was de vakgroep Analytische Biochemie (Farmacie). Een 
aantal personen van deze groep verdient speciale aandacht in dit, toch wel meest 
gelezen, stukje tekst. 
  Ik heb veel kamergenoten de revue zien passeren: Prof. Dr. Rokus de Zeeuw, 
Prof. Dr. Donald Uges, Theo, Andre, Berend, Martijn, Rivca en Therese. Kamer 
3211.266 was een prima stekje en de bijnamen-traditie die daar ontstaan is, mag 
voortgezet worden. De andere kamer naast ‘de grote baas’ was ook één van mijn 
favoriete plaatsen om tijd door te brengen, maar niet alleen om LC-MS data te 
(laten) verwerken. Ik wil Dr. Peter Horvatovich bedanken voor de gemaakte 
nachtelijke uurtjes. Peter, veel succes met je tenure en geluk met je dochter. Dr. 
Theo Reijmers, bedankt voor je hulp met de statistiek. Dr. Frank Suits, many thanks 
for improving our data processing workflow and for the helpful discussions. 
  De andere medewerkers, AIO’s en post-docs van de vakgroepen Analytische 
Biochemie (voorheen Bioanalyse en Toxicologie) en Farmaceutische Analyse wil ik 
bedanken voor de interessante en twijfelachtige, maar altijd vermakelijke, 
gesprekken tijdens de koffiepauzes, lunches, borrels, BBQ’s, labdagen, congressen, 
symposia enz. Het bier en het vlees zijn meestal goed gevallen. 
 
Gedurende mijn promotietijd heb ik ontspanning kunnen vinden tijdens mijn werk 
maar ook daarbuiten. Uiteindelijk werk je toch om te genieten van het leven! 
Daarom wil ik de OZO-ieten Coen, Harry, Job, Leander, Martijn, Niek, Paul, 
Redmer en Rogier bedanken voor het teveel aan bier, de bioscoopbezoeken en de 
jaarlijkse uitputtingsslag. De oud Heren 9-ers van GCHC wil ik bedanken voor de 
gezellige hockeytoernooien. GUIDE cooking-mates Jarir en Jorgen, hopefully we 
can meet next year in Jarir’s holiday-mansion in Bali to do some good cooking. 
 
Mijn paranimfen Theo Klein, William Zuidland en Dennis Kemperman (back-up). 
Bedankt voor jullie opoffering om op gepaste wijze gekleed voor of na mij te gaan. 
Theo (laid-back), onze lunch en niet-lunch gesprekken over het leven, de kunst van 
het koken, speciaal bier, collega’s en de voor- en nadelen van een leven als AIO 
waren momenten van bezinning in mijn hectische leven als AIO, bedankt. William, 
je bent atlijd maar moeilijk te bedanken, ook voor je klussen. Redmer van Tijum, 
ook al ben je dan geen paranimf, bedankt voor de vele tips. Veel geluk met Kirsten 
in Leek. Dennis, mijn ‘kleine’ broertje, dank je dat je mijn back-up paranimf wilt 
zijn en voor je interesse in mijn onderzoek. Ik hoop dat je een leuke baan vindt 
(niet te ver weg hè!). 
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Pap en mam, bedankt voor jullie steun en warmte. Bas en Millan, nog ‘even’ klussen 
en dan wil ik wel eens oom worden. Macha en Andy, komen jullie snel weer naar 
Europa? Mitko, Mirsada en Melissa, velika hvala za prijatan i tih vikendi. Opa en 
oma Pet, bedankt voor mijn mooie en creatieve omslag en de nieuwe heup 
waardoor je er staand bij kunt zijn! Oma Kemperman, kom nog eens langs in 
Groningen. 
 
En dan nu het meest afgezaagde, maar wel het belangrijkste onderdeel, van het 
dankwoord; het deel waarin elke AIO spijt betuigt aan zijn/haar partner voor de 
moeilijke tijd en relatiecrisis: Liefste Kemira, het was niet altijd even makkelijk 
voor jou de afgelopen vijf jaren. Ik kan je niet zeggen hoeveel spijt ik had als ik 
weer eens onze voornemens om zeep hielp om dat het werk dan weer even voor 
ging. Gelukkig voor jou en voor mij is het nu voorbij. Een stukje tekst zoals dit kan 
niet beschrijven hoe gelukkig ik met jou ben en hoe dankbaar ik je ben voor je 
steun. Ik kan maar één ding zeggen: Een dikke KOES voor jou  :-Ä en volim te.  
                                                                   OVER DE AUTEUR  
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Over de auteur 
Ramses Kemperman werd geboren op vrijdag 10 maart in 1978 in Nijmegen (NL). 
Tot aan de derde klas van de basisschool bracht hij zijn levensjaren door in Elst 
(Gelderland), waarna hij naar Roden (Drenthe) verhuisde. Het Atheneum werd in 
1996 afgerond aan het Nienoordcollege in Leek (Groningen), waarna hij Farmacie 
ging studeren aan de Rijksuniversiteit in Groningen. Het doctoraal in de Farmacie 
werd in 2001 behaald met als titel van het afstudeeronderzoek ‘Ontwikkeling en 
optimalisering van immunofixatie-gel electroforese assays voor de detectie en 
kwantificering van β2 transferrine in neus- en oorvocht en Bence-Jones eiwitten in 
urine’. Het apothekersexamen werd afgelegd in 2002, waarna gestart werd aan 
promotietraject in januari 2003. 
  Het promotieonderzoek werd zowel uitgevoerd bij de vakgroep Analytische 
Biochemie (destijds Bioanalyse en Toxicologie) van de Rijksuniversiteit Groningen 
als bij de afdeling Laboratoriumgeneeskunde van het Universitair Medisch Centrum 
in Groningen (destijds Academisch Ziekenhuis Groningen). Er werd onderzoek 
verricht aan de biochemie van psychiatrische stoornissen waaronder autisme en 
schizofrenie. Daarnaast was hij betrokken bij het ontwikkelen, evalueren en 
toepassen van een methode voor de niet-hypothese gedreven ontdekking van 
biologische markers in urine. Zijn interesse gaat uit naar de klinische chemie van 
psychiatrische stoornissen. In zijn vrije tijd doet hij meestal leuke dingen.  
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